

Friday, April 26, 2024

Volume 55 No. 4



NOTICE – Items in this issue will be listed online weekly and printed monthly.

ACHARI VENTURES HOLDINGS CORP I Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
General & administrative	3,098,140	1,287,276	182,920
Franchise tax	81,600	282,342	114,262
Total expenses	3,179,740	1,569,618	297,182
Income on over-allotment	95,104
Interest income on investments held in trust account	429,125	1,411,854	1,875
Change in fair value of warrants	248,953	1,997,334	7,632,666
Fair value in excess of sale of private warrants	4,636,666
Transaction costs allocated to warrant issuance	57,041
Total other income (expense)	678,078	3,409,188	3,035,938
Income (loss) before income tax	(2,501,662)	1,839,570	2,738,756
Current federal income taxes	72,980	216,203	...
Deferred federal income taxes	(688,629)	(246,333)	(62,014)
Change in valuation allowance	688,629	246,333	62,014
Income tax provision	72,980	216,203	...
Net income (loss)	(2,574,642)	1,623,367	2,738,756
Weighted average shares outstanding - basic	3,336,745	12,278,562	4,955,882
Weighted average shares outstanding - diluted	3,336,745	12,278,562	4,955,882
Year end shares outstanding	3,050,941	3,519,465	12,500,000
Net income (loss) per share - basic	\$(0.77)	\$0.13	\$0.55
Net income (loss) per share - diluted	\$(0.77)	\$0.13	\$0.55
Total number of employees	...	3	3
Number of common stockholders	...	1	2
Number of unitholders	...	2	...
Common Shareholders - Number	1

From January 25, 2021 (inception); Reclassified to conform with 2022 presentation; Shares decreased due to the effect of decreased in number of shares subject to possible redemption; As of April 21, 2023; As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022	2021
Cash	48,395	597,306	...
Prepaid expenses	48,106
Prepaid expenses - current	...	180,197	777,503
Total current assets	96,501	777,503	...

Cash & marketable securities held in trust account	6,049,745	44,688,320	...
Total assets	6,146,246	45,465,823	...
Accounts payable & accrued expenses	3,206,121	665,059	...
Income taxes payable	...	216,203	...
Franchise tax payable	42,717	291,137	...
Common Stock redemption payable	...	34,198,758	...
Excise tax liability	391,544
Note Payable- related party	582,000
Total current liabilities	4,222,382	35,371,157	...
Derivative warrant liabilities	107,713	356,666	...
Deferred underwriting fee payable	3,500,000	3,500,000	...
Total liabilities	7,830,095	39,227,823	...
Common stock subject to possible redemption	6,049,745	10,489,562	...
Common stock	250	250	...
Retained earnings (accumulated deficit)	(7,733,844)	(4,251,812)	...
Total stockholder's equity (deficit)	(7,733,594)	(4,251,562)	...

Recent Dividends:

1. Achari Ventures Holdings Corp I common subject to redemption.

No dividends paid.

2. Achari Ventures Holdings Corp I common.

No dividends paid.

Annual Dividends:

1. Achari Ventures Holdings Corp I common subject to redemption.

No dividends paid.

2. Achari Ventures Holdings Corp I common.

No dividends paid.

ACORDA THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Net product revenues	102,421,000	103,845,000	114,189,000
Royalty revenues	15,113,000	14,221,000	14,882,000
License revenue	99,000	500,000	...
Total net revenues	117,633,000	118,566,000	129,071,000
Cost of sales	15,283,000	30,332,000	40,787,000
Research & development expenses	5,152,000	5,804,000	10,420,000
Selling, general & administrative expenses	89,698,000	106,256,000	124,399,000
Goodwill & intangible asset impairments	251,322,000
Amortization of intangible assets	30,764,000	30,764,000	30,764,000
Changes in fair value of derivative liability	...	37,000	1,156,000
Changes in fair value of acquired contingent consideration	(9,634,000)	(6,659,000)	2,895,000
Other operating

income	...	12,554,000	...
Total operating expenses	382,585,000	153,906,000	208,109,000
Operating income (loss)	(264,952,000)	(35,340,000)	(79,038,000)
Interest & amortization of debt discount expense	31,533,000	30,200,000	30,035,000
Interest income	530,000	1,909,000	5,000
Realized gain (loss) on fx currency	(288,000)	(8,000)	...
Other income (expense)	51,000	1,250,000	(6,000)
Gain (loss) on debt extinguishment	...	27,142,000	...
Gain on disposal of property and equipment	171,000
Total other income (expense), net	(31,069,000)	93,000	(30,036,000)
Income (loss) before taxes - domestic	(295,429,000)	(60,179,000)	(112,530,000)
Income (loss) before taxes - foreign	(592,000)	24,932,000	3,456,000
Income (loss) before taxes	(296,021,000)	(35,247,000)	(109,074,000)
Current federal provision for (benefit from) income taxes	118,000	243,000	(230,000)
Current state provision for (benefit from) income taxes	850,000	115,000	182,000
Current foreign provision for (benefit from) income taxes	71,000	37,000	113,000
Total current provision for (benefit from) income taxes	1,039,000	395,000	65,000
Deferred federal provision for (benefit from) income taxes	(25,909,000)	30,234,000	(4,412,000)
Deferred state provision for (benefit from) income taxes	(18,297,000)	40,000	(711,000)
Deferred foreign provision for (benefit from) income taxes	(62,000)
Total deferred provision for (benefit from) income taxes	(44,206,000)	30,274,000	(5,185,000)
Provision for (benefit from) income taxes	(43,167,000)	30,669,000	(5,120,000)
Net income (loss)	(252,854,000)	(65,916,000)	(103,954,000)
Weighted average shares outstanding - basic	1,242,000	985,350	531,050

Retained earnings (accumulated deficit)	(222,798)	(170,427)
Accumulated other comprehensive income (loss)	312	(751)
Total stockholders' equity (deficit)	266,973	188,775
Total Equity	266,973	...

Recent Dividends:

1. Acumen Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Acumen Pharmaceuticals Inc common.

No dividends paid.

ACUTUS MEDICAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022 (revised)	2021 (revised)
Revenue	7,164	3,031	...
Revenue	7,164	3,031	17,263
Cost of products sold	10,301	4,941	32,925
Research & development	3,482	3,118	36,683
Selling, general & administrative	14,066	20,315	63,523
Goodwill impairment	12,026	...
Change in fair value of contingent consideration	123	1,053	(3,746)
Gain on sale of business	9,080	79,465	...
Total cost & operating expenses	129,385
Income (loss) from operations	(11,728)	41,043	(112,122)
Change in fair value of warrant liability	2,937	33	...
Gain (loss) on debt extinguishment	(7,947)	...
Interest income	2,588	868	116
Interest expense	5,655	5,149	5,677
Total other income (expense), net	(130)	(12,195)	(5,561)
Income (loss) before income taxes - U.S.	(117,868)
Income (loss) before income taxes - foreign	185
Income (loss) before income taxes ..	(11,858)	28,848	(117,683)
Income tax expense ..	63	15	...
Net income (loss)	(81,663)	(39,616)	(117,683)
Weighted average shares outstanding - basic	29,095	28,471	28,654
Weighted average shares outstanding - diluted	29,095	28,471	28,654
Year end shares outstanding	29,314	28,555	27,957
Net income (loss) per common share - basic	\$(2.81)	\$(1.40)	\$(4.11)
Net income (loss) per common share - diluted	\$(2.81)	\$(1.40)	\$(4.11)
Number of full time employees	233	...	338
Number of common stockholders	74	...	74
Foreign currency translation adjustments	(460)
Income from continuing operations	(11,921)	28,833	...
Loss from			

discontinued operations before income taxes	(69,530)	(68,382)
Income tax expense - discontinued operations	(212)	(67)
Discontinued operations	(69,742)	(68,449)
Earnings per share from continuing operations	\$(0.41)	\$1.02
Earnings per share-inc from discontinued oper	\$(2.40)	\$(2.40)
Earnings per share-discontinued opers	\$(2.40)	\$(2.40)
Earnings per share from continuing operations	\$(0.41)	\$0.78
Earn per share-inc from discont opers - diluted	\$(2.40)	\$(2.40)
Earning per share-total discont opers - diluted	\$(2.40)	\$(2.40)
Total number of employees	233	...

Restated to reflect discontinued operations; As is; As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022 (revised)
Cash & cash equivalents	19,170	25,584
Marketable securities	3,233	...
Marketable securities, short-term	44,863
Restricted cash	7,030	5,764
Accounts receivable	11,353	21,085
Raw materials	3,428	9,179
Work in process	319	2,025
Finished goods	531	2,123
Inventory	4,278	13,327
Employer retention credit receivable	4,703
Prepaid expenses & other current assets	678	2,541
Assets Held for Sale/Discontinued Operations - Short-Term	510	...
Total current assets	46,252	117,867
Medical diagnostic equipment	14,826
Furniture & fixtures	432
Office equipment	1,494	1,556
Laboratory equipment & software	432	5,148
Leasehold improvements	979	580
Construction in process	7	2,166
Office equipment	1,537	...
Total property & equipment, gross	4,449	24,708
Less: accumulated depreciation - property & equipment	3,624	15,487
Property & equipment, net	825	9,221
Right-of-use asset, net	3,189	3,872
Intangible assets, net	1,583
Other assets	94	897
Assets Held for Sale/Discontinued Operations - Long-Term	3,600	...
Total assets	53,960	133,440
Accounts payable	2,761	4,721
Accrued compensation & related expenses	2,225	6,919
Accrued professional fees	126
Deferred revenue	326
Accrued sales & use tax	639
Accrued clinical studies	390
Clinician council payable	216
Accrued royalties	159

Accrued restructuring	45
Other accrued liabilities	866
Accrued payroll & related expenses	378	...
Biotronik asset acquisition - accrued purchase price	274	...
Accrued liabilities	2,887	9,686
Contingent consideration, short-term	1,800
Operating lease liabilities, short-term	718	319
Warrant liability	409	3,346
Long-term debt, current portion	1,864	...
Current liabilities of discontinued operations	10,303	...
Total current liabilities	18,942	19,872
Operating lease liabilities, long-term	3,243	4,103
Credit agreement	36,776
Less: unamortized debt discount & fees	32,654	(2,342)
Long-term debt	34,434
Other long-term liabilities	12
Total liabilities	54,839	58,421
Common stock	29	29
Additional paid-in capital	599,935	594,173
Accumulated deficit	(599,977)	...
Retained earnings (accumulated deficit)	(518,314)
Accumulated other comprehensive income (loss)	(866)	(869)
Total stockholders' equity (deficit)	(879)	75,019
Total stockholders equity	(879)	...

Recent Dividends:

1. Acutus Medical Inc series A common equivalent preferred.

No dividends paid.

2. Acutus Medical Inc common.

No dividends paid.

Annual Dividends:

1. Acutus Medical Inc series A common equivalent preferred.

No dividends paid.

2. Acutus Medical Inc common.

No dividends paid.

ADOBE INC

Earnings, 3 mos. to (Consol. - \$000):

	03/01/24	03/03/23
Total Revenues	5,182,000	4,655,000
Net Sales	5,182,000	...
Cost & expenses	4,233,000	3,027,000
Operating income	907,000	1,586,000
Interest expense	27,000	32,000
Other income (expense), net	70,000	43,000
Gains or losses	18,000	1,000
Net before taxes	968,000	1,598,000
Income taxes	348,000	351,000
Net income	620,000	1,247,000
Earnings common share		
Primary	\$1.37	\$2.72
Fully Diluted	\$1.36	\$2.71
Common Shares:		
Full Diluted	456,000	459,500
Year-end	453,000	459,000

Consolidated Balance Sheet Items, as of (\$000):

	Assets:	2024
Cash & equivalents	6,254,000	
Current assets	10,008,000	
Net property & equip.	1,988,000	
Total assets	28,751,000	
Liabilities:		
Current liabilities	9,537,000	
Long-term debt	2,138,000	
Stockholders' equity	15,460,060	
Net current assets	471,000	

ADTRAN HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Revenue - network solutions	916,793,000	498,834,000	
Revenue - services & support	108,743,000	64,170,000	
Network Solutions	974,389,000		
Services & Support	174,711,000		
Total revenue	1,025,536,000	563,004,000	
Cost of revenue - network solutions	722,582,000	647,105,000	307,841,000
Cost of revenue - inventory write down	24,313,000		
Cost of revenue - services & support	51,179,000	36,786,000	
Services & Support	69,142,000		
Total cost of revenue	816,037,000	698,284,000	344,627,000
Gross profit	333,063,000	327,252,000	218,377,000
Selling, general & administrative expenses	258,149,000	208,889,000	124,414,000
Research & development expenses	258,311,000	173,757,000	108,663,000
Asset impairments expenses	17,433,000		
Operating income (loss)	(221,271,000)	(72,827,000)	(14,700,000)
Interest & dividend income	2,340,000	2,123,000	2,844,000
Interest expense	16,299,000	3,437,000	34,000
Net investment gain (loss)	2,754,000	(11,339,000)	1,761,000
Other income (expense), net	1,266,000	14,517,000	3,824,000
Income (loss) before income taxes - U.S. entities	(33,720,000)	(14,982,000)	
Income (loss) before income taxes - international entities	(37,243,000)	8,677,000	
Income (loss) before income taxes	(231,210,000)	(70,963,000)	(6,305,000)
Current federal income tax expense (benefit)	2,545,000	4,572,000	11,000
Current state income tax expense (benefit)	26,000	88,000	(63,000)
Current international income tax expense (benefit)	10,004,000	(4,347,000)	4,166,000
Total current income tax expense (benefit)	12,575,000	313,000	4,114,000
Deferred federal income tax expense (benefit)	46,252,000	(47,429,000)	
Deferred state income tax expense (benefit)	6,607,000	(6,776,000)	
Deferred international income tax expense (benefit)	(37,301,000)	(8,183,000)	(1,784,000)
Total deferred income tax expense (benefit)	15,558,000	(62,388,000)	(1,784,000)
Income tax expense (benefit)	28,133,000	(62,075,000)	2,330,000
Net income (loss)	(259,343,000)	(8,888,000)	(8,635,000)
Less: net income (loss) attributable to non-controlling interest	(8,345,000)	6,851,000	
Net income (loss) attributable to			

ADTRAN Holdings, Inc.	(267,688,000)	(2,037,000)	(8,635,000)
Weighted average shares outstanding - basic	78,416,000	62,436,000	48,582,000
Weighted average shares outstanding - diluted	78,416,000	62,436,000	48,582,000
Year end shares outstanding	78,674,000	77,889,000	49,063,000
Net earnings (loss) per common share - basic	\$(3.41)	\$(0.03)	\$(0.18)
Net earnings (loss) per common share - diluted	\$(3.41)	\$(0.03)	\$(0.18)
Dividends per common share	\$0.27	\$0.36	\$0.36
Number of full time employees	3,227	3,307	1,335
Number of common stockholders	47	45	149
Number of beneficiary stockholders		19,485	16,665
Foreign currency translation adjustments		53,396,000	(3,699,000)
Total revenues	1,149,100,000		
Goodwill Impairment	37,874,000		
Basic EPS Excluding ExtraOrdinary Items	\$(3.41)		
Diluted EPS Excluding ExtraOrd Items	\$(3.41)		
Total number of employees	3,227		

Reclassified to conform with 2022 presentation; Shares increased due to the effect issuance of shares for acquisition of ADVA, ADTRAN RSUs and restricted stock vested and options exercised; As of February 27, 2023; As of February 23, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	87,167,000	108,644,000
Short-term investments		340,000
Accounts receivables, gross	216,845,000	279,484,000
Less: allowance for doubtful accounts	400,000	49,000
Accounts receivable	216,445,000	279,435,000
Other receivables	17,450,000	32,831,000
Income tax receivable, net	7,933,000	
Raw materials	152,140,000	186,346,000
Work in process	17,239,000	12,087,000
Finished goods	192,916,000	229,098,000
Inventory	362,295,000	
Inventory, net		427,531,000
Prepaid expenses & other current assets	45,566,000	33,577,000
Total current assets	736,856,000	882,358,000
Engineering & other equipment	183,336,000	170,785,000
Building	79,215,000	82,932,000
Computer hardware & software	101,572,000	80,455,000
Building & land improvements	58,238,000	47,861,000
Furniture & fixtures	21,368,000	22,403,000
Land	5,242,000	5,364,000
Total property, plant & equipment	448,971,000	409,800,000
Less: accumulated depreciation - property, plant & equipment	325,951,000	299,101,000
Property, plant & equipment, net	123,020,000	110,699,000
Deferred tax assets, net	25,787,000	6,210,000
Goodwill	353,415,000	381,724,000
Intangibles, net	327,985,000	401,211,000

Other non-current assets	87,706,000	66,998,000
Long-term investments	27,743,000	32,665,000
Total assets	1,682,512,000	1,881,865,000
Accounts payable	162,922,000	237,699,000
Revolving credit agreements outstanding		95,936,000
Notes payable		24,598,000
Unearned revenue	46,731,000	41,193,000
Accrued expenses	37,607,000	
Accrued expenses & other liabilities		35,235,000
Accrued wages & benefits	27,030,000	44,882,000
Income tax payable, net	5,221,000	9,032,000
Accrued interest payable	29,887,000	
Current operating lease liability	7,720,000	
Total current liabilities	279,511,000	488,575,000
Deferred tax liabilities, net	35,655,000	
Non-current unearned revenue	25,109,000	19,239,000
Pension liability		10,624,000
Deferred compensation liability	29,039,000	26,668,000
Non-current lease obligations	31,420,000	22,807,000
Other non-current liabilities	28,657,000	10,339,000
Bonds payable	195,000,000	
Non-current pension liability	12,543,000	
Total liabilities	636,934,000	578,252,000
Common stock	790,000	781,000
Additional paid-in capital	795,304,000	895,834,000
Unrealized gains (losses) on available-for-sale securities	(382,000)	(836,000)
Defined benefit plan adjustments		(1,016,000)
Foreign currency adjustment	49,964,000	48,180,000
AUS 2018-02 adoption	47,461,000	385,000
Pension Liabilities - Comprehensive Income	(2,506,000)	
Comprehensive Income - Other	385,000	
Accumulated other comprehensive income (loss)		46,713,000
Retained (deficit) earnings	(243,908,000)	
Retained earnings		55,338,000
Treasury stock	5,825,000	
Less treasury stock at cost		4,125,000
Non-controlling interest	451,756,000	309,072,000
Total stockholders' equity	1,045,578,000	1,303,613,000
Total Equity	1,045,578,000	

Includes amount of available-for-sale securities - short-term investments: \$34,000; Includes amount of available-for-sale securities - short-term investments: \$8,913,000

Recent Dividends:**1. ADTRAN Holdings Inc common.**

ExDate	Amt	Declared	Record	Payable
08/17/2022	0.09	08/03/2022	08/18/2022	09/01/2022
11/21/2022	0.09	11/08/2022	11/22/2022	12/06/2022
03/06/2023	0.09	02/21/2023	03/07/2023	03/21/2023
05/22/2023	0.09	05/09/2023	05/23/2023	06/06/2023
08/18/2023	0.09	08/06/2023	08/21/2023	09/05/2023

Annual Dividends:**1. ADTRAN Holdings Inc common.**

2022	0.18	2023	0.27
------	------	------	------

AEROVATE THERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021 (revised)
Research & development	64,219	38,622	14,987
General & administrative	17,190	14,615	8,035
Total operating expenses	81,409	53,237	23,022
Income (loss) from operations	(81,409)	(53,237)	(23,022)
Interest income (expense)	...	1,830	65
Other expense	1	79	3
Interest income	5,945
Total other income (expense)	...	1,751	62
Net income (loss) before income taxes	(75,465)	(51,486)	(22,960)
Provision for income taxes	56	25	3
Net income (loss)	(75,521)	(51,511)	(22,963)
Weighted average shares outstanding - basic	26,332	24,472	12,294
Weighted average shares outstanding - diluted	26,332	24,472	12,294
Year end shares outstanding	27,763	24,723	24,410
Net earnings (loss) per share - basic	\$(2.87)	\$(2.10)	\$(1.87)
Net earnings (loss) per share - diluted	\$(2.87)	\$(2.10)	\$(1.87)
Number of full time employees	...	43	16
Number of common stockholders	13	13	9

¹ Including related party amounts of: \$76,000; ² Including related party amounts of: \$14,000; ³ As is; ⁴ As of March 28, 2022; ⁵ Approximately; ⁶ As of March 27, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	23,491	22,397
Short-term investments	98,948	106,823
Prepaid expenses & other current assets	1,793	2,276
Total current assets	124,232	131,496
Property & equipment, net	288	242
Operating lease right-of-use assets	614	1,003
Other long-term assets	2,284	2,560
Total assets	127,418	135,301
Accounts payable and accrued and other current liabilities	2,396	...
Accounts payable	...	2,575
Accrued research & development	9,285	2,751
Accrued payroll & other employee benefits	4,368	1,691
Other accrued expenses & current liabilities	...	380
Accrued expenses & other current liabilities	14,821	4,822
Operating lease liabilities	420	385
Prepaid expenses	1,168	...
Total current liabilities	17,637	7,782
Operating lease liabilities, net of current portion	255	705
Other liabilities	70	71
Total liabilities	17,962	8,558
Common stock	3	2
Additional paid-in capital	272,640	215,110
Accumulated other comprehensive income (loss)	237	(466)
Retained earnings		

(accumulated deficit)	(163,424)	(87,903)
Total stockholders' equity (deficit)	109,456	126,743
Total Equity	109,456	...

Recent Dividends:
1. Aerovate Therapeutics Inc common.
 No dividends paid.
Annual Dividends:
1. Aerovate Therapeutics Inc common.
 No dividends paid.

ALAUROS THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Collaboration revenue	5,000
Collaboration revenue	5,000	2,922,000	398,000
Research & development	16,279,000	25,018,000	49,643,000
General & administrative	12,219,000	13,142,000	27,564,000
Gain on lease modification	...	133,000	...
Property & equipment & right of use assets impairment	4,803,000	...	740,000
SubTotal	298,000
Restructuring costs	1,269,000
Total operating expenses	34,272,000	38,027,000	77,947,000
Income (loss) from operations	(34,267,000)	(35,105,000)	(77,549,000)
Interest expense	1,921,000	3,154,000	1,189,000
Other income (expense), net	(873,000)	529,000	(13,000)
Total other income (expense), net	...	(2,625,000)	(1,202,000)
Change in fair value of warrants	1,048,000
Net income (loss)	(35,140,000)	(37,730,000)	(78,751,000)
Net income (loss) applicable to common stockholders	...	(37,730,000)	(78,751,000)
Weighted average shares outstanding - basic	15,995,323	14,475,354	14,293,272
Weighted average shares outstanding - diluted	15,995,323	14,475,354	14,293,272
Year end shares outstanding	16,012,522	16,027,384	14,408,496
Net income (loss) per share - basic	\$(2.20)	\$(2.55)	\$(5.55)
Net income (loss) per share - diluted	\$(2.20)	\$(2.55)	\$(5.55)
Number of full time employees	...	34	41
Number of part time employees	...	0	0
Number of common stockholders	167	240	246
Income from cont operations before income tax	(35,140,000)
Earnings per share from continuing operations	\$(2.20)
Earnings per share from continuing operations	\$(2.20)

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-15 stock split, February 1, 2024; ³ As of February 15, 2023; ⁴ As of March 15, 2022; ⁵ Approximately; ⁶ As is

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022

Cash & cash equivalents	6,062,000	39,058,000
Restricted cash	...	13,938,000
Receivables	1,000	4,000
Prepaid expenses & other current assets	2,198,000	799,000
Total current assets	8,261,000	53,799,000
Office & computer equipment	15,000	2,183,000
Software	...	1,291,000
Leasehold improvements	...	9,561,000
Laboratory equipment	15,000	5,232,000
Property & equipment, gross	...	18,267,000
Less: accumulated depreciation	13,000	9,807,000
Property & equipment, net	2,000	8,460,000
Deposits	...	42,000
Right-of-use asset	...	2,136,000
Other non-current assets	...	500,000
Total assets	8,263,000	64,937,000
Accounts payable	616,000	1,389,000
Long-term debt, current	...	16,765,000
Clinical	568,000	2,200,000
Employee compensation	43,000	1,160,000
Preclinical services	...	198,000
Professional services	717,000	534,000
Manufacturing services	12,000	1,177,000
Other consulting services	...	16,000
Other accrued expenses	1,340,000	169,000
Accrued expenses	...	5,454,000
Lease liability, current	...	558,000
Total current liabilities	1,956,000	24,166,000
Lease liability, non-current	...	2,188,000
Other non-current liabilities	...	28,000
Total liabilities	1,956,000	26,382,000
Common stock	16,000	240,000
Additional paid-in capital	922,058,000	918,942,000
Accumulated deficit	(915,767,000)	...
Retained earnings (accumulated deficit)	...	(880,627,000)
Total stockholders' equity (deficit)	6,307,000	38,555,000
Total Equity	6,307,000	...

Recent Dividends:
1. Alauros Therapeutics Inc common.
 No dividends paid.
2. Alauros Therapeutics Inc series 1 preferred.
 No dividends paid.
Annual Dividends:
1. Alauros Therapeutics Inc common.
 No dividends paid.
2. Alauros Therapeutics Inc series 1 preferred.
 No dividends paid.

ALAUROS THERAPEUTICS INC
Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, RSM US LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of Alauros Therapeutics, Inc. (the Company) as of December 31, 2023 and 2022, the related statements of operations, stockholders' equity and cash flows for the years then ended, and the related notes to the financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. The Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations since inception and will be required to raise additional capital to fund operations. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

ALLEGRO MICROSYSTEMS INC

Earnings, 9 mos. to (Consol. – \$000):

	12/29/23	12/23/22
Total Revenues	808,786	704,208
Net Sales	628,439	564,005
Cost & expenses	180,347	140,203
Operating income	2,550	1,144
Interest income	1,581	1,062
Interest expense	30	2,597
Other income (expense), net	177,546	143,425
Foreign currency	17,584	17,943
Net before taxes	159,962	125,482
Income taxes		
Net income	\$0.83	\$0.66
Earnings common share	\$0.82	\$0.65
Primary		
Fully Diluted	194,925	193,101
Common Shares:		
Full Diluted	193,048	191,436
Year-end		

ALPHA TEKNOVA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Revenue	36,684	41,420	36,893
Revenue	36,684	41,420	36,893
Cost of sales	26,388	23,944	19,272
Gross profit	10,296	17,476	17,621
Research & development	5,567	7,737	4,312
Sales & marketing	9,330	9,151	3,777
General & administrative	25,450	28,298	20,392
Amortization of intangible assets	1,148	1,148	1,148
Goodwill impairment	...	16,613	...
Long-lived assets impairment	2,195	4,188	...
Tradename impairment	2,169
Total operating expenses	45,859	67,135	29,629
Income (loss) from operations	(35,563)	(49,659)	(12,008)
Interest income (expense), net	(833)	213	(589)
Other expenses, net	(142)	(55)	40
Loss on extinguishment of debt	(824)
Total other income (expenses), net	(1,515)	268	(629)
Income (loss) before income taxes	(37,078)	(49,391)	(12,637)
Current federal income taxes	6
Current state income taxes	...	7	3
Total current tax expense	6	7	3
Deferred federal income taxes	(279)	(2,055)	(2,604)
Deferred state income taxes	(25)	125	(233)
Total deferred income taxes	(304)	(1,930)	(2,837)
Provision for (benefit from) income taxes	(298)	(1,923)	(2,834)
Net income (loss)	(36,780)	(47,468)	(9,803)
Net income (loss) attributable to common stockholders	...	(47,468)	(9,803)
Weighted average shares outstanding - basic	31,820	28,084	16,088
Weighted average shares outstanding - diluted	31,820	28,084	16,088
Year end shares outstanding	40,794	28,179	28,012

Net earnings (loss) per share - basic	\$(1.16)	\$(1.69)	\$(0.61)
Net earnings (loss) per share - diluted	\$(1.16)	\$(1.69)	\$(0.61)
Number of full time employees	210	285	231
Number of part time employees	1	5	6
Total number of employees	211	290	237
Common Shareholders - Number	16
Number of stockholders	...	5	5

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	28,484	42,236
Accounts receivable, gross	3,968	4,283
Less: allowance for doubtful accounts	20	22
Accounts receivable, net	3,948	4,261
Finished goods, net	...	8,368
Work in process	47	186
Raw materials, net	...	3,693
Inventories - Finished Goods	8,573	...
Inventories - Raw Materials - Net	2,974	...
Inventories, net	11,594	12,247
Income taxes receivable	...	22
Prepaid expenses & other current assets	1,634	2,374
Total current assets	45,660	61,140
Machinery & equipment	30,082	19,433
Office furniture & equipment	842	628
Vehicles	291	229
Leasehold improvements	24,673	12,093
Property, plant & equipment, gross	55,888	32,383
Less: accumulated depreciation	7,528	4,520
Subtotal before construction in progress	...	27,863
Construction in progress	2,004	23,714
Property, plant & equipment, net	50,364	51,577
Operating lease right-of-use assets	16,472	19,736
Intangible assets, net	14,239	17,556
Other non-current assets	1,852	2,252
Total assets	128,587	152,261
Accounts payable	1,493	2,449
Payroll-related	3,826	2,796
Property, plant & equipment	...	1,966
Deferred revenue	16	198
Other current accrued liabilities	...	1,243
Accrued liabilities - Balancing value	709	...
Accrued liabilities	5,579	6,203
Current portion of operating lease liabilities	1,803	2,223
Other	1,028	...
Total current liabilities	8,875	10,875
Deferred tax liabilities	919	1,223
Long-term debt	13,251	21,976
Other accrued liabilities	102	191
Long-term operating lease liabilities	15,404	18,111
Total liabilities	38,551	52,376
Additional paid-in capital	181,822	154,891
Retained earnings

(accumulated deficit)	(91,786)	(55,006)
Common Stock	0	...
Total stockholders' equity (deficit)	90,036	99,885
Total stockholders equity	90,036	...

Recent Dividends:

1. Alpha Teknova Inc common.

No dividends paid.

Annual Dividends:

1. Alpha Teknova Inc common.

No dividends paid.

ALTENERGY ACQUISITION CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Operating & formation costs	180,000
Administration fee - related party	180,000	180,000	45,000
General & administrative expenses	1,689,526	1,352,260	595,595
Consulting Fees
CFO	234,000
Total expenses	2,283,526	1,532,260	640,595
Investment income earned on investment held in trust account	4,216,411	3,376,559	16,146
Transaction costs allocable to warrant liability	926,044
Excess fair value of private warrants over proceeds	4,080,000
Change in fair value of derivative warrants	...	12,591,000	17,270,000
Change in fair value of warrant liabilities	1,410,000
Interest expense	19,404
Income earned on cash and investment accounts	11,337
Total other income (expenses) - net	5,618,344	15,967,559	12,280,102
Net income before income tax provision	3,334,818	14,435,299	...
Current federal income taxes	...	630,066	...
Deferred federal income taxes	...	(239,426)	(134,525)
Change in valuation allowance	...	239,426	134,525
Income tax provision	861,417	630,066	...
Net income (loss)	2,473,401	13,805,233	11,639,507
Weighted average class A common stock outstanding - basic	...	23,000,000	4,175,385
Weighted average class B common stock outstanding - basic	...	5,750,000	5,750,000
Weighted average shares outstanding - basic	14,253,115
Weighted average class A common stock outstanding - diluted	...	23,000,000	4,175,385
Weighted average class B common stock outstanding - diluted	...	5,750,000	5,750,000
Weighted average shares outstanding - diluted	14,253,115

Year end shares outstanding	7,327,478	28,750,000	28,750,000
Net income (loss) per class A common stock - basic	...	\$0.48	\$1.17
Net income (loss) per class B common stock - basic	...	\$0.48	\$1.17
Net income (loss) per share - basic	\$0.17
Net income (loss) per class A common stock - diluted	...	\$0.48	\$1.17
Net income (loss) per class B common stock - diluted	...	\$0.48	\$1.17
Net income (loss) per share - diluted	\$0.17
Number of part time employees	...	3	3
Number of class A common stockholders	3	1	1

□ From February 9, 2021 (inception); □ Reclassified to conform with 2022 presentation; □ As of March 31, 2023; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Cash	74,974	212,232	
Prepaid expenses	153,498	379,264	
Income tax receivable	23,527	...	
Other investments held to maturity	108,610	...	
Total current assets	360,609	591,496	
Investments held in trust account	...	237,373,538	
Other assets	17,591,536	...	
Total assets	17,952,145	237,965,034	
Accounts payable & accrued expenses	127,368	470,200	
Other deferred expenses	2,224,846	12,815	
Due to related party	433,404	15,212	
Loan payable - sponsor	1,000,000	175,000	
Other accrued expenses	
deferred	340,791	...	
Total current liabilities	4,126,409	673,227	
Derivative warrant liabilities	940,000	1,399,000	
Deferred underwriting commission	8,050,000	8,050,000	
Total liabilities	13,116,409	10,122,227	
Class A common stock subject to possible redemption	17,700,146	236,385,597	
Class B common stock	550	575	
Accumulated deficit	(12,864,985)	...	
Retained earnings (accumulated deficit)	...	(8,543,365)	
Class B common stock Issued & Paid	25	...	
Total stockholder's equity (deficit)	(12,864,410)	(8,542,790)	
Total Equity	(12,864,410)	...	

Recent Dividends:

- AltEnergy Acquisition Corp class B common.**
No dividends paid.
- AltEnergy Acquisition Corp class A common.**
No dividends paid.
- AltEnergy Acquisition Corp class A common subject to redemption.**
No dividends paid.

Annual Dividends:

- AltEnergy Acquisition Corp class B common.**
No dividends paid.
- AltEnergy Acquisition Corp class A common.**
No dividends paid.
- AltEnergy Acquisition Corp class A common subject to redemption.**
No dividends paid.

ALTIGEN COMMUNICATIONS INC

Annual Report			
Consolidated Income Statement, Years Ended Sept. 30 (\$):			
	2023	2022	2021
Net revenue - hosted services	7,656,000	7,639,000	7,630,000
Net revenue - software assurance	1,551,000	1,867,000	2,283,000
Net revenue - professional service & other revenue	4,301,000	1,979,000	501,000
Net revenue - software license	173,000	406,000	576,000
Total net revenue	13,681,000	11,891,000	10,990,000
Cost of revenue - hosted services	3,119,000	2,971,000	2,941,000
Cost of revenue - professional services & other revenue	1,842,000	699,000	...
Cost of revenue - software license	72,000	128,000	133,000
Total cost of revenue	5,033,000	3,798,000	3,074,000
Gross profit (loss)	8,648,000	8,093,000	7,916,000
Research & development expenses	5,066,000	4,651,000	3,848,000
Sales & marketing expenses	1,664,000	1,507,000	2,074,000
General & administrative expenses	2,354,000	2,515,000	1,701,000
Litigation expenses	313,000
Total operating expenses	9,084,000	8,673,000	7,936,000
Income (loss) from operations	(436,000)	(580,000)	(20,000)
Gain on extinguishment of debt - Paycheck Protection Program ("PPP") loan forgiveness	804,000
Interest & other income	2,000	1,000	...
Interest expense	74,000
Income (loss) before income taxes	(508,000)	(579,000)	784,000
Provision for (benefit from) current state income taxes	60,000	15,000	(33,000)
Provision for (benefit from) current income taxes	...	15,000	(33,000)
Provision for (benefit from) deferred federal income taxes	1,713,000	49,000	1,332,000
Provision for (benefit from) deferred state income taxes	1,043,000	55,000	(24,000)
Provision for (benefit from) deferred income taxes	...	104,000	1,308,000
Provision for (benefit from) income taxes	2,816,000	119,000	1,275,000
Net income (loss)	(3,324,000)	(698,000)	(491,000)
Weighted average shares outstanding - basic	24,550,000	24,016,000	23,279,000
Weighted average shares outstanding - diluted	24,550,000	24,016,000	23,279,000
Year end shares outstanding	24,918,656	24,222,809	23,748,432
Net income (loss) per share - basic	\$(0.14)	\$(0.03)	\$(0.02)

Net income (loss) per share - diluted	\$(0.14)	\$(0.03)	\$(0.02)
Number of full time employees	...	75	61
Number of common stockholders	...	57	71
Number of beneficiary stockholders	...	1,972	1,766

□ Full-time equivalent

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):		
	2023	2022
Cash & cash equivalents	2,641,000	3,232,000
Accounts receivable, gross	1,426,000	1,190,000
Less allowance for doubtful accounts	40,000	75,000
Accounts receivables, net	1,386,000	1,115,000
Unbilled accounts receivables	109,000	105,000
Prepaid expenses & other current assets	236,000	206,000
Total current assets	4,372,000	4,658,000
Furniture & equipment	172,000	409,000
Computer software	98,000	105,000
Leasehold improvements	53,000	53,000
Total property & equipment	323,000	567,000
Less: accumulated depreciation & amortization	320,000	560,000
Property & equipment, net	3,000	7,000
Operating lease, right-of-use assets	301,000	572,000
Goodwill	2,725,000	2,725,000
Intangible assets, net	1,568,000	1,882,000
Capitalized software development costs, net	1,215,000	1,331,000
Deferred tax assets	3,737,000	6,493,000
Long-term deposit	...	37,000
Total assets	13,921,000	17,705,000
Accounts payable	58,000	53,000
Accrued compensation & benefits	417,000	364,000
Accrued expenses	455,000	530,000
Deferred consideration, current	510,000	500,000
Operating lease liabilities, current	324,000	383,000
Deferred revenue, current	477,000	566,000
Total current liabilities	2,241,000	2,396,000
Deferred consideration, long term	208,000	670,000
Operating lease liabilities, long-term	...	233,000
Deferred revenue, long-term	134,000	206,000
Total liabilities	2,583,000	3,505,000
Common stock	24,000	24,000
Treasury stock at cost	1,565,000	1,565,000
Additional paid-in capital	73,133,000	72,671,000
Retained earnings (accumulated deficit)	(60,254,000)	(56,930,000)
Total stockholders' equity	11,338,000	14,200,000

Recent Dividends:

- Altigen Communications Inc common.**
No dividends paid.

Annual Dividends:

- Altigen Communications Inc common.**
No dividends paid.

ALTIMMUNE INC

Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	2021
Revenues	426,000
Revenues	426,000	(68,000)	4,410,000

Total stockholders' equity (deficit).....	124,701	95,372	
Total Equity	124,701	...	

common stock, pre-funded warrants and common warrants, issuance of common stock per employee stock purchase plan; ⁽¹⁾ As is; ⁽²⁾ As of March 1, 2023; ⁽³⁾ As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	225,110	140,020
Short-term investments	34,606	102,637
Prepaid insurance	755
Prepaid research & development costs	2,617	3,805
Other prepaid expenses	760	678
Prepaid expenses	704	...
Other current assets	63	203
Prepaid expenses & other current assets	4,144	5,441
Total current assets	263,860	248,098
Restricted cash	1,032	1,032
Leasehold improvements	17,245	17,231
Laboratory equipment	1,832	1,764
Furniture & fixtures	692
Computer equipment & software	692	34
Computer equipment and software	33	...
Total property & equipment, gross	19,802	19,721
Less: accumulated depreciation	5,029	2,883
Property & equipment, net	14,773	16,838
Operating lease right-of-use assets	18,009	19,128
Total assets	297,674	285,096
Accounts payable	5,487	7,416
Accrued research & development expenses	4,027	7,720
Accrued compensation	5,607	5,299
Accrued professional services	501	394
Other accrued expenses	100	35
Accrued liabilities	10,235	13,448
Operating lease liabilities, current	2,165	1,316
Other current liabilities	41	180
Total current liabilities	17,928	22,360
Operating lease liabilities, non-current	29,190	31,542
Total liabilities	47,118	53,902
Common stock	78	48
Additional paid-in capital	823,029	669,780
Accumulated other comprehensive income (loss)	(52)	(372)
Retained earnings (accumulated deficit)	(572,499)	(438,262)
Total stockholders' equity (deficit)	250,556	231,194
Total Equity	250,556	...

Foreign currency gain (loss)	(38,926)	281,534	317,402
Total other income (loss)	1,185,207	730,201	319,050
Income (loss) before income taxes			
- foreign	(365,750)	(6,377,901)	(13,229,828)
Income (loss) before income taxes			
- domestic	(13,921,006)	(106,284,126)	(23,897,475)
Income (loss) before income taxes ..	(14,286,756)	(112,662,027)	(37,127,303)
Net income (loss)	(14,286,756)	(112,662,027)	(37,127,303)
Weighted average shares outstanding			
- basic	3,617,607	⁽¹⁾ 1,657,055	⁽²⁾ 1,064,325
Weighted average shares outstanding			
- diluted	3,617,607	⁽¹⁾ 1,657,055	⁽²⁾ 1,064,325
Year end shares outstanding	3,736,673	⁽¹⁾⁽³⁾ 2,655,269	⁽²⁾ 1,092,971
Net income (loss) per share - basic	\$(3.95)	⁽¹⁾ \$(67.99)	⁽²⁾ \$(34.88)
Net income (loss) per share - diluted	\$(3.95)	⁽¹⁾ \$(67.99)	⁽²⁾ \$(34.88)
Number of full time employees	7	9	16
Number of common stockholders	215	⁽¹⁾⁽²⁾ 170	⁽³⁾ 25
Foreign currency translation adjustments	(264,452)	...
Operating income	(15,471,963)
Sales of Goods & Services - Net	583,231
Total number of employees	7

Recent Dividends:
1. AN2 Therapeutics Inc common.
 No dividends paid.
Annual Dividends:
1. AN2 Therapeutics Inc common.
 No dividends paid.

ANGIODYNAMICS INC

Earnings, 9 mos. to (Consol. - \$000):

	02/29/24	02/28/23
Total Revenues	232,934	...
Net Sales	232,934	247,678
Cost & expenses	400,446	263,638
Operating income	(177,986)	(30,344)
Interest expense	(1,047)	1,801
Other income (expense), net	(558)	(427)
Net before taxes	(177,497)	(32,572)
Income taxes	(6,597)	(1,597)
Net income	(170,900)	(30,975)
Earnings common share		
Primary	\$(4.26)	\$(0.79)
Fully Diluted	\$(4.26)	\$(0.79)
Common Shares:		
Full Diluted	40,098	39,436
Year-end	40,425	39,606

ANNEXON INC

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	⁽¹⁾ 2021 (revised)
Research & development	113,756	112,501	100,066
General & administrative	29,967	33,098	30,647
Total operating expenses	143,723	145,599	130,713
Income (loss) from operations	(143,723)	(145,599)	(130,713)
Interest & other income, net	3,652	390
Other income, net	9,486
Income before income taxes - domestic	141,939	130,313
Income before income taxes - foreign	8	10
Net income (loss) before taxes	(134,237)	(141,947)	...
Net income (loss)	(134,237)	(141,947)	(130,323)
Net income (loss) attributable to common stockholders	(141,947)	(130,323)
Weighted average shares outstanding - basic	75,673	54,674	38,316
Weighted average shares outstanding - diluted	75,673	54,674	38,316
Year end shares outstanding	78,369	⁽²⁾ 47,723	38,561
Net income (loss) per share - basic	\$(1.77)	\$(2.60)	\$(3.40)
Net income (loss) per share - diluted	\$(1.77)	\$(2.60)	\$(3.40)
Number of full time employees	71	⁽³⁾ 80	⁽⁴⁾ 61
Number of common stockholders	28	⁽¹⁾⁽²⁾ 27	⁽³⁾ 51
Foreign currency translation adjustments	1	...
Total number of employees	71

Recent Dividends:
1. Annexon Inc common.
 No dividends paid.
Annual Dividends:
1. Annexon Inc common.
 No dividends paid.

APREA THERAPEUTICS INC

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	⁽¹⁾ 2021 (revised)
Research & development	7,627,491	16,402,273	23,895,875
General & administrative	8,427,703	20,969,771	13,550,478
Acquired in-process research & development	76,020,184	...
Total operating expenses	16,055,194	113,392,228	37,446,353
Interest income (expense), net	1,224,133	448,667	1,648

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	21,606,820	28,786,647
Prepaid expenses & other current assets	914,275	1,366,859
Total current assets	22,521,095	30,153,506
Lab equipment	133,226	40,133
Computer equipment	5,258	5,258
Total property & equipment, gross	138,484	45,391
Less: accumulated depreciation & amortization	50,122	43,070
Property & equipment, net	88,362	2,321
Other non-current assets	40,717	...
Total assets	22,650,174	30,155,827
Accounts payable	1,670,369	842,754
Professional fees	75,012
Compensation & benefits	1,016,960	1,397,977
Research & development	688,858
Other accrued liabilities	196,485
Accrued expenses - Balancing value	1,169,302	...
Accrued expenses	2,186,262	2,358,332
Deferred grant revenue	528,974	...
Total current liabilities	4,385,605	3,201,086
Total liabilities	4,385,605	3,201,086
Series A convertible preferred stock	1,311,063	1,311,063
Common stock	3,736	2,655
Additional paid-in capital	335,644,204	330,060,836
Accumulated other comprehensive income (loss)	(10,623,408)
Retained earnings (accumulated deficit)	(10,611,273)	(293,796,405)
Accumulated deficit	(308,083,161)	...

⁽¹⁾ Reclassified to conform with 2022 presentation; ⁽²⁾ Shares increased due to the effect of stock option exercises, issuance of

⁽¹⁾ Reclassified to conform with 2022 presentation; ⁽²⁾ Adjusted for 1-for-20 stock split, February 13, 2023; ⁽³⁾ Shares increased due to the effect of conversion of preferred stock into common stock; ⁽⁴⁾ As of March 28, 2023; ⁽⁵⁾ Approximately; ⁽⁶⁾ As of March 15, 2022

Total stockholders' equity (deficit)	16,953,506	25,643,678	discontinued operations before income tax	9,643,000	5,845,000	...	Machinery, fixtures & equipment	100,424,000	113,413,000
Total Equity	16,953,506	...	Benefit (provision) for income taxes on discontinued operations	(2,121,000)	(1,357,000)	...	Construction-in-progress	1,330,000	3,270,000
Recent Dividends:							Machinery, fixtures and equipment	93,758,000	...
1. Aprea Therapeutics Inc series B convertible preferred.							Property, plant & equipment, gross	...	123,054,000
No dividends paid.							Less accumulated depreciation	70,669,000	...
2. Aprea Therapeutics Inc common.							Less accumulated depreciation & amortization	...	80,708,000
No dividends paid.							Property, plant & equipment, net	29,755,000	42,346,000
3. Aprea Therapeutics Inc Series A convertible preferred.							Right-of-use assets, operating leases, net	27,784,000	29,224,000
No dividends paid.							Goodwill	...	11,389,000
4. Aprea Therapeutics Inc series C convertible preferred.							Intangible assets, net	8,496,000	10,387,000
No dividends paid.							Deferred income taxes	5,808,000	1,353,000
5. Aprea Therapeutics Inc series A convertible preferred.							Deferred charges, net	104,000	203,000
No dividends paid.							Other non-current assets	1,935,000	3,766,000
Annual Dividends:							Total assets	163,295,000	269,043,000
1. Aprea Therapeutics Inc series B convertible preferred.							Accounts payable	16,416,000	22,731,000
No dividends paid.							Accrued salaries, wages & commissions	1,706,000	2,344,000
2. Aprea Therapeutics Inc common.							Accrued taxes, other than income taxes	359,000	1,217,000
No dividends paid.							Advances from customers	...	304,000
3. Aprea Therapeutics Inc Series A convertible preferred.							Accrued insurance	...	553,000
No dividends paid.							Accrued professional fees	694,000	505,000
4. Aprea Therapeutics Inc series C convertible preferred.							Warranty reserve	...	59,000
No dividends paid.							Accrued benefit plans	...	426,000
5. Aprea Therapeutics Inc series A convertible preferred.							Customer rebate liability	...	194,000
No dividends paid.							Current portion of deferred compensation	427,000	...
ASCENT INDUSTRIES CO							Accrued interest	5,108,000	...
Annual Report							Accrued uncertain tax positions	243,000	...
Consolidated Income Statement, Years Ended Dec. 31 (\$):							Other accrued items	484,000	958,000
2023			2022			...	Accrued expenses & other current liabilities	1,129,000	6,560,000
(revised)							Current portion of note payable	360,000	387,000
Net sales	193,179,000	261,993,000	334,715,000				Current portion of long-term debt	...	2,464,000
Total revenues	193,179,000	261,993,000	...				Current portion of earn-out liability	4,000	...
Cost of sales	191,653,000	218,706,000	273,949,000				Current portion of operating lease liabilities	1,140,000	1,056,000
Gross profit	1,526,000	43,287,000	60,766,000				Current portion of finance lease liabilities	292,000	280,000
Selling, general & administrative expense	26,712,000	27,640,000	30,144,000				Advances from customers	62,000	...
Acquisition costs & other	855,000	1,104,000	1,001,000				Current liabilities of discontinued operations	1,473,000	...
Proxy contest costs & recoveries	168,000				Total current liabilities	24,789,000	33,478,000
Earn-out adjustments	1,872,000				Revolving line of credit	...	67,442,000
Asset impairment	233,000				Term loan	...	4,107,000
Goodwill impairment	11,389,000				Less: current portion	...	2,464,000
Operating income (loss)	(37,430,000)	14,543,000	27,348,000				Long-term portion of operating lease liabilities	29,729,000	30,911,000
Interest expense	4,238,000	2,742,000	1,486,000				Long-term portion of finance lease liabilities	1,307,000	1,242,000
Gain (loss) on extinguishment of debt	(223,000)				Other long-term liabilities	60,000	68,000
Change in fair value of interest rate swap	2,000				Total liabilities	55,885,000	134,784,000
Other income (expense), net	593,000	209,000	(143,000)				Common stock	11,085,000	11,085,000
Income (loss) before income taxes	(41,075,000)	12,010,000	25,498,000				Capital in excess of par value	47,333,000	47,021,000
Current income taxes provision (benefit) - federal	(561,000)	(189,000)	6,786,000				Retained earnings	58,517,000	...
Current income taxes provision (benefit) - state	191,000	137,000	538,000				Retained earnings (accumulated deficit)	...	85,146,000
Total current income taxes provision (benefit)	(370,000)	(52,000)	7,324,000				Less: cost of common stock in treasury	9,525,000	8,993,000
Deferred income taxes provision (benefit) - federal	(5,965,000)	(4,903,000)	(1,943,000)				Total shareholders' equity (deficit)	107,410,000	134,259,000
Deferred income taxes provision (benefit) - state	(589,000)	(613,000)	(128,000)				Rep Total Equity & Minority Interest	107,410,000	...
Total deferred income taxes provision (benefit)	(6,554,000)	(5,516,000)	(2,071,000)				Recent Dividends:		
Income tax provision (benefit)	(6,924,000)	(5,568,000)	5,253,000				1. Ascent Industries Co common.		
Net income (loss) from continuing operations	(34,151,000)	17,578,000	...				No dividends paid.		
Income (loss) from discontinued operations before income tax	9,643,000	5,845,000	...				Annual Dividends:		
Benefit (provision) for income taxes on discontinued operations	(2,121,000)	(1,357,000)	...						
Net income (loss)	(26,629,000)	22,066,000	20,245,000						
Weighted average shares outstanding - basic	10,140,000	10,230,000	9,340,000						
Weighted average shares outstanding - diluted	10,140,000	10,410,000	9,456,000						
Year end shares outstanding	11,085,103	11,085,103	10,166,632						
Income (loss) per share from continuing operations - basic	\$(3.37)	\$1.69	...						
Income (loss) per share from discontinued operations - basic	\$0.74	\$0.44	...						
Net income (loss) per share - basic	\$(2.63)	\$2.16	\$2.17						
Income (loss) per share from continuing operations - diluted	\$(3.37)	\$1.72	...						
Earn per share-inc from discount ops - diluted	\$0.74	\$0.43	...						
Income (loss) per share from discontinued operations - diluted	\$0.74	\$0.43	...						
Net income (loss) per share - diluted	\$(2.63)	\$2.12	\$2.14						
Number of full time employees	514	...	638						
Number of part time employees	69						
Total number of employees	514	...	707						
Number of common shareholders	338	...	368						
Earnings per share-total discontinued ops	\$0.74	\$0.44	...						
Cost of revenues/COGS	191,653,000	218,706,000	...						
□ Restated to reflect discontinued operations; □ As of March 28, 2022									
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):									
2023			2022						
(revised)									
Cash & cash equivalents	1,851,000	1,441,000	...						
Accounts receivable, gross	27,067,000						
Less allowance for doubtful accounts	463,000						
Accounts receivable, net	26,604,000	45,120,000	...						
Raw materials	21,020,000	57,518,000	...						
Work-in-process	13,711,000	22,966,000	...						
Finished goods	17,575,000	33,968,000	...						
Inventories	52,306,000						
Total inventories, net	...	114,452,000	...						
Prepaid expenses & other current assets	4,879,000	8,982,000	...						
Current assets of discontinued operations	861,000						
Assets held for sale	2,912,000	380,000	...						
Total current assets	89,413,000	170,375,000	...						
Land	723,000	723,000	...						
Leasehold improvements	3,079,000	4,114,000	...						
Buildings	1,534,000	1,534,000	...						

1. Ascent Industries Co common.

No dividends paid.

ASPEN GROUP INC**Annual Report****Consolidated Income Statement, Years Ended Apr. 30 (\$):**

2023 2022 2021

(revised)

Revenues

Cost of revenues

General & administrative expenses

Bad debt expense

Depreciation & amortization expense

Total operating expenses

Operating income (loss)

Other income (expense)

Interest expense

Total other income (expense), net

Income (loss) before income taxes

Current state income tax expense

Current foreign income tax expense

Current income tax expense

Income tax expense

Net income (loss)

Weighted average shares outstanding - basic

Weighted average shares outstanding - diluted

Year end shares outstanding

Net income (loss) per common share - basic

Net income (loss) per common share - diluted

Number of full time employees

Number of part time employees

Number of common stockholders

As of July 22, 2022; As of July 9, 2021

Consolidated Balance Sheet, Years Ended Apr. 30 (\$):

2023 2022

Cash & cash equivalents

Restricted cash

Accounts receivable, gross

Less: allowance

Accounts receivable, net

Prepaid expenses

Other current assets

Total current assets

Computer equipment & hardware

Furniture & fixtures

Leasehold improvements

Instructional equipment

Software

Construction in progress

Property & equipment, gross

Less: accumulated depreciation & amortization

Property & equipment, net

Goodwill

Intangible assets, net

Courseware, net

Long-term contractual accounts receivable

Deferred financing costs

Operating lease right of use assets, net

Deposits & other assets

Total assets

Accounts payable

Accrued compensation

Accrued foreign taxes

Accrued marketing

Accrued professional fees

Accrued interest

Other accrued expenses

Accrued expenses

Deferred revenue

Advances on tuition

Deferred tuition

Due to students

Operating lease obligations, current portion

Debt, current portion

Other current liabilities

Total current liabilities

Credit facility

Convertible notes

Less: unamortized deferred financing costs

Long-term debt, net

Operating lease obligations, less current portion

Total liabilities

Common stock

Additional paid-in capital

Treasury stock

Retained earnings (accumulated deficit)

Total stockholders' equity

Intangible asset

Total operating expenses

Income (loss) from operations

Interest income

Interest & other income, net

Total other income (expense)

Income (loss) before income taxes

Federal income tax expense (benefit) - deferred

Federal income tax expense (benefit)

State income tax expense (benefit) - deferred

State income tax expense (benefit)

Income Taxes - Federal

Income Taxes - Total - Current

Income tax expense (benefit)

Net income (loss)

Weighted average shares outstanding - basic

Weighted average shares outstanding - diluted

Year end shares outstanding

Net income (loss) per share - basic

Net income (loss) per share - diluted

Number of employees

Number of common stockholders

Earnings per share from continuing operations

Earnings per share from continuing operations

Total number of employees

Recent Dividends:**1. Aspen Group Inc common.**

No dividends paid.

Annual Dividends:**1. Aspen Group Inc common.**

No dividends paid.

ASPEN GROUP INC**Earnings, 6 mos. to Oct 31 (Consol. - \$):**

2023 2022

Total Revenues

Cost & expenses

Operating income

Other income (expense), net

Net before taxes

Income taxes

Net income

Earnings common share - Primary

Fully Diluted

Common Shares: - Full Diluted

Year-end

[□] Adjusted for 1- for -12 stock split, February 12, 2024; [□] Shares increased due to the issuance of common shares under ATM equity offering program and ESPP, and for settlement of RSUs and upon cashless exercise of pre-funded warrants; [□] As of March 20, 2023; [□] As of February 28, 2022**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

2023 2022

Cash & cash equivalents

Marketable securities - short-term

Accounts receivable from collaborations

Prepaid expenses & other current assets

Total current assets

Lab equipment

Office equipment

Leasehold improvement

Total property & equipment

Less: accumulated depreciation

Property & equipment, net

Operating lease right-of-use assets

Other assets

Total assets

Accounts payable

Accrued research & development expenses	3,122,000	expense	(220,996,000)	(102,496,000)	(72,930,000)	Property & equipment, gross	43,474,000
Accrued compensation	5,484,000	Current foreign income tax expense	2,576,000	617,000	331,000	Less: Accumulated depreciation	61,173,000
Accrued restructuring charges	599,000	Current income tax expense	2,576,000	617,000	331,000	Construction in progress	6,979,000
Accrued professional fees & other accrued expenses	260,000	Deferred foreign income taxes - Total - Deferred	(895,000)	- Other	6,696,000
Accrued research & development expenses	885,000	Income Tax expense	1,681,000	617,000	331,000	Other construction in progress	5,256,000
Other accrued expenses	5,744,000	Net income (loss) before allocation to noncontrolling interest	(222,677,000)	(103,113,000)	(73,261,000)	Construction in progress - BB satellite materials	10,721,000
Deferred revenue - short-term	30,915,000	Net income (loss) attributable to noncontrolling interest	135,116,000	71,473,000	42,708,000	Property & equipment, net	53,912,000
Operating lease liabilities - short-term	1,220,000	Net income (loss) attributable to common stockholders	(87,561,000)	(31,640,000)	(30,553,000)	Total property & equipment, net	238,478,000
Total current liabilities	39,225,000	Weighted average common class A shares outstanding	81,824,122	54,437,073	51,729,785	Other non-current assets	2,311,000
Deferred revenue - long-term	55,379,000	- basic	81,824,122	54,437,073	51,729,785	Total other non-current assets	24,073,000
Operating lease liabilities - long-term	1,122,000	Weighted average common class A shares outstanding - diluted	218,366,144	200,024,761	181,530,904	Total assets	360,892,000
Total liabilities	95,726,000	Year end shares outstanding	218,366,144	200,024,761	181,530,904	Operating lease right-of-use assets, net	13,221,000
Common stock	5,000	Net earning (loss) per common class A share - basic	\$(1.07)	\$(0.58)	\$(0.37)	Accounts payable	20,575,000
Additional paid-in capital	826,921,000	Net earning (loss) per common class A share - basic	\$(1.07)	\$(0.58)	\$(0.37)	Accrued payroll liabilities	2,357,000
Accumulated other comprehensive income (loss)	(81,000)	Full-Time Employees (Period End)	272	Accrued research & development	3,855,000
Retained earnings (accumulated deficit)	(785,748,000)	Total number of employees	272	342	386	Accrued construction in progress	1,796,000
Total stockholders' equity (deficiency)	41,097,000	Number of class A common stockholders	...	21	22	Deferred other income	2,499,000
Total Equity	41,097,000	Number of class B common stockholders	...	6	...	Accrued professional services	23,926,000
		Number of class C common stockholders	...	1	...	Other accrued expenses	2,638,000
		Foreign currency translation adjustments	...	(295,000)	...	Accrued expenses & other current liabilities	13,145,000
		Common Shareholders - Number	25	Current operating lease liabilities	1,468,000
						Current Portion of Long-Term Debt	252,000
						Total current liabilities	46,221,000
						Warrant liabilities	29,960,000
						Non-current operating lease liabilities	11,900,000
						Long-term debt	59,252,000
						Total liabilities	147,333,000
						Class A common stock	9,000
						Class B common stock	8,000
						Class C common stock	5,000
						Additional paid-in capital	288,404,000
						Accumulated other comprehensive income (loss)	227,000
						Accumulated Deficit	(189,662,000)
						Retained earnings (accumulated deficit)	(102,101,000)
						Noncontrolling interest	114,568,000
						Total stockholders' equity	213,559,000
						Total Equity	213,559,000

Recent Dividends:

1. **Assembly Biosciences Inc series A non-voting convertible preferred.**
No dividends paid.
2. **Assembly Biosciences Inc common.**
No dividends paid.

Annual Dividends:

1. **Assembly Biosciences Inc series A non-voting convertible preferred.**
No dividends paid.
2. **Assembly Biosciences Inc common.**
No dividends paid.

AST SPACEMOBILE INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenues	13,825,000	12,405,000	
Cost of sales (exclusive of items shown separately below)	6,714,000	7,563,000	
Gross profit	7,111,000	4,842,000	
Engineering services	78,811,000	54,212,000	29,599,000
General & administrative costs	41,601,000	48,332,000	35,636,000
Research & development costs	47,486,000	45,620,000	23,440,000
Depreciation & amortization	54,469,000	4,711,000	2,913,000
Total operating expenses	222,367,000	152,875,000	91,588,000
Gain on remeasurement of warrant liabilities	8,986,000	19,114,000	15,766,000
Other income (expense), net	(10,290,000)	24,154,000	(1,950,000)
Interest income	2,675,000
Total other income, net	1,371,000	43,268,000	13,816,000
Income (loss) before income tax expense - United States	(230,487,000)	(98,774,000)	(70,396,000)
Income (loss) before income tax expense - Foreign	9,491,000	(3,722,000)	(2,534,000)
Income (loss) before income tax

¹ Reclassified to conform with 2022 presentation; ² Approximately; ³ As of March 28, 2023; ⁴ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	85,622,000	238,588,000
Restricted cash	2,475,000	668,000
Prepaid expenses	4,591,000	4,100,000
Other current assets	14,194,000	24,954,000
Total current assets	106,882,000	268,310,000
BlueWalker 3 satellite - construction in progress	...	92,077,000
Land	1,350,000	1,350,000
Buildings	14,555,000	10,268,000
Others property & equipment	299,651,000	1,707,000
Computer, software & equipment	11,112,000	3,153,000
Leasehold improvements	9,111,000	8,197,000
Satellite antenna	7,188,000	5,142,000
Lab, assembly & integration equipment	31,957,000	13,657,000
Others	1,230,000	...
Satellite materials, satellites under construction, and advance launch payments	125,428,000	...
Satellite in orbit	92,464,000	...

Recent Dividends:

1. **AST SpaceMobile Inc class A common subject to possible redemption.**
No dividends paid.
2. **AST SpaceMobile Inc class A common.**
No dividends paid.
3. **AST SpaceMobile Inc class B common.**
No dividends paid.
4. **AST SpaceMobile Inc class C common.**
No dividends paid.

Annual Dividends:

1. **AST SpaceMobile Inc class A common subject to possible redemption.**
No dividends paid.
2. **AST SpaceMobile Inc class A common.**
No dividends paid.
3. **AST SpaceMobile Inc class B common.**
No dividends paid.
4. **AST SpaceMobile Inc class C common.**
No dividends paid.

ASTRONOVA INC
Annual Report
Consolidated Income Statement, Years Ended Jan. 31 (\$):

other current liabilities	...	325	outstanding	39,151	33,394	30,385	liabilities, current	1,878	2,130	
Accrued expenses & other			Net income (loss)				Deferred revenue, current	25,976	22,912	
current liabilities	7,883	4,573	per share - basic	\$(1.66)	\$(1.62)	\$(1.07)	Other current liabilities	486	...	
Other	935	...	Net income (loss)				ESPP Withholding	426	...	
Total current liabilities	12,357	10,457	per share - diluted	\$(1.66)	\$(1.62)	\$(1.07)	Total current liabilities	57,087	56,274	
Long-term operating lease liability	16,870	17,895	Number of full time employees	381	393	270	Finance lease liabilities & lease financing obligations, non-current	13,310	15,487	
Total liabilities	29,227	28,352	Number of class A common stockholders	...	18	15	Operating lease liabilities, non-current	8,151	5,032	
Additional paid-in capital	512,617	406,555	Number of class B common stockholders	...	40	80	Deferred revenue, non-current	4,073	2,611	
Retained earnings (accumulated deficit)	(287,308)	(210,900)	Common Shareholders - Number	20	Debt facility, non-current	4,128	4,306	
Accumulated other comprehensive income (loss)	539	(72)	Total number of employees	381	Total liabilities	86,749	83,710	
Total stockholders' equity (deficit)	225,848	195,583	<p>¹ Shares increased due to the conversion of convertible preferred share to class B common share; ² As is; ³ As of February 28, 2023; ⁴ As of February 28, 2022</p>					Class A common stock	4	2
Total Equity	225,848	...						Class B common stock	...	2

Recent Dividends:**1. Aura Biosciences Inc common.**
No dividends paid.**Annual Dividends:****1. Aura Biosciences Inc common.**
No dividends paid.**BACKBLAZE INC**
Annual Report**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021 (revised)
Revenue	102,019	85,155	67,479
Cost of revenue	52,162	41,292	33,138
Gross profit	49,857	43,863	34,341
Research & development expenses	39,527	33,107	20,536
Sales & marketing expenses	41,270	35,399	19,698
General & administrative expenses	26,965	23,470	12,901
Total operating expenses	107,762	91,976	53,135
Income (loss) from operations	(57,905)	(48,113)	(18,794)
Investment income	1,984	965	...
Interest expense, net	3,792	4,289	3,677
Gain (loss) on extinguishment of debt	2,299
Realized gain (loss) on Simple Agreement for Future Equity ("SAFE")	1,436
Income (loss) before provision for income taxes - United States	...	(51,437)	(21,608)
Income (loss) before provision for income taxes - Current state	(59,713)	(51,437)	(21,608)
income taxes	...	(1)	58
Total current income taxes	...	(1)	58
Deferred federal income taxes	...	(38)	38
Total deferred income taxes	...	(38)	38
Income tax provision (benefit)	...	(39)	96
Net income (loss)	(59,713)	(51,398)	(21,704)
Weighted average shares outstanding - basic	36,011	31,662	20,346
Weighted average shares outstanding - diluted	36,011	31,662	20,346
Year end shares			

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	12,502	6,690
Accounts receivable, net	800	856
Short-term investments	16,799	58,733
Unbilled accounts receivable	2,375	1,637
Prepaid expenses	2,313	1,288
Prepaid subscriptions	...	1,312
Prepaid Physical Media
Hardware	...	246
Capitalized commissions	...	365
Receivable from payment processor	1,276	644
Financed prepaid insurance	1,001	1,545
Deposits	1,448	...
Other prepaid expenses & other current assets	...	1,083
Prepaid expenses & other current assets	8,413	8,120
Total current assets	38,514	74,399
Restricted cash, non-current	4,128	4,306
Data center equipment	37,245	28,531
Leased & financed data center equipment	68,757	62,300
Machinery & equipment	14,004	11,613
Computer equipment	2,472	2,503
Leasehold improvements	1,114	1,268
Construction-in-process	1,371	3,636
Total property & equipment	124,963	109,851
Less: accumulated depreciation	79,363	60,476
Property & equipment, net	45,600	49,375
Operating lease right-of-use assets	9,980	6,881
Capitalized internal-use software, net	32,521	16,704
Other assets	944	793
Total assets	131,687	152,458
Accounts payable	2,281	3,283
Accrued compensation	4,105	2,728
Employee Stock Purchase Plan withholding	...	415
Accrued expenses	1,284	2,881
Accrued sales taxes	...	208
Accrued value-added tax	...	1,220
Financed insurance premiums	893	1,545
Other accrued expenses & other current liabilities	...	421
Accrued expenses & other current liabilities	8,460	9,418
Accrued value-added tax ("VAT") liability	1,266	...
Finance lease liabilities & lease financing obligations, current	18,492	18,531
Operating lease		

liabilities, current	1,878	2,130
Deferred revenue, current	25,976	22,912
Other current liabilities	486	...
ESPP Withholding	426	...
Total current liabilities	57,087	56,274
Finance lease liabilities & lease financing obligations, non-current	13,310	15,487
Operating lease liabilities, non-current	8,151	5,032
Deferred revenue, non-current	4,073	2,611
Debt facility, non-current	4,128	4,306
Total liabilities	86,749	83,710
Class A common stock	4	2
Class B common stock	...	2
Additional paid-in capital	192,388	156,485
Accumulated deficit	(147,454)	...
Retained earnings (accumulated deficit)	...	(87,741)
Total stockholders' equity (deficit)	44,938	68,748
Total Equity	44,938	...

Recent Dividends:**1. Backblaze Inc class B common.**

No dividends paid.

2. Backblaze Inc class A common.

No dividends paid.

Annual Dividends:**1. Backblaze Inc class B common.**

No dividends paid.

2. Backblaze Inc class A common.

No dividends paid.

BAKHU HOLDINGS CORP**Earnings, 6 mos. to Jan 31 (Consol. - \$):**

	2024	2023
Cost & expenses	1,367,761	6,683,539
Operating income	(1,434,597)	(6,750,375)
Interest expense	140,639	95,493
Other income (expense), net	323,078	...
Gains or losses	...	(65,748)
Net income	(1,252,158)	(6,911,616)
Earnings common share		
Primary	\$(0.02)	\$(0.02)
Fully Diluted	\$(0.02)	\$(0.02)
Common Shares:		
Full Diluted	301,302,983	301,290,592
Year-end	301,302,983	301,302,983

BASSETT FURNITURE INDUSTRIES, INC**Earnings, 3 mos. to (Consol. - \$000):**

	03/02/24	02/25/23
Total Revenues	86,554	...
Cost & expenses	88,911	104,996
Operating income	(2,357)	2,702
Interest income	756	...
Other income (expense), net	(104)	(415)
Net before taxes	(1,705)	2,287
Income taxes	(512)	842
Net income	(1,193)	1,445
Earnings common share		
Primary	\$(0.14)	\$0.16
Fully Diluted	\$(0.14)	\$0.16
Common Shares:		
Full Diluted	8,741	8,897
Year-end	8,776	8,862

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2024
Cash & equivalents	40,609
Inventories	62,957
Current assets	149,505
Net property & equip.	83,590
Total assets	361,445
Liabilities:	
Current liabilities	73,285
Stockholders' equity	180,638
Net current assets	76,220

BIOATLA INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):				Property & equipment, gross			operations before income tax		
	2023	2022	2021						
Collaboration & other revenue	250	7,681	8,092	...	(117,255)
Research & development expense	103,731	79,347	58,274	Less: accumulated depreciation & amortization	6,078	5,364	Total number of employees	103	...
General & administrative expense	25,956	28,793	38,416	Property & equipment, net	1,603	2,728	☐ Shares increased due to the effect of issuance of common stock, conversion of series A convertible preferred stock, issuance of restricted stock, exercise of options and purchases under employee stock; ☑ As is; ☒ As of March 21, 2023; ☓ As of February 21, 2022		
Total operating expenses	129,687	108,140	96,690	Operating lease right-of-use-asset, net	1,495	2,423	Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):		
Income (loss) from operations	(129,687)	(108,140)	(96,440)	Other assets	154	154	2023	2022	
Interest income	6,312	1,648	350	Total assets	119,658	225,736	Cash & cash equivalents	176,866	111,899
Interest expense	3	Accounts payable	3,819	4,231	Short-term investments	...	1,150
Gain (loss) on extinguishment of long-term debt	690	Accrued compensation	3,790	3,451	Prepaid expenses & other current assets	2,315	4,770
Other income (expense)	(87)	10	1	Accrued research & development	...	12,649	Total current assets	179,181	117,819
Total other income (expense)	6,225	1,658	1,038	Other accrued expenses	...	1,279	Laboratory equipment	3,852	2,331
Consolidated net income (loss)	(123,462)	(106,482)	(95,402)	Accounts payable and accrued expenses - Balancing value	19,111	...	Computer equipment	130	130
Net income (loss) attributable to BioAtla LLC or BioAtla, Inc.	...	(106,482)	(95,402)	Operating lease liabilities	1,624	1,521	Furniture & fixtures	409	325
Weighted average shares outstanding - basic	47,778	38,927	34,561	Total current liabilities	28,344	23,131	Leasehold improvements	3,195	801
Weighted average shares outstanding - diluted	47,778	38,927	34,561	Operating lease liabilities, less current portion	836	2,460	Construction in progress	4	3,170
Year end units outstanding	48,078	☐47,548	37,291	Liability to licensor	19,806	19,806	Total property & equipment, gross	7,590	6,757
Net earnings (loss) per common share - basic	\$(2.58)	\$(2.74)	\$(2.76)	Total liabilities	48,986	45,397	Less: accumulated depreciation	2,431	916
Net earnings (loss) per common share - diluted	\$(2.58)	\$(2.74)	\$(2.76)	Common stock	5	5	Property & equipment, net	5,159	5,841
Number of full time employees	65	Additional paid-in capital	486,930	473,135	Restricted cash	370	351
Total number of employees	65	☑66	☑56	Retained earnings (accumulated deficit)	(416,263)	(292,801)	Other assets	5,503	3,145
Number of common stockholders	...	☑☑26	☑☑16	Total stockholders' equity (deficit)	70,672	180,339	Operating lease right-of-use assets	9,714	2,151
Number of class B common stockholders	...	☑☑0	☑☑2	Total members' or stockholders' deficit	70,672	...	Total assets	199,927	129,307
Income from cont operations before income tax	(123,462)	Recent Dividends:			Accounts payable	6,851	6,826
Earnings per share from continuing operations	\$(2.58)	1. BioAtla Inc common.			Accrued research & development materials & services	6,952	6,039
Earnings per share from continuing operations	\$(2.58)	No dividends paid.			Accrued professional services	443	208
Common Shareholders - Number	28	2. BioAtla Inc class B common.			Accrued personnel expenses	...	4,774
				No dividends paid.			Other accrued expenses & current liabilities	...	636
				Annual Dividends:			Accrued compensation	5,956	...
				1. BioAtla Inc common.			Accrued expenses & other current liabilities	13,543	11,657
				No dividends paid.			Short-term operating lease liabilities	2,466	618
				2. BioAtla Inc class B common.			Other Current Liabilities	192	...
				No dividends paid.			Total current liabilities	22,860	19,101
				BIOMEA FUSION INC			Long-term operating lease liabilities	7,830	1,667
				Annual Report			Total liabilities	30,690	20,768
				Consolidated Income Statement, Years Ended Dec. 31 (\$000):			Common stock	4	3
	2023	2022	2021	Research & development	102,546	62,713	Additional paid-in capital	418,058	240,107
			(revised)	General & administrative	23,589	20,921	Accumulated other comprehensive income (loss)	...	(1)
				Total operating expenses	...	83,634	Retained earnings (accumulated deficit)	(248,825)	(131,570)
				Income (loss) from operations	(126,135)	(83,634)	Total stockholders' equity (deficit)	169,237	108,539
				Interest & other income (loss), net	8,880	1,806	Total Equity	169,237	...
				Net income (loss)	(117,255)	(81,828)	Recent Dividends:		
				Weighted average shares outstanding - basic	34,107	29,272	1. Biomea Fusion Inc common.		
				Weighted average shares outstanding - diluted	34,107	29,272	No dividends paid.		
				Year end shares outstanding	35,867	29,562	Annual Dividends:		
				Net earnings (loss) per share - basic	\$(3.44)	\$(2.80)	1. Biomea Fusion Inc common.		
				Net earnings (loss) per share - diluted	\$(3.44)	\$(2.80)	No dividends paid.		
				Number of full time employees	103	☑83	BIORA THERAPEUTICS INC		
				Number of common stockholders	40	☑☑46	Annual Report		
				Income from cont			Consolidated Income Statement, Years Ended Dec. 31 (\$000):		
							2023	2022	☐2021
							(revised)		
							Revenues	4	...
							Revenues	4	305
							Research & development expenses	29,838	24,049
								45,785	

				Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):								
				2023		2022						
Selling, general & administrative	37,309	38,037	73,299	☐ Reclassified to conform with 2022 presentation; ☑ Adjusted for 1-for-25 stock split, January 3, 2023; ☒ Shares increased due to the issuance of common shares under employee stock purchase plan, under vesting of restricted stock units and conversion of interest; ☓ Stocks increased due to issuance of common stock, stock options and warrants exercised, issuance upon vesting of restricted stock units and upon conversion of debt; ☔ As is; ☕ Approximately; ☖ As of March 20, 2023; ☗ As of March 15, 2022			Senior secured convertible notes, net	14,591	...			
Total operating expenses	67,147	62,086	119,084				Cash & cash equivalents	15,211	30,486	Total liabilities	132,636	155,812
Income (loss) from operations	(67,143)	(61,781)	(117,837)				Income tax receivable	830	828	Common stock	25	8
Interest expense	9,815	10,990	12,636				Prepaid expenses	2,443	3,634	Additional paid in capital	868,591	743,626
Gain (loss) on warrant liability	18,004	20,904	(54,157)				Other current assets	587	565	Accumulated deficit	(950,958)	...
Other income (expense), net	(65,470)	2,617	5,990				Prepaid expenses & other current assets	3,030	4,199	Retained earnings (accumulated deficit)	...	(826,843)
Income (loss) before income taxes	(124,424)	(49,250)	(178,640)				Current assets of disposal group held for sale	...	2,603	Treasury stock	19,079	...
Current federal income tax expense (benefit)	...	(546)	...				Total current assets	19,071	38,116	Treasury stock - at cost	...	19,078
Current state income tax expense (benefit)	(15)	(347)	...				Computers & software	1,193	2,715	Total stockholders' equity (deficit)	(101,421)	(102,287)
Current foreign income tax expense (benefit)	...	126	...				Building & leasehold improvements	3,263	750	Total Equity	(101,421)	...
Total current income tax expense (benefit)	(15)	(767)	...				Laboratory equipment	423	958	☐ Net of unamortized discount - convertible notes: \$4,914,000		
Deferred federal income tax expense (benefit)	(75)	347	(119)				Furniture, fixtures, & office equipment	799	1,138	Recent Dividends:		
Total deferred income tax expense (benefit)	(75)	347	(119)				Construction in progress	45	92	1. Biora Therapeutics Inc common.		
Income tax expense (benefit)	(90)	(420)	(119)				Building and leasehold improvements	803	...	No dividends paid.		
Income (loss) from continuing operations	(124,334)	(48,830)	(178,521)				Total property & equipment, gross	...	5,653	Annual Dividends:		
Income (loss) from discontinued operations	219	10,673	(68,891)				Less: accumulated depreciation & amortization - property & equipment	...	3,999	1. Biora Therapeutics Inc common.		
Net income (loss)	(124,115)	(38,157)	(247,412)				accumulated depreciation and amortization	2,107	...	No dividends paid.		
Weighted average shares outstanding - basic	15,773	7,635	☒3,846	Property & equipment, net	1,156	1,654	BIOSIG TECHNOLOGIES INC					
Weighted average shares outstanding - diluted	15,773	7,635	☒3,846	Right-of-use assets	1,614	1,482	Annual Report					
Year end shares outstanding	27,838	☒8,928	☒☒7,275	Other assets	3,302	6,201	Consolidated Income Statement, Years Ended Dec. 31 (\$):					
Net income (loss) per share from continuing operations - basic	\$(7.88)	\$(6.40)	☒\$(46.42)	Goodwill	6,072	6,072	2023 2022 2021					
Earnings per share-inc from discontinued oper	\$0.01	Total assets	31,215	53,525	Product sales	...	254,000			
Net income (loss) per share from discontinued operations - basic	\$0.01	\$1.40	☒\$(17.91)	Accounts payable	2,843	3,606	Service	18,000	32,000			
Net income (loss) per share - basic	\$(7.87)	\$(5.00)	☒\$(64.33)	Accrual for reimbursement claims & settlements, current	6,337	8,372	Revenue	18,000	286,000			
Net income (loss) per share from continuing operations - diluted	\$(7.88)	\$(6.40)	☒\$(46.42)	Commissions & bonuses	2,469	1,433	Cost of goods sold	...	57,000			
Earn per share-inc from discount oper	\$0.01	Vacation & payroll benefits	1,367	1,724	Gross profit	18,000	229,000			
Net income (loss) per share - diluted	\$(7.87)	\$(5.00)	☒\$(64.33)	Accrued professional services	2,914	307	Research & development	5,092,000	5,821,000			
Number of full time employees	58	☒54	☒124	Accrued interest	17,319	890	General & administrative expenses	23,077,000	21,380,000			
Total number of employees	58	☒54	☒124	Lease liabilities, current	896	893	Depreciation & amortization	361,000	293,000			
Number of common stockholders	50	☒☒50	☒☒50	Insurance financing	401	445	Total operating expenses	28,530,000	27,494,000			
				Contract liabilities	542	47	Income (loss) from operations	(28,512,000)	(27,265,000)			
				Other accrued expenses & other current liabilities	...	2,050	Interest Income	9,000	...			
				Accrued expenses & other current liabilities	...	16,161	Interest expense (expense), net	(187,000)	3,000			
				Warrant liabilities	40,834	3,538	Gain on settlement of debt	...	553,000			
				Current liabilities of disposal group held for sale	2,220	...	Income (loss) before income taxes	(28,690,000)	(27,262,000)			
				Related party senior secured convertible notes, current portion	1,976	...	Net income (loss)	(28,690,000)	(27,262,000)			
				Accrued interest	173	...	Non-controlling interest	(351,000)	210,000			
				Total current liabilities	62,972	23,305	Net income (loss) attributable to biosig technologies, inc.	(29,041,000)	(27,052,000)			
				Mortgages payable, net of current portion	19,179	...	Preferred stock dividend	9,000	9,000			
				Convertible notes, net	9,966	☒127,811	Preferred stock deemed dividend	...	210,000			
				Embedded derivative liability	22,899	...	Net income (loss) attributable to common shareholders	(29,050,000)	(27,271,000)			
				Lease liabilities, net of current portion	818	601	Weighted average shares outstanding - basic	7,351,794	☒4,263,260			
				Other long-term liabilities	2,211	4,095	Weighted average shares outstanding - diluted	7,351,794	☒4,263,260			
				Other long-term liabilities	3,029	4,696	Year end shares outstanding	9,040,043	☒☒5,461,064			
							Net income (loss) per share - basic	\$(3.95)	☒\$(6.40)			
							Net income (loss) per share - diluted	\$(3.95)	☒\$(6.40)			
							Number of full time employees	...	☒47			
							Number of common stockholders	392	☒☒325			
							EPS - Basic - excluding	...	☒290			

Extraordinary Items			
Applicable to			
Common - Total	\$(3.95)
EPS - Diluted -			
excluding			
Extraordinary Items			
Applicable to			
Common - Total	\$(3.95)

[¶] Adjusted for 1-for-10 stock split, February 2, 2024; [§] Shares increased due to the effect of common stock issued for services, sale of common stock and warrants, sale of common stock under At-the-market offering, common stock issued upon exercise of warra; [¶] As of March 30, 2023; [§] As of March 30, 2022; [¶] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Cash	190,000	357,000	
Accounts receivable	24,000	9,000	
Employee advance	5,000	...	
Inventory, short term	...	336,000	
Net investment in leases, short term	103,000	101,000	
Prepaid expenses & vendor deposits	206,000	325,000	
Total current assets	528,000	1,128,000	
Computer equipment	531,000	397,000	
Furniture & fixtures	109,000	109,000	
Machinery & Equipment	372,000	372,000	
Testing or demo equipment	356,000	304,000	
Leasehold improvements	84,000	84,000	
Property & equipment, gross	1,452,000	1,266,000	
Less: accumulated depreciation	943,000	601,000	
Property & equipment, net	509,000	665,000	
Right-to-use assets, net	412,000	705,000	
Inventory, long term	...	1,141,000	
Net investment in leases, long term	17,000	120,000	
Patents, net	288,000	307,000	
Other assets	44,000	44,000	
Total assets	1,798,000	4,110,000	
Accrued accounting & legal	...	646,000	
Accrued reimbursements & travel	9,000	33,000	
Accrued consulting	804,000	546,000	
Accrued research & development expenses	802,000	625,000	
Accrued marketing	333,000	256,000	
Accrued office & other	290,000	220,000	
Accrued payroll	601,000	513,000	
Accrued settlement related to arbitration	1,277,000	13,000	
Stock based payable	4,116,000	...	
Deferred revenue, short term	...	5,000	
Dividends payable	101,000	91,000	
Lease liability, short term	349,000	313,000	
Customer deposits	16,000	...	
Total current liabilities	4,582,000	3,261,000	
Lease liability, long term	103,000	452,000	
Total long-term liabilities	103,000	452,000	
Total liabilities	4,685,000	3,713,000	
Series C convertible preferred stock	105,000	105,000	
Common stock	9,000	55,000	
Additional paid in capital	241,988,000	216,232,000	
Accumulated deficit	(245,015,000)	...	
Retained earnings (accumulated deficit)	...	(215,974,000)	
Total stockholders' equity (deficit)	(3,018,000)	313,000	
Non-controlling interest	26,000	(21,000)	
Total equity	(2,992,000)	292,000	

Recent Dividends:

- 1. **BioSig Technologies Inc redeemable series A preferred.**
No dividends paid.
 - 2. **BioSig Technologies Inc redeemable series B preferred.**
No dividends paid.
 - 3. **BioSig Technologies Inc common.**
No dividends paid.
 - 4. **BioSig Technologies Inc series D convertible preferred.**
No dividends paid.
 - 5. **BioSig Technologies Inc 9% series C convertible preferred (stated value: \$1,000).**
No dividends paid.
- Annual Dividends:**
- 1. **BioSig Technologies Inc redeemable series A preferred.**
No dividends paid.
 - 2. **BioSig Technologies Inc redeemable series B preferred.**
No dividends paid.
 - 3. **BioSig Technologies Inc common.**
No dividends paid.
 - 4. **BioSig Technologies Inc series D convertible preferred.**
No dividends paid.
 - 5. **BioSig Technologies Inc 9% series C convertible preferred (stated value: \$1,000).**
No dividends paid.

BLUM HOLDINGS INC

Acquisition Development On Feb. 9, 2024, Co. entered into a binding letter of intent (the "Operators Only LOI") with Operators Only Corp. ("Operators Only") and Golden Health & Wellness, Inc., Safe Accessible Solutions, Inc., and Sacramento Commercial Services, Inc. (together the "Targets") and each a "Target") pursuant to which Co. and the Targets intend to enter into a Stock Sale and Purchase Agreement in which Co. will acquire 100% of the common stock of Operators Only, and Operators Only will acquire 100% of the common stock of each Target from the shareholders of each Target (the "Target Shareholders"). At closing, Target Shareholders shall receive an aggregate of \$9,700,000 in consideration for the Targets as follows: (i) secured promissory notes in the aggregate principal amount of approximately \$1,900,000 to be paid in monthly installments of approximately \$55,600 per month over 34 to 42 months (the "Notes"); and (ii) the issuance of 1,835,330 shares of common stock of Co. The Notes may be converted into common stock of Co. at the transaction valuation, on terms to be agreed-upon.

BLUM HOLDINGS INC

Interest Sale Development On Feb. 5, 2024, Co.'s wholly owned subsidiary, Unrivaled Brands, Inc. divested its California cultivation facility, a decision which aligns to a broader realignment strategy concentrating Co.'s efforts on operating and expanding profitable cannabis assets and developing brands.

BLUM HOLDINGS INC

Legal Proceedings On Mar. 6, 2024, Co.'s subsidiary, Unrivaled Brands, Inc. filed a civil complaint against Bernard Steimann, Daniel Troup, and Troup Construction for civil theft, conversion, and declaratory relief arising from the alleged theft of Co.'s signage at approximately 5:30 a.m. the morning of Jan. 18, 2024 from the Blum Santa Ana store. A police report, a copy of which was attached to the complaint, was filed on Jan. 31, 2024 for "Grand Theft from Building \$950 or more".

BLUM HOLDINGS INC

Stock Trading Symbol Stock symbol, BLMH.

BRAZE INC

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):			
	2023	2022 (revised)	2021 (revised)
Revenue	355,426	238,035	150,191
Cost of revenue	115,818	78,511	54,511
Gross profit	239,608	159,524	95,680
Sales & marketing	201,684	127,137	70,661
Research & development	97,293	59,034	29,212
General & administrative	88,771	51,564	27,959
Total operating expenses	387,748	237,735	127,832
Income (loss) from operations	(148,140)	(78,211)	(32,152)
Other income (expense), net	7,977	(121)	720
Income (loss) before provision for income taxes - United States	(138,226)	(76,030)	(33,352)

Income (loss) before provision for income taxes - foreign	(1,937)	(2,302)	1,920
Income (loss) before provision for income taxes	(140,163)	(78,332)	(31,432)
Current state & local income taxes	52	15	26
Current foreign income taxes	496	(100)	451
Total current income taxes	548	(85)	477
Deferred foreign income taxes	35	(80)	60
Total deferred income taxes	35	(80)	60
Provision for (benefit from) income taxes	583	(165)	537
Net income (loss)	(140,746)	(78,167)	(31,969)
Net income (loss) attributable to redeemable non-controlling interest	1,780	1,448	217
Net income (loss) attributable to Braze, Inc.	(138,966)	(76,719)	(31,752)
Weighted average shares outstanding - basic	94,569	34,897	17,972
Weighted average shares outstanding - diluted	94,569	34,897	17,972
Year end shares outstanding	95,975	92,968	19,498
Net income (loss) per share - basic	\$(1.47)	\$(2.20)	\$(1.77)
Net income (loss) per share - diluted	\$(1.47)	\$(2.20)	\$(1.77)
Number of full time employees	1,501	1,164	870
Number of common stockholders	434
Number of common stockholders - class A	20	5	...
Number of common stockholders - class B	2730	2763	...
Foreign currency translation adjustments	(633)	(534)	...

[¶] Reclassified to conform with 2023 presentation; [§] Shares increased due to the effect of issuance of common stock for options, warrant, vesting restricted options, initial public offering, and conversion of preferred stock; [¶] As is; [§] As of July 31, 2021; [¶] As of March 24, 2023; [§] As of March 25, 2022; [¶] Approximately

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):			
	2023	2022 (revised)	
Cash & cash equivalents	68,587	478,937	
Accounts receivable, gross	79,951	65,247	
Less: allowance for doubtful accounts	1,613	743	
Accounts receivable, net	78,338	64,504	
Marketable securities	410,083	35,156	
Prepaid software subscriptions	12,574	19,396	
Prepaid advertising	1,322	704	
Prepaid insurance	2,795	4,372	
Investment interest receivable	2,013	259	
Consumption tax receivable	1,045	667	
Prepaid employee bonuses	538	332	
Prepaid employee benefits	811	233	
Other current assets	5,065	3,625	
Prepaid expenses & other current assets	26,163	29,588	

Total current assets	583,171	608,185	Income (loss) from operations	4,482	23,327	40,130	Restricted cash	211	205
Restricted cash, noncurrent	4,036	4,036	Interest expense	5,128	4,658	7,589	Loose diamonds	8,168	11,894
Capitalized internal-use software	7,344	5,353	Other income (expense), net	4,949	805	(6,601)	Fine jewelry & other inventories	...	27,744
Computer equipment, office equipment, & software	8,111	3,833	Loss on extinguishment of debt	...	(617)	...	Allowance for inventory obsolescence	355	307
Leasehold improvements	9,410	2,470	Income (loss) before tax	4,303	18,857	25,940	Fine jewelry and other	29,975	...
Furniture & fixtures	4,085	966	Deferred income tax expense (benefit) - federal	...	(136)	(259)	Inventories, net - Balancing value	37,788	...
Total property & equipment	28,950	12,622	Deferred income tax expense (benefit) - state	...	(32)	(57)	Inventories, net	...	39,331
Less: accumulated depreciation & amortization	8,611	5,229	Total deferred income tax expense (benefit)	...	(168)	(316)	Prepaid expenses & other current assets	11,048	11,764
Property & equipment, net	20,339	7,393	Federal	(389)	Total current assets	204,856	205,949
Operating lease right-of-use assets	46,261	...	Income Taxes state - Deferred	(99)	Equipment	3,428	2,111
Deferred contract costs	48,451	41,689	Income Taxes - Local - Current	57	Furniture & fixtures	...	1,834
Other assets	3,148	4,959	Income Taxes - Total - Current	57	Leasehold improvements	21,999	12,995
Total assets	705,406	666,262	Income Taxes - Total - Deferred	(488)	Construction in progress	992	3,626
Accounts payable	3,101	2,083	Income tax expense (benefit)	...	(168)	(316)	Software & website	2,585	...
Accrued compensation costs	12,644	14,075	Net income (loss)	4,734	19,025	26,256	Other property & equipment	30,063	726
Accrued software subscriptions	8,454	3,217	Net income allocable to non-controlling interest	(4,150)	(16,890)	(24,728)	Gross property and equipment	...	21,292
Accrued commissions	6,205	5,961	Net income allocable to Brilliant Earth Group, Inc.	584	2,135	1,528	Less: accumulated depreciation	8,016	4,738
Accrued professional service fees	1,779	2,218	Weighted average shares outstanding - basic	12,522	10,688	9,590	Property & equipment, net	22,047	16,554
Accrued advertising	922	660	Weighted average shares outstanding - diluted	12,522	96,505	96,741	Deferred tax assets	9,745	8,948
Accrued tax liability	2,152	1,951	Year end shares outstanding	97,330	95,849	94,778	Operating lease right-of-use assets	34,248	27,812
Other accrued expenses & other current liabilities	5,259	3,541	Net earnings per share - basic	\$0.05	\$0.20	\$0.16	Other assets	2,687	3,311
Accrued expenses & other current liabilities	37,415	31,623	Net earnings per share - diluted	\$0.05	\$0.15	\$0.10	Total assets	273,583	262,574
Deferred revenue	166,092	126,260	Number of full time employees	668	591	420	Accounts payable	4,511	11,032
Operating lease liabilities, current	10,695	...	Number of part time employees	11	15	9	Accrued vendor expenses	12,586	14,769
Total current liabilities	217,303	159,966	Number of class A common stockholders	...	70	60	Inventory received not billed	12,686	7,973
Operating lease liabilities, noncurrent	40,590	...	Number of class B common stockholders	...	29	28	Accrued payroll expenses	6,027	5,301
Other long-term liabilities	755	1,478	Number of class C common stockholders	...	1	1	Sales & other tax payable accrual	4,040	4,137
Total liabilities	258,648	161,444	Income tax benefit	(431)	Provision for sales returns & allowances	2,449	2,332
Redeemable non-controlling interest	1,455	3,235	EPS - Basic - excluding Extraordinary Items	Current portion of TRA	...	502
Class A common stock	6	1	Applicable to Common - Total	\$0.05	Other accrued expenses & other current liabilities	...	2,819
Class B common stock	4	8	Applicable to Common - Diluted - excluding Extraordinary Items	\$0.05	Accrued expenses & other current liabilities	43,824	37,833
Additional paid-in capital	806,044	717,175	Applicable to Common Shareholders - Number	47	Current portion of deferred revenue	19,556	18,505
Accumulated other comprehensive income (loss)	(6,824)	(640)	Total number of employees	679	Current portion of operating lease liabilities	4,993	3,873
Retained earnings (accumulated deficit)	(353,927)	(214,961)	As Is; Approximately; As of March 14, 2023; As of March 18, 2022	Current portion of long-term debt	4,063	3,250
Total stockholders' equity (deficit)	445,303	501,583	Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):	Other	6,036	...
			2023	2022	2021 (revised)		Total current liabilities	76,947	74,493
							Long term - outstanding principal	...	60,125
							Less: long term - debt issuance costs	...	(663)
							Long-term debt, net of debt issuance costs	55,573	59,462
							Operating lease liabilities	35,572	28,537
							Payable pursuant to the tax receivable agreement	8,035	6,893
							Other long-term liabilities	...	48
							Total liabilities	176,127	...
							Class A common stock	4	1
							Class B common stock	5	4
							Class C common stock	1	5
							Additional paid-in capital	8,275	7,256
							Retained earnings (accumulated deficit)	4,247	3,663
							Equity attributable to Brilliant Earth Group, Inc.	12,532	10,929
							Non-controlling interests attributable to Brilliant Earth Group, Inc., LLC	84,924	82,212
							Total stockholders'		

equity & members' (deficit)	97,456	93,141	Income (loss) before provision for income taxes	(30,773,000)	(103,527,000)	(121,182,000)	Operating right-of-use assets, net	46,052,000	45,741,000
Recent Dividends:			Current federal income taxes provision (benefit)	13,000	Goodwill	31,621,000	31,621,000
1. Brilliant Earth Group Inc class A common. No dividends paid.			Current state income tax provision (benefit)	35,000	...	Intangible assets, net	150,856,000	160,208,000
2. Brilliant Earth Group Inc class C common. No dividends paid.			Total current income taxes provision (benefit)	13,000	35,000	...	Other assets	1,326,000	1,380,000
3. Brilliant Earth Group Inc class B common. No dividends paid.			Deferred federal income taxes provision (benefit)	(499,000)	(10,002,000)	(7,833,000)	Total assets	258,476,000	276,780,000
Annual Dividends:			Deferred state income taxes provision (benefit)	(6,117,000)	(1,469,000)	(2,192,000)	Accounts payable - trade & other	8,464,000
1. Brilliant Earth Group Inc class A common. No dividends paid.			Change in valuation allowance	6,538,000	Accrued expenses	10,589,000
2. Brilliant Earth Group Inc class C common. No dividends paid.			Total deferred income taxes provision (benefit)	(78,000)	(11,471,000)	(10,025,000)	Short-term operating lease liability	10,111,000	9,924,000
3. Brilliant Earth Group Inc class B common. No dividends paid.			Valuation allowance (benefit)	11,341,000	10,337,000	Other liabilities	4,117,000	6,241,000
BURGERFI INTERNATIONAL INC			Income tax expense (benefit)	(65,000)	(95,000)	312,000	Short-term borrowings	4,985,000
Annual Report			Net income (loss)	(30,708,000)	(103,432,000)	(121,494,000)	Current portion deferred initial franchise fees	52,608,000	...
Consolidated Income Statement, Years Ended (\$):			Net income (loss) available to common shareholders	(103,432,000)	(121,494,000)	Accounts payable & accrued expenses	7,093,000	...
01/01/24	01/02/23	12/31/23	Weighted average shares outstanding - basic	25,521,098	22,173,694	18,408,247	Accrued offering costs	8,537,000	...
(revised)			Weighted average shares outstanding - diluted	25,521,098	22,173,694	18,624,447	Short-term borrowings, including finance lease	52,834,000	...
Food, beverage and paper costs	42,858,000	...	Year end shares outstanding	26,832,691	22,257,772	21,303,500	Capitalized Leases - Current Portion	226,000	...
Labor and related expenses	50,289,000	...	Net income (loss) per common share - basic	\$(1.20)	\$(4.66)	\$(6.60)	Total current liabilities	82,692,000	40,203,000
Restaurant sales	160,833,000	167,201,000	Net income (loss) per common share - diluted	\$(1.20)	\$(4.66)	\$(7.20)	Derivative warrant liability	182,000	...
Royalty & other fees	7,492,000	9,733,000	Number of full time employees	1,015	808	834	Term loan	54,507,000
Royalty - brand development & co-op	1,775,000	1,786,000	Number of part time employees	1,469	1,771	1,588	Revolving line of credit	4,000,000
Total revenues	170,100,000	178,720,000	Total number of employees	2,484	2,579	2,422	Other notes payable	1,718,000	780,000
Restructuring costs	587,000	...	Number of common stockholders	121	131	88	Finance lease liability	1,350,000	933,000
Restaurant level operating expenses - food, beverage & paper costs	48,487,000	Consolidated Balance Sheet, Years Ended (\$): 01/01/24 01/02/23 Cash & cash equivalents						
Restaurant level operating expenses - labor & related expenses	49,785,000							
Restaurant level operating expenses - other operating expenses	30,277,000	7,556,000	11,917,000	Recent Dividends: 1. BurgerFi International Inc common. No dividends paid. 2. BurgerFi International Inc common stock subject to possible redemption. No dividends paid. 3. BurgerFi International Inc common. No dividends paid. Annual Dividends: 1. BurgerFi International Inc common. No dividends paid. 2. BurgerFi International Inc common stock subject to possible redemption. No dividends paid. 3. BurgerFi International Inc common. No dividends paid.				
Restaurant level operating expenses - occupancy & related expenses	15,656,000	15,607,000	1,190,000	1,320,000	BURGERFI INTERNATIONAL INC Auditor's Report Auditor's Report The following is an excerpt from the Report of the Independent Auditors, KPMG LLP, as it appeared in Co.'s 2024 10-K: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of BurgerFi International, Inc. and subsidiaries (the Company) as of January 1,				
General & administrative expenses	22,477,000	25,974,000	1,469	1,771					
Depreciation & amortization expense	13,154,000	17,138,000	2,484	2,579					
Share-based compensation expense	5,612,000	10,239,000	2,422	2,422					
Brand development & co-op advertising expense ..	4,233,000	3,870,000	2,422	2,422					
Asset impairment	4,524,000	6,946,000	2,422	2,422					
Store closure costs	1,949,000	2,422	2,422					
Restructuring costs ..	2,657,000	1,459,000	2,422	2,422					
Goodwill & intangible asset impairment	66,569,000	2,422	2,422					
Pre-opening costs	203,000	474,000	2,422	2,422					
Operating costs	29,888,000	...	2,422	2,422					
Operating income (loss)	(22,038,000)	(100,054,000)	2,422	2,422					
Other income, net	80,000	2,675,000	2,422	2,422					
Gain on change in value of warrant liability	2,511,000	2,422	2,422					
Interest expense, net	8,828,000	8,659,000	2,422	2,422					
Unrealized gain (loss) on marketable securities held in Trust Account	13,000	...	2,422	2,422					

2024 and January 2, 2023, the related consolidated statements of operations, changes in stockholders' equity, and cash flows for each of the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of January 1, 2024 and January 2, 2023, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company was not in compliance with the minimum liquidity requirement of its credit agreement, which constitutes a breach of the credit agreement and an event of default that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

Net income (loss) per share - basic	\$(0.56)	\$(0.60)	\$(0.84)
Net income (loss) per share - diluted	\$(0.56)	\$(0.60)	\$(0.84)
Number of full time employees	18	19	10
Total number of employees	18
Number of common stockholders	56	60	61
Earnings per share from continuing operations	\$(0.56)

Long-term operating lease liabilities	318	444
Deferred revenue	625	750
Other long-term liabilities	41	36
Total liabilities	67,407	76,564
Preferred stock	1	1
Series A preferred stock	...	1
Common stock	665	556
Additional paid-in capital	679,150	636,963
Retained earnings (accumulated deficit)	(639,850)	(603,298)
875% Series A cumulative, perpetual preferred stock \$ 0 par value; 7,500 shares authorized at , 2022 and , 202; shares issued and outstanding - 2,00 at , 2022 and 2,00 at , 202	1	...
Total stockholders' equity (deficit)	39,967	34,223
Rep Total Equity & Minority Interest	39,967	...

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

CADIZ INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Total revenues (rental income)	1,991
Total revenues	1,991	1,501	564
Cost of sales	2,887	2,067	...
General & administrative expenses	18,797	15,342	17,653
Depreciation expenses	...	654	423
Depreciation	1,247
Operating profit (loss)	(20,940)	(16,562)	(17,512)
Interest on outstanding debt	5,161	5,849	8,485
Unrealized gains (losses) on warrants	(573)
Amortization of debt discount	414	2,414	1,110
Amortization of deferred loan costs	2,364
Interest expense, net	...	8,263	11,386
Interest income	606
Loss on extinguishment of debt	(5,331)	...	(1,399)
Other income	25
Interest income (expense), net	(4,944)
Change in fair value of derivative liability	(220)
Income (loss) before income taxes	(31,435)	(24,825)	(30,297)
Income tax expense (benefit)	11	7	10
Income (loss) from equity-method investments	...	40	(942)
Net income (loss)	(31,446)	(24,792)	(31,249)
Less: preferred stock dividend requirements	5,106	5,106	2,737
Net income (loss) applicable to common stock	(36,552)	(29,898)	(33,986)
Weighted average shares outstanding - basic	65,656	49,871	40,561
Weighted average shares outstanding - diluted	65,656	49,871	40,561
Year end shares outstanding	66,711	55,824	43,656
Income (loss) per share from continuing operations - basic	\$(0.56)

	2023	2022
Cash & cash equivalents	4,502	9,997
Restricted cash	...	1,288
Other accounts receivables	904	...
Accounts receivable	...	454
Inventories	2,106	...
Prepaid expenses & other current assets	508	696
Total current assets	8,020	12,435
Land & land improvements	32,357	30,579
Water programs	29,209	29,210
Pipelines	22,096	22,091
Buildings	1,730	1,715
Leasehold improvements	1,609	1,609
Machinery & equipment	3,929	3,395
Construction in progress	5,664	3,680
Less accumulated depreciation	9,377	8,141
Property, plant, equipment & water programs, net	87,217	84,138
Long-term deposit or prepaid expenses	...	420
Goodwill	5,714	5,714
Right-of-use asset	...	553
Long-term restricted cash	134	2,497
Prepaid rent	420	4,481
Deposits & other assets	...	549
Right-of-use asset	431	...
Total assets	107,374	110,787
Accounts payable	...	1,107
Accrued payroll, bonus, & benefits	90	88
Accrued legal & consulting	284	403
Accrued well development	...	709
Accrued water project	...	85
Other accrued expenses	650	260
Water project	146	...
Accrued liabilities	1,170	1,545
Current portion of long-term debt	182	140
Accounts payable, affiliate	1,245	...
Dividend payable	1,288	1,288
Contingent consideration liabilities	1,450	1,450
Operating lease liabilities	127	109
Deferred gross profit, land sales	373	...
Total current liabilities	5,835	5,639
New senior secured debt	...	50,000
Other loans	37,711	287
Less: debt discount & debt issuance costs, net of accumulated accretion	...	(1,198)
Less: current portion	...	139
Long-term debt, net	...	48,950
Long-term lease obligations with related party, net	22,877	20,745

Recent Dividends:

- CADIZ Inc common.** No dividends paid.
- CADIZ Inc 8.875% series A cumulative preferred.** No dividends paid.
- CADIZ Inc series F convertible preferred.** No dividends paid.
- CADIZ Inc preferred.** No dividends paid.

Annual Dividends:

- CADIZ Inc common.** No dividends paid.
- CADIZ Inc 8.875% series A cumulative preferred.** No dividends paid.
- CADIZ Inc series F convertible preferred.** No dividends paid.
- CADIZ Inc preferred.** No dividends paid.

CAL-MAINE FOODS INC
Earnings, 9 mos. to (Consol. - \$000):

	03/02/24	02/25/23
Total Revenues	1,685,654	...
Net Sales	1,685,654	2,457,537
Cost & expenses	1,515,390	1,626,036
Operating income	170,264	831,501
Other income (expense), net	15,859	12,175
Net before taxes	208,010	852,635
Income taxes	44,658	206,438
Net income	163,352	646,197
Earnings common share		
Primary	\$3.38	\$13.31
Fully Diluted	\$3.37	\$13.25
Common Shares:		
Full Diluted	48,865	48,832
Year-end	49,039	48,986

CANDEL THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development service revenue, related party	...	125	125
Research & development	24,506	20,787	15,178
General & administrative	13,885	14,060	10,673
Total operating expenses	38,391	34,847	25,851
Income (loss) from operations	(38,391)	(34,722)	(25,726)
Grant income	...	48	1,076
Interest & dividend income

Accounts payable & accrued expenses	65,306	...	Other restaurant operating expenses	292,564	274,557	257,774	pensions: \$4,902,000; [Ⓜ] Including stock-based compensation expense - General & administrative expenses: \$6,234,000; [Ⓜ] As is; [Ⓜ] Approximately; [Ⓜ] As of March 1, 2023; [Ⓜ] As of March 2, 2022
Accounts payable	...	103,187	Advertising expense	76,243	69,389	65,433	
Other accrued expenses - Balancing value	8,846	...	General & administrative expenses	105,930	[Ⓜ] 88,072	[Ⓜ] 83,660	
Accrued interest expense	11,932	...	Depreciation & amortization	74,161	78,068	80,798	
Accrued property & equipment purchases	29,433	24,797	Impairment & other lease charges	7,609	21,877	4,470	
Accrued research & development costs	15,913	17,736	Other income (expense), net	6,058	926	1,186	
Accrued professional fees	6,623	8,112	Total operating expenses	1,809,998	1,775,960	1,663,229	
Accrued business combination costs	63,901	...	Income (loss) from operations	66,506	(45,520)	(10,859)	
Short term lease liability	3,086	...	Interest expense	29,112	30,841	28,791	
Other accrued expenses	...	12,446	Gain (loss) on extinguishment of debt	875	...	(8,538)	
Accrued expenses & other current liabilities	...	63,091	Income (loss) before income taxes	38,269	(76,361)	(48,188)	
Convertible debt	51,180	34,829	Current provision (benefit) for federal income taxes	273	
Warrant liability	...	17,171	Current state provision (benefit) for income taxes	439	(37)	(36)	
Deferred compensation	3,200	...	Total current provision (benefit) for income taxes	712	(37)	(36)	
Derivative liability	860	...	Deferred federal provision (benefit) for income taxes	4,383	(16,790)	(12,374)	
Total current liabilities	184,447	218,278	Deferred state provision (benefit) for income taxes	1,489	(5,027)	(4,021)	
Related party derivative liability	25,919	...	Total deferred provision (benefit) for income taxes	5,872	(21,817)	(16,395)	
Operating lease liabilities	35,722	38,608	Increase (decrease) in valuation allowance	(2,111)	21,065	11,272	
Contingent earnout shares liability	41	3,013	Provision (benefit) for income taxes	4,473	(789)	(5,159)	
Warrant liability, non-current	17,390	...	Net income (loss)	33,796	(75,572)	(43,029)	
Financing liability, non-current	28,910	...	Net income (loss) available to common stockholders	...	(75,572)	(43,029)	
Total liabilities	292,429	259,899	Weighted average shares outstanding - basic	51,530	50,718	49,899	
Common stock	...	35	Weighted average shares outstanding - diluted	62,413	50,718	49,899	
Class B common stock	85	...	Year end shares outstanding	51,602	50,903	49,933	
Additional paid-in capital	1,725,728	1,416,361	Income (loss) per share from continuing operations - basic	\$0.53	
Accumulated deficit	(1,481,844)	...	Net income (loss) per share - basic	\$0.53	\$(1.49)	\$(0.86)	
Retained earnings (accumulated deficit)	...	(1,179,823)	Income (loss) per share from continuing operations - diluted	\$0.53	
Preferred Stock - Redeemable - Convertible	5,607	...	Net income (loss) per share - diluted	\$0.53	\$(1.49)	\$(0.86)	
Total stockholder's equity (deficit)	249,576	236,573	Full-Time Employees (Period End)	25,000	
Total Equity	249,576	...	Total number of employees	25,000	[Ⓜ] 24,300	[Ⓜ] 25,500	

Recent Dividends:

- 1. **Canoo Inc common stock subject to possible redemption.**
No dividends paid.
- 2. **Canoo Inc redeemable preferred.**
No dividends paid.
- 3. **Canoo Inc common.**
No dividends paid.
- 4. **Canoo Inc class B common.**
No dividends paid.
- 5. **Canoo Inc class A common.**
No dividends paid.

Annual Dividends:

- 1. **Canoo Inc common stock subject to possible redemption.**
No dividends paid.
- 2. **Canoo Inc redeemable preferred.**
No dividends paid.
- 3. **Canoo Inc common.**
No dividends paid.
- 4. **Canoo Inc class B common.**
No dividends paid.
- 5. **Canoo Inc class A common.**
No dividends paid.

CARROLS RESTAURANT GROUP INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	12/31/23	01/01/23	[Ⓜ] 01/02/22 (revised)
Restaurant sales	1,876,504	1,730,440	1,652,370
Total revenue	1,876,504
Cost of sales	522,163
Food, beverage & packaging costs	...	534,238	499,685
Restaurant wages & related expenses	608,582	585,204	549,933
Restaurant rent expense	128,804	125,481	122,662

[Ⓜ] Reclassified to conform with 2023 presentation; [Ⓜ] Including stock-based compensation expense - General & administrative ex-

Consolidated Balance Sheet, Years Ended (\$000):

	12/31/23	01/01/23
Cash & cash equivalents	44,504	18,364
Trade & other receivables	22,438	19,933
Inventories	15,237	14,417
Prepaid expenses & other current assets	17,521	15,562
Total current assets	99,700	68,276
Land	9,990	7,685
Owned buildings	13,799	12,895
Leasehold improvements	472,125	454,134
Equipment	352,426	342,118
Assets subject to finance leases	29,248	30,873
Property & equipment, gross	877,588	847,705
Less accumulated depreciation & amortization - property & equipment	570,062	535,359
Property & equipment, net	307,526	312,346
Franchise rights, net	298,626	312,804
Goodwill	107,751	107,751
Franchise agreements, at cost	...	45,231
Less accumulated amortization - franchise agreements	...	16,975
Operating right-of-use assets, net	743,250	763,935
Franchise agreements, net	26,048	...
Other assets	9,591	14,350
Total assets	1,592,492	1,607,718
Current portion of long-term debt and finance lease liabilities - Balancing value	7,159	...
Current portion of long-term debt & finance lease liabilities	4,250	7,341
Current portion of operating lease liabilities	49,424	47,408
Accounts payable	37,797	30,491
Accrued interest	8,963	9,643
Accrued payroll, related taxes & benefits	63,787	49,934
Accrued real estate taxes	...	8,896
Other current liabilities	29,120	25,687
Accrued Interest	8,705	...
Current portion of long-term debt and finance lease liabilities	2,909	...
Total current liabilities	204,955	179,400
Senior credit facility - term loan B loans	414,945	167,625
Senior credit facility - revolving credit borrowings	...	12,500
Senior notes	421,788	300,000
Finance lease liabilities	...	12,826
Less: current portion of long-term debt & finance lease liabilities	...	7,341
Less: unamortized debt issuance costs	...	(5,401)
Less: original issue discount	...	(453)
Finance Lease	6,843	...
Operating lease liabilities	758,115	776,465
Deferred income taxes, net	11,090	7,665
Accrued postretirement benefits	1,249	1,347
Accrued occupancy costs	1,766	1,797
Accrued workers' compensation & general

liability claims	3,994	5,239	Provision for				Prepaid expenses	135,199	305,864
Deferred compensation	3,162	3,002	income taxes	1,533,608	325,926	...	Total current assets	160,199	330,864
Lease financing obligations	25	1,179	Net income (loss)	2,905,665	65,456	(80,587)	Cash equivalents held in trust account	155,182,051	187,912,652
Other liabilities	1,026	Weighted average class A public shares outstanding - basic	18,250,000	600,000	Total assets	155,342,250	188,243,516
Other	1,115	...	Weighted average class A private placement outstanding - basic	450,000	14,795	Accrued expenses	212,280	419,086
Total liabilities	1,407,259	1,456,876	Weighted average class B common shares outstanding - basic	4,562,500	4,381,164	Franchise tax payable	413,585	189,802
Voting common stock	539	530	Weighted average class A public shares outstanding - diluted	18,250,000	600,000	Sponsor loan - promissory notes	8,461,958	4,486,710
Additional paid-in capital	296,972	292,708	Weighted average class A private placement outstanding - basic	450,000	14,795	Franchise tax payable	40,000	...
Accumulated deficit	(103,172)	...	Weighted average class B common shares outstanding - basic	4,562,500	4,381,164	Income taxes payable	32,334	...
Retained earnings (accumulated deficit)	(136,968)	Weighted average class A private placement outstanding - basic	4,562,500	4,381,164	Other current liability	381,984	...
Accumulated other comprehensive income (loss)	5,320	8,702	Weighted average class A public shares outstanding - basic	21,089,267	Total current liabilities	5,095,598
Treasury stock, at cost	14,426	14,130	Weighted average class A private placement outstanding - diluted	18,250,000	600,000	Total liabilities	9,542,141	5,095,598
Total stockholders' equity (deficit)	185,233	150,842	Weighted average class A public shares outstanding - diluted	18,250,000	600,000	Class A common stock subject to possible redemption	187,296,924
Total Equity	185,233	...	Year end shares outstanding	19,316,081	23,262,500	23,262,500	Class A common stock	12	45

Recent Dividends:**1. Carrols Restaurant Group Inc series A convertible preferred.**

No dividends paid.

2. Carrols Restaurant Group Inc series D convertible preferred.

No dividends paid.

3. Carrols Restaurant Group Inc series B convertible preferred.

No dividends paid.

4. Carrols Restaurant Group Inc common.

ExDate	Amt	Declared	Record	Payable
08/24/2021	0.41	08/12/2021	08/25/2021	10/05/2021
11/20/2023	0.02	11/09/2023	11/21/2023	12/15/2023
03/08/2024	0.02	02/22/2024	03/11/2024	04/05/2024

Annual Dividends:**1. Carrols Restaurant Group Inc series A convertible preferred.**

No dividends paid.

2. Carrols Restaurant Group Inc series D convertible preferred.

No dividends paid.

3. Carrols Restaurant Group Inc series B convertible preferred.

No dividends paid.

4. Carrols Restaurant Group Inc common.

2021.....	0.41	2023.....	0.02	2024.....	0.02
-----------	------	-----------	------	-----------	------

CF ACQUISITION CORP VII**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	⁽¹⁾ 2021
			(revised)
General & administrative costs	1,141,130	1,068,030	69,616
Administrative expenses - related party	120,000	120,000	3,871
Franchise tax expense	200,000	206,300	7,100
Income (loss) from operations	(1,461,130)	(1,394,330)	(80,587)
Interest income on investments held in the trust account	7,434,148	1,785,712	...
Net income (loss) before provision for income taxes	4,439,273	391,382	(80,587)
Current federal income tax provision	1,517,850	325,926	...
Deferred federal income tax provision (benefit)	(264,107)	(241,096)	...
Change in valuation allowance	270,278	241,096	...
State	15,758
State	(6,171)

Provision for income taxes	1,533,608	325,926	...
Net income (loss)	2,905,665	65,456	(80,587)
Weighted average class A public shares outstanding - basic	18,250,000	600,000
Weighted average class A private placement outstanding - basic	450,000	14,795
Weighted average class B common shares outstanding - basic	4,562,500	4,381,164
Weighted average class A public shares outstanding - basic	21,089,267
Weighted average class A private placement outstanding - diluted	18,250,000	600,000
Weighted average class A private placement outstanding - diluted	450,000	14,795
Weighted average class B common shares outstanding - diluted	4,562,500	4,381,164
Weighted average class A public shares outstanding - diluted	21,089,267
Year end shares outstanding	19,316,081	23,262,500	23,262,500
Net earnings (loss) per class A public share - basic	\$0.00	\$(0.02)
Net earnings (loss) per class A private placement - basic	\$0.00	\$(0.02)
Net earnings (loss) per class B common share - basic	\$0.00	\$(0.02)
Net earnings (loss) per class A public share - diluted	\$0.00	\$(0.02)
Net earnings (loss) per class A private placement - diluted	\$0.00	\$(0.02)
Net earnings (loss) per class B common share - diluted	\$0.00	\$(0.02)
Total number of employees	2	3
Number of units stockholders	7	⁽²⁾ 1	⁽³⁾ 2
Number of class A common stockholders	⁽²⁾ 3	⁽³⁾ 1
Number of class B common stockholders	⁽²⁾ 3	⁽³⁾ 3
Interest expense on mandatorily redeemable Class A common stock	(1,533,745)
EPS - Diluted - including Extraordinary Items Applicable to Common - Total	\$0.14
EPS - Basic - including Extraordinary Items Applicable to Common - Total	\$0.14

⁽¹⁾ Reclassified to conform with 2022 presentation; ⁽²⁾ As of March 31, 2023; ⁽³⁾ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	25,000	25,000

Class A common stock subject to possible redemption	187,296,924	...
Class A common stock	12	45	...
Class B common stock	489	456	...
Retained earnings (accumulated deficit)	(9,208,835)	(4,149,507)	...
Class A common stock subject to possible redemption, 18,250,000 and 0 shares issued and outstanding at redemption value of \$1020 per share as of 31, 2021 and 31, 2020, respectively	155,008,443
Total stockholder's equity	145,800,109	(4,149,006)	...
Total Equity	145,800,109

Recent Dividends:**1. CF Acquisition Corp VII class B common.**

No dividends paid.

2. CF Acquisition Corp VII class A common.

No dividends paid.

3. CF Acquisition Corp VII class A common subject to possible redemption.

No dividends paid.

Annual Dividends:**1. CF Acquisition Corp VII class B common.**

No dividends paid.

2. CF Acquisition Corp VII class A common.

No dividends paid.

3. CF Acquisition Corp VII class A common subject to possible redemption.

No dividends paid.

CHS INC**Earnings, 6 mos. to (Consol. - \$000):**

	02/29/24	02/28/23
Total Revenues	20,478,138	24,072,687
Cost & expenses	20,017,582	23,285,876
Operating income	460,556	786,811
Interest expense	69,217	...
Other income (expense), net	297,036	412,898
Net before taxes	702,504	1,130,492
Income taxes	8,803	55,528
Net income	693,701	1,074,964
Earnings common share Common Shares:		

CINTAS CORPORATION**Earnings, 9 mos. to (Consol. - \$000):**

	02/29/24	02/28/23
Total Revenues	7,125,680	6,531,298
Net Sales	1,571,671	...
Cost & expenses	5,604,641	5,199,432
Operating income	1,521,039	1,331,866
Interest income	2,121	872
Interest expense	76,664	85,459
Net before taxes	1,446,496	1,247,279
Income taxes	289,219	245,470
Net income	1,157,277	1,001,809
Balance for common	1,152,791	997,654
Earnings common share		
Primary	\$11.34	\$9.82
Fully Diluted	\$11.15	\$9.65
Common Shares:		
Full Diluted	103,347	103,363
Year-end	101,444	101,672

COGNITION THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development	37,196	30,324	18,572
General & administrative	13,528	13,227	10,026
Total operating expenses	50,724	43,551	28,598
Income (loss) from operations	(50,724)	(43,551)	(28,598)
Grant income	158	22,217	17,447
Change in the fair value of the derivative liability	2,209
Change in the fair value of the Simple Agreements for Future Equity	(2,236)
Other income (expense), net	24,805	(35)	(88)
Gain (loss) on debt extinguishment	443
Interest expense	27	28	893
Total other income (expense), net	24,936	22,154	16,882
Income (loss) before income tax - domestic	...	(21,384)	(10,910)
Income (loss) before income tax - foreign	...	(13)	(806)
Income (loss) before income tax	(25,788)	(21,397)	(11,716)
Net income (loss)	(25,788)	(21,397)	(11,716)
Cumulative preferred stock dividends	4,532
Net income (loss) attributable to common stockholders	...	(21,397)	(16,248)
Weighted average shares outstanding - basic	30,029	23,640	5,191
Weighted average shares outstanding - diluted	30,029	23,640	5,191
Year end shares outstanding	32,165	28,992	22,230
Net earnings (loss) per share - basic	\$(0.86)	\$(0.91)	\$(3.13)
Net earnings (loss) per share - diluted	\$(0.86)	\$(0.91)	\$(3.13)
Number of full time employees	...	22	19
Number of part time employees	...	3	2
Total number of employees	...	25	21
Number of common stockholders	277	256	...
Foreign currency translation adjustments	...	(1)	...

Reclassified to conform with 2022 presentation; Shares increased due to the effect of exercise of share options and issuance from follow-on public offering; Shares increased due to conversion of convertible preferred stock, common stock in initial public offering, conversion of SAFE, and exercise of options and warrants; As is; As of March 1, 2023; As of March 1, 2022; As of March 20, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	29,922	41,562
Grant receivables	1,281	3,672
Prepaid expenses	3,019	...
Prepaid expenses & other

current assets	...	2,413
Total current assets	34,222	47,647
Equipment	140	1,057
Furniture & fixtures	...	129
Equipment	1,193	...
Property & equipment, gross	1,333	1,186
Less: accumulated depreciation	1,049	953
Property & equipment, net	284	233
Right-of-use assets, operating leases	657	813
Other assets	...	1,732
Total assets	35,163	50,425
Accounts payable	3,695	3,216
Employee compensation, benefits, & related accruals	1,165	870
Research and development costs	2,520	900
Legal reserves, professional fees, & other accruals	370	324
Accrued Expenses - Balancing value	4,055	...
Accrued expenses	...	2,094
Deferred grant income, current	1,701	1,702
Operating lease liabilities, current	174	149
Other current liabilities	544	634
Total current liabilities	10,169	7,795
Operating lease liabilities, noncurrent	520	695
Deferred grant income & other liabilities, noncurrent	...	1,686
Total liabilities	10,689	10,176
Common stock	32	29
Additional paid-in capital	165,826	155,820
Retained earnings (accumulated deficit)	(141,189)	(115,401)
Accumulated other comprehensive income (loss)	(195)	(199)
Total stockholders' equity (deficit)	24,474	40,249
Total Equity	24,474	...

Recent Dividends:
1. Cognition Therapeutics Inc common.
 No dividends paid.
Annual Dividends:
1. Cognition Therapeutics Inc common.
 No dividends paid.

CONCENTRIX CORP

Earnings, 3 mos. to (Consol. - \$000):

	02/29/24	02/28/23
Total Revenues	2,402,748	1,636,404
Cost & expenses	2,254,309	1,480,357
Operating income	148,439	156,047
Other income (expense), net	6,824	(3,714)
Net before taxes	72,824	118,343
Income taxes	20,722	30,473
Net income	52,102	87,870
Balance for common	50,100	86,314
Earnings common share		
Primary	\$0.76	\$1.69
Fully Diluted	\$0.76	\$1.68
Common Shares:		
Full Diluted	65,790	51,476
Year-end	65,572	51,195

Consolidated Balance Sheet Items, as of (\$000):

	2024
Assets:	
Cash & equivalents	234,794
Current assets	2,781,921
Net property & equip.	730,242
Total assets	12,242,859
Liabilities:	
Current liabilities	1,782,766
Long-term debt	5,034,109

Stockholders' equity	4,101,637
Net current assets	999,155

CONIFER HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Gross earned premiums	83,935	135,401	123,050
Ceded earned premiums	(75,146)	(38,690)	(24,248)
Direct	100,214
Assumed	43,620
Premiums Ceded Out to Reinsurance - Unearned	(12,509)
Ceded earned premiums	(2,738)
Net earned premiums	...	96,711	98,802
Net investment income	5,526
Investment Expense	(234)
Investment Income, Gross	5,760
Net investment income	...	3,043	1,968
Net realized investment gains (losses)	...	(1,505)	2,878
Change in fair value of equity securities	...	403	(2,020)
Gain from VSRM, Inc transaction	...	8,810	...
Loss portfolio transfer risk fee	...	(5,400)	...
Other gains (losses)	...	59	11,664
Gains from acquisitions	2,335
Other income	694	2,768	2,671
Net realized investment gains (losses)	(20)
Change in fair value of equity securities	608
Agency commission income	5,680
Total revenue & other income	98,758	104,889	115,963
Losses & loss adjustment expenses, net	...	81,440	69,861
Policy acquisition costs	20,892	22,179	28,451
Operating expenses	17,891	18,789	16,509
Interest expense	3,206	2,971	2,852
Total expenses	124,402	125,379	117,673
Income (loss) before income taxes	(25,644)	(20,490)	(1,710)
Current income tax expense (benefit)	26	(45)	208
Deferred income tax expense (benefit)	(17)	(9,396)	...
Income tax expense (benefit)	9	(9,441)	208
Equity earnings (losses) in affiliates, net of tax	(251)	368	824
Net income (loss)	(25,904)	(10,681)	(1,094)
Weighted average shares outstanding - basic	12,221	10,692	9,692
Weighted average shares outstanding - diluted	12,221	10,692	9,692
Year end shares outstanding	12,223	12,216	9,708
Net income (loss) per share - basic	\$(2.12)	\$(1.00)	\$(0.11)

Net income (loss) per share - diluted	\$(2.12)	\$(1.00)	\$(0.11)	Total liabilities	308,915	293,400	Current foreign income taxes	1,351	1,459	957
Number of full time employees	94	109	151	0 issued and outstanding, respectively))	98,100	...	Income Taxes - Domestic - Current	105
Number of common stockholders	26	27	25	Common stock	(86,683)	97,913	Total current income taxes	1,456	1,524	1,015
Losses and loss adjustment expenses net	82,413	Accumulated deficit	...	(60,760)	Deferred foreign income taxes (benefit)	(101)	(486)	...
Basic EPS - Net Income excl Extra Items applicable to Common - (Company Level)	\$(2.12)	Retained earnings (accumulated deficit)	...	(18,203)	Total deferred income taxes (benefit)	(101)	(486)	...
Diluted EPS - Net Income excl Extra Items applicable to Common - (Company Level)	\$(2.12)	Unrealized gains (losses) on available-for-sale securities	...	(14,528)	Provision for income taxes	1,355	1,038	1,015
Total number of employees	94	Accumulated other comprehensive income (loss)	...	(18,203)	Net income (loss)	(80,183)	(68,494)	(58,229)
				Accumulated other comprehensive income (loss)	...	6,000	Cumulative dividends on Series G redeemable convertible preferred stock	2,917
				Total shareholders' equity	2,889	18,950	Net income (loss) attributable to common stockholders	...	(68,494)	(61,146)
				Total equity	2,889	...	Weighted average shares outstanding - basic	47,175	44,787	25,777

□ Shares increased due to the effect of issuance of common stock private placement and stock-based compensation expense; □ As is; □ As of March 27, 2023; □ As of March 10, 2022

□ Amortized cost - debt securities, at fair value: \$127,119,000; □ Cost - equity securities, at fair value: \$1,905,000

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Fixed maturity securities, at fair value	122,113	...
Investment securities: debt securities, at fair value	20,838	110,201
Investment securities: equity securities, at fair value	2,354	1,267
Investment securities: short-term investments, at fair value	...	25,929
Total investments	145,305	...
Cash & cash equivalents	...	28,035
Premiums & agents' balances receivable, net	...	21,802
Receivable from affiliate	...	1,261
Reinsurance recoverables on unpaid losses	...	82,651
Reinsurance recoverables on paid losses	28,908	6,653
Prepaid reinsurance premiums	...	16,399
Deferred policy acquisition costs	...	10,290
Other assets	6,339	7,862
Premiums and agents' balances receivable, net	29,369	...
Reinsurance recoverables on unpaid losses	70,807	...
Reinsurance recoverables on paid losses	12,619	...
Deferred policy acquisition costs	6,285	...
Cash and cash equivalents	11,125	...
Receivable from affiliate	1,047	...
Total assets	311,804	312,350
Unpaid losses & loss adjustment expenses	...	165,539
Unearned premiums	...	67,887
Reinsurance premium payable	...	6,144
Senior unsecured notes	...	24,186
Subordinated notes	...	9,690
Debt	25,061	33,876
Accounts payable & accrued expenses	5,310	19,954
Unearned premiums	65,150	...
Reinsurance premiums payable	246	...
Unpaid losses and loss adjustment expenses	174,612	...
Funds held under reinsurance agreements	24,550	...
Premiums payable to other insureds	13,986	...

Recent Dividends:
1. Conifer Holdings Inc common.
 No dividends paid.
2. Conifer Holdings Inc preferred.
 No dividends paid.

Annual Dividends:
1. Conifer Holdings Inc common.
 No dividends paid.
2. Conifer Holdings Inc preferred.
 No dividends paid.

COUCHBASE INC Annual Report Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2024	2023	2022
Service	7,435
License	21,514	19,885	19,008
Support & other	150,040	123,010	97,279
Total subscription revenue	171,554	142,895	116,287
Services	8,483	11,929	7,255
Total revenue	180,037	154,824	123,542
Cost of subscription	14,647	10,762	8,529
Cost of services	...	9,497	6,252
Total cost of revenue	22,082	20,259	14,781
Gross profit	157,955	134,565	108,761
Research & development expenses	64,069	57,760	51,639
Sales & marketing expenses	130,558	111,067	89,372
General & administrative expenses	42,663	33,390	24,008
Restructuring	46	1,663	...
Impairment of capitalized internal-use software	5,156
Total operating expenses	242,492	203,880	165,019
Interest expense	43	101	656
Income (loss) from operations	(84,537)	(69,315)	(56,258)
Other income (expense), net	5,752	1,960	(300)
Net income (loss) before income taxes - United States	...	(75,449)	(61,180)
Net income (loss) before income taxes - international	...	7,993	3,966
Net income (loss) before income taxes	(78,828)	(67,456)	(57,214)
Current state income taxes	...	65	58

Weighted average shares outstanding - diluted	47,175	44,787	25,777
Year end shares outstanding	49,080	45,432	43,847
Net earnings (loss) per share - basic	\$(1.70)	\$(1.53)	\$(2.37)
Net earnings (loss) per share - diluted	\$(1.70)	\$(1.53)	\$(2.37)
Full-Time Employees (Period End)	796
Number of employees	796	740	646
Number of common stockholders	102	142	210
Provision for income taxes	1,355

□ Reclassified to conform with 2022 presentation; □ As is; □ Approximately

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2024	2023
Cash & cash equivalents	41,351	40,446
Short-term investments	112,281	127,856
Accounts receivable, gross	45,072	40,020
Less: allowance for loan losses	224	173
Accounts receivable, net	44,848	39,847
Deferred commissions	15,421	13,096
Prepaid expenses	4,793	4,140
Prepaid software	4,429	2,560
Other current assets	1,163	1,534
Prepaid expenses & other current assets	10,385	8,234
Total current assets	224,286	229,479
Computer equipment	3,736	3,586
Furniture & fixtures	418	342
Capitalized internal-use software	8,743	7,884
Leasehold improvements	1,903	1,889
Construction in progress - capitalized internal-use software	2,571	3,395
Total gross property & equipment, gross	17,371	17,096
Accumulated depreciation & amortization	12,044	9,666
Property & equipment, net	5,327	7,430
Operating lease right-of-use assets	4,848	6,940
Deferred commissions, noncurrent	11,400	7,524
Other assets	1,891	1,666
Total assets	247,752	253,039
Accounts payable	4,865	1,407
Accrued bonus	7,056	5,944

<p>Accrued commissions 4,852 3,593</p> <p>Accrued payroll & benefits 4,690 1,995</p> <p>Employee contributions under the ESPP 1,518 1,109</p> <p>Accrued compensation & benefits 18,116 12,641</p> <p>Accrued professional fees 1,190 1,020</p> <p>Sales & value added tax payable 517 737</p> <p>Income taxes payable 173 743</p> <p>Accrued restructuring 1,567</p> <p>Other accrued liabilities 2,009</p> <p>Other accrued expenses 4,581 6,076</p> <p>Operating lease liabilities 3,208 3,117</p> <p>Deferred revenue 81,736 71,716</p> <p>Other 2,701 ..</p> <p>Total current liabilities 112,506 94,957</p> <p>Operating lease liabilities, noncurrent 2,078 4,543</p> <p>Deferred revenue, noncurrent 2,747 3,275</p> <p>Total liabilities 117,331 102,775</p> <p>Additional paid-in capital 621,024 561,547</p> <p>Accumulated other comprehensive income (loss) 56 (807)</p> <p>Retained earnings (accumulated deficit) (490,659) (410,476)</p> <p>Common Stock 0 ..</p> <p>Total stockholders' equity (deficit) 130,421 150,264</p> <p>Total stockholders equity (deficit) 130,421 ..</p>	<p>related parties - corporate (2,342) (1,925) (2,050)</p> <p>Expense reimbursements to related parties - lending segment (2,579) (1,929) (1,921)</p> <p>Interest expense 9,604 9,413</p> <p>General & administrative expenses 8,119 6,869 6,844</p> <p>Transaction costs 4,421 223 143</p> <p>Depreciation & amortization expenses 52,484 20,348 20,112</p> <p>Hotel property expenses 62,493 </p> <p>Income from unconsolidated entity 164 </p> <p>Income (loss) before provision (benefit) for income taxes (50,228) 7,076 2,141</p> <p>Expected federal income tax (benefit) provision 1,287 1,941 1,941</p> <p>State income taxes 43 (40) (40)</p> <p>Change in valuation allowance 300 (273) (273)</p> <p>Other income tax (benefit) provision (499) 1,364 1,364</p> <p>Provision (benefit) for income taxes 1,228 1,131 2,992</p> <p>Net income (loss) (51,456) 5,945 (851)</p> <p>Net loss (income) attributable to noncontrolling interests 2,971 (27) 1</p> <p>Net income (loss) attributable to the company (48,485) 5,918 (850)</p>	<p>Gain on sale of real estate 1,104 </p> <p>(Loss) income from unconsolidated entities (427) </p>
--	---	--

□ Shares increased due to the issuance of common shares and issuance pursuant to share-based compensation; □ As is; □ As of March 22, 2023; □ Approximately; □ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Land	175,715	151,727
Land improvements	5,862	1,837
Buildings & improvements	633,299	455,275
Furniture, fixtures, & equipment	11,627	4,339
Tenant improvements	26,460	34,372
Work in progress	15,915	12,863
Investments in real estate	868,878	660,413
Less: accumulated depreciation	164,116	158,407
Investments in real estate, net	704,762	502,006
Investment in unconsolidated entity	33,505	12,381
Cash & cash equivalents	19,290	46,190
Restricted cash	24,938	11,290
SBA 7(a) loans receivable, subject to credit risk	56,116
SBA 7(a) loans receivable, subject to secured borrowings	6,127
SBA 7(a) loans receivable, held for sale	117
Loans receivable, gross	62,360
Less: deferred capitalized costs, net	(1,293)
Less: loan loss reserves	1,106
Loans receivable, net	62,547
Accounts receivable, net	5,347	3,780
Deferred rent receivable & charges, net	28,222	37,543
Note receivable	57,005	..
Other intangible assets, net	3,948	4,461
Other assets	14,183	10,050
Total assets	891,200	690,248
Mortgage payable	97,100
Deferred loan costs - mortgage payable	(94)
Total secured borrowings - government guaranteed loans	6,237
Revolving credit facility	56,230
Junior subordinated notes	27,070
SBA loan-backed notes	471,561	..
Deferred debt issuance costs - other	(779)
Discount on junior subordinated notes	(1,497)
Accounts payable & accrued expenses	26,426	107,220
Intangible liabilities, net	20
Due to related parties	3,463	3,155
Other liabilities	12,981	17,856
Total liabilities	514,431	312,518
Redeemable preferred stock	15,697
Series A cumulative redeemable preferred stock	185,704	189,048
Series A1 cumulative redeemable preferred stock	256,935	147,514
Series D cumulative redeemable preferred stock	1,190	1,200
Common stock	23	23
Additional paid-in capital	852,476	861,721

Recent Dividends:

1. Couchbase Inc common.

No dividends paid.

Annual Dividends:

1. Couchbase Inc common.

No dividends paid.

COVENANT LOGISTICS GROUP INC

Dividend Announcement On Feb. 13, 2024, Co. declared a quarterly cash dividend of \$0.11 per share of Class A and Class B common stock, payable on Mar. 29, 2024 to stockholders of record on Mar. 1, 2024.

COVENANT LOGISTICS GROUP INC

Official Changes On Jan. 5, 2024, the board of directors (the "Board") of Co. promoted Matisse Long to Chief Accounting Officer. The Board also designated Mr. Long as Co.'s principal accounting officer. James S. Grant, Co.'s Executive Vice President and Chief Financial Officer will continue to serve as principal financial officer but will no longer serve as principal accounting officer.

COVENANT LOGISTICS GROUP INC

Official Changes On Mar.31, 2024, Lynn Doster notified the board of directors (the "Board") of Co. of her decision to retire from her position as Executive Vice President Ü Dedicated and Warehousing Operations, which won't be effective until Dec. 31, 2024.

CREATIVE MEDIA & COMMUNITY TRUST CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Rental & other property income	14,193	56,226	52,838
Interest & other income	12,248	21,366
Hotel income	66,002	33,432	16,722
Other income	39,063
Total revenues	119,258	101,906	90,926
Rental & other property operating expenses	50,526	39,272
Asset management & other fees to related parties Expense reimbursements to	2,627	3,570	9,030

operations - basic	\$(3.33)
Net income (loss) per share - basic	\$(3.33)	\$(1.11)	\$(1.04)
Earnings (loss) per share from continuing operations - diluted	\$(3.33)
Net income (loss) per share - diluted	\$(3.33)	\$(1.11)	\$(1.04)
Dividends per common share	\$0.34	\$0.34	\$0.30
Full-Time Employees (Period End)	5
Total number of employees	5	□5	□5
Number of common stockholders	335	□357	□□□387
Interest	35,098

Distributions in excess of earnings	(921,925)	(837,846)
Total stockholders' equity (deficit)	374,403	361,660
Noncontrolling interests	2,366	373
Total equity (deficit)	376,769	362,033

Recent Dividends:**1. Creative Media & Community Trust Corp common shares of beneficial interest.**

ExDate	Amt	Declared	Record	Payable
06/16/2022	0.09	06/10/2022	06/20/2022	07/05/2022
09/30/2022	0.09	09/22/2022	10/03/2022	10/17/2022
12/23/2022	0.09	12/15/2022	12/27/2022	01/09/2023
03/29/2023	0.09	03/20/2023	03/30/2023	04/11/2023
07/07/2023	0.09	06/27/2023	07/10/2023	07/24/2023
10/05/2023	0.09	09/27/2023	10/09/2023	10/23/2023
12/29/2023	0.09	12/20/2023	01/02/2024	01/16/2024
04/05/2024	0.09	03/27/2024	04/08/2024	04/22/2024

2. Creative Media & Community Trust Corp PMC Investment Corporation 4% cumulative preferred.

ExDate	Amt	Declared	Record	Payable
08/04/2022	0.11	06/10/2022	08/05/2022	08/15/2022
09/01/2022	0.11	06/10/2022	09/05/2022	09/15/2022
10/04/2022	0.11	06/10/2022	10/05/2022	10/17/2022
11/03/2022	0.11	09/22/2022	11/05/2022	11/15/2022
12/02/2022	0.11	09/22/2022	12/05/2022	12/15/2022
01/04/2023	0.11	09/22/2022	01/05/2023	01/17/2023
0.11	0.11	01/12/2023	02/05/2023	02/15/2023
0.11	0.11	01/12/2023	03/05/2023	03/15/2023
0.11	0.11	01/12/2023	04/05/2023	04/17/2023
0.11	0.11	04/04/2023	05/05/2023	05/15/2023
0.11	0.11	04/04/2023	06/05/2023	06/15/2023
0.11	0.11	04/04/2023	07/05/2023	07/17/2023
0.11	0.11	07/12/2023	08/05/2023	08/15/2023
0.11	0.11	07/12/2023	09/05/2023	09/15/2023
0.11	0.11	07/12/2023	10/05/2023	10/16/2023
0.11	0.11	10/13/2023	11/05/2023	11/15/2023
0.11	0.11	10/13/2023	12/05/2023	12/15/2023
0.11	0.11	10/13/2023	01/05/2024	01/15/2024
0.11	0.11	01/02/2024	02/05/2024	02/15/2024
0.11	0.11	01/02/2024	03/05/2024	03/15/2024
0.11	0.11	01/02/2024	04/05/2024	04/15/2024

3. Creative Media & Community Trust Corp series A1 cumulative redeemable preferred.

No dividends paid.

4. Creative Media & Community Trust Corp series D cumulative redeemable preferred.

No dividends paid.

5. Creative Media & Community Trust Corp series A cumulative redeemable preferred.

No dividends paid.

6. Creative Media & Community Trust Corp series L cumulative redeemable preferred.

No dividends paid.

7. Creative Media & Community Trust Corp PMC Investment Corporation 3% cumulative preferred.

ExDate	Amt	Declared	Record	Payable
12/28/2022	1.56	12/15/2022	12/29/2022	01/25/2023

8. Creative Media & Community Trust Corp series A cumulative redeemable preferred.

No dividends paid.

Annual Dividends:**1. Creative Media & Community Trust Corp common shares of beneficial interest.**

2022	0.17	2023	0.34	2024	0.17
------	------	------	------	------	------

2. Creative Media & Community Trust Corp PMC Investment Corporation 4% cumulative preferred.

2022	0.57	2023	1.37	2024	0.46
------	------	------	------	------	------

3. Creative Media & Community Trust Corp series A1 cumulative redeemable preferred.

No dividends paid.

4. Creative Media & Community Trust Corp series D cumulative redeemable preferred.

No dividends paid.

5. Creative Media & Community Trust Corp series A cumulative redeemable preferred.

No dividends paid.

6. Creative Media & Community Trust Corp series L cumulative redeemable preferred.

No dividends paid.

7. Creative Media & Community Trust Corp PMC Investment Corporation 3% cumulative preferred.

2023 1.56

8. Creative Media & Community Trust Corp series A cumulative redeemable preferred.

No dividends paid.

DAVE & BUSTERS ENTERTAINMENT INC**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	02/04/24	01/29/23	01/30/22 (revised)
Food & beverage revenues	770,500	678,333	436,637
Amusement & other revenues	...	1,286,094	867,419
Entertainment revenues	1,434,800
Total revenues	2,205,300	1,964,427	1,304,056
Cost of food & beverage	...	193,742	119,123
Cost of amusement & other cost of products	...	115,122	85,848
Cost of food and beverage (as a percentage of food and beverage revenues)	202,900
Cost of entertainment (as a percentage of entertainment revenues)	134,100
Total cost of products	...	308,864	204,971
Operating payroll & benefits	526,000	470,729	287,263
Other store operating expenses	686,200	600,568	402,661
General & administrative expenses	122,600	137,837	75,501
Depreciation & amortization expense	208,500	169,302	138,329
Pre-opening costs	18,400	14,619	8,150
Total operating costs	1,898,700	1,701,919	1,116,875
Operating income (loss)	306,600	262,508	187,181
Interest expense on debt	...	77,707	43,463
Interest associated with swap agreements	...	4,088	7,547
Amortization of issuance cost	...	8,466	4,244
Interest income	...	628	...
Capitalized interest	...	2,270	1,344
Interest expense, net	(127,400)	(87,363)	(53,910)
Loss on debt extinguishment or refinancing	(16,100)	(1,479)	(5,617)
Income (loss) before provision (benefit) for income taxes	163,100	173,666	127,654
Current income tax provision (benefit)	8,300	2,366	21,899
- federal	...	6,459	4,577
Current income tax provision (benefit) - state & local
Current income tax provision (benefit)

provision (benefit) - foreign	1,300	76	333
Current Tax - State and Local	9,400
Total current income tax provision (benefit)	19,000	8,901	26,809
Deferred income tax provision (benefit)	16,200	25,010	(2,354)
- federal	...	3,142	(5,441)
Deferred income tax provision (benefit) - state & local
Deferred income tax provision (benefit) - foreign	(1,500)	(522)	...
Deferred Tax - State and Local	2,500
Total deferred income tax provision (benefit)	17,200	27,630	(7,795)
Provision (benefit) for income taxes	36,200	36,531	19,014
Net income (loss)	126,900	137,135	108,640
Weighted average shares outstanding - basic	43,200	48,498	48,142
Weighted average shares outstanding - diluted	44,070	49,177	49,264
Year end shares outstanding	40,270	48,410	48,490
Net income (loss) per share - basic	\$2.94	\$2.83	\$2.26
Net income (loss) per share - diluted	\$2.88	\$2.79	\$2.21
Full-Time Employees (Period End)	23,258
Total number of employees	23,258	22,748	13,783
Number of common stockholders	292	374	413
Foreign currency translation adjustments	...	(251)	(28)
Basic EPS Excluding ExtraOrdinary Items	\$2.94
Diluted EPS Excluding ExtraOrdinary Items	\$2.88

[□] Reclassified to conform with 2022 presentation; [■] As is; [▣] As of March 17, 2023; [▢] As of March 18, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	02/04/24	01/29/23
Cash & cash equivalents	37,300	181,591
Operating store - food & beverage	...	10,858
Operating store - amusement	...	18,593
Corporate supplies, warehouse & other inventories	37,200	...
Corporate - amusement, supplies & other	...	15,970
Inventories	...	45,421
Prepaid expenses	18,200	19,469
Income taxes receivable	22,900	25,526
Other current assets	...	21,700
Accounts receivable	21,900	...
Total current assets	137,500	293,707
Land	38,700	26,798
Buildings & building improvements	86,500	49,947
Leasehold improvements	1,205,700	1,103,000
Furniture, fixtures & equipment	692,600	573,111
Games	2,555,300	372,665
Construction in progress	120,000	98,442
Games	411,800	...
Property & equipment, gross	...	2,223,963

Less: accumulated depreciation	1,222,600	1,043,732	Operating revenues	96,846,000	51,630,000	(revised)	doubtful accounts	250,000	250,000
Property & equipment	1,332,700	1,180,231	Operating revenues	96,846,000	51,630,000	24,695,000	Accounts receivable, net	12,735,000	6,945,000
Operating lease right of use assets, net	1,323,300	1,333,596	Operating expenses	88,044,000	46,546,000	29,016,000	Employee retention credit receivable	...	3,035,000
Deferred tax assets	6,000	526	General & administrative	11,430,000	15,455,000	12,046,000	Contract assets	...	5,433,000
Tradenames	178,200	178,200	Depreciation	8,492,000	11,830,000	...	Prepaid expenses	8,654,000	2,252,000
Goodwill	742,500	744,480	Other expense	12,863,000	Other assets	...	1,191,000
Other assets & deferred charges	34,200	30,253	Depreciation & amortization	Prepaid expenses & other current assets	...	8,876,000
Total assets	3,754,400	3,760,993	Total operating costs	110,174,000	73,831,000	53,925,000	Total current assets	37,426,000	38,035,000
Current installments of long-term debt	9,000	8,500	Income (loss) from operations	(13,328,000)	(22,201,000)	(29,230,000)	Land, building & other property & equipment	13,476,000	12,553,000
Accounts payable	118,600	84,696	Interest income	576,000	317,000	220,000	Recording equipment	140,156,000	147,675,000
Deferred amusement revenue	121,200	114,375	Interest expense	103,000	31,000	21,000	Vibrator energy sources	64,690,000	64,110,000
Current portion of operating lease liabilities, net	63,100	64,123	Other income (expense), net	612,000	411,000	(86,000)	Vehicles	23,633,000	20,492,000
Compensation & benefits	29,000	60,607	Gain from employee retention credit	...	2,966,000	...	Property & equipment	241,955,000	244,830,000
Current portion of deferred occupancy costs	2,900	6,820	Income (loss) before income tax	(12,243,000)	(18,538,000)	(29,117,000)	Less accumulated depreciation	225,447,000	226,703,000
Deferred gift card revenue	20,300	16,362	Current United States federal income tax expense (benefits)	(17,000)	(9,000)	...	Property & equipment, net	16,508,000	18,127,000
Accrued interest	14,800	15,802	Current state income taxes (benefits)	42,000	Right-of-use assets	3,208,000	4,010,000
Property taxes	9,700	13,076	Current income tax expense (benefit)	25,000	(9,000)	(27,000)	Intangibles, net	377,000	369,000
Current portion of long-term insurance	5,700	6,700	Deferred United States federal income taxes (benefit)	(114,000)	109,000	...	Total assets	57,519,000	60,541,000
Accrued utilities	...	7,166	Deferred state income taxes	(7,000)	7,000	...	Accounts payable	3,883,000	4,015,000
Sales & use taxes	12,500	9,922	Deferred income tax expense (benefit)	(121,000)	116,000	1,000	Accrued payroll costs & other taxes	3,415,000	1,973,000
Customer deposits	9,700	8,705	Total income tax expense (benefit)	(96,000)	107,000	(26,000)	Accrued self-insurance reserves	338,000	...
Other accrued liabilities	306,000	19,234	Net income (loss)	(12,147,000)	(18,645,000)	(29,091,000)	Other accrued expenses & current liabilities	709,000	...
Utilities	7,500	...	Weighted average shares outstanding - basic	26,752,055	24,971,031	23,570,455	Other accrued liabilities	371,000	1,178,000
Accrued liabilities	...	342,892	Weighted average shares outstanding - diluted	26,752,055	24,971,031	23,570,455	Deferred revenue	11,829,000	7,199,000
Income taxes payable	2,000	1,949	Year end shares outstanding	30,812,329	23,812,329	23,643,934	Current maturities of notes payable & finance leases	1,380,000	275,000
Accrued interest	9,600	...	Income (loss) per share from continuing operations - basic	\$(0.45)	\$(0.75)	...	Current maturities of operating lease liabilities	1,202,000	1,118,000
Total current liabilities	435,600	438,037	Net income (loss) per share - basic	\$(0.45)	\$(0.75)	\$(1.23)	Current maturities of notes payable and finance leases - Balancing value	910,000	...
Deferred income taxes	89,800	66,246	Income (loss) per share from continuing operations - diluted	\$(0.45)	\$(0.75)	\$(1.23)	Current portion of capital lease obligations	470,000	...
Operating lease liabilities	1,558,500	1,567,794	Number of full time employees	281	...	190	Total current liabilities	22,418,000	15,758,000
Other liabilities	135,300	55,670	Number of employees	281	Notes payable & finance leases, net of current maturities	1,289,000	207,000
Credit facility - term loan	...	847,875	Number of common stockholders	66	...	70	Operating lease liabilities, net of current maturities	2,363,000	3,331,000
Senior secured notes	...	440,000	Foreign currency translation adjustments	190,000	Capital lease obligations, less current maturities	1,289,000	...
Less current installments of long-term debt	...	8,500	Severance expense	2,208,000	Deferred tax liabilities, net	15,000	136,000
Less: debt issuance costs - term	1,284,000	...					Total long-term liabilities	3,667,000	3,674,000
Less issue discount on term loan	...	(38,846)					Common stock	308,000	238,000
Less debt issuance costs	...	(17,818)					Additional paid-in capital	156,678,000	155,413,000
Long-term debt, net	...	1,222,711					Accumulated deficit	(123,640,000)	...
Common stock, par value \$0.01; authorized: 400.00 shares; issued: 62.69 shares at 30, 2023 and 62.42 at 29, 2023; outstanding: 42.97 shares at 30, 2023 and 48.41 at 29, 2023	600	...					Retained earnings (accumulated deficit)	...	(112,469,000)
Common stock	...	624					Accumulated other comprehensive income (loss), net	(1,912,000)	(2,073,000)
Paid-in capital	597,600	577,481					Total stockholders' equity	31,434,000	41,109,000
Treasury stock	945,300	638,976					Total Equity	31,434,000	...
Accumulated other comprehensive income (loss)	(900)	(860)							
Retained earnings	599,200	...							
Retained earnings (accumulated deficit)	...	472,266							
Total stockholders' equity (deficit)	251,200	410,535							
Total Equity	251,200	...							

Recent Dividends:
1. Dave & Busters Entertainment Inc common.
 No dividends paid.

Annual Dividends:
1. Dave & Busters Entertainment Inc common.
 No dividends paid.

DAWSON GEOPHYSICAL CO (NEW)

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

☐ Restated to reflect correction of errors; ☒ As of March 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
		(revised)
Cash & cash equivalents	10,772,000	13,914,000
Restricted cash	5,000,000	5,000,000
Short-term investments	265,000	265,000
Accounts receivable, gross	12,985,000	7,195,000
Less: allowance for		

Recent Dividends:

- 1. Dawson Geophysical Co (New) common.**
No dividends paid.
- 2. Dawson Geophysical Co (New) 8.5% senior convertible preferred.**
No dividends paid.

- 3. Dawson Geophysical Co (New) 8% series C convertible exchangeable preferred.**
No dividends paid.

Annual Dividends:

- 1. Dawson Geophysical Co (New) common.**
No dividends paid.
- 2. Dawson Geophysical Co (New) 8.5% senior convertible preferred.**

No dividends paid.
3. Dawson Geophysical Co (New) 8% series C convertible exchangeable preferred.
 No dividends paid.

**DIGITAL HEALTH ACQUISITION CORP
 Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Formation & operational costs	...	3,594,967	...
General & administrative expenses	2,593,765	...	282,671
Income (loss) from operations	(2,593,765)	(3,594,967)	(282,671)
Interest earned on investment held in trust account	358,767	922,644	1,970
Interest expenses - bridge note	1,579,927	125,980	...
Change in fair value of bridge note - bifurcated derivative	(1,630)	86,307	...
Change in fair value of PIPE forward contract derivative	(170,666)	170,666	...
Change in fair value of Investor Note- Bifurcated Derivative	120,267
Default interest expense Bridge Note	429,007
Interest expense Additional Bridge	12,642
Interest expense M2B	22,958
Interest expense - Extension Note	133,748
Initial fair value of Additional Bridge Note	11,111
Initial fair value of ELOC	(204,039)
Change in fair value of Additional Bridge Note	(2,726)
Change in fair value of Exchange Note	(97,814)
Change in fair value of ELOC	319
Total other income, net	(1,820,101)	539,691	...
Income (loss) before provision for income taxes	(4,413,866)	(3,055,276)	...
Current federal income taxes	...	187,225	...
Deferred federal income taxes	...	(741,805)	...
Deferred state income taxes	...	(153,306)	...
Change in valuation allowance	...	895,111	...
Provision for income taxes	...	187,225	...
Net income (loss)	(4,413,866)	(3,242,501)	(280,701)
Weighted average redeemable common shares outstanding - basic	3,981,054
Weighted average shares outstanding - basic	4,096,353	12,741,219	...
Weighted average redeemable common shares outstanding - diluted	3,981,054
Weighted average shares outstanding

- diluted	4,096,353	12,741,219	...
Year end shares outstanding	3,603,966	[□] 4,156,123	^{□□} 14,932,000
Net income (loss) per common share - basic	\$(1.08)	\$(0.25)	...
Net income (loss) per common share - diluted	\$(1.08)	\$(0.25)	...
Total number of employees	...	2	2
Number of common stockholders	15	^{□□} 14	...

[□] From March 30, 2021 (Inception); ^{□□} Non-consolidated; ^{□□□} Shares decreased due to the effect of redemption of common stock; ^{□□□} Shares increased due to issuance of common stock to Sponsor and sale of private placement units; ^{□□□} Approximately; ^{□□} As of April 7, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	1,863	106,998
Total current assets	1,863	106,998
Cash investment held in trust account	1,368,637	7,527,369
Total assets	1,370,500	7,634,367
Accounts payable & accrued expenses	3,303,836	1,886,312
Income taxes payable	187,225	187,225
Bridge note, net of discount	...	292,800
Promissory note - related party	926,500	350,000
Advances from related parties	...	43,900
Bridge note - bifurcated derivative	22,872	364,711
PIPE forward contract derivative	2,621,558	170,666
Sponsor note payable	117,871	...
Excise tax payable	72,396	...
Accrued interest on Exchange Note	23,964	...
Additional Bridge Promissory note, net of discount	102,726	...
Promissory note M2B	167,958	...
ELOC	203,720	...
Extension Note, net of discount	233,774	...
Total current liabilities	7,984,400	3,295,614
Deferred underwriting fee payable	4,370,000	4,370,000
Total liabilities	12,354,400	7,665,614
Common stock subject to redemption	...	7,395,349
Common Stock	350	...
Common stock	1,281,957	347
Additional paid-in capital	550,246	292,973
Accumulated Deficit	(12,816,453)	...
Retained earnings (accumulated deficit)	...	(7,719,916)
Total stockholders' equity (deficit)	(10,983,900)	(7,426,596)
Total Equity	(10,983,900)	...

Recent Dividends:

- 1. Digital Health Acquisition Corp common subject to redemption.**
 No dividends paid.
- 2. Digital Health Acquisition Corp common.**
 No dividends paid.

Annual Dividends:

- 1. Digital Health Acquisition Corp common subject to redemption.**
 No dividends paid.
- 2. Digital Health Acquisition Corp common.**
 No dividends paid.

**DISH NETWORK CORP
 Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Service revenue	14,721,682	16,005,620	16,890,729
Equipment sales & other revenue	573,406	673,787	990,377
Total revenue	15,295,088	16,679,407	17,881,106
Cost of services	8,989,961	9,558,884	10,185,942
Customer service center	2,201,870
Cost of sales - equipment & other	...	1,812,191	1,552,341
Selling, general & administrative expenses	2,521,062	2,545,593	2,214,936
Impairment of long-lived assets	225,017
Equipment leased to customers	1,001,300
Intangible assets	180,621
Depreciation & amortization	1,181,921	717,073	724,852
Total costs & expenses	15,119,831	14,633,741	14,678,071
Operating income (loss)	175,257	2,045,666	3,203,035
Interest income	105,416	42,776	11,338
Interest expense, net of amounts capitalized	38,881	22,781	16,174
Gain on insurance settlement	(1,741,876)
Derivative financial instruments - net realized and/or unrealized gains (losses)	(1,793,387)
Marketable investment securities - realized & unrealized gains (losses) on equity securities	4,085	(1,241)	(3,137)
Derivative instruments - net realized & or unrealized gains (losses)	...	1,015,387	(13,000)
Non-marketable investment securities - gains (losses)	...	27,427	...
Costs related to early redemption of debt	73,024	(922)	(3,587)
Equity in earnings of affiliates	(3,835)	2,616	(1,051)
Other income (expense)	...	(4,285)	41,332
Other income (expense)	(21,763)
Total other income (expense)	(1,675,341)	1,058,977	15,721
Income (loss) before income taxes	(1,500,084)	3,104,643	3,218,756
Current income tax provision - federal	(29,307)	(23,571)	126,435
Current income tax provision - state	29,254	59,690	31,944
Current income tax provision - foreign	3,301	(7,118)	2,387
Total current income tax provision	3,248	29,001	160,766
Deferred income tax provision (benefit) - federal	(293,666)	615,323	509,405
Deferred income tax provision (benefit) - state	(152,725)	85,045	86,822
Decrease (increase)

in valuation allowance	71,481	2,367	5,817
Total deferred income tax provision (benefit)	(374,910)	702,735	602,044
Income tax (benefit) provision, net	(371,662)	731,736	762,810
Net income (loss)	(1,128,422)	2,372,907	2,455,946
Less: net income (loss) attributable to noncontrolling interests, net of tax	(83,801)	(69,674)	(45,304)
Net income (loss) attributable to DISH Network	(1,212,223)	2,303,233	2,410,642
Weighted average shares outstanding-basic	1	530,114	527,844
Weighted average shares outstanding-diluted	1	637,290	636,063
Year end shares outstanding	1	531,096	528,965
Earnings (loss) per share from continuing operations - basic	\$(1,212,223.00)
Net earnings (loss) per share-basic	\$(1,212,223.00)	\$4.34	\$4.57
Earnings (loss) per share from continuing operations - diluted	\$(1,212,223.00)
Net earnings (loss) per share-diluted	\$(1,212,223.00)	\$3.61	\$3.79
Total number of employees	14,200	14,500	14,500
Number of class A common stockholders	6,409	6,473	6,473
Number of class B common stockholders	1	1	1
Foreign currency translation adjustments	(4,160)

□ As is; □ Approximately; □ As of February 14, 2023; □ As of February 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	373,641	1,785,056
Marketable investment securities	8,122	835,983
Trade accounts receivable, gross	944,324	998,243
Allowance for credit losses	53,991	44,431
Trade accounts receivable, net	890,333	953,812
Finished goods	407,620	447,322
Work-in-process & service repairs	35,464	19,351
Raw materials	6,251	35,700
Consignment	47,723	...
Inventory	497,058	...
Inventories, net	...	502,373
Other current assets	2,308	532,886
Prepays and other assets	572,199	...
Total current assets	2,343,661	4,610,110
Restricted cash, cash equivalents & marketable investment securities	108,879	104,614
Equipment leased to customers	1,181,193	1,318,272
Satellites	1,718,865	1,718,865
Satellite acquired under finance lease agreements	344,447	344,447
Furniture, fixtures, equipment & other property & equipment	...	1,215,496

5G Network Deployment equipment	4,263,327	770,153
Software	...	1,354,656
Buildings & improvements	381,757	380,519
Land	17,513	17,513
Construction in progress	1,802,000	3,170,623
Computer equipment held for sale	2,111,305	...
Furniture, fixtures, equipment and other	908,924	...
Total property & equipment	12,729,331	10,290,544
Less: accumulated depreciation	5,327,384	4,650,425
Property & equipment, net	7,401,947	5,640,119
FCC authorizations	...	36,933,073
Intangible assets, net	159,490	565,109
Other investment securities	168,825	168,200
Operating lease assets	2,934,862	2,687,522
Other noncurrent assets, net	181,118	1,897,815
FCC authorizations	38,114,249	...
Total noncurrent assets	49,069,370	47,996,452
Total assets	51,413,031	52,606,562
Trade accounts payable	673,291	924,438
Deferred revenue & other current liabilities	...	711,474
Accrued programming	1,427,762	1,298,777
Accrued interest	1,251,438	258,799
Other accrued expenses	1,552,610	1,283,570
Current portion of long-term debt & finance lease obligations	3,041,429	1,547,190
Current portion of long-term debt & capital lease obligations	2,984,970	...
Deferred revenue and other	638,471	...
Accrued interest	258,603	...
Finance lease	56,459	...
Operating Lease Liabilities - Current	301,172	...
Portion/Short-Term	7,592,166	6,024,248
Total current liabilities	67,199	...
Finance lease
Long-term debt & finance lease obligations, net of current portion	18,178,288	19,801,948
Long-term debt & capital lease obligations, net of current portion	18,111,089	...
Long-term deferred satellite services revenue	861,896	...
Deferred tax liabilities	4,557,262	4,930,135
Operating lease liabilities	2,992,863	2,687,883
Long-term deferred revenue & other long-term liabilities	...	753,708
Total liabilities	...	34,197,922
Redeemable noncontrolling interests	438,382	464,359
Class A common stock	...	2,927
Class B common stock	...	2,384
Additional paid-in capital	4,916,120	4,851,392
Foreign currency translation adjustment	(2,679)	(3,004)
Unrealized or recognized gains (losses)	3	(25)
Accumulated other comprehensive income (loss) - Balancing value	(2,676)	...
Accumulated other comprehensive income (loss)	...	(3,029)
Accumulated earnings (deficit)	11,876,627	13,088,850
Total DISH Network Corporation stockholders' equity (deficit)	16,790,071	17,942,524

Noncontrolling interests	2,103	1,757
Total stockholders' equity (deficit)	16,792,174	17,944,281

Recent Dividends:
1. DISH Network Corp class B common.
 No dividends paid.
2. DISH Network Corp class A common.
 No dividends paid.
3. DISH Network Corp common.
 No dividends paid.
Annual Dividends:
1. DISH Network Corp class B common.
 No dividends paid.
2. DISH Network Corp class A common.
 No dividends paid.
3. DISH Network Corp common.
 No dividends paid.

DOMO INC Annual Report
Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2024	2023	2022
Subscription	46,045
Professional Services and Other	29,425
Revenue: subscription	...	271,290	223,010
Revenue: professional services & other	33,489	37,355	34,951
Subscription	285,500
Total revenue	318,989	308,645	257,961
Cost of revenue: subscription	...	43,295	40,907
Cost of revenue: professional services & other	...	29,783	26,239
Total cost of revenue	...	73,078	67,146
Gross profit	243,519	235,567	190,815
Sales & marketing expenses	163,902	173,300	143,722
Research & development	85,049	95,093	81,027
General & administrative expenses	49,449	56,047	54,536
Total operating expenses	298,400	324,440	279,285
Income (loss) from operations	(54,881)	(88,873)	(88,470)
Other income (expense), net	(19,431)	(15,499)	(14,102)
Income (loss) before income taxes	(74,312)	(104,372)	(102,572)
Current state income taxes	81	135	5
Current foreign income taxes	884	586	80
Current income taxes	965	721	85
Deferred foreign income taxes	292	458	(546)
Provision for income taxes	1,257	1,179	(461)
Net income (loss)	(75,569)	(105,551)	(102,111)
Weighted average shares outstanding - basic	36,050	34,092	32,021
Weighted average shares outstanding - diluted	36,050	34,092	32,021
Year end shares outstanding	36,920	34,837	32,993
Net earnings (loss) per share - basic	\$(2.10)	\$(3.10)	\$(3.19)
Net earnings (loss) per share - diluted	\$(2.10)	\$(3.10)	\$(3.19)
Full-Time Employees (Period End)	958
Total number of

employees	958	□967	□917
Number of class A common stockholders	...	□1	□1
Number of class B common stockholders	...	□91	□102
Common Shareholders - Number	91
Foreign currency translation adjustments	...	(710)	...
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$(2.10)
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$(2.10)

□ As is

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2024	2023
Money market funds	11,942	...
Cash	45,297	...
Cash & cash equivalents	60,939	66,500
Accounts receivable, gross	70,908	81,042
Less: allowances for doubtful accounts	3,711	2,084
Accounts receivable, net	67,197	78,958
Contract acquisition costs, net	16,006	15,908
Prepaid expenses & other current assets	9,602	7,447
Restricted cash	3,700	...
Total current assets	153,744	168,813
Capitalized internal-use software development costs	55,018	44,399
Computer equipment & software	62,122	2,038
Leasehold improvements	3,949	3,070
Furniture, vehicles & office equipment	1,158	813
Computer equipment and software	1,997	...
Property & equipment, gross	...	50,320
Less accumulated depreciation & amortization	35,119	28,945
Property & equipment, net	27,003	21,375
Right-of-use assets	11,746	15,255
Contract acquisition costs, noncurrent, net	19,542	22,299
Intangible assets, net	2,740	2,794
Goodwill	9,478	9,478
Other assets	1,407	2,102
Total assets	225,660	242,116
Accounts payable	4,313	12,120
Accrued expenses	16,284	13,772
Accrued bonus	8,057	6,708
Accrued payroll & benefits	4,541	11,476
Accrued commissions	4,677	5,438
Accrued payroll taxes	...	2,841
Employee stock purchase plan liability	2,475	3,071
Sales & other taxes payable	1,339	1,111
Other accrued liabilities	4,231	4,889
Employee stock purchase plan liability	1,826	...
Accrued expenses & other current liabilities	43,430	49,306
Lease liabilities	4,807	4,905
Deferred revenue	185,250	182,273
Total current liabilities	237,800	248,604
Lease liabilities, noncurrent	11,135	15,271

Deferred revenue	2,736	3,609
Other long-term liabilities	14,001	12,425
Credit facility	...	113,427
Less: unamortized debt issuance costs	...	(4,820)
Long-term debt, net	113,534	108,607
Total liabilities	379,206	388,516
Class A common stock	34	3
Class B common stock	3	32
Additional paid-in capital	1,252,200	1,183,921
Accumulated other comprehensive income	(180)	(322)
Retained earnings (accumulated deficit)	(1,405,603)	(1,330,034)
Total stockholders' equity (deficit)	(153,546)	(146,400)
Total Equity	(153,546)	...

Recent Dividends:**1. Domo Inc class A common.**

No dividends paid.

2. Domo Inc class B common.

No dividends paid.

Annual Dividends:**1. Domo Inc class A common.**

No dividends paid.

2. Domo Inc class B common.

No dividends paid.

DRILLING TOOLS INTERNATIONAL HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	□2021 (revised)
General & administrative expenses	68,264,000	1,281,902	252,254
Loss from operations	27,899,000	(1,281,902)	(252,254)
Interest earned on investments held in trust account	...	2,843,649	16,874
Domestic	17,352,000
International	2,442,000
Income (loss) before provision for income taxes	19,794,000	1,561,747	(235,380)
Current Federal	162,000
Current Foreign	656,000
Current state	785,000
Income Taxes - Total - Current	1,603,000
Deferred federal	3,826,000
Deferred foreign	34,000
Deferred state	(417,000)
Income Taxes - Total - Deferred	3,443,000
Provision for income taxes	5,046,000	546,045	...
Net income (loss)	14,748,000	1,015,702	(235,380)
Accumulated dividends on redeemable convertible preferred stock	314,000
Net income available to common shareholders	14,434,000
Weighted average shares outstanding - basic	21,421,610	26,851,000	9,182,858
Weighted average shares outstanding - diluted	25,131,024	26,851,000	9,182,858
Year end shares outstanding	29,768,568	26,851,000	26,851,000
Net earnings (loss) per share - basic	\$0.67	\$0.04	\$(0.03)
Net earnings (loss) per share - diluted	\$0.59	\$0.04	\$(0.03)
Number of part time employees	...	2	2

Number of common stockholders	86	□2	□7
Tool rental	119,239,000
Product sale	32,795,000
Cost of tool rental revenue	30,960,000
Cost of product sale revenue	4,559,000
Depreciation and amortization expense	20,352,000
Gain on sale of property	101,000
Unrealized gain (loss) on equity securities	(255,000)
Interest expense	(1,103,000)
Other expense	(6,359,000)
Total Revenue	152,034,000
Total operating costs and expenses	124,135,000
Loss on asset disposal	(489,000)
Non-Operating Income/Expense - Total	(8,105,000)
Full-Time Employees (Period End)	394
Total number of employees	394

□ From September 2, 2021 (inception); □ As of March 20, 2023;

□ As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	6,003,000	207,915
Prepaid insurance	1,110,000	170,503
Prepaid income taxes	362,000	4,527
Accounts receivable, net	29,929,000	...
Raw Materials - Net	5,022,000	...
Finished Goods	16,000	...
Inventories, net	5,034,000	...
Deposits on inventory	2,146,000	...
Prepaid rent	372,000	...
Prepaid equipment	331,000	...
Prepaid other	214,000	...
Prepaid expenses and other current assets	4,553,000	...
Investment equity securities, at fair value	888,000	...
Provision - Accounts & Notes Receivable - Trade	1,458,000	...
Allowance for obsolete inventory	4,000	...
Other Current Assets	18,000	...
Accounts receivable, net - Balancing value	27,187,000	...
Contract Assets - Short-Term - Unbilled Revenue in Excess of Advance Consideration & Progress Billings	4,200,000	...
Total current assets	46,408,000	382,945
Cash & marketable securities held in trust account	879,000	213,475,172
Rental tools and equipment	188,949,000	...
Office furniture, fixtures and equipment	2,389,000	...
Buildings and improvements	6,672,000	...
Transportation and equipment	793,000	...
Property, Plant & Equipment - Accumulated Depreciation & Impairment	133,003,000	...
Property, plant and equipment, net	65,800,000	...
Operating lease right-of-use asset	18,786,000	...
Intangible assets, net	216,000	...

Deferred financing costs, net.....	409,000	...	
Total assets.....	132,498,000	213,858,117	
Accrued expenses.....	10,579,000	482,828	
Accrued offering costs.....	978,000	...	
Promissory note - related party.....	...	2,070,000	
Deferred tax liability.....	...	91,572	
Accounts payable.....	7,751,000	...	
Accrued expenses and other current liabilities.....	1,373,000	...	
Current portion of operating lease liabilities.....	3,958,000	...	
Accrued compensation and related benefits.....	4,999,000	...	
Accrued professional services.....	189,000	...	
Accrued interest.....	58,000	...	
Accrued property taxes.....	60,000	...	
Other.....	147,000	...	
Income tax payable.....	1,586,000	...	
Deferred Income - Short-Term.....	1,042,000	...	
Unbilled lost-in-hole revenue.....	76,000	...	
Sales tax payable.....	71,000	...	
Total current liabilities.....	22,288,000	...	
Operating lease liabilities, less current portion.....	14,893,000	...	
Deferred tax liabilities, net.....	6,627,000	...	
Total liabilities.....	43,808,000	2,644,400	
Common stock subject to possible redemption.....	...	213,183,552	
Common stock, par value \$001; 65,000,000 shares authorized; 53,175,028 shares issued at 31, 2022 and 31, 2021; and 52,363,872 shares outstanding at 31, 2022 and 31, 2021.....	3,000	...	
Common stock.....	...	615	
Additional paid-in capital.....	95,218,000	...	
Accumulated deficit.....	(6,306,000)	...	
Retained earnings (accumulated deficit).....	...	(1,970,450)	
Accumulated other comprehensive loss.....	(225,000)	...	
Total stockholders' equity.....	88,690,000	(1,969,835)	
Total Equity.....	88,690,000	...	

administrative.....	25,204	29,105	23,900
Total costs & operating expenses.....	87,559	106,224	89,081
Income (loss) from operations.....	(71,786)	(92,740)	(76,939)
Interest expense.....	5,466	4,132	3,559
Interest income.....	2,208	1,082	158
Other income (expense), net.....	87	(963)	46,487
Income (loss) before provision for income taxes.....	(74,957)	(96,753)	(33,853)
Foreign.....	6
Income Taxes - Total - Current.....	6
Provision for income taxes.....	6	23	64
Net income (loss).....	(74,963)	(96,776)	(33,917)
Weighted average shares outstanding - basic.....	1,476	1,388	1,131
Weighted average shares outstanding - diluted.....	1,476	1,388	1,131
Year end shares outstanding.....	1,479	1,469	1,152
Net earnings (loss) per common share - basic.....	\$(50.78)	\$(69.60)	\$(30.00)
Net earnings (loss) per common share - diluted.....	\$(50.78)	\$(69.60)	\$(30.00)
Number of full time employees.....	25	56	43
Number of common stockholders.....	17	20	17
Foreign currency translation adjustments.....	...	(100)	...
Earnings per share from continuing operations.....	\$(50.78)
Earnings per share from continuing operations.....	\$(50.78)
Total number of employees.....	25

& equipment.....	1,170	895
Property & equipment, net.....	627	696
Operating lease right-of-use assets.....	...	561
Other assets.....	360	1,347
Total assets.....	38,826	120,139
Accounts payable.....	2,115	8,975
Accrued contract research costs.....	2,909	4,188
Accrued contract manufacturing costs.....	818	2,101
Accrued compensation & related benefits.....	3,046	6,167
Product revenue reserves.....	2,277	1,373
Accrued franchise tax.....	438	...
Other accrued expenses.....	9,966	1,826
Accrued liabilities.....	...	15,655
Current portion of operating lease liabilities.....	84	491
Accrued interest.....	478	...
Current portion of long-term debt.....	41,119	...
Total current liabilities.....	53,284	25,121
Face value of long term debt.....	...	40,531
Exit fee.....	...	2,600
Unamortized debt discount associated with exit fee, debt issuance costs & loan origination fees.....	...	(3,506)
Debt, net of current portion.....	...	39,625
Operating lease liabilities.....	...	83
Total liabilities.....	53,284	64,829
Common stock.....	1	44
Additional paid-in capital.....	497,866	492,759
Accumulated other comprehensive income (loss).....	(169)	(300)
Accumulated deficit.....	(512,156)	...
Retained earnings (accumulated deficit).....	...	(437,193)
Total stockholders' equity (deficit).....	(14,458)	55,310
Total Equity.....	(14,458)	...

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-30 stock split, January 8, 2024; □ Shares increased due to the effect of issuance of common stock upon offering at-the-market, options exercised, to lender, under production development agreement, restricted stock units; □ As is; □ Approximately; □ As of March 13, 2023; □ As of March 7, 2022

Recent Dividends:
1. Eiger BioPharmaceuticals Inc convertible preferred.
 No dividends paid.
2. Eiger BioPharmaceuticals Inc series A-1 redeemable convertible preferred.
 No dividends paid.
3. Eiger BioPharmaceuticals Inc common.
 No dividends paid.
Annual Dividends:
1. Eiger BioPharmaceuticals Inc convertible preferred.
 No dividends paid.
2. Eiger BioPharmaceuticals Inc series A-1 redeemable convertible preferred.
 No dividends paid.
3. Eiger BioPharmaceuticals Inc common.
 No dividends paid.

Recent Dividends:
1. Drilling Tools International Holdings Inc common, subject to redemption/tender.
 No dividends paid.
2. Drilling Tools International Holdings Inc common.
 No dividends paid.
Annual Dividends:
1. Drilling Tools International Holdings Inc common, subject to redemption/tender.
 No dividends paid.
2. Drilling Tools International Holdings Inc common.
 No dividends paid.

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents.....	25,440	25,798
Short-term debt securities.....	...	73,150
Accounts receivable, net.....	1,682	1,749
Raw materials.....	531	...
Work-in-progress.....	940	...
Finished goods.....	85	...
Inventories.....	1,556	2,853
Prepaid expenses & other current assets.....	9,161	13,985
Total current assets.....	37,839	117,535
Computer equipment & software.....	116	736
Furniture.....	...	116
Leasehold improvements.....	101	101
Lab equipment.....	...	271
Construction in progress.....	305	367
Office furniture & equipment.....	271	...
Computer equipment and software.....	1,004	...
Total property & equipment.....	1,797	1,591
Less: accumulated depreciation - property		

ELIEM THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development expenses.....	15,411	26,214	23,322
General & administrative expenses.....	24,864	18,921	12,350
Total operating expenses.....	40,275	45,135	35,672
Income (loss) from operations.....	(40,275)	(45,135)	(35,672)
Change in fair			

EIGER BIOPHARMACEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Product revenue, net.....	15,523	12,734	12,142
Total revenue.....	15,773	13,484	12,142
Other revenue.....	250	750	...
Cost of sales.....	24	1,837	745
Research & development expenses.....	62,331	75,282	64,436
Selling, general &			

value of redeemable convertible preferred stock tranche liability	(11,718)	Other long-term liabilities	22	...	Total deferred income tax provision (benefit)	14,300	(26,500)	(3,000)
Foreign currency gain (loss)	536	(1,484)	(170)	Operating lease liabilities, net of current portion	15	180	Income tax provision (benefit)	35,300	33,000	80,000
Other income, net	4,620	1,375	80	Total liabilities	2,870	6,277	Net income (loss)	70,400	223,600	415,000
Total other income (expense)	5,156	(109)	(11,808)	Common stock	3	3	Weighted average shares outstanding			
Net income (loss)	(35,119)	(45,244)	(47,480)	Additional paid-in capital	263,577	249,930	- basic	57,248	57,024	...
Accretion of redeemable convertible preferred stock to redemption value & cumulative preferred stock dividends	4,548	Accumulated other comprehensive income (loss)	(2)	(358)	Weighted average shares outstanding - diluted	57,758	57,461	...
Net income (loss) attributable to common stockholders	...	(45,244)	(52,028)	Retained earnings (accumulated deficit)	(155,979)	(120,860)	Year end shares outstanding	57,333	57,055	...
Weighted average shares outstanding - basic	26,987	26,312	12,261	Total stockholders' equity (deficit)	107,599	128,715	Earnings (loss) per share - basic	\$1.23	\$3.92	...
Weighted average shares outstanding - diluted	26,987	26,312	12,261	Cash & cash equivalents	93,112	43,585	Earnings (loss) per share - diluted	\$1.22	\$3.89	...
Year end shares outstanding	27,699	26,568	26,235	Total Equity	107,599	...	Full-Time Employees (Period End)	2,200
Net earnings (loss) per share - basic	\$(1.30)	\$(1.72)	\$(4.24)	Recent Dividends:			Total number of employees	2,200	1,900	2,029
Net earnings (loss) per share - diluted	\$(1.30)	\$(1.72)	\$(4.24)	1. Eliem Therapeutics Inc common.			Number of common stockholders	6,900	7,400	...
Number of full time employees	9	30	19	No dividends paid.			Dividends Per Share - Common - Gross - by Period End Date	\$0.60
Number of part time employees	2	13	12	Annual Dividends:						
Total number of employees	11	43	31	1. Eliem Therapeutics Inc common.						
Number of common stockholders	...	16	37	No dividends paid.						
Foreign currency translation adjustments	...	(1,484)	...	EMBECTA CORP Annual Report						
Income from cont operations before income tax	(35,119)	Consolidated Income Statement, Years Ended Sept. 30 (\$000):						
					2023	2022	2021	□ September 30, 2021 and prior financial of Diabetes Care Business of Becton, Dickinson and Company; □ As is; □ Approximately; □ As of April 1, 2022; □ As of November 30, 2022		
				Revenues	1,120,800	Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):		
				Revenues	1,120,800	1,129,500	1,165,000	2023	2022	
				Cost of products sold	370,900	354,600	365,000	Cash & cash equivalents	326,500	330,900
				Gross profit	749,900	774,900	800,000	Trade receivables, gross	17,700	35,300
				Selling & administrative expense	341,300	294,800	240,000	Less: allowance for doubtful accounts	1,000	13,000
				Research & development expense	85,200	66,900	63,000	Less: allowance for cash discounts	16,700	(100)
				Impairment expense	2,500	58,900	...	Trade receivables, net	...	22,200
				Other operating expenses	99,400	44,700	5,000	Materials	32,100	23,400
				Total operating expenses	528,400	465,300	308,000	Work in process	8,100	5,600
				Operating income	221,500	309,600	492,000	Finished products	111,900	93,800
				Interest expense, net	107,000	46,200	...	Total Inventories	152,100	...
				Other income (expense), net	(8,800)	(6,800)	3,000	Inventories	...	122,800
				Income (loss) before income taxes - domestic	...	(29,100)	88,000	Amounts due from Becton, Dickinson & Company	142,400	110,900
				Income (loss) before income taxes - foreign	...	285,700	407,000	Prepaid expenses & other current assets	...	77,900
				Income (loss) before income taxes	105,700	256,600	495,000	Prepaid expenses and other	111,400	...
				Current federal income tax provision (benefit)	2,600	20,400	19,000	Total current assets	749,100	664,700
				Current state income tax provision (benefit)	(800)	3,400	4,000	Land	2,300	1,400
				Current foreign income tax provision (benefit)	19,200	35,700	60,000	Buildings	124,500	123,700
				Total current income tax provision (benefit)	21,000	59,500	83,000	Machinery, equipment & fixtures	747,900	505,100
				Deferred domestic income tax provision (benefit)	(2,000)	Leasehold improvements	9,100	6,500
				Deferred federal income tax provision (benefit)	5,900	(31,100)	...	Construction in progress	44,800	64,900
				Deferred state income tax provision (benefit)	700	(4,600)	...	Machinery, equipment and fixtures	567,200	...
				Deferred foreign income tax provision (benefit)	7,700	9,200	(1,000)	Property, plant & equipment, gross	...	701,600
								Less: accumulated depreciation	447,700	400,000
								Property, plant & equipment, net	300,200	301,600
								Goodwill & other intangible assets	24,700	24,600
								Deferred income taxes & other assets	39,300	95,500
								Right-of-use assets	23,000	...
								Deferred Income Taxes and Other Assets	140,400	...
								Deferred Tax - Asset - Net	78,100	...
								Total assets	1,214,400	1,086,400
								Accounts payable	53,500	41,400
								Accrued expenses - Balancing value	112,200	...
								Accrued expenses	118,100	104,300
								Amounts due to Becton, Dickinson & Company	73,100	66,500

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of issuance of shares in initial public offering and conversion of redeemable convertible preferred stock; □ As is; □ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022	
Short-term marketable securities	13,686	79,981	
Recoverable research & development tax credits	2,024	6,492	
Prepaid research & development expenses	34	2,549	
Prepaid expenses	847	1,330	
Other assets	552	456	
Prepaid expenses & other current assets	3,457	10,827	
Total current assets	110,255	134,393	
Operating lease right-of-use assets	199	471	
Other long-term assets	15	128	
Total assets	110,469	134,992	
Accounts payable	66	750	
Accrued payroll	1,111	2,900	
Accrued research & development expenses	...	1,902	
Other accrued expenses	...	245	
Accrued expenses	...	5,047	
Operating lease liabilities	334	300	
Accrued expenses and other current liabilities	2,433	...	
Accrued expenses - Balancing value	1,322	...	
Total current liabilities	2,833	6,097	

Salaries, wages & related items	62,100	48,500	Loss on embedded conversion option	4,504,104	Long term lease liability	544,382	547,692
Current debt obligations	9,500	9,500	Other income (expense)	23,721 (981,595)	Asset retirement obligations	27,468,427	25,000,740
Current finance lease liabilities	3,600	3,600	Interest expense	1,000,427	Total liabilities	57,659,156	48,309,194
Income taxes	33,600	27,200	Income (loss) before taxes	(12,601,797)	Common stock	85,025	81,615
Current lease liabilities	5,900	...	Income tax provision	(132,192)	Additional paid-in capital	99,490,253	75,303,479
Total current liabilities	353,500	301,000	Net income (loss)	(12,469,605)	Retained earnings (accumulated deficit)	(64,618,818)	(52,149,213)
Deferred income taxes & other liabilities	41,800	46,100	Net income (loss) weighted average shares outstanding	7,084,130 (18,614,962)	Total stockholders' equity (deficit)	34,956,460	23,235,881
Term loan	945,300	...	- basic	22,718,890	Total Equity	34,956,460	...
5.00% notes	500,000	...	Weighted average shares outstanding - diluted	22,718,890			
6.75% notes	200,000	...	Year end shares outstanding	25,503,530			
Less: current debt obligations	9,500	...	Net income (loss) per share - basic	...			
Less: debt issuance costs and discounts	(37,700)	...	Net income (loss) per share - diluted	...			
Long-term debt	1,593,900	1,598,100	Number of full time employees	50			
Non current finance lease liabilities	31,500	32,600	Total number of employees	50			
Common stock	600	600	Number of common stockholders	1,250			
Additional paid-in capital	27,900	10,000	Production and Ad Valorem Taxes	3,044,411			
Retained earnings (accumulated deficit)	(541,100)	(577,100)	Diluted EPS	...			
Accumulated other comprehensive income (loss)	(309,100)	(324,900)	Excluding ExtraOrd Items	...			
Total equity	(821,700)	(891,400)		...			
Deferred Income Taxes and Other Liabilities	57,200			
Total Equity	(821,700)			
Non-current lease liabilities	15,400			

Recent Dividends:

1. Embecta Corp common.
No dividends paid.

Annual Dividends:

1. Embecta Corp common.
No dividends paid.

EMPIRE PETROLEUM CORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):
2023 2022 2021 (revised)

Oil sales	36,684,494	44,978,554	22,326,289
Gas sales	1,726,754	4,534,370	2,288,481
Natural gas liquids sales	...	3,659,451	2,888,747
Total product revenues	...	53,172,375	27,503,517
Other revenue	70,480	102,429	174,609
Gain (loss) on derivatives	(65,693)	(387,930)	(586,181)
NGL Sales	1,660,256
Total revenue	40,076,291	52,886,874	27,091,945
Lease operating expense	23,584,039	13,283,758	...
Production & ad valorem taxes	28,625,481	3,943,466	2,102,772
Depletion, depreciation & accretion	3,096,533
Depreciation, depletion & amortization	...	1,949,191	2,502,275
Accretion of asset retirement obligation	1,756,022	1,357,906	1,214,479
Impairment	...	936,620	...
General & administrative	15,178,935	12,331,489	8,462,031
Total cost & expenses	51,701,382	44,102,711	27,565,315
Operating income (loss)	(11,625,091)	8,784,163	(473,370)
Convertible debt modification inducement expense	2,276,813
Loss on convertible debt redemption option	3,169,201

Reclassified to conform with 2022 presentation; Adjusted for 1- for -4 stock split, March 7, 2022; Approximately; As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):
2023 2022

Cash	11,944,442	...
Derivative instruments	406,806	121,584
Cash & cash equivalents	7,792,508	...
Prepays	757,500	...
Accounts receivable	8,354,636	7,780,239
Inventory	1,433,454	...
Inventory - oil in tanks	1,840,274	...
Prepays	1,048,434	...
Total current assets	18,744,904	22,734,973
Oil & natural gas properties, successful efforts	93,509,803	63,986,339
Less: accumulated depreciation & depletion	22,996,805	...
Less: accumulated depreciation, depletion & impairment	20,116,696	...
Total oil & gas properties, net	43,869,643	...
Other property & equipment, gross	2,998,018	1,878,325
Accumulated depreciation	1,114,807	436,796
Other property & equipment, net	1,883,211	1,441,529
Total property & equipment, net	45,311,172	2,779,000
Sinking fund	...	719,930
Utility & other deposits	1,474,503	719,930
Sub Total	70,512,998	...
Total assets	92,615,616	71,545,075
Accounts payable	16,437,219	5,843,366
Accrued expenses	7,075,302	9,461,010
Current portion of lease liability	432,822	256,975
Current portion of long term notes payable	1,060,004	...
Current portion of long-term debt	44,225	2,059,309
Total current liabilities	25,049,572	17,620,660
Long-term debt	...	4,063,115
Long-term note payable - related party	4,596,775	1,076,987

Recent Dividends:
1. Empire Petroleum Corp common.
No dividends paid.

Annual Dividends:
1. Empire Petroleum Corp common.
No dividends paid.

ENGLOBAL CORP. Annual Report

Consolidated Income Statement, Years Ended (\$):
12/30/23 12/31/22 12/25/21

Air handling sales	39,036,000
Operating revenues	39,036,000	40,189,000	36,410,000
Operating costs	39,402,000	44,401,000	37,053,000
Gross profit (loss)	(366,000)	(4,212,000)	(643,000)
Selling, general & administrative expenses	14,527,000	14,115,000	12,833,000
Operating income (loss)	(14,893,000)	(18,327,000)	(13,476,000)
Interest income (expense), net	...	(223,000)	(212,000)
Interest expense	219,000
Other income (expense), net	63,000	75,000	8,063,000
Income (loss) before income taxes	(15,049,000)	(18,475,000)	(5,625,000)
Current provision (benefit) for income taxes - state	104,000	39,000	60,000
Total current provision (benefit) for income taxes	104,000	39,000	60,000
Deferred provision (benefit) for income taxes - federal	(20,000)	(37,000)	(35,000)
Deferred provision (benefit) for income taxes - state	20,000	37,000	35,000
Provision (benefit) for federal & state income taxes	104,000	39,000	60,000
Net income (loss)	(15,153,000)	(18,514,000)	(5,685,000)
Weighted average shares outstanding - basic	4,996,000	4,446,750	3,986,000
Weighted average shares outstanding - diluted	4,996,000	4,446,750	3,986,000
Year end shares outstanding	5,156,583	4,475,077	4,403,834
Earnings (loss) per share from continuing operations - basic	\$(3.03)
Net income (loss) per common share - basic	\$(3.03)	\$(4.16)	\$(1.44)
Earnings (loss) per share from continuing operations - diluted	\$(3.03)
Net income (loss) per common share - diluted	\$(3.03)	\$(4.16)	\$(1.44)
Number of full time

employees	134	^{□□} 302	^{□□} 198
Total number of employees	134
Number of common stockholders	39	^{□□} 87	^{□□} 11,870

[□] Adjusted for 1-for-8 stock split, December 1, 2023; [□] Shares increased due to common stock issued; [□] Approximately; [□] Full-time equivalent employees

Consolidated Balance Sheet, Years Ended (\$):	2023		2022	
	12/30/23	12/31/22	12/30/22	12/31/21
Cash	3,464,000
Mutual funds	615,000
Amounts billed	10,106,000	9,061,000
Amounts unbilled	662,000	619,000
Retainage	93,000
Less: allowance for uncollectible accounts	4,336,000	2,129,000
Trade receivables, net	6,432,000	7,644,000
Prepaid expenses	1,397,000
Other receivables - employee	19,000
Other receivable	35,000
Inventory	129,000
Prepaid expenses & other current assets	3,296,000	1,580,000
Payroll taxes receivable	102,000	1,547,000
Contract assets	4,934,000
Prepaid expenses and other current assets	992,000
Total current assets	11,437,000	19,169,000
Building	340,000
Computer equipment & software	1,479,000	1,500,000
Shop equipment	2,364,000	2,609,000
Furniture & fixtures	196,000
Leasehold improvements	828,000
Autos & trucks	100,000	100,000
Building & leasehold improvements	7,000
Property & equipment, gross	4,290,000	5,233,000
Accumulated depreciation & amortization - property & equipment	2,930,000	3,476,000
Property & equipment, net	1,360,000	1,757,000
Goodwill	720,000	720,000
Right of use asset	5,079,000	8,072,000
Deposits & other assets	191,000	305,000
Total other assets	5,270,000	8,377,000
Total assets	18,787,000	30,023,000
Accounts payable	7,005,000	4,454,000
Accrued compensation & benefits	1,445,000	2,002,000
Current portion of leases	1,726,000	1,849,000
Contract liabilities	956,000
Accrual for known contingencies	17,000
Customer prepayments	17,000
Current portion of capital leases	263,000
Warranty reserve	1,195,000	511,000
State income taxes payable	30,000
Unearned revenue	50,000
Insurance payable	509,000
Short-term debt	1,047,000	1,661,000
Total current liabilities	12,056,000
Long-term unearned revenue	375,000	425,000
Long term leases	5,761,000	7,217,000
Long-term leases	548,000
Total liabilities	20,342,000	19,698,000
Common stock	5,000	36,000
Additional paid-in capital	61,354,000	58,050,000
Retained earnings (accumulated deficit)	(62,914,000)	(47,761,000)
Total stockholders' equity	(1,555,000)	10,325,000
Total Equity	(1,555,000)

Recent Dividends:
1. ENGlobal Corp. common.
No dividends paid.
Annual Dividends:
1. ENGlobal Corp. common.
No dividends paid.

EQUILLIUM INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Revenue	36,084,000
Revenue	36,084,000	15,759,000	...
Research & development expenses	37,039,000	37,547,000	26,379,000
Acquired in-process research & development expenses	23,049,000	...
General & administrative expenses	13,567,000	17,239,000	11,407,000
Total operating expenses	50,606,000	77,835,000	37,786,000
Income (loss) from operations	(14,522,000)	(62,076,000)	(37,786,000)
Interest expense	491,000	1,053,000	1,073,000
Interest income	2,334,000	420,000	57,000
Other income (expense), net	(76,000)	281,000	(250,000)
Loss before income taxes	(12,755,000)
Total other income (expense), net	1,767,000	(352,000)	(1,266,000)
Net income (loss)	(13,335,000)	(62,428,000)	(39,052,000)
Weighted average shares outstanding - basic	34,726,384	33,727,945	28,806,310
Weighted average shares outstanding - diluted	34,726,384	33,727,945	28,806,310
Year end shares outstanding	35,254,752	34,414,149	29,455,668
Net earnings (loss) per share - basic	\$(0.38)	\$(1.85)	\$(1.36)
Net earnings (loss) per share - diluted	\$(0.38)	\$(1.85)	\$(1.36)
Number of full time employees	44	36	45
Total number of employees	44
Number of common stockholders	50	^{□□} 46	^{□□} 34
Foreign currency translation adjustments	252,000	...
Income tax expense ..	580,000

[□] Approximately; [□] As of March 16, 2023; [□] As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	23,216,000	59,107,000
Short-term investments	17,650,000	11,916,000
Accounts receivable	3,735,000	2,838,000
Prepaid expenses & other current assets	4,748,000	2,874,000
Total current assets	49,349,000	76,735,000
Operating lease right-of-use assets	796,000	1,191,000
Furniture & fixtures	60,000	60,000
Machinery & lab equipment	584,000	534,000
Computer equipment	15,000	26,000
Leasehold improvements	20,000	20,000
Less: accumulated depreciation & amortization	364,000	249,000
Property & equipment, net	315,000	391,000
Other assets	70,000	104,000

Total assets	50,530,000	78,421,000
Accounts payable	4,707,000	3,977,000
Accrued payroll & other employee benefits	3,054,000	2,975,000
Accrued clinical development	2,265,000	3,253,000
Other accruals	947,000	472,000
Accrued non-clinical research	431,000	465,000
Accrued interest	74,000
Accrued expenses	6,697,000	7,239,000
Current portion of deferred revenue	15,729,000	14,700,000
Current portion of long-term notes payable	5,714,000
Current portion of operating lease liabilities	440,000	408,000
Total current liabilities	27,573,000	32,038,000
Long-term notes payable	3,239,000
Long-term deferred revenue	10,378,000
Long-term operating lease liabilities	384,000	824,000
Total liabilities	27,957,000	46,479,000
Common stock	3,000	3,000
Additional paid-in capital	208,170,000	204,268,000
Accumulated other comprehensive income (loss)	140,000	76,000
Retained earnings (accumulated deficit)	(185,740,000)	(172,405,000)
Total stockholders' equity (deficit)	22,573,000	31,942,000
Total Equity	22,573,000	...

Recent Dividends:

1. Equillum Inc common.

No dividends paid.

Annual Dividends:

1. Equillum Inc common.

No dividends paid.

ERASCA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
			(revised)
Research & development expenses	103,821	112,457	73,922
In-process research & development expenses	102,000	10,848
General & administrative expenses	37,704	32,993	22,616
Contribution of common stock to Erasca Foundation	17,497
Total operating expenses	141,525	247,450	124,883
Income (loss) from operations	(141,525)	(247,450)	(124,883)
Interest income	16,712	4,902	190
Other income (expense), net	(229)	(257)	314
Change in fair value of preferred stock purchase right liability	1,615
Net Income before Tax	(125,042)
Total other income (expense), net	16,483	4,645	2,119
Net income (loss)	(125,042)	(242,805)	(122,764)
Weighted average shares outstanding - basic	150,185	122,025	66,291
Weighted average shares outstanding - diluted	150,185	122,025	66,291

Year end shares outstanding	151,090	149,333	119,103
Net earnings (loss) per share - basic	\$(0.83)	\$(1.99)	\$(1.85)
Net earnings (loss) per share - diluted	\$(0.83)	\$(1.99)	\$(1.85)
Number of full time employees	129	123	
Number of common stockholders	55	53	96

No dividends paid.
Annual Dividends:
1. Erasca Inc common.
 No dividends paid.

ESCALADE, INC.
Annual Report

Consolidated Income Statement, Years Ended (\$000):

	12/31/23	12/31/22 (revised)	12/25/21 (revised)
Total revenues	263,566
Net sales	263,566	313,757	313,612
Cost of products sold	201,795	240,118	236,482
Selling, administrative & general expenses	41,480	44,765	43,367
Amortization	2,480	2,559	1,867
Operating income (loss)	17,811	26,315	31,896
Interest expense	5,349	3,780	1,510
Income (loss) before income taxes	12,493	22,614	30,549
Current provision (benefit) for income taxes - federal	3,472	4,149	4,819
Current provision (benefit) for income taxes - state	583	720	758
Total current provision (benefit) for income taxes	4,055	4,869	5,577
Deferred provision (benefit) for income taxes - federal	(1,230)	(502)	408
Deferred provision (benefit) for income taxes - state	(161)	258	159
Total deferred provision (benefit) for income taxes	(1,391)	(244)	567
Provision (benefit) for income taxes	2,664	4,625	6,144
Net income (loss)	9,829	17,989	24,405
Weighted average shares outstanding - basic	13,714	13,572	13,747
Weighted average shares outstanding - diluted	13,904	13,689	13,866
Year end shares outstanding	13,737	13,594	13,493
Income (loss) per share from continuing operations - basic	\$0.72
Net income (loss) per share - basic	\$0.72	\$1.33	\$1.78
Income (loss) per share from continuing operations - diluted	\$0.71
Net income (loss) per share - diluted	\$0.71	\$1.31	\$1.76
Cash dividends per common share	\$0.60
Number of full time employees	472	584	670
Number of part time employees	7	9	6
Total number of employees	479	593	676
Number of common stockholders	93	97	97

As is; As of February 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	93,075	284,217
Short-term marketable securities	219,275	151,403
Prepaid expenses & other current assets	8,326	8,876
Total current assets	320,676	444,496
Long-term marketable securities	9,642	...
Laboratory equipment	5,620	4,815
Furniture & fixtures	4,099	4,104
Leasehold improvements	18,173	17,837
Computer equipment & software	29,559	1,559
Software	1,667	...
Property & equipment, gross	...	28,315
Less accumulated depreciation & amortization	7,232	3,500
Property & equipment, net	22,327	24,815
Operating lease assets	37,861	40,418
Restricted cash	408	408
Other assets	4,383	4,772
Total assets	395,297	514,909
Accounts payable	2,000	23,049
Accrued research & development expenses	8,803	11,523
Accrued compensation	10,311	9,395
Unvested early exercised stock option liability	464	1,690
Accrued professional services	435	873
Accrued property & equipment	13	638
Other accruals	160	217
Accrued expenses & other current liabilities	20,186	24,336
Operating lease liabilities	3,970	1,305
Total current liabilities	26,156	48,690
Operating lease liabilities, net of current portion	51,889	53,793
Other liabilities	566	573
Total liabilities	...	103,056
Common stock	15	15
Additional paid-in capital	922,607	893,850
Accumulated other comprehensive income (loss)	77	(1,041)
Retained earnings (accumulated deficit)	(606,013)	(480,971)
Total stockholders' equity (deficit)	316,686	411,853
Total Equity	316,686	...

Recent Dividends:
1. Erasca Inc common.

Cash & cash equivalents	16	3,967
Receivables, gross	50,637	57,911
Less: allowances	652	492
Receivables	49,985	57,419
Raw materials	4,050	7,789
Work in process	2,308	3,478
Finished goods	86,104	110,603
Inventories	92,462	...
Inventories	...	121,870
Prepaid expenses	4,280	4,942
Prepaid income tax	88	...
Total current assets	146,831	188,198
Land	1,306	1,306
Buildings & leasehold improvements	58,707	27,406
Machinery & equipment	29,194	27,497
Buildings and leasehold improvements	28,207	...
Total cost	...	56,209
Accumulated depreciation & amortization	34,921	31,458
Property, plant & equipment, net	23,786	24,751
Operating lease right-of-use assets	8,378	9,100
Intangible assets	28,640	31,120
Goodwill	42,326	42,326
Other assets	391	400
Assets held for sale	2,653	2,823
Total assets	253,005	298,718
Current portion of long-term debt	7,143	7,143
Trade accounts payable	9,797	9,414
Accrued employee compensation	2,653	3,647
Accrued customer related allowances & accruals	5,325	...
Customer co-op & volume allowances	...	1,641
Customer return accruals & other allowances	...	4,225
Other accrued items	7,305	11,807
Accrued liabilities	15,283	21,320
Current operating lease liabilities	1,041	993
Income tax payable	...	71
Total current liabilities	33,264	38,941
Senior secured revolving credit facility	...	55,000
Term loan	...	39,881
Current portion of long-term debt	...	7,143
Long-term debt	43,753	87,738
Deferred income tax liability	3,125	4,516
Operating lease liabilities	7,897	8,641
Other liabilities	387	407
Total liabilities	88,426	140,243
Common stock	4,480	13,594
Retained earnings (accumulated deficit)	160,099	144,881
Total stockholders' equity	164,579	158,475
Rep Total Equity & Minority Interest	164,579	...

Recent Dividends:
1. Escalade, Inc. common.

ExDate	Amt	Declared	Record	Payable
03/16/2021	0.14	03/04/2021	03/17/2021	03/24/2021
05/28/2021	0.14	04/15/2021	06/01/2021	06/08/2021
09/03/2021	0.14	08/05/2021	09/07/2021	09/14/2021
12/03/2021	0.14	10/28/2021	12/06/2021	12/13/2021
03/11/2022	0.15	02/17/2022	03/14/2022	03/21/2022
05/27/2022	0.15	04/14/2022	05/31/2022	06/07/2022
09/02/2022	0.15	08/04/2022	09/06/2022	09/13/2022
12/02/2022	0.15	10/27/2022	12/05/2022	12/12/2022
03/10/2023	0.15	02/22/2023	03/13/2023	03/20/2023
06/09/2023	0.15	05/09/2023	06/12/2023	06/19/2023
08/28/2023	0.15	07/27/2023	08/29/2023	09/05/2023
01/04/2024	0.15	10/26/2023	01/05/2024	01/12/2024

Annual Dividends:**1. Escalade, Inc. common.**

2021.....	0.56	2022.....	0.60	2023.....	0.45
2024.....	0.15				

EXCELFIN ACQUISITION CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
			(revised)
Financial services & administrative fee - related party	120,000	570,000	357,500
Franchise tax	201,622	214,291	159,452
General & administrative expenses	6,918,905	1,260,378	189,705
Operating Profit/Income from Operations	(7,240,527)
Total expenses	7,240,527	2,044,669	706,657
Income earned on investments held in trust account	4,938,218	3,288,133	9,686
Total other income (expense), net	4,938,218	3,288,133	9,686
Net income (loss) before provision for income taxes	(2,302,309)	1,243,464	(696,971)
Current federal income taxes	...	620,346	...
Deferred federal income taxes	...	(352,928)	(146,364)
Change in valuation allowance	...	352,928	146,364
Income Taxes - Federal - Current	985,212
Income Taxes - Federal- Deferred	(815,393)
Income Taxes - Other - Deferred/Current	1,062,679
Income Taxes -State and local - Deferred	(247,286)
Provision for income taxes	985,212	620,346	...
Net income (loss)	(3,287,521)	623,118	(696,971)
Weighted average class A shares outstanding - basic	...	23,000,000	5,295,533
Weighted average class B shares outstanding - basic	...	5,750,000	5,172,680
Weighted average class A shares outstanding - diluted	9,417,482
Weighted average class B shares outstanding - diluted	...	5,750,000	5,172,680
Year end shares outstanding	7,951,533	28,750,000	28,750,000
Net income (loss) per class A share - basic	...	\$0.02	\$(0.07)
Net income (loss) per class B share - basic	...	\$0.02	\$(0.07)
Net income (loss) per share - basic	\$(0.22)
Net income (loss) per class A share - diluted	...	\$0.02	\$(0.07)
Net income (loss) per class B share - diluted	...	\$0.02	\$(0.07)

Net income (loss) per share - diluted	\$(0.22)
Total number of employees	...	4	4
Number of units stockholders	...	3	1
Number of class A common stockholders	1	3	1

¹ From March 15, 2021 (inception); ² Reclassified to conform with 2022 presentation; ³ As of March 29, 2023; ⁴ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Current asset - cash	45,219	...
Cash	...	351,432
Prepaid expenses	72,319	457,974
Total current assets	117,538	809,406
Investments held in trust account	...	237,735,165
Cash and investments held in trust	23,995,629	...
Deferred Tax Asset	9,474	...
Total assets	24,122,641	238,544,571
Accounts payable & accrued expenses	5,874,382	310,901
Income tax payable	...	620,346
Franchise tax payable	96,158	211,090
Accrued offering costs	400,907	415,907
Due to related party	322,724	538,558
Working capital loan - sponsor	1,296,654	300,000
Franchise tax payable	36,400	...
Excise tax payable	2,170,277	...
Unrecognized tax benefit	130,909	...
Total current liabilities	10,328,411	2,396,802
Deferred underwriting commission	...	8,050,000
Deferred underwriting fee payable	1,610,000	...
Total Non-Current Liabilities	1,610,000	...
Total liabilities	11,938,411	10,446,802
Class A common stock subject to possible redemption	23,750,019	236,903,730
Class B common stock	575	575
Retained earnings (accumulated deficit)	(11,566,364)	(8,806,536)
Total stockholders' equity (deficit)	(11,565,789)	(8,805,961)
Total Equity	(11,565,789)	...

Recent Dividends:

1. ExcelFin Acquisition Corp class B common. No dividends paid.
2. ExcelFin Acquisition Corp class A common, subject to redemption. No dividends paid.

Annual Dividends:

1. ExcelFin Acquisition Corp class B common. No dividends paid.
2. ExcelFin Acquisition Corp class A common, subject to redemption. No dividends paid.

EXCELFIN ACQUISITION CORP**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of ExcelFin Acquisition Corp. (the "Company") as of December 31, 2023 and 2022, the related statements of operations, changes in stockholders' deficit and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Ex-

planatory Paragraph Ú Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the Company is a Special Purpose Acquisition Corporation that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses on or before April 25, 2024, provided necessary monthly extension deposits are made to the Company's Trust Account. There is no assurance that the Company will obtain the necessary approvals, satisfy the required closing conditions, raise the additional capital it needs to fund its operations, and complete the transaction prior to April 25, 2024, if at all. The Company also has no approved plan in place to extend the business combination deadline and fund operations for any period of time after April 25, 2024, in the event that it is unable to complete a business combination by that date. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans with regard to these matters are also described in Note 1. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern."

FASTENAL CO.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2024	2023
Total Revenues	1,895,100,000	...
Net Sales	1,895,100,000	859,100,000
Cost & expenses	1,504,900,000	465,900,000
Operating income	390,200,000	393,200,000
Interest income	1,600,000	400,000
Interest expense	2,000,000	3,900,000
Net before taxes	389,800,000	389,700,000
Income taxes	92,100,000	94,600,000
Net income	297,700,000	295,100,000
Earnings common share		
Primary	\$0.52	\$0.52
Fully Diluted	\$0.52	\$0.52
Common Shares:		
Full Diluted	574,100,000	572,632,589
Year-end	572,525,495	571,024,422

Consolidated Balance Sheet Items, as of (\$):

	2024
Assets:	
Cash & equivalents	237,100,000
Inventories	1,496,300,000
Current assets	3,083,500,000
Net property & equip.	1,013,000,000
Total assets	4,532,700,000
Liabilities:	
Current liabilities	637,900,000
Long-term debt	200,000,000
Stockholders' equity	3,429,200,000
Net current assets	2,445,600,000

FINCH THERAPEUTICS GROUP INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):	2023	2022	2021
			(revised)
Collaboration revenue	...	861	18,532
Services revenue from related party	107
Total revenue	107	861	18,532
Research & development	7,199	57,893	57,279
General & administrative	26,910	38,088	21,238
Impairment of goodwill	...	18,057	...
Restructuring expense	3,818	2,416	...
Total operating expenses	83,968	116,454	78,517
Net income (loss) from operations	(83,861)	(115,593)	(59,985)
Gain on extinguishment of Paycheck Protection Program ("PPP") loan	(1,366)	...	1,827
Interest income (expense), net	1,570	252	22

Gain (loss) on disposal of fixed assets, net	637	(7)	28
Other income (expense), net	4,053	702	(52)
Gain on lease termination	(752)
Total other income (expense), net	5,646	947	1,825
Income (loss) before income taxes	(78,215)	(114,646)	(58,160)
Net income (loss)	(74,754)	(114,646)	(58,160)
Net loss attributable to common stockholders	...	(114,646)	(58,160)
Weighted average shares outstanding	1,605	1,590	1,307
- basic	1,605	1,590	1,307
Weighted average shares outstanding - diluted	1,605	1,590	1,307
Year end shares outstanding	1,606	1,602	1,584
Net earnings (loss) per share - basic	\$(46.59)	\$(72.00)	\$(44.40)
Net earnings (loss) per share - diluted	\$(46.59)	\$(72.00)	\$(44.40)
Total number of employees	...	18	189
Number of common stockholders	66	70	77
Income tax benefit	(3,461)
Impairment of in-process research and development	32,900
Impairment of long-lived assets	13,141

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-30 stock split, June 12, 2023; ³ Shares increased due to the effect of conversion of redeemable convertible preferred stock into common stock upon initial public offering & initial public offering; ⁴ As is; ⁵ As of March 20, 2023; ⁶ Approximately; ⁷ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	25,124	71,038
Accounts receivable	...	144
Prepaid expenses & other current assets	723	3,369
Total current assets	25,847	74,551
Lab equipment	...	4,146
Office furniture & fixtures	...	1,406
Leasehold improvements	...	13,972
Construction work-in-progress	...	316
Software	869	4,883
Computer equipment	...	499
Total property & equipment, gross	869	25,222
Less: accumulated depreciation	275	9,286
Property & equipment, net	594	15,936
Operating right-of-use assets	26,584	32,752
In-process research & development	...	32,900
Restricted cash, non-current	...	2,568
Other assets	...	4,232
Restricted Cash	2,348	...
Total assets	55,373	162,939
Accounts payable	141	1,097
Accrued research & development	...	1,967
Accrued legal & professional fees	1,301	5,852
Accrued compensation & benefits	125	880

Other accrued expenses	...	1,462
Accrued expenses & other current liabilities	260	10,161
Operating lease liabilities, current	1,723	3,431
Accrued expenses and other current liabilities	2,220	...
Accrued other	116	...
Refundable tax credit	418	...
Total current liabilities	4,084	14,689
Deferred tax liability	...	3,461
Loan payable, non-current	...	14,653
Operating lease liabilities, non-current	28,403	34,255
Other liabilities	...	170
Total liabilities	32,487	67,228
Common stock	2	48
Additional paid-in capital	373,279	371,304
Retained earnings (accumulated deficit)	(350,395)	(275,641)
Total stockholders' equity (deficit)	22,886	95,711
Total Equity	22,886	...

Recent Dividends:

1. Finch Therapeutics Group Inc common.

No dividends paid.

Annual Dividends:

1. Finch Therapeutics Group Inc common.

No dividends paid.

FIRSTHAND TECHNOLOGY VALUE FUND INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Investment income - unaffiliated dividends	171,613
Investment income - unaffiliated interest	37,275	3,318	30,906
Investment income - affiliated or controlled interest	85,356	(10,015,197)	6,116,176
Investment income - foreign tax withholding	...	3,457	...
Total investment income	122,631	(10,008,422)	6,318,695
Investment advisory fees	455,559	1,366,496	2,220,811
Administration fees	116,785	118,009	122,177
Custody fees	8,743	17,338	24,661
Transfer agent fees	33,296	38,054	39,737
Registration & filing fees	35,300	33,800	32,700
Professional fees	398,882	397,138	367,471
Printing fees	299,958	60,853	80,307
Trustees fees	43,841	200,000	200,000
Compliance fees	110,336	118,777	120,487
Miscellaneous fees	81,068	88,580	46,907
Total gross expenses	1,583,768	2,439,045	3,255,258
Less waiver and/or reimbursement	(2,542,716)
Total net expenses (income)	(958,948)	2,439,045	3,255,258
Net investment income (loss), before taxes	1,081,579	(12,447,467)	3,063,437
Net investment income (loss), net of deferred taxes	1,081,579	(12,447,467)	3,063,437
Net realized gains (losses) from security transactions on: affiliated or controlled	(7,864,998)	(3,131,579)	11,753,038
Net realized gains (losses) from security

transactions on: foreign currency	16	1,914	27
Net realized gains (losses), net of deferred taxes	(7,864,982)	(3,129,665)	11,753,065
Net change in unrealized appreciation (depreciation) on: non-affiliated investments	...	(280,160)	(551,274)
Net change in unrealized appreciation (depreciation) on: affiliated or controlled investments & foreign currency	(21,615,371)	(48,442,656)	(21,673,270)
Net change in unrealized appreciation (depreciation) on: affiliated or controlled warrants investments	(950,446)	154,915	20,298
Net change in unrealized appreciation (depreciation), net of deferred taxes	(22,565,817)	(48,567,901)	(22,204,246)
Net realized & unrealized gains (losses) on investments, net of deferred taxes	(30,430,799)	(51,697,566)	(10,451,181)
Net increase (decrease) in net assets resulting from operations, net of deferred taxes	(29,349,220)	(64,145,033)	(7,387,744)
Year end shares outstanding	6,893,056	6,893,056	6,893,056
Net investment income (loss) per share	\$0.16	\$(1.81)	\$0.44
Income (loss) from operations per share	\$(4.26)	\$(9.31)	\$(1.07)
Number of common stockholders	950	1,100	1,200
Number of beneficiary stockholders	...	10,500	10,500
Weighted average shares outstanding	6,889,488
Weighted average shares outstanding - diluted	6,889,488

¹ Approximately; ² As of February 28, 2023; ³ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Investment securities - unaffiliated investments at acquisition cost	...	1,772,422
Investment securities - affiliated investments at acquisition cost	...	662,235
Investment securities - controlled investments at acquisition cost	...	140,355,353
Investment securities - total acquisition cost	...	142,790,010
Investment securities - unaffiliated investments at market value	...	772,422
Investment securities - affiliated investments at market value	...	337,500
Investment securities -

controlled investments at market value		39,012,002	
Foreign currency at value	2,765	3,404	
Receivable from dividends & interest	8,161	14,463	
Other assets	63,649	64,066	
Investments, market value, total	173,502		
Affiliated investments at market value	299,932		
Controlled investments at market value	8,260,345		
Total assets	8,808,354	40,203,857	
Payable to affiliates	7,183,782	9,188,187	
Trustees' fees payable	13,891	50,000	
Consulting fee payable	43,000	46,000	
Accrued expenses & other payables	307,310	310,079	
Total liabilities	7,547,983	9,594,266	
Net assets		30,609,591	
Common stock	6,893	6,893	
Paid-in-capital	176,770,722	176,770,722	
Total distributable earnings (loss)	(175,517,244)	(146,168,024)	
Net assets	1,260,371	30,609,591	
Net assets value per share		\$4.44	
NET ASSETS	1,260,371		

Recent Dividends:

1. Firsthand Technology Value Fund Inc common.

No dividends paid.

Annual Dividends:

1. Firsthand Technology Value Fund Inc common.

No dividends paid.

FLUENT INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenue	298,399,000		
Revenue	298,399,000	361,134,000	329,250,000
Cost of revenue (exclusive of depreciation & amortization)	219,884,000	267,487,000	243,716,000
Loss on impairment of intangible assets	55,405,000		
Sales & marketing expenses	18,576,000	17,121,000	12,681,000
Product development expenses	18,454,000	18,159,000	15,789,000
General & administrative expenses	35,334,000	53,470,000	48,205,000
Depreciation & amortization expenses	10,876,000	13,214,000	13,170,000
Goodwill impairment & write-off of intangible assets		111,255,000	354,000
Gain (loss) on disposal of property & equipment		(19,000)	
Total costs & expenses	358,529,000	480,725,000	333,915,000
Income (loss) from operations	(60,130,000)	(119,591,000)	(4,665,000)
Interest expense, net	3,204,000	1,965,000	2,184,000
Loss on early extinguishment of debt			(2,964,000)
Income (loss) before income taxes	(63,334,000)	(121,556,000)	(9,813,000)
Current income tax expense (benefit) - federal	(24,000)	1,392,000	
Current state income tax expense (benefit)	(70,000)	606,000	(108,000)

Current foreign income tax expense (benefit)	123,000	3,000	156,000
Total current income tax expense (benefit)	29,000	2,001,000	48,000
Deferred federal income tax expense (benefit)	(3,352,000)	(3,730,000)	(3,494,000)
Deferred state income tax expense (benefit)	(462,000)	(537,000)	(813,000)
Deferred foreign income tax expense (benefit)	20,000	1,000	(102,000)
Less: valuation allowance	3,649,000	4,041,000	4,607,000
Total deferred income tax expense (benefit)	(145,000)	(225,000)	198,000
Income tax expense (benefit)	(116,000)	1,776,000	246,000
Net income (loss)	(63,218,000)	(123,332,000)	(10,059,000)
Weighted average shares outstanding - basic	13,770,355	13,568,766	13,329,552
Weighted average shares outstanding - diluted	13,770,355	13,568,766	13,329,552
Year end shares outstanding	13,551,054	13,347,551	13,160,877
Net earnings (loss) per share from continuing operations - basic	\$(4.62)		
Net income (loss) per share - basic	\$(4.62)	\$(9.06)	\$(0.78)
Net earnings (loss) per share from continuing operations - diluted	\$(4.62)		
Net income (loss) per share - diluted	\$(4.62)	\$(9.06)	\$(0.78)
Number of full time employees	274	272	261
Number of part time employees		3	4
Total number of employees	274	275	265
Number of common stockholders	236	223	191

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	15,804,000	25,547,000
Account receivable, gross	56,762,000	63,708,000
Less: allowance for doubtful accounts	231,000	544,000
Accounts receivable, net	56,531,000	63,164,000
Prepaid expenses & other current assets		3,506,000
Total current assets	78,406,000	92,217,000
Computer & network equipment	600,000	592,000
Furniture, fixtures & office equipment	905,000	888,000
Leased furniture, fixtures & office equipment	875,000	875,000
Leasehold improvements	1,260,000	1,260,000
Total cost of property & equipment	3,640,000	3,615,000
Less: accumulated depreciation & amortization - property & equipment		2,651,000
Accumulated depreciation and amortization	3,049,000	

Property & equipment, net	591,000	964,000
Operating lease right-of-use assets	3,395,000	5,202,000
Intangible assets, net	26,809,000	28,745,000
Goodwill	1,261,000	55,111,000
Other non-current assets	1,405,000	1,730,000
Total assets	111,867,000	183,969,000
Accounts payable	10,954,000	6,190,000
Accrued interest expense	30,534,000	
Accrued expenses & other current liabilities		35,626,000
Deferred revenue	430,000	1,014,000
Current portion of long-term debt	5,000,000	5,000,000
Current portion of operating lease liability	2,296,000	2,389,000
Total current liabilities	49,214,000	50,219,000
New credit facility term loan	25,488,000	40,594,000
Less: current portion of long-term debt		5,000,000
Long-term debt, net		35,594,000
Operating lease liability, net	1,699,000	3,743,000
Other non-current liabilities	1,062,000	458,000
Total liabilities	77,463,000	90,014,000
Common shares	43,000	
Common stock		42,000
Treasury stock	11,407,000	
Treasury stock, at cost		11,171,000
Additional paid-in capital	427,286,000	423,384,000
Retained earnings (accumulated deficit)	(381,518,000)	(318,300,000)
Total shareholders' equity (deficit)	34,404,000	93,955,000
Total shareholders equity	34,404,000	

□ Less unamortized discount and financing costs - credit facility term loan: \$656,000

Recent Dividends:

1. Fluent Inc series A non-voting convertible preferred.

No dividends paid.

2. Fluent Inc common.

No dividends paid.

3. Fluent Inc series B non-voting convertible preferred.

No dividends paid.

Annual Dividends:

1. Fluent Inc series A non-voting convertible preferred.

No dividends paid.

2. Fluent Inc common.

No dividends paid.

3. Fluent Inc series B non-voting convertible preferred.

No dividends paid.

FORTRESS BIOTECH INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022 (revised)	2021 (revised)
Product revenue, net	59,662	70,995	63,134
Collaboration revenue	5,229	1,882	5,389
Revenue - related party			268
Other revenue	19,519	2,674	
Net revenue	103	192	
Net revenue	84,513	75,743	68,791
Cost of goods sold - product revenue	26,660	30,775	32,084
Research & development expenses			113,240
Research & development expenses - licenses acquired	4,324	677	15,625
Selling, general & administrative expenses	101,747	134,199	86,843

				Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):		
				2023	2022	(revised)
Wire transfer fraud loss	9,540			
General & administrative	94,124	113,656	...			
Total operating expenses	226,855	279,307	257,332			
Income (loss) from operations	(142,342)	(203,564)	(188,541)			
Interest income	3,003	1,398	649	Cash & cash equivalents	80,927	178,266
Interest expense	11,915	...	11,394	Accounts receivable, gross	15,722	28,608
Amortization of fees	3,400	...	3,914	Allowance for doubtful accounts	500	400
Interest expense & financing fee	15,315	13,642	15,308	Accounts receivable, net	15,222	28,208
Change in fair value of derivative liability	(447)	Raw materials	4,640	...
Grant income	(3,403)	1,215	...	Work-in-process	884	...
Change in fair value of investments	39,294	Finished goods	4,987	...
Change in fair value of subsidiary's warrant liabilities	4,424	1,129	...	Inventory reserve	305	...
Total other income (expense)	(11,291)	(9,900)	24,188	Inventory	10,206	14,159
Income (loss) before income tax expense	(153,633)	(213,464)	(164,353)	Other receivables - related party	167	138
Current state income tax expense	254	449	473	Prepaid expenses & other current assets	10,500	9,661
Income Taxes - Current-Federal	33	Total current assets	117,022	230,432
Income Taxes - Deferred-State	39	Computer equipment	595	739
Income Taxes - Deferred-Federal	194	Furniture & fixtures	1,017	1,387
Income tax expense	521	449	473	Machinery & equipment	...	8,632
Net income (loss)	(154,154)	(213,913)	(164,826)	Leasehold improvements	13,175	13,175
Net income (loss) attributable to non-controlling interests	93,517	127,338	100,123	Buildings	581	581
Net loss attributable to Fortress	(60,637)	(86,575)	...	Construction in progress	29	952
Common stock dividend to series A convertible preferred stockholders	8,032	8,032	...	Total property & equipment	15,397	25,466
Net income (loss) attributable to common stockholders	(68,669)	(94,607)	(64,703)	Less: accumulated depreciation	8,892	12,446
Weighted average shares outstanding - basic	8,111	5,925	5,447	Property & equipment, net	6,505	13,020
Weighted average shares outstanding - diluted	8,111	5,925	5,447	Operating lease right-of-use asset, net	16,990	19,991
Year end shares outstanding	15,093	7,366	6,762	Restricted cash	2,438	2,688
Net income (loss) from continuing operations per common share - basic	\$(8.47)	\$(15.97)	\$(11.85)	Intangible asset - license	20,287	...
Net income (loss) per share - basic	\$(8.47)	\$(15.97)	\$(11.85)	Intangible asset, net	...	27,197
Net income (loss) from continuing operations per common share - diluted	\$(8.47)	\$(15.97)	\$(11.85)	Other assets	4,284	973
Number of full time employees	186	...	173	Total assets	167,526	294,301
Number of common stockholders	432	...	475	Accounts payable	34,810	...
Total number of employees	186	Accrued salaries, bonuses & employee benefits	8,531	...
				Accounts payable	...	57,244
				Professional fees	...	1,693
				Salaries, bonus & related benefits	...	9,772
				Research & development	...	7,390
				Research & development - license maintenance fees	...	632
				Research & development - milestones	...	4,600
				Accrued royalties payable	2,015	2,627
				Accrued coupon & rebates	9,987	7,604
				Return reserve	73,562	3,689
				Accrued interest	...	342
				Other accounts payable & accrued expenses	...	1,853
				Accounts payable & accrued expenses	...	97,446
				Deferred revenue	...	728
				Accounts payable & accrued expenses - related party	18,219	...
				Income taxes payable	843	722
				Common stock warrant liabilities	886	13,869
				Partner company convertible note, short-term, at fair value	3,000	...
				Operating lease liabilities, short-term	2,523	2,447
				Partner company convertible preferred shares, short-term, net	3,931	2,052
				Partner company line of credit	...	2,948
				Partner company installment payments - licenses, short-term	...	7,235
				Other short-term liabilities	...	163
				Total current liabilities	84,908	127,715
				Notes payable, long-term, net	60,856	91,730
				Operating lease liabilities - long-term	18,282	21,572
				Partner company installment payments - licenses, long-term, net	...	1,412
				Total liabilities	165,939	244,276
				Cumulative redeemable perpetual preferred stock	3	3
				Common stock	15	110
				Additional paid-in capital	717,396	675,841
				Retained earnings (accumulated deficit)	...	(634,233)
				Accumulated deficit	(694,870)	...
				Total stockholders' equity attributed to the Company	22,544	41,721
				Non-controlling interests	(20,957)	8,304
				Total stockholders' equity (deficit)	1,587	50,025

Recent Dividends:
1. Fortress Biotech Inc 9.375% series A cumulative redeemable perpetual.
 No dividends paid.
2. Fortress Biotech Inc common.
 No dividends paid.
3. Fortress Biotech Inc convertible preferred series A.
 No dividends paid.
Annual Dividends:
1. Fortress Biotech Inc 9.375% series A cumulative redeemable perpetual.
 No dividends paid.
2. Fortress Biotech Inc common.
 No dividends paid.
3. Fortress Biotech Inc convertible preferred series A.
 No dividends paid.

FORTUNE RISE ACQUISITION CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	(revised)
Formation cost	2,060,089
Formation & operating costs	...	959,457	97,513
Franchise tax expenses	138,050	199,759	35,961
Income (loss) from operations	(2,198,139)	(1,159,216)	(133,474)
Interest earned on investment held in trust account	2,342,684
Dividend earned on investments held in trust account	...	1,466,677	1,310
Income (loss) before income taxes	144,545	307,461	(132,164)
Current federal income taxes	516,672	167,624	...
Current state income taxes	63,302	103,722	...
Deferred federal income taxes	(354,847)	(124,849)	(27,755)
Deferred state income taxes	(14,353)	(31,561)	...
Valuation allowance	...	240,134	27,755
Income Taxes - Other - Deferred/Current	285,476
Income taxes provision (benefit)	496,250	355,070	...
Net income (loss)	(351,705)	(47,609)	(132,164)
Weighted average common stock subject to possible redemption outstanding - basic	...	9,775,000	1,643,844
Weighted average shares outstanding

- basic	3,109,250	2,290,520	Common stock subject to possible redemption, 9,775,000 shares at conversion value of \$1020 per share	34,882,535	Total number of employees	2	2																																																																																				
Weighted average common stock subject to possible redemption			Total stockholder's equity (deficit)	25,785,778	(4,331,738)	...	Number of stockholders - class A	5	1																																																																																				
outstanding - diluted	9,775,000	1,643,844	Total Equity	25,785,778	Number of units stockholders	...	2																																																																																				
Weighted average shares outstanding - diluted	3,109,250	2,290,520					Operating Expenses - Total	3,730,488	...																																																																																				
Year end shares outstanding	6,271,798	12,884,250	12,884,250				EPS - Basic - including Extraordinary Items		...																																																																																				
Net income (loss) per common stock subject to possible redemption - basic	...	\$0.04	\$4.20				Applicable to Common - Total	\$0.14	...																																																																																				
Net income (loss) per share - basic	...	\$(0.15)	\$(3.07)				Shares used to calculate Diluted EPS - Total	32,057,741	...																																																																																				
Net income (loss) per common stock subject to possible redemption - diluted	...	\$0.04	\$4.20				Shares used to calculate Basic EPS - Total	32,057,741	...																																																																																				
Net income (loss) per share - diluted	...	\$(0.15)	\$(3.07)				EPS - Diluted - including Extraordinary Items		...																																																																																				
Total number of employees	...	1	3				Applicable to Common - Total	\$0.14	...																																																																																				
Number of class A common stockholders	...	9	3						...																																																																																				
Number of units holder	16	1																																																																																				
Number of class B common stockholders	...	8	8						...																																																																																				
Shares used to calculate Basic EPS - Total	8,585,640																																																																																				
Shares used to calculate Diluted EPS - Total	8,585,640																																																																																				
EPS - Basic - including Extraordinary Items																																																																																				
Applicable to Common - Total	\$(0.04)																																																																																				
EPS - Diluted - including Extraordinary Items																																																																																				
Applicable to Common - Total	\$(0.04)																																																																																				
<p>□ From February 1, 2021 (date of inception); □ Reclassified to conform with 2022 presentation; □ As of April 12, 2023</p> <p>Consolidated Balance Sheet, Years Ended Dec. 31 (\$):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> <th>□□2021 (revised)</th> </tr> </thead> <tbody> <tr> <td>Current assets - cash</td> <td>12,910</td> <td>172,314</td> <td></td> </tr> <tr> <td>Prepaid expenses</td> <td>106,658</td> <td>4,000</td> <td></td> </tr> <tr> <td>Prepaid expenses - related party</td> <td>...</td> <td>25,000</td> <td></td> </tr> <tr> <td>Total current assets</td> <td>119,568</td> <td>201,314</td> <td></td> </tr> <tr> <td>Investments held in trust account</td> <td>34,851,146</td> <td>101,942,526</td> <td>530</td> </tr> <tr> <td>Total assets</td> <td>34,970,714</td> <td>102,143,840</td> <td>530</td> </tr> <tr> <td>Accounts payable & accrued expenses</td> <td>293,182</td> <td>156,052</td> <td></td> </tr> <tr> <td>Due to a related party</td> <td>2,903</td> <td>50,000</td> <td></td> </tr> <tr> <td>Promissory note - related party</td> <td>4,763,735</td> <td>733,750</td> <td></td> </tr> <tr> <td>Income taxes payable</td> <td>...</td> <td>271,346</td> <td></td> </tr> <tr> <td>Franchise taxes payable</td> <td>703,866</td> <td>199,759</td> <td></td> </tr> <tr> <td>Total current liabilities</td> <td>5,763,686</td> <td>1,410,907</td> <td></td> </tr> <tr> <td>Deferred tax liability</td> <td>...</td> <td>83,724</td> <td></td> </tr> <tr> <td>Deferred underwriters' discount</td> <td>3,421,250</td> <td>3,421,250</td> <td></td> </tr> <tr> <td>Total liabilities</td> <td>9,184,936</td> <td>4,915,881</td> <td></td> </tr> <tr> <td>Class A common stock subject to possible redemption</td> <td>...</td> <td>101,559,697</td> <td></td> </tr> <tr> <td>Class A common stock</td> <td>244</td> <td>66</td> <td></td> </tr> <tr> <td>Class B common stock</td> <td>66</td> <td>244</td> <td></td> </tr> <tr> <td>Accumulated deficit</td> <td>(9,097,067)</td> <td>...</td> <td></td> </tr> <tr> <td>Retained earnings (accumulated deficit)</td> <td>...</td> <td>(4,332,048)</td> <td></td> </tr> </tbody> </table>											2023	2022	□□2021 (revised)	Current assets - cash	12,910	172,314		Prepaid expenses	106,658	4,000		Prepaid expenses - related party	...	25,000		Total current assets	119,568	201,314		Investments held in trust account	34,851,146	101,942,526	530	Total assets	34,970,714	102,143,840	530	Accounts payable & accrued expenses	293,182	156,052		Due to a related party	2,903	50,000		Promissory note - related party	4,763,735	733,750		Income taxes payable	...	271,346		Franchise taxes payable	703,866	199,759		Total current liabilities	5,763,686	1,410,907		Deferred tax liability	...	83,724		Deferred underwriters' discount	3,421,250	3,421,250		Total liabilities	9,184,936	4,915,881		Class A common stock subject to possible redemption	...	101,559,697		Class A common stock	244	66		Class B common stock	66	244		Accumulated deficit	(9,097,067)	...		Retained earnings (accumulated deficit)	...	(4,332,048)	
	2023	2022	□□2021 (revised)																																																																																										
Current assets - cash	12,910	172,314																																																																																											
Prepaid expenses	106,658	4,000																																																																																											
Prepaid expenses - related party	...	25,000																																																																																											
Total current assets	119,568	201,314																																																																																											
Investments held in trust account	34,851,146	101,942,526	530																																																																																										
Total assets	34,970,714	102,143,840	530																																																																																										
Accounts payable & accrued expenses	293,182	156,052																																																																																											
Due to a related party	2,903	50,000																																																																																											
Promissory note - related party	4,763,735	733,750																																																																																											
Income taxes payable	...	271,346																																																																																											
Franchise taxes payable	703,866	199,759																																																																																											
Total current liabilities	5,763,686	1,410,907																																																																																											
Deferred tax liability	...	83,724																																																																																											
Deferred underwriters' discount	3,421,250	3,421,250																																																																																											
Total liabilities	9,184,936	4,915,881																																																																																											
Class A common stock subject to possible redemption	...	101,559,697																																																																																											
Class A common stock	244	66																																																																																											
Class B common stock	66	244																																																																																											
Accumulated deficit	(9,097,067)	...																																																																																											
Retained earnings (accumulated deficit)	...	(4,332,048)																																																																																											
<p>Recent Dividends:</p> <p>1. Fortune Rise Acquisition Corp class B common. No dividends paid.</p> <p>2. Fortune Rise Acquisition Corp class A common. No dividends paid.</p> <p>3. Fortune Rise Acquisition Corp class A common subject to redemption. No dividends paid.</p> <p>Annual Dividends:</p> <p>1. Fortune Rise Acquisition Corp class B common. No dividends paid.</p> <p>2. Fortune Rise Acquisition Corp class A common. No dividends paid.</p> <p>3. Fortune Rise Acquisition Corp class A common subject to redemption. No dividends paid.</p>																																																																																													
<p>FTAC EMERALD ACQUISITION CORP</p> <p>Annual Report</p> <p>Consolidated Income Statement, Years Ended Dec. 31 (\$):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> <th>□□2021 (revised)</th> </tr> </thead> <tbody> <tr> <td>Operating & formation costs</td> <td>3,730,488</td> <td>1,776,887</td> <td>100,518</td> </tr> <tr> <td>Income (loss) from operations</td> <td>(3,730,488)</td> <td>(1,776,887)</td> <td>(100,518)</td> </tr> <tr> <td>Interest income earned on investments held in trust account</td> <td>11,207,609</td> <td>3,619,061</td> <td>530</td> </tr> <tr> <td>Non-redemption agreement expense</td> <td>(708,400)</td> <td>...</td> <td>...</td> </tr> <tr> <td>Total other income</td> <td>...</td> <td>3,619,061</td> <td>530</td> </tr> <tr> <td>Income (loss) before provision for income taxes</td> <td>6,768,721</td> <td>1,842,174</td> <td>(99,988)</td> </tr> <tr> <td>Current federal income taxes</td> <td>...</td> <td>726,410</td> <td>...</td> </tr> <tr> <td>Deferred federal income taxes</td> <td>...</td> <td>329,186</td> <td>20,997</td> </tr> <tr> <td>Change in valuation allowance</td> <td>903,665</td> <td>(329,186)</td> <td>(20,997)</td> </tr> <tr> <td>Federal-Current</td> <td>2,325,087</td> <td>...</td> <td>...</td> </tr> <tr> <td>Federal-Deferred</td> <td>(903,665)</td> <td>...</td> <td>...</td> </tr> <tr> <td>Provision for income taxes</td> <td>2,325,087</td> <td>726,410</td> <td>...</td> </tr> <tr> <td>Net income (loss)</td> <td>4,443,634</td> <td>1,115,764</td> <td>(99,988)</td> </tr> </tbody> </table>											2023	2022	□□2021 (revised)	Operating & formation costs	3,730,488	1,776,887	100,518	Income (loss) from operations	(3,730,488)	(1,776,887)	(100,518)	Interest income earned on investments held in trust account	11,207,609	3,619,061	530	Non-redemption agreement expense	(708,400)	Total other income	...	3,619,061	530	Income (loss) before provision for income taxes	6,768,721	1,842,174	(99,988)	Current federal income taxes	...	726,410	...	Deferred federal income taxes	...	329,186	20,997	Change in valuation allowance	903,665	(329,186)	(20,997)	Federal-Current	2,325,087	Federal-Deferred	(903,665)	Provision for income taxes	2,325,087	726,410	...	Net income (loss)	4,443,634	1,115,764	(99,988)																												
	2023	2022	□□2021 (revised)																																																																																										
Operating & formation costs	3,730,488	1,776,887	100,518																																																																																										
Income (loss) from operations	(3,730,488)	(1,776,887)	(100,518)																																																																																										
Interest income earned on investments held in trust account	11,207,609	3,619,061	530																																																																																										
Non-redemption agreement expense	(708,400)																																																																																										
Total other income	...	3,619,061	530																																																																																										
Income (loss) before provision for income taxes	6,768,721	1,842,174	(99,988)																																																																																										
Current federal income taxes	...	726,410	...																																																																																										
Deferred federal income taxes	...	329,186	20,997																																																																																										
Change in valuation allowance	903,665	(329,186)	(20,997)																																																																																										
Federal-Current	2,325,087																																																																																										
Federal-Deferred	(903,665)																																																																																										
Provision for income taxes	2,325,087	726,410	...																																																																																										
Net income (loss)	4,443,634	1,115,764	(99,988)																																																																																										
<p>Consolidated Balance Sheet, Years Ended Dec. 31 (\$):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> </tr> </thead> <tbody> <tr> <td>Cash</td> <td>29,844</td> <td>72,753</td> </tr> <tr> <td>Prepaid & other current assets</td> <td>...</td> <td>185,213</td> </tr> <tr> <td>Prepaid income taxes</td> <td>83,503</td> <td>...</td> </tr> <tr> <td>Prepaid expenses</td> <td>192,712</td> <td>...</td> </tr> <tr> <td>Total current assets</td> <td>306,059</td> <td>257,966</td> </tr> <tr> <td>Reimbursement receivable</td> <td>...</td> <td>1,155,000</td> </tr> <tr> <td>Investments held in trust account</td> <td>165,653,149</td> <td>254,251,750</td> </tr> <tr> <td>Total assets</td> <td>165,959,208</td> <td>255,664,716</td> </tr> <tr> <td>Accounts payable & accrued expenses</td> <td>114,659</td> <td>111,063</td> </tr> <tr> <td>Due to related party</td> <td>286,451</td> <td>21,535</td> </tr> <tr> <td>Income tax payable</td> <td>...</td> <td>359,410</td> </tr> <tr> <td>Excise tax payable</td> <td>967,916</td> <td>...</td> </tr> <tr> <td>Promissory note - related party</td> <td>2,025,000</td> <td>...</td> </tr> <tr> <td>Total current liabilities</td> <td>3,394,026</td> <td>492,008</td> </tr> <tr> <td>Deferred underwriters' discount</td> <td>...</td> <td>8,704,270</td> </tr> <tr> <td>Deferred advisory fee</td> <td>1,155,000</td> <td>1,155,000</td> </tr> <tr> <td>Total liabilities</td> <td>4,549,026</td> <td>10,351,278</td> </tr> <tr> <td>Class A common stock subject to possible redemption</td> <td>...</td> <td>253,814,255</td> </tr> <tr> <td>Class A common stock</td> <td>959</td> <td>98</td> </tr> <tr> <td>Class B common stock</td> <td>165,721,882</td> <td>861</td> </tr> <tr> <td>Additional paid-in capital</td> <td>6,984,216</td> <td>...</td> </tr> <tr> <td>Retained earnings (accumulated deficit)</td> <td>(11,296,875)</td> <td>(8,501,776)</td> </tr> <tr> <td>Total stockholder's equity (deficit)</td> <td>161,410,182</td> <td>(8,500,817)</td> </tr> <tr> <td>Total Equity</td> <td>161,410,182</td> <td>...</td> </tr> </tbody> </table>											2023	2022	Cash	29,844	72,753	Prepaid & other current assets	...	185,213	Prepaid income taxes	83,503	...	Prepaid expenses	192,712	...	Total current assets	306,059	257,966	Reimbursement receivable	...	1,155,000	Investments held in trust account	165,653,149	254,251,750	Total assets	165,959,208	255,664,716	Accounts payable & accrued expenses	114,659	111,063	Due to related party	286,451	21,535	Income tax payable	...	359,410	Excise tax payable	967,916	...	Promissory note - related party	2,025,000	...	Total current liabilities	3,394,026	492,008	Deferred underwriters' discount	...	8,704,270	Deferred advisory fee	1,155,000	1,155,000	Total liabilities	4,549,026	10,351,278	Class A common stock subject to possible redemption	...	253,814,255	Class A common stock	959	98	Class B common stock	165,721,882	861	Additional paid-in capital	6,984,216	...	Retained earnings (accumulated deficit)	(11,296,875)	(8,501,776)	Total stockholder's equity (deficit)	161,410,182	(8,500,817)	Total Equity	161,410,182	...									
	2023	2022																																																																																											
Cash	29,844	72,753																																																																																											
Prepaid & other current assets	...	185,213																																																																																											
Prepaid income taxes	83,503	...																																																																																											
Prepaid expenses	192,712	...																																																																																											
Total current assets	306,059	257,966																																																																																											
Reimbursement receivable	...	1,155,000																																																																																											
Investments held in trust account	165,653,149	254,251,750																																																																																											
Total assets	165,959,208	255,664,716																																																																																											
Accounts payable & accrued expenses	114,659	111,063																																																																																											
Due to related party	286,451	21,535																																																																																											
Income tax payable	...	359,410																																																																																											
Excise tax payable	967,916	...																																																																																											
Promissory note - related party	2,025,000	...																																																																																											
Total current liabilities	3,394,026	492,008																																																																																											
Deferred underwriters' discount	...	8,704,270																																																																																											
Deferred advisory fee	1,155,000	1,155,000																																																																																											
Total liabilities	4,549,026	10,351,278																																																																																											
Class A common stock subject to possible redemption	...	253,814,255																																																																																											
Class A common stock	959	98																																																																																											
Class B common stock	165,721,882	861																																																																																											
Additional paid-in capital	6,984,216	...																																																																																											
Retained earnings (accumulated deficit)	(11,296,875)	(8,501,776)																																																																																											
Total stockholder's equity (deficit)	161,410,182	(8,500,817)																																																																																											
Total Equity	161,410,182	...																																																																																											
<p>Recent Dividends:</p> <p>1. FTAC Emerald Acquisition Corp class A common. No dividends paid.</p> <p>2. FTAC Emerald Acquisition Corp class A common subject to possible redemption. No dividends paid.</p> <p>3. FTAC Emerald Acquisition Corp class B common. No dividends paid.</p> <p>Annual Dividends:</p> <p>1. FTAC Emerald Acquisition Corp class A common. No dividends paid.</p> <p>2. FTAC Emerald Acquisition Corp class A common subject to possible redemption. No dividends paid.</p> <p>3. FTAC Emerald Acquisition Corp class B common. No dividends paid.</p>																																																																																													

FTAI INFRASTRUCTURE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Total revenues	320,472	261,966	120,219
Operating expenses	253,672	208,157	98,541
General & administrative	12,833	10,891	8,737
Acquisition & transaction expenses	4,140	16,844	14,826
Management fees & incentive allocation to affiliate	12,467	12,964	15,638
Depreciation & amortization	80,992	70,749	54,016
Asset impairment	743
Total expenses	364,847	319,605	191,758
Equity in losses of unconsolidated entities	(24,707)	(67,399)	(13,499)
Gain (loss) on sale of assets, net	6,855	(1,603)	16
Gain (loss) on extinguishment of debt	(2,036)
Interest expense	99,603	53,239	16,019
Other income (expense)	6,586	(3,169)	(8,930)
Total other income (expense)	(112,905)	(125,410)	(38,432)
Income (loss) before income taxes	(157,280)	(183,049)	(109,971)
Current provision for (benefit from) income taxes - federal	7	2	13
Current provision for (benefit from) income taxes - state & local	447	482	224
Total current provision for (benefit from) income taxes	454	484	237
Deferred provision for (benefit from) income taxes - federal	1,082	3,824	(3,820)
Deferred provision for (benefit from) income taxes - state & local	934	154	(44)
Deferred provision for (benefit from) income taxes - foreign	...	6	(3)
Total deferred provision for (benefit from) income taxes	2,016	3,984	(3,867)
Provision for (benefit from) income taxes	2,470	4,468	(3,630)
Net income (loss)	(159,750)	(187,517)	(106,341)
Less: net loss attributable to non-controlling interests in consolidated subsidiaries	38,414	33,933	26,472
Less: dividends & accretion of redeemable preferred stock	62,400	23,657	...
Net income (loss) attributable to stockholders & former Parent	(183,736)	(177,241)	(79,869)
Weighted average			

shares outstanding - basic	102,961	102,747	99,387
Weighted average shares outstanding - diluted	102,961	102,747	99,387
Year end shares outstanding	100,590	99,445	...
Income (loss) per share - basic	\$(1.78)	\$(1.73)	\$(0.80)
Income (loss) per share - diluted	\$(1.78)	\$(1.73)	\$(0.80)
Full-Time Employees (Period End)	700
Total number of employees	700	690	600
Number of common stockholders	19	17	...
Comprehensive income (loss) attributable to stockholders/Former Parent	282
Dividends Per Share - Common - Gross - by Period End Date	\$0.12
Income Taxes - Total	2,470

December 31, 2021 and prior financials are combined financials before the spin-off from Fortress Transportation & Infrastructure Investors LLC; Reclassified to conform with 2022 presentation; As is; Approximately; As of March 31, 2022; As of March 2, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	29,367	36,486
Restricted cash	58,112	113,156
Accounts receivable, net	55,990	60,807
Other current assets	42,034	67,355
Total current assets	185,503	277,804
Leasing equipment, gross	...	44,179
Less: accumulated depreciation	276,307	9,272
Leasing equipment, net	35,587	34,907
Operating lease right-of-use assets, net	69,748	71,015
Land, site improvements & rights	182,319	183,640
Construction in progress	76,491	127,941
Buildings & improvements	18,769	19,356
Bridges & tunnels	176,753	173,868
Terminal machinery & equipment	1,215,197	1,141,505
Track & track related assets	103,888	100,068
Railroad equipment	8,999	8,463
Railcars & locomotives	85,162	100,200
Computer hardware & software	16,058	11,733
Furniture & fixtures	1,887	1,745
Other property, plant & equipment	...	11,336
Other	21,613	...
Total property, plant & equipment, gross	1,907,136	1,879,855
Less: accumulated depreciation	...	206,047
Property, plant, & equipment, net	1,630,829	1,673,808
Investments	72,701	73,589
Intangible assets, net	52,621	60,195
Goodwill	275,367	260,252
Other assets	57,253	26,829
Total assets	2,379,609	2,478,399
Accounts payable & accrued liabilities	130,796	136,048
Operating lease liabilities	7,218	7,045
Other current liabilities	12,623	16,488
Total current liabilities	150,637	159,581
Delaware River Partners LLC revolver	...	25,000

EB-5 loan agreement	...	62,200
Transtar revolver	...	10,000
Total loans payable	...	97,200
Series 2020 bonds	...	263,980
Series 2021 bonds	...	425,000
Senior notes	...	474,828
Total bonds payable	...	1,163,808
Debt, gross	...	1,261,008
Less: debt issuance costs	...	(30,851)
Debt, net	1,340,910	1,230,157
Operating lease liabilities	62,441	63,147
Other liabilities	87,530	236,130
Total liabilities	1,641,518	1,689,015
Redeemable preferred stock	325,232	264,590
Common stock	1,006	994
Additional paid in capital	843,971	911,599
Retained earnings (accumulated deficit)	(182,173)	(60,837)
Accumulated other comprehensive income (loss)	(178,515)	(300,133)
Stockholders' or former parent company equity	484,289	551,623
Non-controlling interests in equity of consolidated subsidiaries	(71,430)	(26,829)
Total equity	412,859	524,794

Recent Dividends:
1. FTAI Infrastructure Inc common. No dividends paid.

Annual Dividends:
1. FTAI Infrastructure Inc common. No dividends paid.

G-III APPAREL GROUP LTD. Annual Report

	2024	2023	2022 (revised)
Net sales	3,098,242,000	3,226,728,000	2,766,538,000
Cost of goods sold	1,856,395,000	2,125,591,000	1,778,349,000
Gross profit	1,241,847,000	1,101,137,000	988,189,000
Selling, general & administrative expenses	924,223,000	833,151,000	648,015,000
Depreciation & amortization	27,523,000	27,762,000	27,626,000
Asset impairments, net of gain on lease terminations	...	349,686,000	1,455,000
Operating profit (loss)	283,343,000	(109,462,000)	311,093,000
Other income	(3,149,000)	27,894,000	9,549,000
Interest & financing charges, net	39,595,000	56,602,000	49,666,000
Income (loss) before income taxes - U.S.	218,528,000	(106,086,000)	234,034,000
Income (loss) before income taxes - non-U.S.	22,071,000	(32,084,000)	36,942,000
Income (loss) before income taxes	240,599,000	(138,170,000)	270,976,000
Current income tax expense (benefit) - federal	42,376,000	27,982,000	39,283,000
Current income tax expense (benefit) - state & city	9,768,000	8,278,000	4,484,000
Current income tax expense (benefit) - foreign	9,971,000	14,647,000	5,991,000
Total current income tax expense (benefit)	62,115,000	50,907,000	49,758,000
Deferred income tax expense (benefit) - federal	6,469,000	(50,764,000)	17,090,000
Deferred income tax

expense (benefit) - state & city.....	878,000	(4,457,000)	2,116,000
Deferred income tax expense (benefit) - foreign.....	(3,603,000)	526,000	1,911,000
Total deferred income tax expense (benefit).....	3,744,000	(54,695,000)	21,117,000
Income tax expense (benefit).....	65,859,000	(3,788,000)	70,875,000
Net income (loss).....	174,740,000	(134,382,000)	200,101,000
Less: income (loss) attributable to noncontrolling interests.....	1,428,000	1,321,000	492,000
Net income (loss) attributable to G-III Apparel Group, Ltd.....	176,168,000	(133,061,000)	200,593,000
Weighted average shares outstanding - basic.....	45,859,000	47,653,000	48,426,000
Weighted average shares outstanding - diluted.....	47,000,000	47,653,000	49,516,000
Year end shares outstanding.....	45,728,000	46,716,000	47,916,000
Net income (loss) per common share - basic.....	\$3.84	\$(2.79)	\$4.14
Net income (loss) per common share - diluted.....	\$3.75	\$(2.79)	\$4.05
Number of full time employees.....	3,500	3,600	2,900
Number of part time employees.....	1,100	1,100	700
Total number of employees.....	4,600
Number of common stockholders.....	21,300	16	18
Number of beneficiary stockholders.....	...	27,700	27,700
Foreign currency translation adjustments.....	...	2,965,000	...
Total revenues.....	3,098,242,000
Asset impairments.....	6,758,000
Basic EPS Excluding ExtraOrdinary Items..	\$3.84
Diluted EPS Excluding ExtraOrd Items.....	\$3.75
Comprehensive income attributable to G-III Apparel Group, Ltd.....	183,202,000
□ Reclassified to conform with 2023 presentation; □ Approximately; □ As of March 23, 2023; □ As of March 23, 2022			
Consolidated Balance Sheet, Years Ended Jan. 31 (\$):			
	2024	2023	
Cash & cash equivalents.....	507,829,000	191,652,000	
Accounts receivable, gross.....	563,834,000	693,260,000	
Less: allowance for doubtful accounts.....	1,471,000	18,297,000	
Accounts receivable, net.....	562,363,000	674,963,000	
Inventories.....	520,426,000	709,345,000	
Prepaid income taxes.....	1,356,000	5,886,000	
Prepaid expenses & other current assets.....	68,344,000	70,654,000	
Total current assets.....	1,660,318,000	1,652,500,000	
Investments in unconsolidated affiliates.....	22,472,000	24,467,000	
Machinery & equipment.....	2,586,000	2,437,000	
Leasehold improvements.....	91,329,000	83,768,000	
Furniture & fixtures.....	...	130,340,000	
Computer equipment & software.....	134,540,000	52,293,000	
Computer equipment and			

software.....	59,957,000
Property & equipment, gross.....	288,412,000	268,838,000	
Less: accumulated depreciation - property & equipment.....	233,328,000	215,096,000	
Property & equipment, net.....	55,084,000	53,742,000	
Operating lease assets.....	216,886,000	239,665,000	
Other assets, net.....	45,147,000	52,644,000	
Other intangibles, net.....	31,676,000	34,842,000	
Deferred income tax assets, net.....	19,248,000	26,389,000	
Trademarks.....	630,333,000	628,156,000	
Total assets.....	2,681,164,000	2,712,405,000	
Current portion of notes payable.....	15,026,000	135,518,000	
Accounts payable.....	182,531,000	169,508,000	
Accrued bonuses.....	38,298,000	16,831,000	
Other accrued expenses.....	102,237,000	98,755,000	
Accrued expenses.....	140,535,000	115,586,000	
Customer refund liabilities.....	84,054,000	89,760,000	
Current operating lease liabilities.....	56,587,000	52,917,000	
Income tax payable.....	14,676,000	14,875,000	
Other current liabilities.....	219,000	905,000	
Contract Liabilities.....	5,200,000	...	
Other accrued expenses - Balancing value.....	97,037,000	...	
Total current liabilities.....	493,628,000	579,069,000	
Secured notes.....	...	400,000,000	
Revolving credit facility.....	...	80,087,000	
Note issued to LVMH Moet Hennessy Louis Vuitton Inc. ("LVMH").....	...	125,000,000	
Unsecured loans.....	402,807,000	10,866,000	
Overdraft facilities.....	...	3,657,000	
Foreign credit facility.....	...	7,792,000	
Subtotal.....	...	627,402,000	
Less: net debt issuance costs.....	...	(4,246,000)	
Less: debt discount.....	...	(3,798,000)	
Less: current portion of long-term debt.....	...	135,518,000	
Notes payable, net.....	...	483,840,000	
Deferred income tax liabilities, net.....	42,736,000	44,783,000	
Noncurrent operating lease liabilities.....	178,247,000	204,974,000	
Other non-current liabilities.....	15,764,000	15,141,000	
Total liabilities.....	...	1,327,807,000	
Redeemable noncontrolling interests.....	(2,278,000)	(850,000)	
Common stock.....	264,000	264,000	
Additional paid-in capital.....	458,841,000	468,712,000	
Accumulated other comprehensive income (loss).....	(3,207,000)	(11,653,000)	
Retained earnings (accumulated deficit).....	1,160,112,000	983,944,000	
Common stock held in treasury, at cost.....	65,750,000	55,819,000	
Total stockholders' equity (deficit).....	1,550,260,000	1,385,448,000	
Total equity.....	1,550,260,000	...	
□ Excludes debt issuance costs, net of amortization - Net debt issuance costs: \$4,000,000			
Recent Dividends:			
1. G-III Apparel Group Ltd. common.			
No dividends paid.			
Annual Dividends:			
1. G-III Apparel Group Ltd. common.			
No dividends paid.			
GAIA INC (NEW)			
Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$'000):			
	2023	2022	2021
		(revised)	(revised)

Streaming revenue.....	80,423	82,035	...
Revenues, net.....	80,423	82,035	79,573
Streaming.....	11,629	10,915	...
Cost of revenues.....	10,526
Gross profit.....	68,794	71,120	69,047
Selling & operating expenses.....	67,156	64,155	60,577
Corporate, general & administration.....	6,205	7,181	6,125
Acquisition costs.....	...	49	360
Total operating expenses.....	73,361	71,385	67,062
Income (loss) from operations.....	(4,567)	(265)	1,985
Interest & other income (expense).....	(467)	(257)	(265)
Gain (loss) from equity method investment.....	(501)	(511)	...
SEC settlement.....	...	2,000	...
Income (loss) before income taxes - domestic.....	1,720
Income (loss) before income taxes - Current state income tax expense (benefit).....	7	...	16
Total current income tax expense.....	7	...	16
Deferred federal income tax expense (benefit).....	49	189	(1,892)
Deferred state income tax expense (benefit).....	4	13	(135)
Total deferred income tax expense (benefit).....	53	202	(2,027)
Provision for (benefit from) income taxes.....	60	202	(2,011)
Net income (loss) from continuing operations.....	(5,595)	(3,235)	3,731
Income (loss) from discontinued operations.....	...	(360)	...
Net income (loss).....	(5,595)	(3,595)	3,731
Net (income) loss attributable to noncontrolling interest.....	(207)	(296)	...
Net income (loss) attributable to Gaiam, Inc.....	(5,802)	(3,891)	...
Weighted average shares outstanding - basic.....	21,501	20,716	19,307
Weighted average shares outstanding - diluted.....	21,501	20,716	19,834
Year end shares outstanding.....	23,148	20,806	20,461
Earnings (loss) per share - continuing operations - basic.....	\$(0.27)	\$(0.17)	\$0.19
Earnings per share-inc from discontinued oper.....	\$0.00	\$(0.02)	...
Earnings (loss) per share - discontinued operations - basic.....	\$0.00	\$(0.02)	...
Net earnings (loss) per share - basic.....	\$(0.27)	\$(0.19)	\$0.19
Earnings (loss) per share - continuing operations - diluted.....	\$(0.27)	\$(0.17)	\$0.19
Earnings (loss) per share - discontinued operations -			

Table with 4 columns: Description, 2023, 2022, 2021. Rows include diluted net earnings, number of employees, stockholders, and share-totaled discount.

1. Gaia Inc (New) class B common. No dividends paid.
2. Gaia Inc (New) class A common. No dividends paid.
Annual Dividends:
1. Gaia Inc (New) class B common. No dividends paid.
2. Gaia Inc (New) class A common. No dividends paid.

GAIN THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

Table with 4 columns: Description, 2023, 2022, 2021 (revised). Rows include revenues, expenses, operating income, net income, and weighted average shares.

Shares increased due to the effect of conversion of series A & B preferred stock, issuance of common stock, warrants cashless exercise, and stock option exercise; Approximately; As of February 28, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

Table with 4 columns: Description, 2023, 2022, 2021 (revised). Rows include cash, money market, marketable securities, and tax credits.

Table with 4 columns: Description, 2023, 2022, 2021. Rows include prepaid & deferred expenses, other receivable, prepaid D&O insurance, equipment, and total equity.

Recent Dividends:
1. Gain Therapeutics Inc common. No dividends paid.
Annual Dividends:
1. Gain Therapeutics Inc common. No dividends paid.

GALERA THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

Table with 4 columns: Description, 2023, 2022, 2021 (revised). Rows include Research & development expenses.

Restated to reflect correction of errors; Reclassified to conform with 2022 presentation; Approximately; As is; As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

Table with 4 columns: Description, 2023, 2022, 2021. Rows include cash & cash equivalents, notes receivable, prepaid expenses, total current assets, and total equity.

Restated to reflect correction of errors

Recent Dividends:

expenses	24,115	31,012	52,417
General & administrative expenses	22,836	20,214	20,951
Income (loss) from operations	(51,226)	(73,368)
Interest income	1,595	506	32
Interest expense	11,414	11,571	7,194
Foreign exchange gain (loss)	(3)	(1)	(4)
Income (loss) before income tax expense (benefit) - domestic	(62,281)	(80,587)
Income (loss) before income tax expense (benefit) - foreign	(11)	53
Income (loss) before income tax expense (benefit)	(59,082)	(62,292)	(80,534)
Deferred state income tax expense (benefit)	(70)	...
Income tax expense (benefit)	(70)	...
Net income (loss)	(59,082)	(62,222)	(80,534)
Weighted average shares outstanding - basic	44,549	27,087	25,789
Weighted average shares outstanding - diluted	44,549	27,087	25,789
Year end shares outstanding	54,392	28,510	26,459
Net earnings (loss) per share - basic	\$(1.33)	\$(2.30)	\$(3.12)
Net earnings (loss) per share - diluted	\$(1.33)	\$(2.30)	\$(3.12)
Total number of employees	□31	□□30
Number of common stockholders	12	□□13	□□13
Loss from operations	49,260
Restructuring costs	2,309

related benefits	121	2,655
Accrued research & development expenses	2,672	6,764
Accrued professional fees & other expenses	213	335
Accrued expenses - Balancing value	443	...
Accrued expenses	3,449	9,754
Lease liabilities	133	44
Total current liabilities	4,957	13,379
Royalty purchase liability	151,049	139,635
Lease liabilities, net of current portion	1,117	...
Deferred tax liability	203	203
Total liabilities	157,326	153,217
Common stock	54	28
Additional paid-in capital	306,167	269,137
Accumulated other comprehensive income (loss)	(22)
Retained earnings (accumulated deficit)	(437,406)	(378,324)
Total stockholders' equity (deficit)	(131,185)	(109,181)
Total Equity	(131,185)	...

Income before income taxes (benefit) - foreign	(170,453)	(178,557)
Income (loss) before income taxes (benefit) & gain (loss) from equity method investment ...	(163,976)	(175,330)
Gain (loss) from equity method investment, net of tax	(3,824)	(2,468)
Current federal & state provision for (benefit from) income taxes	1,432
Current foreign provision for (benefit from) income taxes	256,296	822
Federal and State ...	(1,768)	...
Total current provision for (benefit from) income taxes	254,528	2,254
Deferred federal & state provision for (benefit from) income taxes	614
Deferred foreign provision for (benefit from) income taxes	10,339	30
Income Taxes - Local - Deferred	(810)	...
Total deferred provision for (benefit from) income taxes	9,529	644
Provision for (benefit from) income taxes	264,057	2,898
Net income (loss)	(428,033)	(180,696)
Net income (loss) attributable to noncontrolling interest	3,859	8,385
Net income (loss) attributable to GitLab Inc.	(424,174)	(172,311)
Weighted average class A & class B common shares outstanding - basic ...	154,283	148,407
Weighted average class A & class B common shares outstanding - diluted	154,283	148,407
Year end shares outstanding	157,557	151,144
Net income (loss) per class A & B common share - basic	\$(2.75)	\$(1.16)
Net income (loss) per class A & B common share - diluted	\$(2.75)	\$(1.16)
Number of class A common stockholders	□□8
Number of class B common stockholders	□□157
Foreign currency translation adjustments	(180,696)	...
Comprehensive loss attributable to GitLab	421,134	...
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$(2.75)	...

Recent Dividends:
1. Galera Therapeutics Inc common.
 No dividends paid.

Annual Dividends:
1. Galera Therapeutics Inc common.
 No dividends paid.

GITLAB INC Annual Report Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2024	2023	□2022 (revised)
Subscription - self-managed & software-as-a-service ("SaaS")	369,349	226,163
License - self-managed & other	73,600	54,987	26,490
Subscription-self-managed and SaaS	506,306
Total revenue	579,906	424,336	252,653
Subscription - self-managed & SaaS	40,841	23,668
License - self-managed & other	10,839	6,317
Total cost of revenue	59,708
Total cost of revenue	59,708	51,680	29,985
Gross profit (loss)	520,198	372,656	222,668
Sales & marketing ...	356,393	309,992	190,754
Research & development	200,840	156,143	97,217
General & administrative	150,405	117,932	63,654
Total operating expenses	(707,638)	584,067	351,625
Income (loss) from operations	(187,440)	(211,411)	(128,957)
Interest income	39,114	14,496	736
Gain from deconsolidation of Melano Inc.	17,798	...
Foreign exchange gains (losses), net	(3,157)	4,364	(29,140)
Other income (expense), net	189	(577)	(1,710)
Other income (expense), net	(11,826)	21,585	(30,850)
Income before income taxes (benefit) - US	(4,877)	19,486

□ As is; □ As of March 1, 2022; □ As of March 4, 2023; □ As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	18,257	4,266
Short-term investments	27,331
Restricted cash	50
Refundable Prescription Drug User Fee Act ("PDUFA") fee	3,242
Prepaid expenses & other current assets	3,372	3,646
Total current assets	21,629	38,535
Laboratory equipment	1,398
Computer hardware & software	179	292
Leasehold improvements	46	270
Furniture & fixtures	179
Computer hardware and software	305	...
Property & equipment, gross	530	2,139
Less: accumulated depreciation	459	...
Less: accumulated depreciation & amortization	1,701
Property & equipment, net	71	438
Acquired intangible asset	2,258	2,258
Goodwill	881	881
Right-of-use lease assets	1,212	43
Other assets	90	1,881
Total assets	26,141	44,036
Accounts payable	1,375	3,581
Accrued compensation &		

EPS - Diluted - excluding Extraordinary Items			Acquisition related consideration withheld in escrow	2,500		Fixed maturities	33,852	25,751
Applicable to Common - Total	\$(2.75)		Indirect taxes payable	2,212	4,498	Equity securities	1,100	2,692
Impairment loss of equity method investment in Arch, formerly Meltano	8,858		Customer refunds		3,465	Cash & cash equivalents	790	363
Common Shareholders - Number	79		Acquisition related contingent cash consideration	3,928		Other invested assets	(5,966)	10,856
Full-Time Employees (Period End)	2,130		Other current liabilities		263	Total investment income	55,444	29,776
Total number of employees	2,130		Accrued expenses & other current liabilities	286,178	25,954	Investment expense	(2,149)	(2,642)
			Accrued commissions		8,512	Investment Income, Gross - Insurance	56,960	
			Payroll taxes payable		3,013	Investment Expense - Insurance	(1,516)	
			Accrued team member related payables, excluding commissions		9,251	Net investment income		27,627
			Accrued compensation & benefits	35,809	20,776	Net realized investment gains (losses)	(2,107)	
			Deferred revenue, current	338,348	254,382	Other income (loss)	1,435	31,365
			Total current liabilities	662,073	306,296	Total revenues	528,129	628,534
			Deferred revenue, non-current	23,794	28,355	Net losses & loss adjustment expenses		359,228
			Early exercised options liability		1,800	Acquisition costs & other underwriting expenses		236,381
			Acquisition related contingent cash consideration		3,443	Corporate & other operating expenses	23,383	24,421
			Deferred tax liabilities		849	Interest expense		3,004
			Long term taxes payable		647	Gain (loss) on extinguishment of debt		(3,529)
			Operating lease liabilities - long-term portion		413	Income (loss) before income taxes	32,976	1,971
			Contingent liability for labor matters		2,504	Current foreign income tax expense (benefit)	14	4
			Other long-term liabilities		168	Current U.S. federal income tax expense (benefit)	2,207	422
			Other non-current liabilities	14,060	9,824	Total current income tax expense (benefit)	2,221	426
			Total liabilities	699,927	344,475	Deferred U.S. federal income tax expense (benefit)	5,326	2,395
			Additional paid-in capital	1,718,661	1,497,373	Total deferred income tax expense (benefit)	5,326	2,395
			Retained earnings (accumulated deficit)	(1,149,822)	(725,648)	Income tax expense (benefit)	7,547	2,821
			Accumulated other comprehensive income (loss)	2,335	(705)	Net income (loss)	25,429	(850)
			Class A Common stock	0		Preferred stock distributions	440	
			Class B Common stock	0		Less: preferred stock distributions		440
			Total GitLab Inc. stockholders' equity (deficit)	571,174	771,020	Net income (loss) available to common shareholders	24,989	(1,290)
			Noncontrolling interests	46,760	53,705	Weighted average shares outstanding - basic	13,553	14,482
			Total stockholders' equity (deficit)	617,934	824,725	Weighted average shares outstanding - diluted	13,666	14,482
						Year end shares outstanding	13,565	13,867

Reclassified to conform with 2022 presentation; Shares increased due to conversion of preferred stock, issuance of common stock with business combination, exercised stock options and warrants exercised; As Is; As of March 20, 2023; As of April 1, 2022

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2024	2023
Cash & cash equivalents	287,996	295,402
Short-term investments	748,289	641,249
Accounts receivable, gross	167,404	132,043
Allowance for doubtful accounts	673	1,564
Accounts receivable, net of allowance for doubtful accounts of \$462, \$1,022, and \$617 as of 31, 2020 and 2021, and 31, 2021, respectively	166,731	
Accounts receivable, net		130,479
Deferred contract acquisition costs, current	32,300	26,505
Prepaid software subscriptions		7,771
Prepaid expenses for the company's events		1,885
Prepaid advertising costs		367
Prepaid payroll deposits		510
Prepaid insurance		3,199
Prepaid taxes		592
Other prepaid expenses		1,915
Restricted cash		2,500
Revenue contract asset		1,532
Interest receivable		2,310
Other current assets		1,746
Prepaid expenses & other current assets	45,601	24,327
Total current assets	1,280,917	1,117,962
Computer & office equipment	9,182	8,581
Leasehold improvements	1,154	1,208
Property & equipment, gross	10,336	9,789
Less: accumulated depreciation	7,382	3,992
Property & equipment, net	2,954	5,797
Operating lease right-of-use assets	405	998
Equity method investment		12,682
Goodwill	8,145	8,145
Intangible assets, net	1,733	3,901
Deferred contract acquisition costs, non-current	19,317	15,628
Other long-term assets	4,390	4,087
Total assets	1,317,861	1,169,200
Accounts payable	1,738	5,184
Accrued expenses	279,628	10,686
Income taxes payable		859
Operating lease liabilities - current portion	410	716
Employee stock purchase plan ("ESPP") employee contributions		2,967

Recent Dividends:
1. GitLab Inc class B common.
 No dividends paid.
2. GitLab Inc class A common.
 No dividends paid.
Annual Dividends:
1. GitLab Inc class B common.
 No dividends paid.
2. GitLab Inc class A common.
 No dividends paid.

**GLOBAL INDEMNITY GROUP LLC
 Annual Report
 Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021
Ceded written premiums		(136,272)	
Change in net unearned premiums		11,140	
Ceded written premiums	(17,078)		
Change in net unearned premiums	(74,038)		
Gross Written Premiums	416,397		
Net earned premiums	473,357		
Net earned premiums	602,471	595,610	

Income (loss) per share - basic	\$1.84	\$(0.09)	\$2.00
Income (loss) per share - diluted	\$1.83		
Net income (loss) per share - diluted	\$1.83	\$(0.09)	\$1.97
Dividends per share		\$1.00	\$1.00
Full-Time Employees (Period End)	266		
Total number of employees	266	355	360
Number of class A common stockholders		150	170

Number of class A common beneficiary stockholders	140
Number of class B common stockholders	...	2	□3
Foreign currency translation adjustments	...	14	(242)
Dividends per common share	\$1.00
Net losses and loss adjustment expenses	289,153
Acquisition costs and other underwriting expenses	182,617

□ As is; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Fixed maturities available for sale, at fair value	□1,248,198	...
Equity securities, at fair value	16,508	17,520
Other invested assets	38,236	38,176
Other invested assets	38,236	...
Total investments	1,348,537	...
Fixed Maturities Securities Available for sale, at fair value	1,293,793	...
Cash and cash equivalents	38,037	...
Cash & cash equivalents	...	38,846
Premiums receivable, net	...	□168,743
Reinsurance receivables, net	16,989	□85,721
Funds held by ceding insurers	...	19,191
Deferred federal income taxes	...	47,099
Deferred acquisition costs	42,445	64,894
Intangible assets	14,456	14,810
Goodwill	4,820	4,820
Prepaid reinsurance premiums	...	17,421
Lease right of use assets	9,715	11,739
Other assets	26,362	23,597
Provision - Insurance Receivables	4,796	...
Provision - Insurance Receivables	8,992	...
Premiums receivable, net - Balancing value	106,954	...
Reinsurance receivables, net - Balancing value	89,431	...
Accounts receivable	102,158	...
Reinsurance receivables, net	80,439	...
Deferred federal income taxes	36,802	...
Prepaid reinsurance premiums	4,958	...
Receivable for securities sold	3,858	...
Deferred Tax Debit - Asset	50,304	...
Deferred Tax (Credit) - Asset	(13,502)	...
Total assets	1,729,576	1,800,775
Unpaid losses & loss adjustment expenses	...	832,404
Unearned premiums	182,852	269,353
Ceded balances payable	...	17,241
Payable for securities purchased	...	66
Contingent commissions	...	8,816
Lease liabilities	12,733	15,701
Other liabilities	24,770	30,965
Federal income taxes payable	5,632	...
Unpaid losses and loss

adjustment expenses	850,599
Ceded balances payable	2,642
Federal income tax payable	1,595
Total liabilities	1,080,823	1,174,546	...
Series A cumulative fixed rate preferred shares	...	4,000	...
Additional paid-in capital	454,791
Additional paid-in capital	...	451,305	...
Unrealized gains (losses) on available for sale securities	(22,715)	(42,958)	...
Foreign currency items	(148)	(100)	...
Accumulated other comprehensive income	(22,863)
Accumulated other comprehensive income (loss), net of taxes	...	(43,058)	...
Retained earnings	244,988
Retained earnings (accumulated deficit)	...	233,468	...
Class A common shares in treasury	32,163	19,486	...
Series A cumulative fixed rate preferred shares	4,000
Total shareholders'	648,753	626,229	...
Rep Total Equity & Minority Interest	648,753

□ Amortized cost - fixed maturities available for sale, at fair value: \$1,301,723,000; □ Net of allowance for expected credit loss - premiums receivable: \$3,322,000; □ Net of allowance for expected credit loss - reinsurance receivables: \$8,992,000

Recent Dividends:

1. Global Indemnity Group LLC series A cumulative fixed rate preferred.
No dividends paid.

2. Global Indemnity Group LLC class A ordinary.

ExDate	Amt	Declared	Record	Payable
03/19/2021	0.25	02/16/2021	03/22/2021	03/31/2021
06/18/2021	0.25	06/07/2021	06/21/2021	06/30/2021
09/22/2021	0.25	09/11/2021	09/23/2021	09/30/2021
12/17/2021	0.25	12/04/2021	12/20/2021	12/31/2021
03/18/2022	0.25	03/03/2022	03/21/2022	03/31/2022
06/16/2022	0.25	06/02/2022	06/20/2022	06/30/2022
10/03/2022	0.25	09/23/2022	10/04/2022	10/11/2022
12/22/2022	0.25	12/08/2022	12/23/2022	12/30/2022
03/23/2023	0.25	03/02/2023	03/24/2023	03/31/2023
06/22/2023	0.25	06/01/2023	06/23/2023	06/30/2023
10/05/2023	0.25	09/28/2023	10/09/2023	10/16/2023
12/21/2023	0.25	12/07/2023	12/22/2023	12/29/2023
03/20/2024	0.35	03/06/2024	03/21/2024	03/28/2024

3. Global Indemnity Group LLC class B ordinary.
No dividends paid.

Annual Dividends:

1. Global Indemnity Group LLC series A cumulative fixed rate preferred.
No dividends paid.

2. Global Indemnity Group LLC class A ordinary.

2021	1.00	2022	1.00	2023	1.00
2024	0.35				

3. Global Indemnity Group LLC class B ordinary.
No dividends paid.

GLOBAL-E ONLINE LTD Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Revenue	569,946	409,049	245,274
Revenue	569,946	409,049	245,274
Cost of revenue	336,343	250,871	□153,841
Gross profit	233,603	158,178	91,433
Research & development expenses	97,568	81,206	29,761
Sales & marketing expenses

expenses	217,035	206,100	104,687
General & administrative expenses	56,059	60,196	22,643
Total operating expenses	370,662	347,502	157,091
Operating profit (loss)	(137,059)	(189,324)	(65,658)
Financial expenses, net	(5,262)	12,093	8,570
Income before income taxes - Israel	...	(170,138)	...
Income before income taxes - foreign	...	(31,279)	...
Profit (loss) before income taxes	(131,797)	(201,417)	(74,228)
Current income taxes - foreign	2,059	1,512	...
Current income taxes	2,059	1,512	...
Deferred income taxes - foreign	(51)	(7,524)	...
Deferred income taxes	(51)	(7,524)	...
Provision for income taxes (benefits)	2,008	(6,012)	705
Net profit (loss)	(133,805)	(195,405)	(74,933)
Net earnings (loss) attributable to ordinary shareholders	...	(195,405)	(74,933)
Weighted average shares outstanding - basic	164,354	157,691	101,737
Weighted average shares outstanding - diluted	164,354	157,691	101,737
Year end shares outstanding	165,774	150,457	□150,457
Net earnings (loss) per share - basic	\$(0.81)	\$(1.24)	\$(0.74)
Net earnings (loss) per share - diluted	\$(0.81)	\$(1.24)	\$(0.74)
Full-Time Employees (Period End)	923
Total number of employees	923	767	□473
Number of ordinary stockholders	29	44	□456

□ Including related party costs - cost of revenue: US\$90,315,000; □ Shares increased due to conversion of preferred shares to ordinary shares, exercise of options and vested RSUs granted to employees, issuance of ordinary shares in IPO and exercise of warrants; □ As is; □ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
		(revised)
Cash & cash equivalents	200,081	165,033
Short-term deposits	96,939	46,353
Accounts receivable, gross	28,522	17,148
Less: allowance for credit losses	681	724
Accounts receivable, net	27,841	16,424
Indirect tax receivables and related prepaid expenses	46,802	43,293
Prepaid expenses	14,805	7,847
Other prepaid expenses	...	764
Prepaid expenses & other current assets	63,967	51,904
Marketable securities	20,403	16,813
Funds receivable, including cash in banks	111,232	78,125
Other	2,360	...
Total current assets	520,463	374,652
Computer & software	3,176	2,637
Furniture & office equipment	1,836	1,382

Leasehold improvements	9,631	8,883
Property & equipment, gross	14,643	12,902
Less: accumulated depreciation & amortization	4,407	2,619
Property & equipment, net	10,236	10,283
Operating lease right-of-use assets	23,052	19,718
Long term deposits	3,552	3,225
Deferred contract acquisition costs, noncurrent	2,668	1,825
Deferred tax assets	...	171
Other assets, noncurrent	...	3,739
Commercial agreement asset	192,721	282,963
Goodwill	367,566	...
Intangible assets	78,024	...
Goodwill & other intangible assets	...	466,024
Other Non-Current Assets	4,078	...
Total long-term assets	681,897	787,948
Total assets	1,202,360	1,162,600
Accounts payable	50,943	52,220
Accrued expenses	25,806	16,185
Accrued indirect taxes & related liabilities	37,654	26,347
Accrued compensation & benefits	26,821	19,918
Advancements from customers	10,522	9,163
Other current liabilities	6,503	4,377
Accrued expenses & other current liabilities	111,232	75,990
Funds payable to customers	...	78,125
Short term operating lease liabilities	4,031	3,245
Accrued expenses and other current liabilities	107,306	...
Total current liabilities	273,512	209,580
Deferred tax liabilities, net	6,507	6,558
Long term operating lease liabilities	19,291	16,579
Other long-term liabilities	1,071	1,762
Total liabilities	300,381	234,479
Additional paid-in capital	1,360,250	1,253,093
Accumulated comprehensive income (loss)	(1,420)	(1,926)
Retained earnings (accumulated deficit)	(456,851)	(323,046)
Total shareholders' equity (deficit)	901,979	928,121
Total shareholders equity	901,979	...

Recent Dividends:
1. Global-E Online Ltd ordinary.
 No dividends paid.
Annual Dividends:
1. Global-E Online Ltd ordinary.
 No dividends paid.

GLYCOMIMETICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Revenue from collaboration and license agreements	10,000
Revenue from collaboration & license agreements	10,000	75,000	1,159,767
Research & development expense	20,071,656	28,390,879	47,491,567
Personnel-related	...	6,425,000	5,788,000
Stock-based compensation	...	2,798,000	3,872,000
Legal, consulting

& other professional expenses	...	8,964,000	6,652,000
Other general & administrative expense	...	900,000	803,000
General & administrative expense	19,213,637	19,087,443	17,115,405
Total costs & expenses	39,285,293	47,478,322	64,606,972
Income (loss) from operations	(39,275,293)	(47,403,322)	(63,447,205)
Interest income	2,375,873	714,520	19,768
Loss and comprehensive loss before income taxes	(36,899,420)
Net income (loss)	(36,899,420)	(46,688,802)	(63,427,437)
Weighted average shares outstanding - basic	63,342,465	52,531,173	51,453,204
Weighted average shares outstanding - diluted	63,342,465	52,531,173	51,453,204
Year end shares outstanding	64,393,744	54,377,798	52,313,894
Net income (loss) per common share - basic	\$(0.58)	\$(0.89)	\$(1.23)
Net income (loss) per common share - diluted	\$(0.58)	\$(0.89)	\$(1.23)
Number of full time employees	35	38	52
Number of part time employees	...	1	...
Total number of employees	35	39	...
Number of common stockholders	21	21	24
Basic EPS - Net Income excl Extra Items applicable to Common - (Company Level)	\$(0.58)
Diluted EPS - Net Income excl Extra Items applicable to Common - (Company Level)	\$(0.58)

[□] Rounding difference, breakdown taken from the notes; [□] As of March 27, 2023; [□] As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	41,792,830	47,870,619
Prepaid research & development expenses	1,420,642	2,300,209
Other prepaid expenses	401,442	399,861
Other receivables	175,820	144,016
Total current assets	43,790,734	50,714,705
Furniture & fixtures	...	342,203
Laboratory equipment	...	1,343,081
Office equipment	...	17,762
Computer equipment	...	309,826
Leasehold improvements	...	616,133
Property & equipment	...	2,629,005
Less accumulated depreciation	...	2,386,615
Property & equipment, net	...	242,390
Prepaid research & development expenses	603,737	50,000
Deposits	154,176	52,320
Operating lease right-of-use asset	767,828	751,174
Total assets	45,316,475	51,810,589
Accounts payable	868,115	970,191
Accrued bonuses	399,763	...
Accrued research & development expenses	1,824,689	3,484,742
Accrued bonuses	2,561,913	2,664,613

Accrued consulting & other professional fees	439,192	499,592
Accrued employee benefits	...	300,653
Other accrued expenses	...	42,406
Lease liabilities	741,558	918,555
Total current liabilities	6,835,230	8,880,752
Lease liabilities, net of current portion	66,844	...
Total liabilities	6,902,074	8,880,752
Common stock	64,394	54,378
Additional paid-in capital	494,835,219	462,461,251
Retained earnings (accumulated deficit)	(456,485,212)	(419,585,792)
Total stockholders' equity (deficit)	38,414,401	42,929,837
Total Equity	38,414,401	...

Recent Dividends:
1. GlycoMimetics Inc common.
 No dividends paid.
2. GlycoMimetics Inc series A-1 convertible preferred.
 No dividends paid.
Annual Dividends:
1. GlycoMimetics Inc common.
 No dividends paid.
2. GlycoMimetics Inc series A-1 convertible preferred.
 No dividends paid.

GOLD RESOURCE CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Total revenues	97,728,000
Sales, net	97,728,000	138,724,000	125,196,000
Production costs	774,000	80,949,000	72,234,000
Depreciation & amortization	...	27,226,000	15,996,000
Depreciation, depletion, amortization	26,126,000
Reclamation & remediation	76,143,000	801,000	219,000
Total cost of sales	103,043,000	108,976,000	88,449,000
Mine gross profit	(5,315,000)	29,748,000	36,747,000
General & administrative expenses	6,583,000	8,048,000	6,900,000
Mexico exploration expenses	4,167,000	4,244,000	4,831,000
Michigan Back Forty Project expenses	1,642,000	8,805,000	55,000
Restructuring expenses	2,423,000
Stock-based compensation expense	681,000	1,955,000	875,000
Realized & unrealized gain (loss) on zinc zero cost collar	...	(170,000)	(3,000,000)
Unrealized currency exchange gain (loss)	174,000	(1,286,000)	(493,000)
Realized currency exchange gain (loss)	(860,000)	(121,000)	111,000
Realized & unrealized gain (loss) from gold & silver rounds, net	...	28,000	(53,000)
Impairment loss on gold & silver coins & bullion	1,619,000
Gain (loss) from sale of investments, net	12,000
Gain (loss) on disposal of fixed assets	(13,000)	(330,000)	(26,000)
Increase (decrease) in reserve for inventory	(1,466,000)

Employee benefit obligation	3,364,000		947,000	Accounts receivable, net	4,335,000	5,085,000	04/09/2021	0.00	03/22/2021	04/12/2021	04/23/2021
Interest on streaming liabilities		906,000		Stockpiles - underground mine	534,000	597,000	06/14/2021	0.01	04/29/2021	06/15/2021	06/30/2021
Severance	(408,000)	688,000		Concentrates	1,768,000	3,271,000	09/14/2021	0.01	07/28/2021	09/15/2021	09/30/2021
Other income (expense)		(985,000)	388,000	Dore, net	169,000	653,000	12/14/2021	0.01	10/28/2021	12/15/2021	12/29/2021
Other income (expense), net		(4,288,000)	(1,020,000)	Subtotal - product inventory	2,471,000	4,521,000	03/14/2022	0.01	02/24/2022	03/15/2022	03/31/2022
Total costs & expenses		27,510,000	19,104,000	Materials & supplies	6,823,000	8,979,000	06/14/2022	0.01	04/28/2022	06/15/2022	06/30/2022
Income (loss) before income taxes - U.S. operations	(8,958,000)	(18,317,000)	(6,369,000)	Inventories, net	9,294,000	13,500,000	09/14/2022	0.01	07/28/2022	09/15/2022	09/30/2022
Income (loss) before income taxes - foreign operations, Mexico	(12,794,000)	20,555,000	24,012,000	Advances to suppliers	266,000	867,000	12/14/2022	0.01	11/01/2022	12/15/2022	12/30/2022
Income (loss) before income taxes	(21,752,000)	2,238,000	17,643,000	Prepaid insurance	1,103,000	1,298,000					
Current income tax expense (benefit) - U.S. state	(3,000)	(254,000)	305,000	Prepaid income tax	4,589,000	432,000					
Current income tax expense (benefit) - foreign	906,000	12,358,000	11,426,000	Other current assets	654,000	1,242,000					
Total current income taxes expense (benefit)	903,000	12,104,000	11,731,000	Total current assets	26,495,000	46,099,000					
Deferred income tax expense (benefit) - U.S. federal	(691,000)	(895,000)		Asset retirement costs	6,227,000	7,449,000					
Deferred income tax expense (benefit) - U.S. state		25,000		Construction-in-progress	243,000	351,000					
Deferred income tax expense (benefit) - foreign	(5,947,000)	(2,675,000)	(2,116,000)	Furniture & office equipment	1,781,000	1,732,000					
Total deferred income taxes expense (benefit)	(6,638,000)	(3,545,000)	(2,116,000)	Land	9,033,000	9,033,000					
Provision (benefit) for income taxes	(5,735,000)	8,559,000	9,615,000	Mineral interest	79,543,000	79,543,000					
Net income (loss)	(16,017,000)	(6,321,000)	8,028,000	Light vehicles & other mobile equipment	2,126,000	2,327,000					
Weighted average shares outstanding - basic	88,514,243	88,368,250	75,301,253	Machinery & equipment	42,887,000	41,343,000					
Weighted average shares outstanding - diluted	88,514,243	88,368,250	75,608,627	Mill facilities & infrastructure	36,396,000	35,917,000					
Year end shares outstanding	88,694,038	88,398,109	88,338,774	Mine development	115,230,000	105,263,000					
Net income (loss) per common share from continuing operations - basic	\$(0.18)			Software & licenses	1,554,000	1,552,000					
Net income (loss) per common share - basic	\$(0.18)	\$(0.07)	\$0.11	Subtotal property, plant & mine development	295,020,000	284,510,000					
Net income (loss) per common share from continuing operations - diluted	\$(0.18)			Accumulated depreciation & amortization - property, plant & mine development	156,394,000	131,947,000					
Number of full time employees	488	16	10	Property, plant & mine development, net	138,626,000	152,563,000					
Number of common stockholders	200	200	200	Deferred tax assets, net	13,301,000						
Total number of employees	488			Other non-current assets	5,464,000	5,509,000					
				Total assets	183,886,000	204,171,000					
				Accounts payable	8,378,000	13,329,000					
				Mining royalty taxes payable, net	1,199,000	3,945,000					
				Contingent consideration		2,211,000					
				Accrued bonus	67,000						
				Accrued royalty payments	726,000	1,787,000					
				Employee profit sharing obligation	67,000	2,206,000					
				Other payables	888,000	1,204,000					
				Total current liabilities	11,325,000	24,682,000					
				Reclamation & remediation liabilities	11,795,000	10,366,000					
				Gold & silver stream agreements liability	44,932,000	43,466,000					
				Deferred tax liabilities, net	14,077,000	9,224,000					
				Contingent consideration	3,548,000	2,179,000					
				Accrued non-current labor obligation		1,050,000					
				Share-based compensation liability		884,000					
				Other long-term liabilities		556,000					
				Other non-current liabilities	1,516,000	2,490,000					
				Total liabilities	87,193,000	92,407,000					
				Common stock	89,000	89,000					
				Additional paid-in capital	111,970,000	111,024,000					
				Retained earnings (accumulated deficit)	(8,311,000)	7,706,000					
				Treasury stock at cost	5,884,000	5,884,000					
				Accumulated other comprehensive income (loss)	(1,171,000)	(1,171,000)					
				Total shareholders' equity	96,693,000	111,764,000					
				Total Equity	96,693,000						

□ Reclassified to conform with 2022 presentation; □ Shares increased due to stock options exercised and common stock issued for vested restricted stock units; □ As of February 24, 2022; □ Approximately; □ As of March 9, 2023; □ As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	6,254,000	23,675,000

Recent Dividends:

1. Gold Resource Corp common.

ExDate	Amt	Declared	Record	Payable
01/08/2021	0.00	12/28/2020	01/11/2021	01/25/2021
02/10/2021	0.00	01/27/2021	02/11/2021	02/23/2021
03/10/2021	0.00	02/23/2021	03/11/2021	03/23/2021

Annual Dividends:

1. Gold Resource Corp common.

2021.....0.04 2022.....0.04

GORES HOLDINGS IX INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

2023 2022 □ □ 2021 (revised)

Professional fees & other expenses	1,836,585	1,430,672	2,042
State franchise taxes, other than income tax	200,000	200,000	4,070
Net income (loss) from operations	(2,036,585)	(1,630,672)	(6,112)
Gain from change in fair value of public & private warrant liabilities	1,808,333	11,366,667	
Allocated expense for warrant issuance cost		617,225	
Other income - dividend income	26,426,823	7,564,018	
Net income (loss) before income taxes	26,198,571	16,682,788	(6,112)
Current income tax expense - federal	2,862,562	121,667	
Income Taxes - Local - Current	79,831		
Total current income tax expense		121,667	
Deferred income tax expense - federal	(62,535)	507,087	
Deferred income tax expense - state	71,486	2,098	
Total deferred domestic income taxes		509,185	
Income Taxes - Total - Current	2,942,393		
Income Taxes - Total - Deferred	8,951		
Provision for income tax	2,951,344	630,852	
Net income (loss)	23,247,227	16,051,936	(6,112)
Weighted average shares outstanding of class A common stock - basic		50,631,000	
Weighted average shares outstanding of class F common stock - basic		13,125,000	6,364,313
Weighted average shares outstanding - basic	65,625,000		
Weighted average shares outstanding of class A common stock - diluted		50,631,000	
Weighted average shares outstanding of class F common stock - diluted		13,125,000	6,364,313
Weighted average shares outstanding - diluted	65,625,000		
Year end shares outstanding	65,625,000	65,625,000	15,093,750
Net income (loss) per class A common stock - basic		\$(0.47)	
Net income (loss)			

				Consolidated Income Statement, Years Ended Dec. 31			Net income (loss)		
				2023	2022	2021	(29,510)	(271,068)	(44,480)
						(revised)			
per class F common stock - basic	...	\$(0.47)	\$0.00						
Net earnings (loss) per common share - basic	\$0.35	15,051	6,660	4,237	3,200
Net income (loss) per class A common stock - diluted	...	\$(0.47)	...	29,695	6,660	4,237	3,664
Net income (loss) per class F common stock - diluted	...	\$(0.47)	\$0.00	70,388	89,979	97,325	9,131	4,625	4,087
Net earnings (loss) per common share - diluted	\$0.35	73,809	87,897	87,897	6,660	4,237	3,664
Total number of employees	...	3	3	6,672	16,170	9,428	6,660	4,237	3,664
Number of units stockholders	6	1	1	24,238	9,131	4,625	4,087
Number of class A stockholders	...	1	1	39,478	6,660	4,237	3,664
Number of class F stockholders	...	4	4	70,388	89,979	97,325	9,131	4,625	4,087

□ From January 19, 2021 (inception); □ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of accretion of carrying value to redemption value and increase in redemption value of class A common stock subject to redemption; □ As of March 16, 2023; □ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	1,842,524	378,072
Prepaid expenses	25,186	944,461
Total current assets	1,867,710	1,322,533
Investments held in Trust		
Account	555,541,639	531,940,494
Total assets	557,409,349	533,263,027
Accrued expenses, formation & offering costs	360,875	27,446
State franchise tax accrual	40,000	200,000
Income tax payable	2,596,715	121,667
Notes payable - related party	650,000	600,000
Total current liabilities	3,647,590	949,113
Public warrants derivative liability	2,100,000	3,325,000
Private warrants derivative liability	1,000,000	1,583,333
Deferred income tax payable	518,136	509,185
Deferred underwriting compensation	18,375,000	18,375,000
Total liabilities	25,640,726	24,741,631
Class A common stock subject to possible redemption	554,482,346	531,037,712
Class F common stock	1,313	1,313
Retained earnings (accumulated deficit)	(22,715,036)	(22,517,629)
Total stockholder's equity (deficit)	(22,713,723)	(22,516,316)

Recent Dividends:

- Gores Holdings IX Inc class F common. No dividends paid.
 - Gores Holdings IX Inc class A common subject to redemption. No dividends paid.
- Annual Dividends:**
- Gores Holdings IX Inc class F common. No dividends paid.
 - Gores Holdings IX Inc class A common subject to redemption. No dividends paid.

GRAYSCALE ZCASH TRUST (ZEC)

New Accountant On Mar. 1, 2024, Co. dismissed Marcum LLP and engaged KPMG LLP as Co.'s independent registered public accounting firm.

GREENIDGE GENERATION HOLDINGS INC Annual Report

				Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):		
				2023	2022	2021	2023	2022	2021
Weighted average shares outstanding				45,933	19,159	19,159	13,312	15,217	15,217
Weighted average shares outstanding - diluted				13,906	9,231	9,231	347	348	348
Year end units outstanding				6,259	13,906	9,231	358	2,696	2,696
Earnings (loss) per share from continuing operations - basic	\$(4.36)	\$(63.70)	\$6.50	26,167	36,946	23,989	477	6,266	6,266
Earnings per share-inc from discontinued operations - diluted	\$(0.07)	35,136	8,474	8,474	569
Earnings (loss) per share from discontinued operations - basic	\$(0.07)	\$(0.30)	\$(18.00)	9,903	1,780	...	2,818
Net income (loss) per share - basic	\$(4.43)	\$(64.00)	\$(14.10)	4,000	176,307	...	5,694	1,260	1,260
Earnings (loss) per share from continuing operations - diluted	\$(4.36)	\$(63.70)	\$5.70	(87,280)	(323,142)	(64,541)	857	798	798
Earn per share-inc from discontinued operations - diluted	\$(0.07)	2,409	16,694	3,688	...	6,473	6,473
Earnings (loss) per share from discontinued operations - basic	\$(0.07)	\$(0.30)	\$(18.00)	...	14	153	3,864
Net income (loss) per share - basic	\$(4.43)	\$(64.00)	\$(12.30)	512	(15)	275	24,432	33,058	33,058
Earnings (loss) per share from continuing operations - diluted	\$(4.36)	\$(63.70)	\$5.70	(16,892)	(233,163)	32,784	...	81,979	81,979
Earn per share-inc from discontinued operations - diluted	\$(0.07)	12,659	21,575	3,689
Earnings (loss) per share from discontinued operations - basic	\$(0.07)	\$(0.30)	\$(18.00)	22
Net income (loss) per share - diluted	\$(4.43)	\$(64.00)	\$(12.30)	512	(15)	275
Number of full time employees	40	2,409	16,694	3,688
Total number of employees	40	347	14	153
Number of common class A stockholders	...	26	...	(12,147)	(21,576)	(3,283)
Number of common class B stockholders	...	10	...	Income (loss) before income taxes - Domestic	...	(254,739)
Depreciation	13,602	Income (loss) from continuing operations before taxes	(29,039)	(254,739)	29,501
Common Shareholders - Number	44	Current tax provision - state	...	(53)	2,344
				Current tax provision - total	...	(53)	2,344
				Deferred tax provision - federal	...	11,771	5,763
				Deferred tax provision - state	...	3,284	(206)
				Deferred tax provision - total	...	15,055	5,557
				Provision for income taxes	...	15,002	7,901
				Net income (loss) from continuing operations	(29,039)	(269,741)	21,600	8,154	14,203
				Income (loss) from discontinued operations, net of tax	(471)	(1,327)	(66,080)	...	8,460
								1,367	45
								6,229	18,349
								...	7,381
								45	...
								7,679	...
								32,195	...

□ Restated to reflect the discontinued operation of Support.com business; □ Adjusted for 1- for -10 reverse stock split, May 16, 2023; □ As is

						Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):		
						2023 2022		
Property & equipment, gross	55,669	130,417	(expense), net	(5,278)	4,206	8,620		
Less: accumulated depreciation	10,574	...	Income (loss) before income taxes	...	10,252	11,725	Cash & cash equivalents	18,364
Property & equipment, net	45,095	130,417	- United States	Accounts receivable, gross	34,787
Other long-term assets	1,652	292	Income (loss) before income taxes	...	9,061	4,534	Less allowance for doubtful accounts	474
Total assets	71,179	163,767	- foreign	Accounts receivable, net	34,313
Accounts payable	3,495	9,608	Income (loss) before income taxes	(1,919)	19,313	16,259	Unbilled accounts receivable	7,677
Accrued emissions expense	10,520	6,052	Current federal income tax expense (benefit)	(10)	60	(372)	Contract assets	...
Accrued expenses	6,116	11,327	Current state & local income tax expense (benefit)	264	774	856	Prepaid expenses	1,915
Short-term environmental liability	363	600	Current foreign income tax expense (benefit)	871	1,546	804	Prepaid income tax & income tax receivable	258
Long-term debt, current portion	...	67,161	Total current income tax expense (benefit)	1,125	2,380	1,288	Other current assets	928
Current liabilities held for sale	483	3,974	Deferred federal income tax expense (benefit)	(1,340)	(11,496)	...	Prepaid income tax and income tax receivable	1,758
Total current liabilities	20,977	98,722	Deferred state & local income tax expense (benefit)	(216)	(8,347)	...	Total current assets	65,213
Long-term debt, net of current portion & deferred financing fees	68,710	84,585	Deferred foreign income tax expense (benefit)	82	Buildings & improvements	4,635
Environmental liabilities	29,866	27,400	Total deferred income tax expense (benefit)	(1,474)	(19,843)	...	Equipment & furniture	20,881
Other long-term liabilities	2,650	107	Income tax expense (benefit)	(349)	(17,463)	1,288	Software	18,030
Total liabilities	122,203	210,814	Net income (loss)	(1,570)	36,776	14,971	Software development & equipment installations in progress	1,842
Common stock	1	5	Less: loss from redemption of preferred stock	...	1,380	...	Less: accumulated depreciation	36,533
Cumulative translation adjustment	345	357	Less: preferred stock dividend	496	Net property, plant & equipment	8,855
Additional paid-in capital	319,992	293,769	Less: earnings attributable to participating securities	1,858	Right-of-use assets	25,417
Accumulated deficit	(369,974)	...	Income (loss) attributable to common stockholders	(1,570)	35,396	12,617	Other intangible assets, net	2,820
Retained earnings (accumulated deficit)	...	(340,464)	Weighted average shares outstanding - basic	7,310	7,101	6,802	Goodwill	1,926
Common stock subscription receivable	(698)	...	- diluted	7,310	7,457	7,209	Deferred tax assets, net	17,268
Total stockholders' equity	(51,024)	(47,047)	Year end shares outstanding	7,225	7,403	6,976	Other long-term assets	23,272
Total Equity	(51,024)	...	Net income (loss) per share - basic	\$(0.21)	Total other assets	129
			Net income (loss) per share - basic - diluted	\$(0.21)	\$4.98	\$1.85	Right of Use Tangible Assets - Operating Lease	
			Number of full time employees	1,709	1,881	1,937	- Net	25,288
			Number of part time employees	253	823	1,155	Total assets	122,757
			Total number of employees	1,962	Accounts payable & accrued expenses	23,176
			Number of common stockholders	743	870	1,002	Accrued payroll & related expenses	5,615
			Foreign currency translation adjustments	...	(5,248)	...	Deferred revenue & customer advances	3,195
							Customer postage & program deposits	1,815
							Other current liabilities	9,495
							Short-term lease liabilities	4,815
							Capitalized Leases - Current Portion	42
							Operating Lease Liabilities - Current Portion/Short-Term	4,773
							Total current liabilities	48,111
							Capitalized Lease Obligations - Long-Term	4
							Pension liabilities - qualified plan	10,540
							Pension liabilities - nonqualified plan	18,630
							Long-term lease liabilities	23,691
							Other long-term liabilities	1,928
							Operating Lease Liabilities - Long-Term	23,687
							Total liabilities	102,900
							Common stock	12,221
							Additional paid-in capital	157,889
							Retained earnings (accumulated deficit)	...
							Less treasury stock	951,083
							Defined benefit pension items	(42,456)
							Foreign currency items	(1,634)
							Accumulated other comprehensive income (loss)	(44,090)
							Total stockholders' equity (deficit)	19,857
								18,808

Recent Dividends:**1. Greenidge Generation Holdings Inc class B common.**

No dividends paid.

2. Greenidge Generation Holdings Inc class A common.

No dividends paid.

Annual Dividends:**1. Greenidge Generation Holdings Inc class B common.**

No dividends paid.

2. Greenidge Generation Holdings Inc class A common.

No dividends paid.

HARTE HANKS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2023	2022	2021 (revised)					
Operating revenue	191,492	206,278	194,596	Year end shares outstanding	7,225	7,403	6,976	
Revenues	191,492	Income (loss) per share from continuing operations - basic	\$(0.21)	
Labor	97,968	104,772	109,917	Net income (loss) per share - basic	\$(0.21)	\$4.98	\$1.85	
Production & distribution	59,568	65,701	50,264	Income (loss) per share from continuing operations - diluted	\$(0.21)	
Advertising, selling, general & administrative expenses	20,673	17,970	17,858	Net income (loss) per share - diluted	\$(0.21)	\$4.75	\$1.76	
Restructuring expense	5,687	...	6,359	Number of full time employees	1,709	1,881	1,937	
Depreciation & amortization expense	4,237	2,728	2,559	Number of part time employees	253	823	1,155	
Total operating expenses	188,133	191,171	186,957	Total number of employees	1,962	
Operating income (loss)	3,359	15,107	7,639	Number of common stockholders	743	870	1,002	
Interest expense, net	135	(438)	(903)	Foreign currency translation adjustments	...	(5,248)	...	
Gain from extinguishment of debt (Paycheck Protection Program term note)	10,000					
Other income (expense), net	(5,413)	4,644	(477)					
Total other income								

Reclassified to conform with 2022 presentation; As is; As of January 31, 2022

Other current assets	9,090	7,262
Total current assets	406,715	473,055
Land	7,289	7,277
Buildings	22,760	22,529
Land & buildings	72,460	...
Equipment	141,989	134,304
Furniture & fixtures	67,522
Leasehold improvements	205,568	170,773
Construction in progress	6,089	5,501
Total property & equipment, gross	456,155	407,906
Less: accumulated depreciation & amortization	272,206	238,430
Property & equipment, net	183,949	169,476
Operating right-of-use assets	280,755	263,391
Finance right-of-use assets, net	1,837	2,279
Tradename intangible asset	23,500	23,500
Deferred income taxes, net	3,024	3,025
Other assets, net	9,442	4,434
Total assets	909,222	939,160
Accounts payable	96,431	190,648
Operating lease obligations	71,448	72,544
Credit facility	45,296	36,264
Finance lease obligations	538	1,132
Accrued payroll expenses	8,488	11,361
Other accrued expenses	14,013	15,803
Total current liabilities	236,214	327,752
Operating lease obligations	245,649	229,388
Finance lease obligations	1,423	1,305
Unrecognized tax benefits	213	368
Other liabilities	6,698	4,116
Total liabilities	490,197	562,929
Common stock	402	399
Paid-in capital	221,668	213,182
Retained earnings (accumulated deficit)	1,228,257	1,137,481
Treasury stock	1,031,302	974,831
Total stockholders' investment (deficit)	419,025	376,231
Total Equity	419,025	...

Recent Dividends:**1. Hibbett Inc common.**

ExDate	Amt	Declared	Record	Payable
07/07/2021	0.25	06/24/2021	07/08/2021	07/20/2021
09/08/2021	0.25	08/25/2021	09/09/2021	09/21/2021
12/08/2021	0.25	11/23/2021	12/09/2021	12/21/2021
03/16/2022	0.25	03/02/2022	03/17/2022	03/29/2022
06/08/2022	0.25	05/25/2022	06/09/2022	06/21/2022
09/07/2022	0.25	08/24/2022	09/08/2022	09/20/2022
12/07/2022	0.25	11/22/2022	12/08/2022	12/20/2022
03/15/2023	0.25	03/03/2023	03/16/2023	03/28/2023
06/07/2023	0.25	05/23/2023	06/08/2023	06/20/2023
09/06/2023	0.25	08/22/2023	09/07/2023	09/19/2023
12/06/2023	0.25	11/20/2023	12/07/2023	12/19/2023
03/20/2024	0.25	03/06/2024	03/21/2024	04/02/2024

Annual Dividends:**1. Hibbett Inc common.**

2021.....0.75	2022.....1.00	2023.....1.00
2024.....0.25		

HOOGER FURNISHERS CORP**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	01/28/24	01/29/23	01/30/22 (revised)
Net sales	433,226	583,102	593,612
Cost of sales	322,705	461,056	488,508
Inventory valuation expense	1,829	28,752	3,402
Gross profit (loss)	108,692	93,294	101,702
Selling & administrative			

expenses	92,678	95,815	84,475
Trade name impairment charges	13	...
Intangible asset amortization	3,656	3,512	2,384
Operating income (loss)	12,358	(6,046)	14,843
Other income, net	1,653	416	373
Interest expense, net	1,573	519	110
Income (loss) before income taxes ..	12,438	(6,149)	15,106
Current federal income tax expense (benefit)	6	1,024	650
Current foreign income tax expense (benefit)	47	75	107
Current state income tax expense (benefit)	223	307
Total current income tax expense (benefit)	53	1,322	1,064
Deferred federal income tax expense (benefit)	2,227	(2,617)	1,980
Deferred state income tax expense (benefit)	293	(542)	344
Total deferred income tax expense (benefit)	2,520	(3,159)	2,324
Income tax expense (benefit)	2,573	(1,837)	3,388
Unvested participating restricted stock dividends	153
Net income (loss)	9,865	(4,312)	11,718
Less: dividends on unvested restricted shares	103	46
Net earnings allocated to unvested restricted stock	156	...	61
Earnings available for common shareholders	9,556	(4,415)	11,611
Weighted average shares outstanding - basic	10,684	11,593	11,852
Weighted average shares outstanding - diluted	10,838	11,593	11,970
Year end shares outstanding	10,672	11,197	11,922
Net earnings (loss) per share - basic	\$0.91	\$(0.37)	\$0.99
Net earnings (loss) per share - diluted	\$0.91	\$(0.37)	\$0.97
Cash dividends declared per share	\$0.89	\$0.82	\$0.74
Number of full time employees	1,203	1,259	1,294
Total number of employees	1,203
Number of beneficiary stockholders	7,500	11,500	9,600
Total revenues	433,226
Basic EPS Excluding ExtraOrdinary Items ..	\$0.91
Diluted EPS Excluding ExtraOrd Items	\$0.91

Gross accounts receivable	54,897	67,600
Receivable from factor	51,280	...
Customer allowances	3,702
Allowance for doubtful accounts	3,617	1,769
Trade accounts receivable, net	62,129
Finished furniture	75,354	115,015
Furniture in process	1,702	1,943
Materials & supplies	10,538	13,509
Reduction to last-in, first-out (LIFO) basis	25,779	33,792
Inventories at FIFO	87,594	...
Inventories	61,815	96,675
Prepaid expenses & other current assets	5,530	6,418
Income tax recoverable	3,014	3,079
Total current assets	164,798	187,303
Buildings & land improvements	32,723
Computer software & hardware	8,994	15,887
Buildings	33,785	...
Machinery & equipment	11,708	11,013
Leasehold improvements	12,436	11,894
Furniture & fixtures	7,256	5,991
Other property, plant & equipment	694
Other	698	...
Less: accumulated depreciation	47,700	53,427
Land	1,077	1,077
Construction-in-progress	888	1,158
Property, plant & equipment, net	29,142	27,010
Cash surrender value of life insurance policies	28,528	27,576
Deferred taxes	12,005	14,484
Operating leases right-of-use assets	50,801	68,949
Intangible assets, net	28,622	31,779
Goodwill	15,036	14,952
Other assets	14,654	9,663
Total non-current assets	178,788	194,413
Total assets	343,586	381,716
Current portion of long-term debt	1,393	1,393
Trade accounts payable	16,470	16,090
Accrued salaries, wages & benefits	7,400	9,290
Customer deposits	5,920	8,511
Current portion of operating lease liabilities	6,964	7,316
Other accrued expenses	3,262	7,438
Total current liabilities	41,409	50,038
Term loan	21,481	...
Long-term debt	22,874
Deferred compensation	7,418	8,178
Operating lease liabilities	46,414	63,762
Income tax accrual	889	...
Other long-term liabilities	843
Total long-term liabilities	76,202	95,657
Total liabilities	117,611	145,695
Common stock	49,524	50,770
Retained earnings	175,717	...
Retained earnings (accumulated deficit)	184,386
Accumulated other comprehensive income (loss)	734	865
Total stockholders' equity (deficit)	225,975	236,021
Total stockholders' equity	225,975	...

Reclassified to conform with 2022 presentation; As is; Approximately

Consolidated Balance Sheet, Years Ended (\$000):

	01/28/24	01/29/23
Cash & cash equivalents	43,159	19,002

Recent Dividends:**1. Hooker Furnishings Corp common.**

ExDate	Amt	Declared	Record	Payable
03/16/2021	0.18	03/01/2021	03/17/2021	03/31/2021

06/15/2021	0.18	06/03/2021	06/16/2021	06/30/2021
09/15/2021	0.18	09/03/2021	09/16/2021	09/30/2021
12/16/2021	0.20	12/07/2021	12/17/2021	12/31/2021
03/16/2022	0.20	03/01/2022	03/17/2022	03/31/2022
06/16/2022	0.20	06/02/2022	06/17/2022	06/30/2022
09/16/2022	0.20	09/07/2022	09/19/2022	09/30/2022
12/15/2022	0.22	12/05/2022	12/16/2022	12/30/2022
03/16/2023	0.22	03/03/2023	03/17/2023	03/31/2023
06/15/2023	0.22	06/06/2023	06/16/2023	06/30/2023
09/15/2023	0.22	09/05/2023	09/18/2023	09/29/2023
12/14/2023	0.23	12/04/2023	12/15/2023	12/29/2023
03/15/2024	0.23	03/04/2024	03/18/2024	03/29/2024

Annual Dividends:

1. Hooker Furnishings Corp common.

20210.74	20220.82	20230.89
20240.23				

HUMACYTE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Grant revenue	...	1,565,000	1,263,000
Research & development	76,550,000	63,260,000	61,341,000
General & administrative	23,497,000	22,883,000	21,130,000
Total operating expenses	100,047,000	86,143,000	82,471,000
Income (loss) from operations	(100,047,000)	(84,578,000)	(81,208,000)
Interest income	5,467,000	2,629,000	16,000
Change in fair value of contingent earnout liability	(10,023,000)	75,767,000	55,772,000
Interest expense	6,599,000	6,200,000	4,348,000
Gain on Paycheck Protection Program loan forgiveness	(2,421,000)	...	3,284,000
Change in fair value of common stock warrant liabilities	...	417,000	56,000
Transaction costs expensed	49,000
Change in fair value of derivative liabilities	(260,000)
Employee retention credit	(3,107,000)
Net Income before Tax	(110,776,000)
Total other income (expenses), net	(10,729,000)	72,613,000	54,731,000
Net income (loss)	(110,776,000)	(11,965,000)	(26,477,000)
Weighted average shares outstanding - basic	103,420,238	103,051,366	39,970,398
Weighted average shares outstanding - diluted	103,420,238	103,051,366	39,970,398
Year end shares outstanding	103,673,728	103,229,013	103,003,646
Net earnings (loss) per share - basic	\$(1.07)	\$(0.12)	\$(0.66)
Net earnings (loss) per share - diluted	\$(1.07)	\$(0.12)	\$(0.66)
Number of full time employees	183	164	145
Number of part time employees	1
Total number of employees	183	164	146
Number of common stockholders	195	201	188

☐ As of March 10, 2023; ☒ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	80,448,000	149,772,000
Short-term investments	...	2,107,000

Accounts receivable	...	31,000
Prepaid expenses & other current assets	2,830,000	2,298,000
Total current assets	83,278,000	154,208,000
Finance lease right-of-use assets, net	17,313,000	19,373,000
Operating lease right-of-use assets, net	...	682,000
Scientific equipment	...	27,821,000
Computer equipment	125,000	167,000
Software	682,000	209,000
Furniture & fixtures	1,066,000	988,000
Leasehold improvements	27,844,000	26,355,000
Construction in progress	...	680,000
Scientific and manufacturing equipment	28,400,000	...
Property & equipment, gross	58,117,000	56,220,000
Less: accumulated depreciation	31,326,000	26,181,000
Property & equipment, net	26,791,000	30,039,000
Other long-term assets	841,000	...
Total assets	128,223,000	204,302,000
Accounts payable	6,490,000	1,595,000
Accrued external research, development & manufacturing costs	...	2,437,000
Accrued employee compensation & benefits	5,238,000	4,227,000
Accrued professional fees	...	444,000
Accrued expenses	9,340,000	7,108,000
Silicon Valley Bank loan payable, current portion	...	8,571,000
Finance lease obligation, current portion	2,560,000	2,256,000
Operating lease obligation, current portion	53,000	50,000
Accrued expenses - Balancing value	4,102,000	...
Total current liabilities	18,443,000	19,580,000
Contingent earnout liability	37,916,000	27,893,000
Finance lease obligation, net of current portion	16,293,000	18,853,000
Silicon Valley Bank loan payable, net of current portion	...	20,336,000
Operating lease obligation, net of current portion	...	632,000
Common stock warrant liabilities	789,000	80,000
Revenue interest liability	38,600,000	...
Contingent derivative liability	2,636,000	...
Total liabilities	114,677,000	87,374,000
Common stock	10,000	10,000
Additional paid-in capital	550,850,000	543,456,000
Retained earnings (accumulated deficit)	(537,314,000)	(426,538,000)
Total stockholders' equity (deficit)	13,546,000	116,928,000
Total stockholders equity (deficit)	13,546,000	...

Recent Dividends:

1. Humacyte Inc class B common.

No dividends paid.

2. Humacyte Inc class A common.

No dividends paid.

3. Humacyte Inc class A common stock subject to possible redemption.

No dividends paid.

4. Humacyte Inc common.

No dividends paid.

Annual Dividends:

1. Humacyte Inc class B common.

No dividends paid.

2. Humacyte Inc class A common.

No dividends paid.

3. Humacyte Inc class A common stock subject to possible redemption.

No dividends paid.

4. Humacyte Inc common.

No dividends paid.

HYPERFINE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Device	8,746,000	5,246,000	715,000
Service	2,286,000	1,568,000	781,000
Total sales	11,032,000	6,814,000	1,496,000
Cost of sales - device	1,812,000	4,231,000	2,058,000
Cost of sales - service	4,463,000	1,676,000	605,000
Total cost of sales	6,275,000	5,907,000	2,663,000
Gross margin (loss)	...	907,000	(1,167,000)
Research & development expense	22,493,000	28,156,000	25,842,000
General & administrative expense	20,276,000	32,406,000	27,497,000
Sales & marketing expense	10,103,000	14,219,000	10,362,000
Total operating expenses	52,872,000	74,781,000	63,701,000
Income (loss) from operations	(48,115,000)	(73,874,000)	(64,868,000)
Interest income	3,842,000	761,000	18,000
Other expense, net	(35,000)	51,000	1,000
Income (loss) before provision for income taxes (benefit)	(44,238,000)	(73,164,000)	(64,851,000)
Net income (loss)	(44,238,000)	(73,164,000)	(64,851,000)
Weighted average shares outstanding - basic	71,316,424	70,449,191	3,690,523
Weighted average shares outstanding - diluted	71,316,424	70,449,191	3,690,523
Year end shares outstanding	71,896,237	70,677,776	70,332,349
Net income (loss) per common share - basic	\$(0.62)	\$(1.04)	\$(17.57)
Net income (loss) per common share - diluted	\$(0.62)	\$(1.04)	\$(17.57)
Number of full time employees	...	136	186
Number of part time employees	7
Total number of employees	...	136	193
Number of class A common stockholders	...	144	199
Number of class B common stockholders	...	6	2
Common Shareholders - Number	123

☐ Shares increased due to the effect of stock options exercised, conversion of convertible preferred stock to class A and class B common stock, net equity infusion, and issuance of class A common stock; ☒ As of February 15, 2023; ☓ As of February 15, 2022; ☑ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	75,183,000	117,472,000
Restricted cash	621,000	771,000
Accounts receivable, gross	3,510,000	2,283,000
Allowance for doubtful accounts	321,000	180,000
Accounts receivable, less allowance of \$32 and \$0 in 2021 and 2020, respectively	3,189,000	...

		2023	2022	[□] 2021 (revised)			
Accounts receivable, net	2,103,000				Work in process	9,918,000	10,691,000
Unbilled receivables	942,000	454,000			Finished Goods	7,513,000	
Raw materials	1,757,000	2,241,000	Revenue	295,000	Inventory - Balancing		
Finished goods	4,825,000	2,381,000	Revenue	295,000	value	28,811,000	
Inventory	6,582,000	4,622,000	Cost of revenue	15,656,000	Inventory		35,553,000
Prepaid expenses & other current assets	2,391,000	3,194,000	Research & development	43,729,000	Deposit for fuel cell components	2,927,000	6,092,000
Due from related parties		48,000	Selling, general, & administrative	121,164,000	Vehicle inventory deposits	262,000	2,074,000
Total current assets	88,908,000	128,664,000	Total operating expenses	188,314,000	Production equipment deposits	623,000	235,000
Laboratory equipment	986,000	923,000	Income (loss) from operations	(188,019,000)	Other prepaid expenses	1,333,000	1,877,000
Research devices	1,532,000	1,709,000	Change in fair value of private placement warrant liability	962,000	Prepaid insurance	3,827,000	3,201,000
Sales & marketing devices	490,000	524,000	Change in fair value of earnout liability	9,202,000	VAT receivable from government	363,000	1,886,000
Computer equipment	668,000	623,000	Gain (loss) on equity securities	(14,267,000)	Prepaid expenses & other current assets	9,335,000	15,365,000
Construction in progress	595,000	359,000	Foreign currency exchange loss & other expense, net	1,402,000	Total current assets	152,523,000	312,854,000
Tooling	505,000	372,000	Investment income & interest expense, net	9,006,000	Land & building	24,604,000	2,818,000
Trade show assets	254,000	254,000	Total other income (expense)	3,501,000	Machinery & equipment	12,420,000	15,832,000
Leased devices	397,000	453,000	Income before income taxes - United States	(129,862,000)	Software	3,403,000	2,350,000
Other property & equipment	6,038,000	353,000	Income (loss) before income taxes - Non - U.S.	(54,656,000)	Leasehold improvements	3,306,000	2,123,000
Other	611,000		Net income (loss) before income taxes	(184,518,000)	Construction in progress	2,652,000	2,499,000
Property & equipment, gross		5,570,000	Income tax expense	(492,000)	Land and building	2,823,000	
Less: accumulated depreciation & amortization	3,039,000	2,322,000	Net income (loss) before income taxes	(184,026,000)	Total property, plant, & equipment		25,622,000
Property & equipment, net	2,999,000	3,248,000	Less: net loss attributable to noncontrolling interest	(16,000)	Less: accumulated depreciation & amortization	6,035,000	3,202,000
Other long term assets	2,292,000	2,139,000	Net income (loss) attributable to Hyzon Motors Inc.	(184,042,000)	Property, plant, & equipment, net	18,569,000	22,420,000
Total assets	94,199,000	134,051,000	Weighted average shares outstanding - basic	244,774,000	Right-of-use assets	4,741,000	9,181,000
Accounts payable	1,214,000	678,000	Weighted average shares outstanding - diluted	244,774,000	Investments in equity securities	763,000	15,030,000
Deferred grant funding		771,000	Year end shares outstanding	245,081,497	Other assets	6,157,000	15,411,000
Deferred revenue	1,453,000	1,378,000	Net earnings (loss) per share - basic	\$(0.75)	Equity method investments	8,382,000	
Due to related parties	61,000		Net earnings (loss) per share - diluted	\$(0.75)	Total assets	191,135,000	374,896,000
Bonus		2,674,000	Total number of employees	360	Accounts payable	1,479,000	13,798,000
Contracted services		1,127,000	Number of full time employees	360	Payroll & payroll related expenses	5,261,000	4,638,000
Special purpose acquisition company ("SPAC") bonus & other costs	621,000		Number of common stockholders - Class A	86	Accrued professional fees		10,016,000
Legal fees		261,000	Comprehensive loss attributable to Hyzon	(184,403,000)	Accrued product warranty costs	30,116,000	942,000
Payroll & related benefits	676,000	1,876,000	Restructuring and related charges	7,765,000	Accrued contract manufacturer costs		1,409,000
Other accrued expenses & other current liabilities		38,000			Accrued contract termination costs		2,688,000
Accrued expenses & other current liabilities	4,558,000	5,976,000			Accrued Orten Holding GmbH cancellation costs		1,192,000
Accrued expenses and other current liabilities - Balancing value	5,419,000				Other accrued expenses		4,702,000
Operating Lease Liabilities - Current Portion/Short-Term	185,000				Accrued liabilities		25,587,000
Total current liabilities	8,768,000	8,803,000			Related party payables	265,000	433,000
Long term deferred revenue	968,000	1,526,000			Current portion of lease liabilities	1,821,000	2,132,000
Other noncurrent liabilities	64,000				Contract liabilities	8,872,000	3,919,000
Operating Lease Liabilities - Long-Term	64,000				Accrued liabilities - Balancing value	24,855,000	
Total liabilities	9,800,000	10,329,000			Operating Lease Liabilities - Current Portion/Short-Term	1,821,000	
Class A common stock	5,000	5,000			Total current liabilities	42,553,000	45,869,000
Class B common stock	2,000	2,000			Lease liabilities	5,733,000	7,492,000
Additional paid-in capital	338,114,000	333,199,000			Private placement warrant liability		1,122,000
Retained earnings (accumulated deficit)	(253,722,000)	(209,484,000)			Earnout liability	1,725,000	10,927,000
Total stockholders' equity (deficit)	84,399,000	123,722,000			Deferred income taxes		526,000
Total Equity	84,399,000				Other liabilities	2,964,000	1,901,000
					Deferred underwriting fee payable	160,000	
					Operating Lease Liabilities - Long-Term	5,733,000	
					Accrued SEC settlement	8,000,000	
					Total liabilities	61,135,000	67,837,000
					Common stock	25,000	25,000
					Treasury stock, at cost	6,446,000	6,446,000
					Additional paid-in capital	380,261,000	372,942,000
					Retained earnings (accumulated deficit)	(242,640,000)	(58,598,000)
					Accumulated other comprehensive income (loss)	(514,000)	(153,000)
					Total Hyzon Motors Inc. stockholders' equity	130,686,000	307,770,000

Recent Dividends:

1. **Hyperfine Inc class A common.**

No dividends paid.

2. **Hyperfine Inc class B common.**

No dividends paid.

Annual Dividends:

1. **Hyperfine Inc class A common.**

No dividends paid.

2. **Hyperfine Inc class B common.**

No dividends paid.

HYZON MOTORS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

[□] Reclassified to conform with 2022 presentation; [■] Full-time equivalents; [■] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	112,280,000	60,554,000
Short-term investments		194,775,000
Unbilled receivable	1,599,000	
Accounts receivable	498,000	29,000
Related party receivable		6,578,000
Raw materials	11,380,000	24,862,000

Noncontrolling interest	(686,000)	(711,000)	
Total stockholders' equity	130,000,000	307,059,000	

Recent Dividends:

- 1. **Hyzon Motors Inc class A common.**
No dividends paid.
- 2. **Hyzon Motors Inc class B common.**
No dividends paid.

Annual Dividends:

- 1. **Hyzon Motors Inc class A common.**
No dividends paid.
- 2. **Hyzon Motors Inc class B common.**
No dividends paid.

INTEGRAL ACQUISITION CORP I

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 ⁽¹⁾⁽²⁾
Formation & operating costs	2,414,736	1,120,668	385,971
Income (loss) from operations	(1,120,668)	(385,971)	(385,971)
Unrealized gain (loss) on change in fair value of forward purchase agreement liability	(1,700,783)	6,001	6,001
Unrealized gain in trust account	376,801
Interest income	2,742,369	1,271,533	8,409
Unrealized gain (loss) on change in fair value of FPA	1,696,965
Total other income (expenses)	4,439,334	(52,449)	14,410
Income (loss) before provision for income taxes	2,024,598	(1,173,117)	(371,561)
Income tax provision - federal - current	190,069
Income tax benefits (provision) - federal - deferred	(80,521)	(78,028)	(78,028)
Change in valuation allowance	159,649	78,028	78,028
Provision for income taxes	497,003	269,197	...
Net income (loss)	1,527,595	(1,442,314)	(371,561)
Weighted average common stock subject to redemption outstanding - basic	11,500,000	2,054,859	2,054,859
Weighted average non-redeemable common stock outstanding - basic	2,875,000	2,875,000	2,875,000
Weighted average common stock subject to redemption outstanding - diluted	11,500,000	2,054,859	2,054,859
Weighted average non-redeemable common stock outstanding - diluted	2,575,000	2,875,000	2,875,000
Year end shares outstanding	4,073,342	14,375,000 ⁽³⁾	14,375,000
Net income (loss) per common stock subject to redemption - basic	\$(0.10)	\$(0.08)	\$(0.08)
Net income (loss) per non-redeemable common stock - basic	\$(0.10)	\$(0.08)	\$(0.08)
Net income (loss) per common stock subject to possible			

redemption - diluted	...	\$(0.10)	\$(0.08)
Net income (loss) per non-redeemable common stock - diluted	...	\$(0.10)	\$(0.08)
Number of part time employees	...	2	...
Total number of employees	2
Number of units stockholders	...	1 ⁽⁴⁾	...
Number of class A common stockholders	3	1	1 ⁽⁵⁾
Basic and diluted net income (loss) per Common Stock subject to redemption	\$0.18
Basic and diluted net income (loss) per non-redeemable Common Stock	\$0.18
Shares used to calculate Diluted EPS - Total	8,615,571
Shares used to calculate Basic EPS - Total	8,615,571

⁽¹⁾ From February 16, 2021 (Inception); ⁽²⁾ Reclassified to conform with 2022 presentation; ⁽³⁾ Shares increased due to issuance of class B common stock to initial stockholders and initial public offering of class A common stock; ⁽⁴⁾ As of March 1, 2023; ⁽⁵⁾ As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	75,891	601,088
Prepaid franchise tax	18,350	...
Prepaid expenses	...	234,276
Prepaid expenses	7,223	...
Total current assets	101,464	835,364
Investments held in trust account	...	118,064,355
Marketable securities and cash held in Trust Account	12,956,224	...
Total assets	13,057,688	118,899,719
Accrued offering costs & expenses	841,202	35,499
Income taxes payable	53,363	190,069
Franchise tax payable	1,076,073	60,164
Promissory note - related party	414,917	...
Working Capital Loans	910,083	...
Due to related party	80,000	...
Total current liabilities	3,375,638	285,732
Deferred tax liability	...	79,128
Deferred underwriting commission	...	6,050,000
Forward purchase agreement liability	...	2,708,717
Total liabilities	3,375,638	9,123,577
Class A common stock subject to possible redemption	117,737,665	288
Class B common stock	288	288
Accumulated deficit	(3,241,895)	...
Retained earnings (accumulated deficit)	...	(7,961,811)
Class A common stock subject to possible redemption, 11,500,000 shares at redemption value of \$1015 per share	12,923,657	...
Total stockholders' equity (deficit)	9,682,050	(7,961,523)
Total Equity	9,682,050	...

Recent Dividends:

- 1. **Integral Acquisition Corp I class B common.**

- No dividends paid.
 - 2. **Integral Acquisition Corp I class A common.**
No dividends paid.
 - 3. **Integral Acquisition Corp I class A common subject to redemption.**
No dividends paid.
- Annual Dividends:**
- 1. **Integral Acquisition Corp I class B common.**
No dividends paid.
 - 2. **Integral Acquisition Corp I class A common.**
No dividends paid.
 - 3. **Integral Acquisition Corp I class A common subject to redemption.**
No dividends paid.

INTELGENX TECHNOLOGIES CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 ⁽¹⁾
Revenues	1,039,000	950,000	1,535,000
Total revenues	1,039,000	950,000	1,535,000
Cost of royalty, license & other revenue	1,733,000
Research & development expenses	3,274,000	3,031,000	2,717,000
Manufacturing expense	...	1,858,000	2,256,000
Selling, general & administrative expenses	4,757,000	4,697,000	3,753,000
Depreciation of tangible assets	766,000	777,000	791,000
Total expenses	10,530,000	10,363,000	9,517,000
Operating income (loss)	(9,491,000)	(9,413,000)	(7,982,000)
Interest income	41,000
Finance & interest income	...	4,000	152,000
Financing & interest expense	1,625,000	1,281,000	1,488,000
Gain on debt extinguishment	1,148,000
Net financing & interest expense	(436,000)	(1,277,000)	(1,336,000)
Income (loss) before income taxes	(9,927,000)	(10,690,000)	(9,318,000)
Deferred income tax	(6,000)
Net income (loss)	(9,927,000)	(10,690,000)	(9,312,000)
Weighted average shares outstanding - basic	174,654,565	164,746,054	137,003,313
Weighted average shares outstanding - diluted	174,654,565	164,746,054	137,003,313
Year end shares outstanding	174,658,096	174,646,196	154,571,289
Net earnings (loss) per common share - basic	\$(0.06)	\$(0.07)	\$(0.07)
Net earnings (loss) per common share - diluted	\$(0.06)	\$(0.07)	\$(0.07)
Number of common stockholders	49	48 ⁽²⁾⁽³⁾	48 ⁽⁴⁾
Foreign currency translation adjustments	...	6,000	...
Basic EPS Excluding ExtraOrdinary Items	\$(0.06)
Diluted EPS Excluding ExtraOrdinary Items	\$(0.06)

⁽¹⁾ Reclassified to conform with 2022 presentation; ⁽²⁾ Approximately; ⁽³⁾ As of March 29, 2023; ⁽⁴⁾ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	2,282,000	1,210,000
Short-term investments	...	1,317,000
Accounts receivable	622,000	709,000

Prepaid expenses	223,000	137,000
Investment tax credits receivable	168,000	159,000
Security deposits	75,000	194,000
Raw materials	...	62,000
Inventory	71,000	62,000
Total current assets	3,441,000	3,788,000
Manufacturing equipment, cost	2,755,000	4,589,000
Less: accumulated depreciation - manufacturing equipment	2,034,000	1,695,000
Laboratory & office equipment, cost	382,000	1,536,000
Less: accumulated depreciation - laboratory & office equipment	...	1,117,000
Computer equipment, cost	...	152,000
Less: accumulated depreciation - computer equipment	1,239,000	118,000
Leasehold improvements, cost	3,366,000	3,267,000
Less: accumulated depreciation - leasehold improvements	2,574,000	2,189,000
Leasehold improvements, net	792,000	1,078,000
Computer Software	29,000	...
Leased improvements & equipment, gross	...	9,544,000
Less: accumulated depreciation - leasehold improvements & equipment	...	5,119,000
Accumulated Depreciation, Computer Software	132,000	...
Leasehold improvements & equipment, net	3,958,000	4,425,000
Security deposits	250,000	245,000
Operating lease right-of-use-asset	633,000	732,000
Total assets	8,282,000	9,190,000
Accounts payable & accrued liabilities	2,661,000	2,102,000
Current portion of operating lease liability	248,000	236,000
Current portion of finance lease liability	90,000	36,000
Deferred revenue	1,118,000	...
Convertible debentures	2,557,000	...
Term loan	500,000	...
Accrued interest expense	1,249,000	...
Total current liabilities	8,423,000	2,374,000
Loans payable	7,401,000	5,500,000
Convertible notes	4,438,000	4,272,000
Operating lease liability	230,000	425,000
Finance lease liability	37,000	42,000
Total liabilities	20,529,000	12,613,000
Capital stock	1,000	1,000
Additional paid-in capital	68,662,000	67,340,000
Retained earnings (accumulated deficit)	(78,457,000)	(68,530,000)
Accumulated other comprehensive income (loss)	(2,453,000)	(2,234,000)
Total shareholders' equity (deficit)	(12,247,000)	(3,423,000)
Total Equity	(12,247,000)	...

Recent Dividends:
1. IntelGenx Technologies Corp common.
 No dividends paid.
Annual Dividends:
1. IntelGenx Technologies Corp common.
 No dividends paid.

INTELLICHECK INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
		(revised)	(revised)
REVENUES	18,906,000	15,966,000	...
Revenues	18,906,000	15,966,000	16,393,000

Cost of revenues	1,375,000	1,275,000	3,511,000
Gross profit (loss)	17,531,000	14,691,000	12,882,000
Selling, general & administrative expenses	15,127,000	12,707,000	14,895,000
Research & development expenses	4,680,000	6,014,000	5,480,000
Total operating expenses	19,807,000	18,721,000	20,375,000
Income (loss) from operations	(2,276,000)	(4,030,000)	(7,493,000)
Gain on forgiveness of unsecured promissory note	10,000
Interest & other (expense) income	234,000	(5,000)	5,000
Total other income (expense)	234,000	(5,000)	15,000
Net income (loss) before provision for income taxes	(2,042,000)	(4,035,000)	(7,478,000)
us-gaap:Current Federal Tax Benefit	112,000
us-gaap:Current State and Local Tax Expense	(507,000)
Income Taxes - Total - Current	(62,000)	124,000	...
Provision for income taxes	(62,000)	124,000	...
Net income (loss)	(1,980,000)	(4,159,000)	(7,478,000)
Weighted average shares outstanding - basic	19,243,179	18,838,971	18,598,410
Weighted average shares outstanding - diluted	19,243,179	18,838,971	18,598,410
Year end shares outstanding	19,354,335	18,957,366	18,660,369
Net income (loss) per common share - basic	\$(0.10)	\$(0.22)	\$(0.40)
Net income (loss) per common share - diluted	\$(0.10)	\$(0.22)	\$(0.40)
Number of full time employees	49
Number of common stockholders	28	...	30
Earnings per share from continuing operations	\$(0.10)	\$(0.22)	...
Earnings per share from continuing operations	\$(0.10)	\$(0.22)	...

□ Restated to reflect correction of errors; □ Restated to reflect change in classification of certain option awards with regards to error in equity compensation accounting; □ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022	2021
		(revised)	(revised)
Cash & cash equivalents	3,980,000	5,196,000	...
Short-term investments	5,000,000	4,880,000	...
Accounts receivable, gross	4,772,000	2,657,000	...
Less: allowance	69,000	20,000	...
Accounts receivable, net of allowance of \$1,613 and \$4,884, respectively	4,703,000	2,637,000	...
Other current assets	692,000	608,000	...
Total current assets	14,375,000	13,321,000	...
Computer equipment & software	1,886,000	1,796,000	...
Furniture & fixtures	139,000	139,000	...
Office equipment	618,000	614,000	...
Property & equipment, gross	2,643,000	2,549,000	...
Less - accumulated depreciation & amortization	1,977,000	1,800,000	...
Property & equipment, net	666,000	749,000	...
Goodwill	8,102,000	8,102,000	...
Intangible assets, net	575,000	273,000	...

Other assets	90,000	8,000
Total assets	23,808,000	22,453,000
Accounts payable	884,000	358,000
Accrued professional fees	1,000	259,000
Accrued payroll & related	1,159,000	1,040,000
Incentive bonuses	824,000	846,000
Other accrued expenses	3,245,000	3,156,000
Other	197,000	174,000
Sales tax accrual	1,064,000	837,000
Deferred revenue, current portion	2,209,000	906,000
Equity awards liability	4,000	54,000
Liability for shares withheld	190,000	221,000
Income taxes payable	...	90,000
Total current liabilities	6,532,000	4,785,000
Deferred revenue, long-term portion	...	1,000
Total liabilities	6,532,000	4,786,000
Common stock	19,000	19,000
Additional paid-in capital	150,822,000	149,233,000
Accumulated deficit	(133,565,000)	(131,585,000)
Total stockholders' equity (deficit)	17,276,000	17,667,000
Total Equity	17,276,000	17,667,000

Recent Dividends:
1. Intellicheck Inc series A 8% convertible redeemable preferred.
 No dividends paid.
2. Intellicheck Inc common.
 No dividends paid.
Annual Dividends:
1. Intellicheck Inc series A 8% convertible redeemable preferred.
 No dividends paid.
2. Intellicheck Inc common.
 No dividends paid.

INTERLINK ELECTRONICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
			(revised)
Revenue, net	13,940	7,493	7,478
Cost of revenue	7,381	3,632	3,420
Gross profit	6,559	3,861	4,058
Engineering, research & development	2,326	1,220	893
Selling, general & administrative	4,672	3,309	3,244
Total operating expenses	6,998	4,529	4,137
Income (loss) from operations	(439)	(668)	(79)
Other income (expense), net	164	2,611	(50)
Total other income (expense), net	164
Income (loss) before income tax provision (benefit) - domestic	...	(1,363)	921
Income (loss) before income tax provision (benefit) - foreign	...	580	792
Income (loss) before income taxes	(275)	1,943	(129)
Current federal income taxes (benefit)	27	254	(113)
Current state income taxes (benefit)	10	13	1
Current foreign income taxes (benefit)	154	130	198
Total current income taxes

(benefit).....	191	397	86
Deferred federal income taxes (benefit).....	267
Deferred state income taxes (benefit).....	253
Deferred foreign income taxes (benefit).....	(83)	(126)	(1)
Total deferred income taxes (benefit).....	(83)	(126)	519
Income tax expense (benefit).....	108	271	605
Net income (loss)	(383)	1,672	(734)
Less: preference stock dividends.....	400	400	48
Net income (loss) applicable to common stockholders	(783)	1,272	(782)
Weighted average shares outstanding - basic.....	9,887	22,285	22,278
Weighted average shares outstanding - diluted.....	9,887	22,285	22,278
Year end shares outstanding.....	9,860	22,309	22,282
Income (loss) per share from continuing operations - basic....	\$(0.08)
Net earnings (loss) per share - basic.....	\$(0.08)	\$0.06	\$(0.04)
Income (loss) per share from continuing operations - diluted.....	\$(0.08)
Net earnings (loss) per share - diluted....	\$(0.08)	\$0.06	\$(0.04)
Number of full time employees.....	107	98	89
Total number of employees.....	107
Number of common stockholders.....	24	23	26
Foreign currency translation adjustments.....	...	(194)	...
Revenue, net.....	13,940

Reclassified to conform with 2022 presentation; Adjusted for 50% stock dividend, March 25, 2024; As is

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	4,304	10,091
Accounts receivable, net	2,167	1,178
Raw materials	1,986	1,632
Work-in-process	232	192
Finished goods	258	285
Inventories	2,476	2,112
Prepaid expenses & other current assets	381	321
Total current assets	9,328	13,702
Furniture, machinery & equipment	2,009	1,688
Leasehold improvements	412	417
Property & equipment, gross	2,421	2,105
Less: accumulated depreciation	2,108	1,921
Property, plant & equipment, net	313	184
Intangible assets, net	2,654	76
Goodwill	2,461	650
Right-of-use assets	143	172
Deferred tax assets	83	134
Other assets	80	65
Total assets	15,062	14,983

Accounts payable.....	464	273
Accrued wages & benefits	204	320
Accrued vacation	185	223
Accrued other liabilities	103	25
Accrued liabilities.....	492	568
Lease liabilities, current	126	131
Accrued income taxes	293	117
Total current liabilities	1,375	1,089
Lease liabilities, long term	33	46
Deferred tax liabilities	626	...
Total long-term liabilities	659	46
Total liabilities	2,034	1,135
Series A convertible preferred stock	2
Common stock	10	7
Additional paid-in-capital	62,279	62,617
Accumulated other comprehensive income (loss)	200	(98)
Accumulated deficit	(49,463)	...
Retained earnings (accumulated deficit)	(48,680)
Preferred Stock	2	...
Total stockholders' equity	13,028	13,848
Rep Total Equity & Minority Interest	13,028	...

As reported by the Company

Recent Dividends:

1. Interlink Electronics Inc common. No dividends paid.
2. Interlink Electronics Inc series A convertible preferred. No dividends paid.

Annual Dividends:

1. Interlink Electronics Inc common. No dividends paid.
2. Interlink Electronics Inc series A convertible preferred. No dividends paid.

Weighted average shares outstanding - diluted.....	517,777,847	510,794,145	477,723,996
Year end shares outstanding.....	519,787,870	514,889,916	502,584,176
Net income (loss) per share - basic	\$0.00	\$0.00
Net income (loss) per share - diluted	\$0.00	\$0.00
Number of full time employees.....	40	32	30
Number of part time employees.....	...	1	2
Total number of employees.....	40	33	32
Number of common stockholders	486	490	503

Reclassified to conform with 2022 presentation; As of March 11, 2023; As of March 22, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,688,141	2,375,817
Accounts receivable, gross	1,469,298	...
Accounts receivable	1,469,298	1,596,886
Work in progress	744,793
Inventories	927,111	744,793
Prepays & other current assets	672,934	1,023,129
Total current assets	5,757,484	5,740,625
Restricted cash	880,752	840,049
Furniture & fixtures	287,463	284,020
Transportation equipment.....	114,708	114,708
Plant & improvements	526,205	501,334
Production equipment	4,569,980	3,997,193
Property, plant & equipment, gross	5,498,356	4,897,255
Less accumulated depreciation	3,033,279	2,872,769
Property, plant & equipment, net	2,465,077	2,024,486
Capitalized lease disposal costs, net	6,611	228,125
Financing lease right-of-use asset	12,621
Operating lease right-of-use asset.....	2,183,988	2,311,082
Goodwill	1,384,255	1,384,255
Patents & other intangibles, net	3,538,458	3,703,353
Capitalized lease disposal costs, net	688,462	...
Total long-term assets	11,147,603	10,503,971
Total assets	16,905,087	16,244,596
Accounts payable	559,597	382,392
Accrued liabilities	1,482,179	1,472,504
Unearned revenue	932,682	879,365
Current portion of operating lease right-of-use liability	140,733	131,572
Current portion of financing lease liability	2,832	5,513
Current portion of related party notes payable, net of debt discount	620,000
Current installments of notes payable	155,733	23,348
Total current liabilities	3,273,756	3,514,694
Accrued long-term liabilities	75,000	112,500
Related party notes payable, net of current portion & debt discount.....	1,620,000	1,000,000
Notes payable, net of current portion	270,732	34,406
Asset retirement obligation	1,474,463	942,378
Financing lease liability, net of current portion	2,832
Operating lease

right-of-use liability, net of current portion	2,091,511	2,232,244
Mandatorily redeemable convertible preferred stock, net of current portion & discount	4,063,000	4,063,000
Total long-term liabilities	9,594,706	8,387,360
Total liabilities	12,868,462	11,902,054
Common stock	5,197,879	5,148,899
Additional paid-in capital	126,168,605	125,654,486
Retained earnings (accumulated deficit)	(127,329,859)	(126,460,843)
Equity (deficit) attributable to International Isotopes Inc. stockholders	4,036,625	4,342,542
Total equity (deficit)	4,036,625	4,342,542

Recent Dividends:**1. International Isotopes Inc series C redeemable convertible preferred.**

No dividends paid.

2. International Isotopes Inc series B mandatorily redeemable convertible preferred.

No dividends paid.

3. International Isotopes Inc common.

No dividends paid.

Annual Dividends:**1. International Isotopes Inc series C redeemable convertible preferred.**

No dividends paid.

2. International Isotopes Inc series B mandatorily redeemable convertible preferred.

No dividends paid.

3. International Isotopes Inc common.

No dividends paid.

INTUITIVE SURGICAL INC**Earnings, 3 mos. to Mar 31 (Consol. - \$000):**

	2024	2023
Total Revenues	1,890,600	1,696,200
Cost & expenses	1,421,200	1,308,600
Operating income	469,400	387,600
Net before taxes	538,500	421,800
Income taxes	(8,900)	61,000
Net income	547,400	360,800
Earnings common share		
Primary	\$1.54	\$1.01
Fully Diluted	\$1.51	\$1.00
Common Shares:		
Full Diluted	360,500	356,000
Year-end	354,700	350,400

Consolidated Balance Sheet Items, as of (\$000):

	2024	2023
Assets:		
Cash & equivalents	2,839,500	1,299,300
Inventories	7,632,700	3,799,600
Net property & equip.	15,828,000	1,375,100
Total assets	13,962,600	6,257,600
Liabilities:		
Current liabilities	13,962,600	6,257,600
Stockholders' equity		
Net current assets		

INVESTVIEW INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Subscription revenue, net of refunds, incentives, credits, & chargebacks	56,036,052	48,260,197	40,918,453
Mining revenue	11,348,156	11,796,215	23,056,457
Mining equipment repair revenue	23,378	172,056	7,460
Cryptocurrency revenue	513,285	1,614,568	8,249,310
Digital wallet revenue		5,868	

Total revenue, net	67,920,871	61,848,904	72,231,680
Cost of sales & service	10,736,709	8,249,790	6,107,358
Commissions	31,716,399	26,986,048	29,127,854
Selling & marketing expenses	560,065	58,617	76,662
Salary & related expenses	7,112,954	7,441,829	3,946,151
Professional fees	1,378,367	2,615,016	1,574,292
Impairment expense		14,632,823	140,233
Bad debt expense		3,975	719,342
Gain (loss) on disposal of assets	(223,630)	266,838	12,927
General & administrative expenses		10,740,430	58,927,950
Selling, general & administrative expenses	9,531,431		
Impairment loss	2,056,386		
Total operating costs & expenses	63,315,941	70,461,690	100,606,915
Net income (loss) from operations	4,604,930	(8,612,786)	(28,375,235)
Gain (loss) on debt extinguishment		455	571,466
Gain (loss) on fair value of derivative liability	18,691	44,945	352,931
Realized gain (loss) on cryptocurrency	255,268	(1,575,164)	1,291,082
Interest expense	18,750	18,750	16,660
Interest expense, related parties		2,650,324	2,279,397
Other income (expense)	1,389,796	193,235	91,220
Debt discount	(1,239,603)		
Total other income (expense)	405,402	(4,005,603)	10,642
Income before income taxes - domestic		(12,618,389)	(28,278,452)
Income before income taxes - foreign			(86,141)
Income (loss) before income taxes	5,010,332	(12,618,389)	(28,364,593)
Current federal income taxes	2,138,412	52,167	797,827
Current state income taxes	40,000	274,388	10,000
Total current income tax expense	2,178,412	326,555	807,827
Income tax expense (benefit)	2,178,412	326,555	807,827
Net income (loss)	2,831,920	(12,944,944)	(29,172,420)
Dividends on preferred stock	819,340	819,340	614,504
Net income (loss) applicable to common shareholders	2,012,580	(13,764,284)	(29,786,924)
Weighted average shares outstanding - basic	2,559,093,504	2,677,718,626	2,986,026,570
Weighted average shares outstanding - diluted	3,595,522,075	2,677,718,626	2,986,026,570
Year end shares outstanding	2,333,356,496	2,636,275,489	2,904,210,762
Net income (loss) per common share - basic		\$(0.01)	\$(0.01)
Net income (loss) per common share - diluted		\$(0.01)	\$(0.01)
Number of full time employees		29	33
Number of part time employees		4	4
Total number of employees		33	37
Number of common stockholders	630	730	730

Income Taxes - Total	2,178,412		
-------------------------	-----------	--	--

¹ For 9 months due to fiscal year end change; ² As of March 24, 2023; ³ As of March 31, 2022; ⁴ Approximately; ⁵ As of April 13, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	20,912,276	20,467,256
Restricted cash, current	230,354	781,537
Prepaid assets	492,607	366,561
Receivables	2,232,725	1,255,542
Inventory		249,480
Income tax paid in advance		535,932
Other current assets	585,632	2,360,957
Total current assets	24,453,594	26,017,265
Furniture, fixtures, & equipment	717	76,716
Computer equipment	11,308	12,869
Leasehold improvements		40,528
Data processing equipment		13,200,939
Software	14,084,670	
Fixed assets, gross	14,096,695	13,331,052
Less: accumulated depreciation	7,559,872	4,822,778
Fixed assets, net	6,536,823	8,508,274
Restricted cash, long term		240,105
Other restricted assets, long term		113,139
Operating lease right-of-use asset	110,427	223,692
Deposits	2,588,127	473,598
Total assets	33,688,971	35,576,073
Accrued salaries & wages	187,419	
Payroll liabilities		197,300
Income tax payable	1,004,535	240,603
Customer advance		96,609
Deferred revenue	2,703,398	2,074,574
Derivative liability	5,732	24,426
Dividend liability	256,392	236,630
Operating lease liability, current	109,628	148,226
Related party payables, net of discounts, current		1,201,927
Debt, net of discounts, current	715,127	2,938,757
Related party payables	1,203,247	
Total current liabilities	12,039,571	11,767,838
Operating lease liability, long term	6,048	79,432
Less: current portion	1,162,349	
Related party debt, net of discounts, long term	501,062	824,581
Loan with the U.S. small business administration		543,237
Long term notes for APEX lease buyback		7,925,166
Total debt, long term portion		8,468,403
Less: current portion		(2,938,757)
Debt, net of discounts, long term		5,529,646
Accrued liabilities, long term	1,189,643	
Total long term liabilities	2,859,102	6,433,659
Total liabilities	14,898,673	18,201,497
Preferred stock		252
Common stock	2,333,356	2,636,275
Additional paid in capital	104,056,807	104,350,746
Accumulated other comprehensive income (loss)	(23,218)	(23,218)
Accumulated deficit	(87,576,899)	
Retained earnings (accumulated deficit)		(89,589,479)
Preferred stock, par value: \$0.001; 50,000,000 shares authorized, 46,612 and		

none issued and outstanding as of 30, 2020 and 31, 2020, respectively	252	...
Total Investview Inc. stockholders' equity (deficit)	18,790,298	17,374,576
Total stockholders' equity (deficit)	18,790,298	...

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	200,641	92,076
Marketable securities	...	279,915
Prepaid external research, development & manufacturing costs	19,962	843
Prepaid insurance	1,770	2,392
Prepaid compensation & other	1,575	1,314
Interest receivable	933	377
Prepaid expenses & other current assets	24,240	4,926
Total current assets	224,881	376,917
Property & equipment, net	1,896	2,282
Operating lease right-of-use asset	2,229	3,777
Other non-current assets	175	191
Total assets	229,181	383,167
Accounts payable	7,953	1,517
Accrued external research, development & manufacturing costs	...	13,955
Accrued professional & consultant fees	...	1,153
Accrued Payroll	10,752	...
Accrued employee compensation	...	5,985
Other accrued expenses	...	818
Accrued expenses - Balancing value	30,108	...
Accrued expenses - Operating lease liabilities, current	1,443	1,559
Other current liabilities	35	44
Total current liabilities	50,291	25,031
Operating lease liabilities, non-current	722	2,165
Early-exercise liability	700	1
Total liabilities	51,713	27,197
Common stock	11	11
Additional paid-in capital	909,539	889,657
Accumulated other comprehensive loss	(13)	(272)
Retained earnings (accumulated deficit)	(732,069)	(533,426)
Total stockholders' equity (deficit)	177,468	355,970
Total Equity	177,468	...

Other income (expense), net	527	60	2,348
Income (loss) from operations before provision for (benefit from) income taxes - United States	...	(7,544)	(5,233)
Income (loss) from operations before provision for (benefit from) income taxes - foreign	...	62	48
INcome (loss) from operations before provision for income taxes - state	(9,480)	(7,482)	(5,185)
Current provision for income taxes - state	31	47	20
Current provision for (benefit from) income taxes - foreign	58	18	18
Total current provision for (benefit from) income taxes	89	65	38
Deferred provision for (benefit from) income taxes - federal	1	1	1
Deferred provision for (benefit from) income taxes - state	...	(1)	1
Total deferred provision for (benefit from) income taxes	1	...	2
Provision for (benefit from) income taxes	90	65	40
Net income (loss)	(9,570)	(7,547)	(5,225)
Weighted average shares outstanding - basic	16,128	15,938	15,421
Weighted average shares outstanding - diluted	16,128	15,938	15,421
Year end shares outstanding	16,253	15,990	15,876
Income (loss) per share - continuing operations - basic	\$(0.59)
Net income (loss) per share - basic	\$(0.59)	\$(0.47)	\$(0.34)
Income (loss) per share - continuing operations - diluted	\$(0.59)
Net income (loss) per share - diluted	\$(0.59)	\$(0.47)	\$(0.34)
Number of full time employees	111	130	119
Number of part time employees	18	34	51
Total number of employees	129
Number of common stockholders	33	33	33
Foreign currency translation adjustments	...	(69)	...

Recent Dividends:
1. InvestView Inc series B cumulative redeemable perpetual preferred (stated value: \$25 per share).
 No dividends paid.

2. InvestView Inc common.
 No dividends paid.

Annual Dividends:
1. InvestView Inc series B cumulative redeemable perpetual preferred (stated value: \$25 per share).
 No dividends paid.

2. InvestView Inc common.
 No dividends paid.

INVIVYD INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development	158,658	179,214	182,891
Acquired in-process research & development	...	4,400	7,500
Warrant expense	4,975	17,373	...
Selling, general & administrative	49,125	47,044	36,517
Total operating expenses	212,758	248,031	226,908
Income (loss) from operations	(212,758)	(248,031)	(226,908)
Other income (expense), net	14,115	6,714	118
Total other income (expense), net	14,115	6,714	118
Net income (loss)	(198,643)	(241,317)	(226,790)
Net loss attributable to common stockholders	(198,643)	(241,317)	(226,790)
Weighted average shares outstanding - basic	109,526	108,268	42,621
Weighted average shares outstanding - diluted	109,526	108,268	42,621
Year end shares outstanding	110,161	109,044	110,783
Net income (loss) per share - basic	\$(1.81)	\$(2.23)	\$(5.32)
Net income (loss) per share - diluted	\$(1.81)	\$(2.23)	\$(5.32)
Number of full time employees	94	84	101
Number of part time employees	1	2	2
Total number of employees	95	86	103
Number of common stockholders	11	19	42
Income from cont operations before income tax	(198,643)

Recent Dividends:
1. Invivyd Inc common.
 No dividends paid.
Annual Dividends:
1. Invivyd Inc common.
 No dividends paid.

IRIDEX CORP.

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	12/30/23	12/31/22	01/01/22 (revised)
Product revenues	51,869
Total revenues	51,869	56,972	53,903
Cost of revenues	30,062	31,604	31,072
Gross profit	21,807	25,368	22,831
Research & development expenses	6,829	7,175	6,868
Sales & marketing expenses	...	18,178	14,637
General & administrative expenses	8,748	7,557	8,859
Sales, general & administrative expenses	16,237
Total operating expenses	31,814	32,910	30,364
Income (loss) from operations	(10,007)	(7,542)	(7,533)

As is; Full time equivalent; Approximately; As of March 2, 2023; As of March 3, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	12/30/23	12/31/22
Cash & cash equivalents	7,034	13,922
Accounts receivable,

Reclassified to conform with 2022 presentation; Includes related-party amounts - Research & development: \$8,154,000; Includes related-party amounts - Research & development: \$4,150,000; Includes related-party amounts - Acquired in-process research & development: \$4,400,000; Includes related-party amounts - Acquired in-process research & development: \$7,500,000; Includes related-party amounts - warrant expense: \$17,373,000; As is; As of February 1, 2023; As of February 1, 2022; As of March 16, 2023; As of March 24, 2022

gross	6,873	6,619
Less: allowance for doubtful accounts	146	390
Accounts receivable, net	6,727	6,229
Receivable from related party	2,927	3,539
Raw materials	5,288	5,820
Work in process	156	320
Finished goods	4,462	4,468
Inventories	9,906	10,608
Prepaid expenses & other current assets	856	1,468
Total current assets	27,450	35,766
Equipment	11,597	11,527
Leasehold improvements	2,494	2,494
Less: accumulated depreciation & amortization	13,740	13,559
Property & equipment, net	351	462
Intangible assets, net	1,642	1,977
Goodwill	965	965
Operating lease right-of-use assets, net	2,632	1,665
Other long-term assets	1,396	1,455
Total assets	34,436	42,290
Accounts payable	4,499	3,858
Payable to related party	228	15
Accrued compensation	1,619	2,448
Accrued warranty	1,996	...
Legal & professional fees	...	384
Sales & marketing expenses	...	96
Temporary help & consulting	...	196
Royalties payable	149	106
Tax payable	100	65
Deferred rent	925	...
Other accrued expenses	323	701
Accrued Expenses - Balancing value	1,424	...
Other current liabilities	925	968
Accrued warranty	308	168
Deferred revenue	2,404	2,411
Operating lease liabilities	995	1,037
Total current liabilities	12,974	12,453
Accrued warranty	138	106
Deferred revenue	10,025	11,742
Operating lease liabilities	1,751	732
Other long-term liabilities	26	26
Total liabilities	24,914	25,059
Common stock	172	169
Additional paid-in capital	88,444	86,802
Accumulated other comprehensive income (loss)	(52)	(24)
Retained earnings (accumulated deficit)	(79,042)	(69,716)
Total stockholders' equity (deficit)	9,522	17,231
Total Equity	9,522	...

Recent Dividends:**1. IRIDEX Corp. common.**

No dividends paid.

2. IRIDEX Corp. convertible preferred.

No dividends paid.

Annual Dividends:**1. IRIDEX Corp. common.**

No dividends paid.

2. IRIDEX Corp. convertible preferred.

No dividends paid.

IRIDIUM COMMUNICATIONS INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2024	2023
Total Revenues	203,853,000	205,273,000
Cost & expenses	104,338,000	106,306,000
Operating income	49,771,000	23,148,000

Other income (expense), net	43,000	219,000
Equity earnings	1,567,000	1,155,000
Net before taxes	29,151,000	5,477,000
Income taxes	7,931,000	(5,453,000)
Net income	19,653,000	9,775,000
Earnings common share		
Primary	\$0.16	\$0.08
Fully Diluted	\$0.16	\$0.08
Common Shares:		
Full Diluted	123,993,000	128,738,000
Year-end	121,643,000	125,924,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2024		
Cash & equivalents	174,025,000		
Inventories	92,538,000		
Current assets	376,792,000		
Net property & equip.	2,158,250,000		
Total assets	2,735,958,000		
Liabilities:			
Current liabilities	113,001,000		
Long-term debt	1,587,507,000		
Stockholders' equity	853,685,000		
Net current assets	263,791,000		

KINNATE BIOPHARMA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31****(\$000):**

	2023	2022	2021 (revised)
Research & development expenses	90,767	88,150	67,166
General & administrative expenses	28,241	30,371	22,945
Restructuring costs	2,168
Total operating expenses	121,176	118,521	90,111
Income (loss) from operations	(121,176)	(118,521)	(90,111)
Other income (expense), net	8,527
Other income, net	8,527	2,250	348
Net income (loss)	(112,649)	(116,271)	(89,763)
Net income (loss) attributable to Kinnate Biopharma Inc.	...	(116,271)	(89,763)
Weighted average shares outstanding - basic	46,575	44,066	43,601
Weighted average shares outstanding - diluted	46,575	44,066	43,601
Year end shares outstanding	47,124	44,342	43,856
Net income (loss) per share - basic	\$(2.42)	\$(2.64)	\$(2.06)
Net income (loss) per share - diluted	\$(2.42)	\$(2.64)	\$(2.06)
Number of full time employees	27	84	61
Common Shareholders - Number	11
Number of stockholders	...	11	14
Foreign currency translation adjustments	...	1	...
Income from cont operations before income tax	(112,649)
Total number of employees	27

□ As is, □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	56,998	29,261
Cash at consolidated joint venture	...	25,725

Short-term investments	97,036	172,214
Prepaid expenses & other current assets	4,143	3,637
Total current assets	158,177	230,837
Furniture & fixtures	760	760
Computers & equipment	433	442
Computer software	99	99
Leasehold improvements	2,520	2,511
Property & equipment, gross	3,812	3,812
Less: accumulated depreciation	1,540	741
Property & equipment, net	2,272	3,071
Right-of-use lease assets	2,488	3,377
Long-term investments	10,259	39,139
Restricted cash	371	371
Other non-current assets	38	2,031
Total assets	173,605	278,826
Accounts payable	2,031	2,970
Accrued research & development	5,784	7,884
Accrued compensation	2,452	4,832
Accrued legal fees	454	243
Other accruals	127	247
Accrued restructuring costs	255	...
Accrued Expenses - Balancing value	9,072	...
Accrued expenses	...	13,206
Current portion of operating lease liabilities	892	991
Total current liabilities	11,995	17,167
Operating lease liabilities, long-term	2,283	3,191
Total liabilities	14,278	20,358
Redeemable convertible noncontrolling interests	...	35,000
Common stock	5	4
Additional paid-in capital	531,346	484,237
Accumulated other comprehensive income (loss)	(12)	(1,410)
Retained earnings (accumulated deficit)	(372,012)	(259,363)
Total stockholders' equity (deficit)	159,327	223,468
Total Equity	159,327	...

Recent Dividends:**1. Kinnate Biopharma Inc common.**

No dividends paid.

Annual Dividends:**1. Kinnate Biopharma Inc common.**

No dividends paid.

KIRKLAND'S INC**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	02/03/24	01/28/23	01/29/22 (revised)
Net sales	468,690	498,825	558,180
Total revenue	468,690
Cost of sales	341,700
Total cost of sales	...	379,036	369,752
Gross profit	126,990	119,789	188,428
Compensation & benefits expenses	82,152	85,231	84,931
Other operating expenses	62,863	69,183	70,786
Depreciation expenses (exclusive of depreciation included in cost of sales)	4,522	6,055	6,612
Asset impairment expenses	...	2,071	754
Total operating expenses	151,404	162,540	163,083
Operating income (loss)	(24,414)	(42,751)	25,345
Interest expense	3,317	1,735	320

Other income	499	335	344	Employee medical insurance reserves	456	701	attributable to common stockholders	...	(25,643,000)	(44,451,000)
Income (loss) before income taxes	(27,232)	(44,151)	25,369	Deferred e-commerce revenue	750	685	Weighted average shares outstanding - basic	65,933,820	35,551,120	10,631,774
Current federal income tax expense (benefit)	46	(153)	3,269	Accrued payroll taxes	...	251	Weighted average shares outstanding - diluted	65,933,820	35,551,120	10,631,774
Current state income tax expense (benefit)	473	696	74	Income taxes payable	...	173	Year end shares outstanding	89,546,422	38,349,122	19,068,126
Income tax expense (benefit)	519	543	3,343	Other accrued expenses	1,431	1,014	Net income (loss) per share - basic	\$(0.34)	\$(0.72)	\$(4.18)
Net income (loss)	(27,751)	(44,694)	22,026	Gift cards	12,008	...	Net income (loss) per share - diluted	\$(0.34)	\$(0.72)	\$(4.18)
Weighted average shares outstanding - basic	12,871	12,703	13,670	Accrued expenses	23,163	26,069	Number of full time employees	...	111	55
Weighted average shares outstanding - diluted	12,871	12,703	14,615	Operating lease liabilities	40,018	41,499	Number of part time employees	...	1	...
Year end shares outstanding	12,926	12,754	12,631	Revolving line of credit	34,000	15,000	Number of class A common stockholders	...	14,499	15,493
Earnings (loss) per share - continuing operations - basic	\$(2.16)	Other liabilities	4,486	3,553	Number of class B common stockholders	...	12	17
Net earnings (loss) per share - basic	\$(2.16)	\$(3.52)	\$1.61	Total liabilities	247,449	244,473				
Earnings (loss) per share - diluted	\$(2.16)	\$(3.52)	\$1.51	Common stock	176,552	175,450				
Number of full time employees	900	1,000	1,000	Accumulated deficit	(173,428)	...				
Number of part time employees	3,200	3,200	3,500	Retained earnings (accumulated deficit)	...	(145,677)				
Total number of employees	4,100	Total shareholders' equity (deficit)	3,124	29,773				
Number of common stockholders	13,236	30	30	Total Equity	3,124	...				
Number of beneficiary stockholders	...	15,976	14,803							
Impairment of tangible assets	1,867							

Reclassified to conform with 2023 presentation; As is; As approximately; As of March 13, 2023; As of March 14, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	02/03/24	01/28/23
Cash & cash equivalents	3,805	5,171
Inventories, net	74,090	84,071
Prepaid expenses & other current assets	7,614	5,089
Total current assets	85,509	94,331
Equipment	19,144	19,614
Furniture & fixtures	63,823	66,906
Leasehold improvements	100,393	103,525
Computer software & hardware	78,580	81,685
Projects in progress	647	743
Property & equipment, gross	262,587	272,473
Accumulated depreciation	232,882	233,797
Property & equipment, net	29,705	38,676
Operating lease right-of-use assets	126,725	134,525
Other assets	8,634	6,714
Total assets	250,573	274,246
Accounts payable	...	43,739
Accounts payable to related party vendor	46,010	...
Accrued gift cards	1,543	14,077
Accrued salaries & wages	1,952	3,514
Accrued workers' compensation & general liability reserves	2,062	1,948
Accrued sales returns reserve	1,549	1,475
Loyalty program deferred revenue	1,412	1,232
Accrued sales taxes	...	999

Recent Dividends:

1. Kirkland's Inc common.

No dividends paid.

Annual Dividends:

1. Kirkland's Inc common.

No dividends paid.

KNIGHTSCOPE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Service	9,874,000
Product	4,947,000
Service revenue	5,162,000
Product revenue	469,000
Service	7,169,000
Product	5,628,000
Revenue, net	12,797,000	5,631,000	3,407,000
Cost of services	8,804,000
Cost of product	146,000
Cost of revenue, net	14,821,000	...	5,464,000
Gross profit (loss)	(2,024,000)	(3,319,000)	(2,057,000)
Research & development	6,351,000	8,449,000	5,601,000
Sales & marketing	5,179,000	8,500,000	12,017,000
General & administrative	12,585,000	11,700,000	4,880,000
Restructuring charges	149,000
Total operating expenses	24,264,000	28,649,000	22,498,000
Income (loss) from operations	(26,288,000)	(31,968,000)	(24,555,000)
Interest income (expense), net	(551,000)	(9,235,000)	(4,333,000)
Change in fair value of warrant liabilities	(15,718,000)
Change in fair value of warrant & derivative liability	4,910,000	20,857,000	...
Change in fair value of convertible note	...	(4,650,000)	...
Other income (expense), net	(189,000)	(647,000)	763,000
Total other income (expense)	4,170,000	6,325,000	(19,288,000)
Net income (loss) before income tax expense	(22,118,000)	(25,643,000)	(43,843,000)
Net loss	(22,118,000)	(25,643,000)	(43,843,000)
Preferred stock dividends	608,000
Net loss	608,000

Non-consolidated; Shares increased due to the exercise of warrants and options, conversion of debt obligations, proceeds of offering and equity sale, issuance for consulting services and conversion of shares; Shares increased due to the effect of share conversion to common stock, and stock options exercised; As of February 24, 2023; As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,282,000	4,810,000
Restricted cash	100,000	...
Accounts receivable, gross	...	1,599,000
Allowance for doubtful accounts - accounts receivable	...	229,000
Accounts receivable	2,090,000	1,370,000
Raw materials	2,112,000	2,032,000
Finished goods	126,000	528,000
Work in process	82,000	...
Inventory	2,320,000	2,560,000
Prepaid inventory	...	66,000
Prepaid expense	...	901,000
Research & development tax credit	...	376,000
Other current assets	...	6,000
Prepaid expenses & other current assets	1,421,000	1,349,000
Total current assets	8,213,000	10,089,000
Autonomous Security Robots, net	8,845,000	5,850,000
Computer equipment	...	258,000
Software	...	8,000
Furniture, fixtures & equipment	...	788,000
Leasehold improvements	...	46,000
Property, equipment & software, gross	...	1,100,000
Less: accumulated depreciation	...	486,000
Property, equipment & software, net	857,000	614,000
Operating lease right-of-use-assets	1,458,000	2,012,000
Goodwill	1,922,000	1,344,000
Intangible assets, net	1,557,000	2,056,000
Other assets	122,000	117,000
Total assets	22,974,000	22,082,000
Accounts payable	1,858,000	2,457,000
Accrued expenses	1,145,000	2,403,000
Deferred revenue	1,741,000	1,711,000
Debt obligations	...	2,144,000
Operating lease liabilities, current	733,000	731,000
Other current liabilities	1,469,000	1,063,000
Total current liabilities	6,946,000	10,509,000
Convertible notes, net of fees & discount	...	8,152,000
Promissory notes	...	546,000
Total debt	1,242,000	8,698,000

Less: current portion of debt obligations	2,144,000	
Debt obligations	6,554,000	
Derivative liability	271,000	1,146,000
Preferred stock warrant liability	5,976,000	10,011,000
Other noncurrent liabilities	259,000	356,000
Operating lease liabilities, noncurrent	711,000	1,309,000
Total liabilities	15,405,000	29,885,000
Preferred stock		35,783,000
Class A common stock	9,000	28,000
Class B common stock	80,000	10,000
Additional paid-in capital	134,735,000	95,716,000
Accumulated deficit	(161,458,000)	
Retained earnings (accumulated deficit)		(139,340,000)
Preferred Stock, \$0001 par value; 43,405,324 and 25,794,920 shares authorized as of 31, 2020 and 2019, respectively, 25,770,360 and 22,820,982 shares issued and outstanding at 31, 2020 and 2019, respectively; aggregate liquidati	34,203,000	
Total stockholders' equity (deficit)	7,569,000	(43,586,000)
Total Equity	7,569,000	

Recent Dividends:

1. **Knightscope Inc class B common.**
No dividends paid.

2. **Knightscope Inc class A common.**
No dividends paid.

Annual Dividends:

1. **Knightscope Inc class B common.**
No dividends paid.

2. **Knightscope Inc class A common.**
No dividends paid.

KODIAK SCIENCES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021 (revised)
Research & development	206,298	267,591	217,340
General & administrative expenses	71,023	73,788	49,711
Total operating expenses	277,321	341,379	267,051
Income (loss) from operations	(277,321)	(341,379)	(267,051)
Interest income	16,733	7,071	298
Interest expense	13	18	47
Other income (expense), net	110	503	(190)
Income before income taxes - United States		(163,240)	(46,590)
Income before income taxes - foreign		(170,550)	(220,326)
Total loss before income taxes		333,790	(266,916)
Income (loss) before provision for income taxes	(260,491)	(333,823)	
Net income (loss)	(260,491)	(333,823)	(266,990)
Net income (loss) attributable to common stockholders		(333,823)	(266,990)
Weighted average shares outstanding - basic	52,414	52,250	51,789
Weighted average shares outstanding			

- diluted	52,414	52,250	51,789
Year end shares outstanding	52,509	52,334	51,826
Net earnings (loss) per share - basic	\$(4.97)	\$(6.39)	\$(5.16)
Net earnings (loss) per share - diluted	\$(4.97)	\$(6.39)	\$(5.16)
Number of full time employees	111		
Total number of employees	111	112	93
Number of common stockholders	23	22	22

Reclassified to conform with 2022 presentation; As is; As of February 28, 2023; As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	285,507	190,433
Prepaid expenses & other current assets	3,802	7,072
Marketable securities		288,500
Total current assets	289,309	486,005
Restricted cash	6,324	6,324
Furniture & fixtures	2,042	1,969
Machinery & equipment	39,709	12,763
Computer Software & hardware	143,034	374
Leasehold improvement	96,534	43,483
Construction in progress	4,371	4,519
Computer software	378	
Total property & equipment, gross		63,108
Less: accumulated depreciation	22,552	6,724
Property & equipment, net	120,482	56,384
Operating lease right-of-use asset	54,541	59,369
Other assets	8,716	58,546
Total assets	479,372	666,628
Accounts payable	13,608	9,130
Accrued clinical trial & related costs	2,701	18,334
Accrued salaries & benefits	6,078	6,033
Accrued manufacturing & research & development costs		5,978
Accrued leasehold improvements		1,893
Accrued legal fees		245
Accrued professional fees		39
Accrued other liabilities	714	919
Accrued research & development	8,662	
Accrued & other current liabilities	18,351	33,440
Operating lease liability	9,770	9,926
Accrued legal fees and professional fees	196	
Total current liabilities	41,729	52,496
Operating lease liability, net of current portion	71,862	77,807
Liability related to sale of future royalties	100,000	99,996
Other liabilities		162
Total liabilities	213,591	230,461
Common stock	5	5
Additional paid-in capital	1,418,307	1,329,509
Accumulated other comprehensive income (loss)		(1,307)
Retained earnings (accumulated deficit)	(1,152,531)	(892,040)
Total stockholders' equity (deficit)	265,781	436,167
Total Equity	265,781	

As reported by the Company

Recent Dividends:

1. **Kodiak Sciences Inc common.**

No dividends paid.

Annual Dividends:

1. **Kodiak Sciences Inc common.**

No dividends paid.

KURA SUSHI USA INC**Earnings, 6 mos. to (Consol. - \$000):**

	02/29/24	02/28/23
Total Revenues	108,766	
Net Sales	108,766	83,262
Cost & expenses	113,086	86,294
Operating income	(4,531)	(3,205)
Interest income	1,594	157
Interest expense		30
Net before taxes	(2,957)	(3,078)
Income taxes	88	25
Net income	(3,045)	(3,103)
Earnings common share		
Primary	\$(0.27)	\$(0.32)
Fully Diluted	\$(0.27)	\$(0.32)
Common Shares:		
Full Diluted	11,162	9,795
Year-end	11,226	9,819

LAKELAND INDUSTRIES, INC.**Annual Report****Consolidated Income Statement, Years Ended Jan. 31 (\$):**

	2024	2023	2022
Net sales	124,688,000	112,846,000	118,386,000
Cost of goods sold	73,496,000	66,997,000	67,473,000
Gross profit (loss)	51,192,000	45,849,000	50,913,000
Operating expenses	45,200,000		
Operating expenses	45,200,000	40,308,000	34,866,000
Operating profit (loss)	5,993,000	5,541,000	16,047,000
Other income (expense), net	3,415,000	(33,000)	121,000
Interest expense	52,000	37,000	15,000
Income (loss) before taxes - domestic	8,648,000	15,322,000	1,519,000
Income (loss) before taxes - foreign	708,000	(9,851,000)	14,634,000
Income (loss) before taxes	9,356,000	5,471,000	16,153,000
Current federal income tax expense (benefit)	17,000	2,000	(171,000)
Current state & other income tax expense (benefit)	58,000	68,000	88,000
Current foreign income tax expense (benefit)	4,674,000	3,450,000	4,205,000
Total current income tax expense (benefit)	4,749,000	3,520,000	4,122,000
Domestic	(186,000)		
Deferred domestic income tax expense (benefit)		(756,000)	526,000
Deferred foreign income taxes	(633,000)	834,000	133,000
Total deferred income taxes	(819,000)	78,000	659,000
Income tax expense (benefit)	3,930,000	3,598,000	4,781,000
Net income (loss)	5,425,000	1,873,000	11,372,000
Weighted average shares outstanding - basic	7,352,356	7,562,187	7,900,131
Weighted average shares outstanding - diluted	7,539,705	7,737,963	8,053,876
Year end shares outstanding	7,364,757	7,325,005	7,615,967
Income (loss) per share - continuing operations - basic	\$0.74		

Net income (loss) per common share - basic	\$0.74	\$0.25	\$1.44
Income (loss) per share - continuing operations - diluted	\$0.72
Net income (loss) per common share - diluted	\$0.72	\$0.24	\$1.41
Number of full time employees	1,700	1,550	...
Number of part time employees	50	50	...
Total number of employees	1,750	...	1,800
Number of common stockholders	30	...	36
Total revenues	124,688,000
Dividends per common share	\$0.12

capital	79,420,000	78,475,000
Retained earnings	69,282,000	64,765,000
Accumulated other comprehensive gain (loss)	(5,360,000)	(3,691,000)
Total stockholders' equity (deficit)	123,450,000	119,990,000
Rep Total Equity & Minority Interest	123,450,000	119,990,000

Restated to reflect correction of errors

Recent Dividends:
1. Lakeland Industries, Inc. common.

ExDate	Amt	Declared	Record	Payable
02/14/2023	0.03	02/01/2023	02/15/2023	02/22/2023
05/12/2023	0.03	05/01/2023	05/15/2023	05/22/2023
08/14/2023	0.03	08/01/2023	08/15/2023	08/22/2023
11/14/2023	0.03	11/01/2023	11/15/2023	11/22/2023
02/14/2024	0.03	02/01/2024	02/15/2024	02/22/2024

Annual Dividends:
1. Lakeland Industries, Inc. common.

2023 0.12 2024 0.03

Approximately; As of April 8, 2022

Consolidated Balance Sheet, Years Ended Jan. 31 (\$):

	2024	2023 (revised)
Cash & cash equivalents	25,222,000	24,639,000
Accounts receivable, gross	20,026,000	18,096,000
Less: allowance for doubtful accounts	857,000	800,000
Accounts receivable, net	19,169,000	17,296,000
Raw materials	27,417,000	29,036,000
Work-in-process	668,000	952,000
Finished goods	29,719,000	32,855,000
Excess & obsolete reserves	6,554,000	4,668,000
Other STOCKS	51,250,000	1,000
Inventories	...	58,176,000
Income tax receivable & other current assets	3,111,000	3,517,000
Prepaid VAT and other taxes	2,753,000	1,963,000
Total current assets	101,505,000	105,591,000
Machinery & equipment	10,773,000	5,436,000
Leasehold improvements	2,388,000	2,094,000
Computer hardware & software	988,000	492,000
Land & building	7,625,000	9,508,000
Computer equipment	5,430,000	5,015,000
Less accumulated depreciation & amortization	17,600,000	14,406,000
Construction-in-progress	1,081,000	1,001,000
Property & equipment, net	10,685,000	9,140,000
Operating leases right-of-use assets	10,969,000	5,472,000
Deferred tax assets	3,097,000	2,764,000
Other assets	110,000	100,000
Goodwill	13,669,000	8,473,000
Intangible assets, net	6,830,000	6,042,000
Equity investments	4,719,000	5,354,000
Convertible debt investments	2,161,000	...
Total assets	153,745,000	142,936,000
Accounts payable	7,378,000	6,558,000
Accrued compensation & benefits	3,922,000	2,522,000
Other accrued expenses	2,487,000	4,068,000
Income tax payable	1,454,000	609,000
Short-term borrowings	298,000	405,000
Accrued earnout agreement	643,000	3,182,000
Current portion of operating lease liability	2,164,000	1,253,000
Long-term portion of Canada loan	731,000	...
Deferred income taxes	2,097,000	769,000
Long-term portion of operating lease liability	9,121,000	3,580,000
Total liabilities	30,294,000	22,946,000
Common stock	87,000	87,000
Treasury stock	19,979,000	19,646,000
Additional paid-in		

LEXARIA BIOSCIENCE CORP

Earnings, 6 mos. to (Consol. - \$):

	2024	2023
Total Revenues	296,278	117,760
Cost & expenses	2,103,425	3,136,804
Operating income	(1,837,771)	(3,079,944)
Gains or losses	(37,942)	(79,631)
Net income	(1,837,771)	(3,079,944)
Earnings common share		
Primary	\$(0.18)	\$(0.52)
Fully Diluted	\$(0.18)	\$(0.52)
Common Shares:		
Full Diluted	9,970,489	5,950,998
Year-end	12,387,673	5,950,998

LEXICON PHARMACEUTICALS, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Cost of Sales	85,000
Net product revenue	1,110,000
Royalties & other revenue	94,000	139,000	298,000
Total revenues	1,204,000	139,000	298,000
Research & development	58,887,000	52,816,000	55,046,000
Selling, general & administrative	113,982,000	48,083,000	32,342,000
Total operating expenses	172,954,000	100,899,000	87,388,000
Income (loss) from operations	(171,750,000)	(100,760,000)	(87,090,000)
Interest expense	13,101,000	2,780,000	802,000
Interest & other income, net	7,732,000	1,596,000	134,000
Net income (loss) before taxes	(177,119,000)
Net income (loss)	(177,119,000)	(101,944,000)	(87,758,000)
Weighted average shares outstanding - basic	221,130,000	165,733,000	145,652,000
Weighted average shares outstanding - diluted	221,130,000	165,733,000	145,652,000
Year end shares outstanding	244,924,695	188,726,000	148,917,000
Net income (loss) per common share - basic	\$(0.80)	\$(0.62)	\$(0.60)
Net income (loss) per common share - diluted	\$(0.80)	\$(0.62)	\$(0.60)
Total number of employees	...	135	87
Number of common stockholders	313	257	298
Basic EPS Excluding			

ExtraOrdinary Items	\$(0.80)
Diluted EPS Excluding ExtraOrd Items	\$(0.80)

Reclassified to conform with 2022 presentation; Including stock-based compensation - research and development expenses: \$4,253,000; Including stock-based compensation - research and development expenses: \$4,284,000; Including stock-based compensation - selling, general and administrative expenses: \$7,267,000; Including stock-based compensation - selling, general and administrative expenses: \$6,293,000; Shares increased due to the effect of issuance of shares; As of February 28, 2023; As of February 28, 2022; Approximately; As of February 27, 2023; As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	22,465,000	46,345,000
U.S. treasury securities - fair value	...	73,680,000
Corporate debt securities - fair value	...	18,332,000
Accounts receivable, net	1,010,000	28,000
Inventory	381,000	...
Prepaid expenses & other current assets	5,130,000	2,481,000
Total current assets	176,547,000	140,866,000
Computers & software	1,939,000	2,209,000
Furniture & fixtures	...	1,794,000
Leasehold improvements	2,178,000	2,052,000
Computers and software	2,408,000	...
Total property & equipment	6,525,000	6,055,000
Less: accumulated depreciation & amortization	4,538,000	3,984,000
Property & equipment, net	1,987,000	2,071,000
Goodwill	44,543,000	44,543,000
Operating lease right-of-use-assets	5,524,000	6,819,000
Other assets	828,000	...
Total assets	229,429,000	194,299,000
Accounts payable	14,389,000	10,395,000
Accrued research & development services	3,705,000	3,252,000
Accrued compensation & benefits	9,591,000	7,830,000
Short term lease liability	1,291,000	1,291,000
Other accrued expenses	...	404,000
Accrued liabilities	17,157,000	12,777,000
Other	2,570,000	...
Total current liabilities	31,546,000	23,172,000
Long-term debt, net of issuance costs	99,508,000	48,579,000
Long-term operating lease liabilities	5,265,000	5,424,000
Total liabilities	136,319,000	77,175,000
Common stock	245,000	189,000
Additional paid-in capital	1,862,558,000	1,709,144,000
Retained earnings (accumulated deficit)	(1,766,839,000)	(1,589,720,000)
Accumulated other comprehensive gain (loss)	31,000	(428,000)
Treasury stock	2,885,000	2,061,000
Total stockholders' equity (deficit)	93,110,000	117,124,000
Total equity (deficit)	93,110,000	117,124,000

Recent Dividends:
1. Lexicon Pharmaceuticals, Inc. common.

No dividends paid.

Annual Dividends:

1. Lexicon Pharmaceuticals, Inc. common.

No dividends paid.

LOTTERY.COM INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021	Cash	359,826	102,766	income, net	1,747,000		
Cost of revenue	5,545,531	Accounts receivable	24,241	208,647	Interest income	...	(117,000)	(179,000)		
Revenue	6,482,638	Prepaid expenses	19,020,159	19,409,323	(expense), net		
Revenue	6,482,638	6,779,057	68,527,394	Other current assets	825,948	718,550	Net income (loss)	31,823,000	38,900,000	38,262,000		
Cost of revenue	5,545,531	4,310,750	19,158,707	Total current assets	20,230,174	20,439,286	before taxes		
Gross profit	937,107	2,468,307	49,368,687	Notes receivable	2,000,000	2,000,000	Current taxes -		
Personnel costs	4,935,072	37,114,485	21,585,534	Investments	250,000	250,000	U.S. federal	6,898,000	6,990,000	...		
Professional fees	6,773,012	6,613,546	8,279,798	Goodwill	12,880,558	19,590,758	Current taxes -		
General & administrative	9,216,243	8,931,681	5,020,495	Intangible assets, net	17,681,874	23,982,445	state & local	3,190,000	3,252,000	2,198,000		
Depreciation & amortization	4,195,504	5,601,374	4,292,606	Computer & equipment	124,199	124,199	Total current tax	10,088,000	10,242,000	2,198,000		
Total operating expenses	25,119,831	58,261,086	39,178,433	Furniture & fixtures	16,898	16,898	expense		
Income (loss) from operations	(24,182,724)	(55,792,779)	10,190,254	Software	2,026,200	2,026,200	Deferred tax		
Refund of Tender Bid-Subsidiary	(136,429)	Property & equipment, gross	2,167,297	2,167,297	expense (benefit) -	(1,238,000)	1,322,000	(7,254,000)		
Interest expense	383,569	764,839	19,789,451	Less: Accumulated depreciation	2,145,988	2,059,219	U.S. federal		
Other expense	...	3,721,291	2,907,518	Property & equipment, net	21,309	108,078	Deferred tax	(888,000)	(906,000)	(2,582,000)		
Total other income (expenses), net	(519,998)	(4,486,130)	(22,696,969)	Other long term assets	12,884,686	13,009,686	expense (benefit) -	...	416,000	(9,836,000)		
Income before income taxes - domestic	...	(58,379,329)	...	Total assets	65,948,601	79,380,253	state & local		
Income before income taxes - foreign	...	(1,899,580)	...	Account payable & accrued expenses	8,009,534	...	Total deferred tax		
Net income (loss) before income tax	(24,702,722)	(60,278,909)	(12,506,715)	Trade payables	...	7,607,633	expense (benefit) -	...	416,000	(9,836,000)		
Current federal income taxes	101,378	Deferred revenue	357,143	464,286	Total deferred tax (benefit) expense	(2,126,000)		
Current state income taxes	...	104,356	...	Notes payable - current	6,075,594	3,755,676	Provision for (benefit from)		
Current income taxes	...	104,356	...	Accrued interest	11,519,474	484,172	income taxes	7,962,000	10,658,000	(7,638,000)		
Deferred federal income taxes	(1,653,067)	Accrued & other expenses	...	4,626,973	Net income (loss)	23,861,000	28,242,000	45,900,000		
Income tax expense (benefit)	...	104,356	(1,551,689)	Other liabilities	1,070,233	625,028	Net income (loss) attributable to common shares	45,900,000		
Net income (loss)	(24,702,722)	(60,383,265)	(10,955,026)	Accrued interest	867,236	...	Weighted average shares outstanding		
Net income attributable to noncontrolling interest	...	379,916	(136,924)	Total current liabilities	27,899,214	17,563,768	- basic	15,427,975	15,198,754	15,107,958		
Net income (loss) attributable to Lottery.com Inc.	...	□(59,999,072)	□(11,092,605)	Total liabilities	27,899,214	17,563,768	Weighted average shares outstanding		
Weighted average shares outstanding - basic	2,704,032	□2,522,225	1,299,942	Common stock	2,877	50,540	- diluted	16,460,383	15,955,668	16,058,111		
Weighted average shares outstanding - diluted	2,704,032	□2,522,225	1,299,942	Additional paid-in capital	269,690,569	267,549,357	Year end shares outstanding	15,489,364	15,195,698	15,123,338		
Year end shares outstanding	2,877,046	□2,527,045	2,340,413	Accumulated other comprehensive income (loss)	(144,729)	3,622	Net earnings (loss) per share - basic	\$1.55	\$1.86	\$3.04		
Net income (loss) per common share - basic	\$(9.12)	□\$(23.80)	\$(8.60)	Accumulated deficit	(233,759,640)	...	Net earnings (loss) per share - diluted	\$1.45	\$1.77	\$2.86		
Net income (loss) per common share - diluted	\$(9.12)	□\$(23.80)	\$(8.60)	Retained earnings (accumulated deficit)	...	(208,187,210)	Number of full time employees	909	769	607		
Number of full time employees	20	Total Lottery.com Inc. stockholders' equity	35,789,077	59,416,309	Number of part time employees	1,082	641	578		
Number of part time employees	23	Noncontrolling interest	2,260,310	2,400,176	Total number of employees	1,991		
Total number of employees	...	10	43	Total equity	38,049,387	61,816,485	Number of common stockholders	148	□170	□180		
Number of common stockholders	114	□114	□208	Recent Dividends:	Provision for income taxes	7,962,000		
Foreign currency translation adjustments	...	4,277	(655)	1. Lottery.com Inc common stock subject to possible redemption.	EPS - Basic - excluding Extraordinary Items		
□2021 and prior periods for Trident Acquisitions Corp. prior to reverse recapitalization with AutoLotto, Inc.; □ As reported by the Company; □ Adjusted for 1-for-20 stock split, August 10, 2023; □ As of June 15, 2023; □ As of March 25, 2022				Annual Dividends:	Common - Total	\$1.55		
				1. Lottery.com Inc common stock subject to possible redemption.	EPS - Diluted - excluding Extraordinary Items		
				No dividends paid.	Common - Total	\$1.45		
				2. Lottery.com Inc common.						
				No dividends paid.						
				Annual Dividends:						
				1. Lottery.com Inc common stock subject to possible redemption.						
				No dividends paid.						
				2. Lottery.com Inc common.						
				No dividends paid.						
				LOVESAC CO						
				Annual Report						
				Consolidated Income Statement, Years Ended (\$):						
				02/04/24	□01/29/23	01/30/22						
				Total revenue	700,265,000	...						
				Net sales	700,265,000	651,545,000						
				Cost of merchandise sold	299,222,000	305,719,000						
				Gross profit	401,043,000	345,826,000						
				Selling, general & administration expenses	264,314,000	216,103,000						
				Advertising & marketing	94,050,000	79,864,000						
				Depreciation & amortization	12,603,000	10,842,000						
				Depreciation	12,174,000	...						
				Amortization of Intangibles excluding Goodwill	429,000	...						
				Total operating expenses	370,967,000	306,809,000						
				Operating income (loss)	30,076,000	39,017,000						
				Interest (expense)						
				Consolidated Balance Sheet, Years Ended (\$):								
						02/04/24	□01/29/23					
				Cash & cash equivalents	87,036,000	43,533,000						
				Other receivables	13,463,000	...						
				Trade accounts receivable	...	9,469,000						
				Merchandise inventories	98,440,000	119,962,000						
				Tenant allowance receivable	...	6,160,000						
				Barter credits	...	3,770,000						
				Rebate receivable	...	2,780,000						
				Prepaid insurance	...	2,009,000						
				Prepaid catalog costs & related	...	1,557,000						
				Prepaid taxes	...	1,000,000						
				Prepaid software licenses	...	945,000						
				Deposits	...	662,000						
				Prepaid rent	...	505,000						
				Prepaid inventory	...	49,000						
				Other prepaid expenses & other current assets	...	1,640,000						

Prepaid expenses & other current assets	21,077,000	
Prepaid expenses	11,664,000	
Other current assets	3,845,000	
Total current assets	214,448,000	194,041,000
Office & store furniture, & equipment	13,089,000	8,933,000
Software	5,206,000	3,996,000
Leasehold improvements	80,501,000	60,964,000
Computers	5,254,000	4,032,000
Tools, dies, molds	779,000	868,000
Vehicles	497,000	497,000
Construction in process	7,826,000	6,329,000
Property & equipment, gross		85,619,000
Less accumulated depreciation & amortization	42,345,000	32,715,000
Property & equipment, net	70,807,000	52,904,000
Operating lease right-of-use assets	155,856,000	138,271,000
Goodwill	144,000	144,000
Intangible assets, net	1,457,000	1,411,000
Deferred tax asset	10,803,000	9,420,000
Other assets	28,665,000	21,863,000
Total other assets		32,838,000
Total assets	482,180,000	418,054,000
Accounts payable	28,821,000	24,576,000
Accrued warehouse expenses		5,625,000
Customer return liability		4,483,000
Accrued professional fees		2,167,000
Accrued freight & shipping		2,131,000
Accrued occupancy		1,278,000
Accrued state income taxes	7,675,000	1,187,000
Accrued insurance		1,026,000
Accrued credit card fees		770,000
Accrued advertising fees		739,000
Warranty liability		721,000
Other accrued expenses	38,622,000	3,265,000
Accrued expenses - Balancing value	30,947,000	
Accrued expenses		23,392,000
Payroll payable	6,998,000	6,783,000
Customer deposits	8,257,000	6,760,000
Current operating lease liabilities	17,628,000	21,898,000
Sales taxes payable	6,030,000	5,430,000
Total current liabilities	106,356,000	88,839,000
Deferred rent		452,000
Operating lease liabilities, long term	157,876,000	135,955,000
Total liabilities	264,684,000	224,794,000
Common stock	155	
Additional paid-in capital	183,095,000	182,554,000
Accumulated earnings	34,401,000	
Retained earnings (accumulated deficit)		10,706,000
Total stockholders' equity (deficit)	217,496,000	193,260,000
Total Equity	217,496,000	

□ Non-consolidated

Recent Dividends:

1. Lovesac Co common.

No dividends paid.

Annual Dividends:

1. Lovesac Co common.

No dividends paid.

LUCID DIAGNOSTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021
			(revised)
Revenue	2,428,000		
Revenue	2,428,000	377,000	500,000
Cost of revenue	5,979,000	3,614,000	585,000
Sales & marketing	16,404,000	16,134,000	5,260,000
General &			

administrative expenses	19,254,000	23,685,000	12,778,000
Amortization of acquired intangible assets	2,021,000	1,649,000	
Research & development expenses	7,252,000	11,466,000	9,296,000
Total operating expenses	50,910,000	56,548,000	27,919,000
Income (loss) from operations	(48,482,000)	(56,171,000)	(27,419,000)
Interest expense - senior unsecured promissory note	416,000		659,000
Income (loss) before provision for income tax	(52,666,000)	(56,171,000)	(28,078,000)
Deferred income taxes - Federal	(9,281,000)	(12,703,000)	(4,862,000)
Deferred income taxes - State & Local	(6,897,000)	1,209,000	(4,833,000)
Current & deferred tax (benefit) expense		(11,494,000)	(9,695,000)
Less: valuation allowance reserve	16,178,000	11,494,000	9,695,000
Net income (loss)	(52,666,000)	(56,171,000)	(28,078,000)
Weighted average shares outstanding - basic	41,756,129	36,172,421	18,603,619
Weighted average shares outstanding - diluted	41,756,129	36,172,421	18,603,619
Year end shares outstanding	42,329,864	40,518,792	□34,917,907
Net earnings (loss) per share - basic	\$(1.26)	\$(1.55)	\$(1.51)
Net earnings (loss) per share - diluted	\$(1.26)	\$(1.55)	\$(1.51)
Number of full time employees		□74	
Number of common stockholders	256	□□19	□□13
Change in fair value - Senior Secured Convertible Note	(2,980,000)		
Interest income	424,000		
Loss on issue and offering costs - Senior Secured Convertible Note	(1,186,000)		
Debt extinguishments loss - Senior Secured Convertible Note	(26,000)		
Other (Income) expense	(4,184,000)		
EPS - Basic - excluding Extraordinary Items			
Applicable to Common - Total	\$(1.26)		
EPS - Diluted - excluding Extraordinary Items			
Applicable to Common - Total	\$(1.26)		

□ Reclassified to conform with 2022 presentation; □ Shares increase due to issuance of common stock - conversion of senior unsecured promissory note and issuance of common stock in initial public offering; □ As of March 9, 2023; □ Approximately; □ As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	18,896,000	22,474,000
Accounts receivable	45,000	17,000
Advanced payments to		

service providers & suppliers	266,000	371,000
Prepaid insurance	607,000	52,000
Deposits	1,981,000	1,331,000
EsoCheck cell collection supplies		59,000
EsoGuard mailer supplies		52,000
Prepaid expenses, deposits & other current assets	2,854,000	1,865,000
Inventory	278,000	
Total current assets	22,073,000	24,356,000
Computer & office equipment	252,000	223,000
Laboratory equipment	1,702,000	1,526,000
Furniture & fixtures	146,000	131,000
Leasehold improvements	1,000	1,000
Total fixed assets, gross	2,101,000	1,881,000
Less: accumulated depreciation	767,000	289,000
Fixed assets, net	1,334,000	1,592,000
Operating lease right-of-use assets	1,307,000	2,008,000
Intangible assets, net	1,424,000	3,445,000
Other assets	1,132,000	1,108,000
Total assets	27,270,000	32,509,000
Accounts payable	1,146,000	1,056,000
Compensation & employee benefits	1,178,000	879,000
CWRU amended license agreement - royalty fee	96,000	10,000
Operating expenses	2,018,000	558,000
Accrued expenses & other current liabilities	549,000	1,447,000
Operating lease liabilities	1,106,000	962,000
Due to: PAVmed Inc. - MSA fee, operating expenses & interest expense		4,960,000
Due To: PAVmed Inc. - Senior Unsecured Promissory Note	9,339,000	
Senior Secured Convertible Note - at fair value	13,950,000	
Accrued expenses and other current liabilities - Balancing value	3,841,000	
Total current liabilities	29,382,000	8,425,000
Operating lease liabilities, less current portion	199,000	1,037,000
Total liabilities	29,581,000	9,462,000
Common stock	42,000	41,000
Additional paid-in capital	129,763,000	121,081,000
Retained earnings (accumulated deficit)	(150,741,000)	(98,075,000)
Preferred stock, \$ 000 par value, 20,000,000 shares authorized; Series A Convertible Preferred Stock, issued and outstanding ,625 at , 202 and no shares issued and outstanding at , 2022	18,625,000	
Total stockholders' equity (deficit)	(2,311,000)	23,047,000
Total Equity	(2,311,000)	

Recent Dividends:

1. Lucid Diagnostics Inc preferred.

No dividends paid.

2. Lucid Diagnostics Inc common.

No dividends paid.

Annual Dividends:

1. Lucid Diagnostics Inc preferred.

No dividends paid.

2. Lucid Diagnostics Inc common.

No dividends paid.

LYRA THERAPEUTICS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):				Payroll & employee related expenses			Deferred federal income tax provision (benefit) ...			
2023	2022	2021 (revised)		2023	2022	2021 (revised)	2023	2022	2021 (revised)	
Total revenues	1,558	4,670	2,975	...	(2,000)	1,200,000	(1,183,000)	
Collaboration revenue	1,558	1,363	285	3,473	3,435	1,961	10,000	81,000	(131,000)	
Research & development	48,029	38,797	29,694	...	659	...	113,000	(55,000)	(414,000)	
General & administrative	19,057	17,556	14,206	9,374	9,030	5,434	121,000	1,226,000	(1,728,000)	
Loss on impairment of long-lived assets	1,592	1,316	...	1,658	1,275	1,231	1,109,000	4,011,000	(950,000)	
Total operating expenses	68,678	57,669	43,900	19,597	14,470	19,597	Net income (loss)	(2,239,000)	(4,490,000)	
Income (loss) from operations	(67,120)	(56,306)	(43,615)	21,447	667	12,136	Weighted average shares outstanding	1,866,000	1,913,000	
Interest income	4,499	12,136	14,077	53,180	- basic	1,913,000	1,990,000	
Interest income (expense)	...	1,041	102	53,180	29,214	57	Weighted average shares outstanding	1,866,000	2,088,000	
Total other income (expense)	4,499	1,041	102	89,420	80,754	89,420	- diluted	1,866,000	1,913,000	
Income (loss) before income tax expense	(62,621)	(55,265)	(43,513)	400,685	329,387	33	Year end shares outstanding	1,860,154	1,858,800	
Income tax expense	59	13	...	33	10	33	Earnings (loss) per share from continuing operations - basic	\$(1.20)	...	
Net income (loss)	(62,680)	(55,278)	(43,513)	(311,355)	(248,675)	(311,355)	Net income (loss) per common share - basic	\$(1.20)	\$(2.35)	
Net income (loss) attributable to common stockholders	...	(55,278)	(43,513)	89,420	80,754	89,420	Earnings (loss) per share from continuing operations - diluted	
Weighted average shares outstanding - basic	49,804	30,236	12,986	Net income (loss) per common share - diluted	\$(1.20)	\$(2.35)	
Weighted average shares outstanding - diluted	49,804	30,236	12,986	Number of full time employees	213	228	
Year end shares outstanding	57,215	31,828	13,007	Number of part time employees	0	1	
Net earnings (loss) per share - basic	\$(1.26)	\$(1.83)	\$(3.35)	ANNATECH INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):			Total number of employees	213	228	
Net earnings (loss) per share - diluted	\$(1.26)	\$(1.83)	\$(3.35)	2023	2022	2021 (revised)	Number of common stockholders	1,063	1,089	
Number of full time employees	88	58	53	Net sales	131,955,000	137,208,000	159,762,000	Depreciation & amortization	1,628,000	...
Number of common stockholders	68	70	58	Cost of sales	29,090,000	33,060,000	34,149,000	Foreign currency translation adjustments	...	(2,546,000)
Total number of employees	88	Gross profit (loss)	102,865,000	104,148,000	125,613,000	Total revenues	131,955,000	...
				Commissions & incentives expenses	53,588,000	55,483,000	63,784,000			
				Selling & administrative expenses	48,613,000	27,470,000	29,427,000			
				Depreciation & amortization expenses	1,628,000	1,627,000	1,719,000			
				Other operating costs	...	19,973,000	21,634,000			
				Total operating expenses	103,829,000	104,553,000	116,564,000			
				Income (loss) from operations	(964,000)	(405,000)	9,049,000			
				Interest income	4,000	88,000	66,000			
				Other income (expense), net	(170,000)	(162,000)	(223,000)			
				Income (loss) before income taxes	(5,378,000)	(7,822,000)	6,947,000			
				- U.S.	(5,378,000)	(7,822,000)	6,947,000			
				Income (loss) before income taxes	4,248,000	7,343,000	1,945,000			
				- foreign	4,248,000	7,343,000	1,945,000			
				Income (loss) before income taxes	(1,130,000)	(479,000)	8,892,000			
				Current federal income tax provision (benefit)	180,000	241,000	(17,000)			
				Current state income tax provision (benefit)	15,000	(37,000)	(161,000)			
				Current foreign income tax provision (benefit)	793,000	2,581,000	956,000			
				Total current income tax provision (benefit)	988,000	2,785,000	778,000			

Reclassified to conform with 2022 presentation; Shares increased due to the effect of exercise of common stock options, issuance of common stock, pre-funded warrants and RSU vesting; As is; Approximately; As of March 1, 2023; As of March 1, 2022

As of February 28, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):				Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
2023	2022	2021 (revised)		2023	2022	2021 (revised)
Cash & cash equivalents	22,353	32,550	...	Cash & cash equivalents	7,731,000	13,777,000
Short-term investments	80,400	65,344	...	Restricted cash	938,000	944,000
Prepaid expenses & other current assets	2,068	2,935	...	Accounts receivable, gross	1,369,000	1,191,000
Total current assets	104,821	100,829	...	Less allowance of doubtful accounts	1,278,000	973,000
Laboratory equipment	2,736	5,022	...	Accounts receivable, net	91,000	218,000
Computer software & equipment	662	675	...	Income tax receivable	465,000	423,000
Office furniture & fixtures	...	323	...	Raw materials	5,104,000	3,302,000
Leasehold improvements	461	397	...	Finished goods	9,431,000	11,841,000
Computer software and equipment	105	Inventory reserves for obsolescence	...	417,000
Total property & equipment, gross	3,964	6,417	...	Inventories, net - Balancing value	14,535,000	...
Less: accumulated depreciation	1,921	4,174	...	Inventories, net	...	14,726,000
Property & equipment, net	2,043	2,243	...	Prepaid expenses & other current assets	1,774,000	2,389,000
Operating lease right-of-use assets	33,233	2,223	...	Deferred commissions	2,130,000	2,476,000
Restricted cash	1,392	1,392	...	Total current assets	27,664,000	34,953,000
Other assets	1,111	3,281	...	Office furniture & equipment	2,116,000	2,351,000
Total assets	142,600	109,968	...	Computer hardware	3,160,000	3,515,000
Accounts payable	3,131	2,616	...	Computer software	46,095,000	45,623,000
				Automobiles	110,000	110,000
				Leasehold improvements	3,867,000	4,079,000
				Assets held under capital leases	1,236,000	...

Mannatech Inc			Marblegate Acquisition Corp			Marblegate Acquisition Corp		
	2023	2022		2023	2022		2023	2022
Righth of use ("ROU") assets - finance leases	182,000		Income (loss) from operations	(1,670,335)	(503,572)	Loss from operations	5,747,453	
Less accumulated depreciation & amortization	52,631,000	52,479,000	Interest income on marketable securities held in trust account	427,781	3,305,765	35,823	12,094,325	
Construction in progress		378,000	Unrealized gain (loss) on marketable securities held in trust account	8,873		(16,895)		
Property & equipment, net	3,953,000	3,759,000	Change in fair value of warrant liabilities		233,870	259,350		
Construction in progress	194,000		Transaction costs associated with the initial public offering			42,344		
Long-term restricted cash	718,000	476,000	Total other income (expense), net	436,654	3,539,635	235,934		
Other assets	7,066,000	8,439,000	Income (loss) before provision for income taxes	(5,310,799)	1,869,300	(267,638)		
Deferred tax assets, net	1,611,000	1,501,000	Current provision for income taxes - federal	78,830	638,962			
Total assets	41,206,000	49,128,000	Deferred provision for income taxes - federal	(406,286)	294,477			
Current portion of finance leases	269,000	61,000	Change in the valuation allowance	406,286	(294,477)			
Current portion of note payable	240,000		Provision for income taxes	78,830	638,962			
Accounts payable		4,361,000	Net income (loss)	(5,389,629)	1,230,338	(267,638)		
Accrued asset purchases		66,000	Weighted average class A shares outstanding - basic		27,696,716	7,457,143		
Accrued compensation	1,707,000	1,737,000	Weighted average class B common stock & non-redeemable class A shares outstanding - basic	12,094,325	11,213,333	10,529,533		
Accrued royalties	38,000	41,000	Weighted average class A shares outstanding - diluted		11,213,333	10,529,533		
Accrued sales & other taxes	201,000	290,000	Year end shares outstanding	11,850,938	12,223,724	41,213,333		
Other accrued operating expenses	506,000	473,000	Net income (loss) per class A share - basic		\$0.03	\$0.01		
Customer deposits & sales returns	515,000	641,000	Net income (loss) per class B common stock & non-redeemable class A share - diluted		\$0.03	\$0.01		
Accrued travel expenses related to corporate events	131,000	834,000	Earnings (loss) per share - basic	\$(0.45)				
Accrued shipping & handling costs	291,000	528,000	Net income (loss) per class A share - diluted		\$0.03	\$0.01		
Rent expense	3,000		Net income (loss) per class B common stock & non-redeemable class A share - diluted		\$0.03	\$0.01		
Accrued legal & accounting fees	865,000	1,300,000	Total number of employees		3	3		
Current portion of operating lease liabilities	1,661,000	1,600,000	Number of class A common stockholders	4	1	1		
Accrued Expenses - Balancing value	861,000		Number of unitholders		3	3		
Commissions & incentives payable	8,175,000	9,256,000						
Accounts payable to related parties	4,010,000							
Taxes payable	1,521,000	3,281,000						
Current notes payable		263,000						
Deferred revenue	4,786,000	5,106,000						
Total current liabilities	25,780,000	29,838,000						
Finance leases, excluding current portion	956,000	88,000						
Other long-term liabilities	3,986,000	5,026,000						
Total liabilities	30,722,000	34,952,000						
Common stock	274							
Additional paid-in capital	33,309,000	33,377,000						
Retained earnings (accumulated deficit)	(1,301,000)	1,686,000						
Foreign currency translation	(1,427,000)	(608,000)						
Pension postretirement benefit obligation	412,000	400,000						
Accumulated other comprehensive income (loss)	(1,015,000)	(208,000)						
Treasury stock	20,509,000	20,679,000						
Total shareholders' equity (deficit)	10,484,000	14,176,000						
Total Equity	10,484,000							

Mannatech Inc			Marblegate Acquisition Corp			Marblegate Acquisition Corp		
	2023	2022		2023	2022		2023	2022
Recent Dividends:								
1. Mannatech Inc common.								
No dividends paid.								
2. Marblegate Acquisition Corp class A common stock subject to possible redemption.								
No dividends paid.								
3. Marblegate Acquisition Corp class A common.								
No dividends paid.								
Annual Dividends:								
1. Marblegate Acquisition Corp class B common.								
No dividends paid.								
2. Marblegate Acquisition Corp class A common stock subject to possible redemption.								
No dividends paid.								
3. Marblegate Acquisition Corp class A common.								
No dividends paid.								
MARCHEX INC								
Annual Report								
Consolidated Income Statement, Years Ended Dec. 31 (\$):								
	2023	2022	2021					
			(revised)					
Operating & formation costs	5,747,453	1,670,335	503,572	Revenue	49,910,000			
				Revenue	49,910,000	52,170,000	53,476,000	
				Service costs	20,582,000	20,462,000	21,694,000	
				Sales & marketing expenses		13,517,000	13,549,000	
				Product development expenses	15,355,000	14,355,000	16,112,000	
				General & administrative expenses	10,205,000	9,787,000	9,294,000	
				Amortization of intangible assets				
				from acquisitions	1,987,000	2,124,000	4,481,000	
				Acquisition & disposition related benefits		74,000	142,000	
				Acquisition related costs	12,000			

Income (loss) from operations	(9,643,000)	(8,149,000)	(11,796,000)	Total number of employees	164	Accumulated deficit	(321,231,000)	...
Gain on loan extinguishment	5,185,000	Number of class A common stockholders	...	1	1	Retained earnings (accumulated deficit)	...	(311,321,000)
Interest income & foreign currency	319,000	99,000	3,000	Number of class B common stockholders	...	40	40	Total stockholders' equity	35,870,000	44,112,000
Interest expense	282,000	...	37,000	Number of Common Shareholders	39	Total Equity	35,870,000	...
Other income	(199,000)	(11,000)	2,487,000	Sales and	11,412,000	Recent Dividends:		
Interest income & other income, net	...	88,000	2,453,000	Basic EPS Excluding ExtraOrdinary Items	\$(0.23)	1. Marchex Inc class A common.		
Interest Expense and Other, Net	(173,000)	Diluted EPS	No dividends paid.		
Foreign Exchange Gain/Loss - Non-Business	(11,000)	Excluding ExtraOrd Items	\$(0.23)	2. Marchex Inc class B common.		
Income (loss) from continuing operations before provision for income taxes - U.S.	(9,829,000)	(7,525,000)	(1,173,000)	□ Reclassified to conform with 2022 presentation; □ Components of amortization of intangible assets from acquisitions - service costs: \$467,000; □ Components of amortization of intangible assets from acquisitions - sales and marketing: \$1,657,000; □ Components of amortization of intangible assets from acquisitions - service costs: \$2,248,000; □ Components of amortization of intangible assets from acquisitions - sales and marketing: \$2,121,000; □ Components of amortization of intangible assets from acquisitions - general and administrative: \$112,000; □ As of March 31, 2023; □ As of March 29, 2022; □ Approximately						
Income (loss) from continuing operations before provision for income taxes - foreign	13,000	(536,000)	(2,985,000)	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):						
Income (loss) before provision for income taxes	(9,816,000)	(8,061,000)	(4,158,000)				2023	2022		
Current state provision (benefit) for income taxes	78,000	58,000	204,000	Cash & cash equivalents	14,607,000	20,474,000	Grant income	1,241,710
Current provision (benefit) for income taxes - foreign	...	39,000	...	Accounts receivable, gross	7,514,000	8,563,000	Related party service revenue	3,311,133	3,513,544	...
Deferred federal provision (benefit) for income taxes	25,000	67,000	20,000	Allowance for doubtful accounts	120,000	167,000	Total revenues	3,311,133	3,513,544	1,241,710
Deferred state provision (benefit) for income taxes	(9,000)	20,000	106,000	Accounts receivable, net	7,394,000	8,396,000	Research & development	10,416,789	11,968,428	27,794,879
Deferred foreign provision (benefit) for income taxes	(98,000)	Prepaid expenses & other current assets	1,805,000	2,015,000	General & administrative	7,475,722	11,336,120	12,924,826
Income tax expense (benefit)	94,000	184,000	232,000	Total current assets	23,806,000	30,885,000	Total operating expenses	17,892,511	23,304,548	40,719,705
Income (loss) from continuing operations	...	(8,245,000)	...	Computer & other related equipment	260,000	14,939,000	Income (loss) from operations	(14,581,378)	(19,791,004)	(39,477,995)
Net income (loss)	(9,910,000)	(8,245,000)	(4,390,000)	Purchased & internally developed software	2,699,000	3,090,000	Arbitration settlement	...	232,974	2,406,576
Net income (loss) applicable to common stockholders	...	(8,245,000)	(4,390,000)	Furniture & fixtures	...	1,273,000	Interest income	539,158	248,063	5,700
Weighted average class A shares outstanding - basic	...	4,661,000	4,661,000	Leasehold improvements	...	1,732,000	Net income (loss)	(8,236,814)	(29,930,694)	(41,878,871)
Weighted average class B shares outstanding - basic	...	38,560,000	39,256,000	Construction in progress	25,000	1,400,000	Weighted average shares outstanding
Weighted average shares outstanding - basic	42,621,000	Computer and other related equipment	1,012,000	...	- basic	8,809,382	8,351,003	7,650,567
Weighted average class B shares outstanding - diluted	...	43,221,000	43,917,000	Property & equipment, gross	3,996,000	22,434,000	Weighted average shares outstanding
Weighted average shares outstanding - diluted	42,621,000	Less: accumulated depreciation & amortization	1,598,000	18,384,000	- diluted	8,809,382	8,351,003	7,650,567
Year end shares outstanding	43,323,000	43,158,000	42,052,000	Property & equipment, net	2,398,000	4,050,000	Year end shares outstanding	8,900,000	8,405,771	8,307,868
Net income (loss) per class B share - basic	...	\$(0.19)	\$(0.10)	Other assets, net	1,482,000	973,000	Net income (loss) per share - basic	\$(0.94)	\$(3.58)	\$(5.47)
Net income (loss) per share - basic	\$(0.23)	Right-of-use lease asset	1,631,000	738,000	Net income (loss) per share - diluted	\$(0.94)	\$(3.58)	\$(5.47)
Net income (loss) per class B share - diluted	...	\$(0.19)	\$(0.10)	Goodwill	17,558,000	17,558,000	Number of full time employees	8	...	56
Net income (loss) per share - diluted	\$(0.23)	Intangible assets from acquisitions, net	602,000	2,590,000	Number of common stockholders	36	...	398
Number of full time employees	164	193	187	Total assets	47,477,000	56,794,000	Income from continuing operations before income tax	(14,042,220)	(19,775,915)	...
				Accounts payable	1,533,000	2,037,000	Income from continuing operations	(14,045,895)	(19,775,915)	...
				Accrued benefits & payroll	3,294,000	3,566,000	Gain on disposal of discontinued operations, net of \$63,000 in tax	8,731,487
				Other accrued expenses & current liabilities	...	3,825,000	Loss from discontinued operations before income taxes	(2,922,406)	(10,154,779)	...
				Deferred acquisition payments	3,217,000	...	Earnings per share from continuing operations	\$(1.59)	\$(2.37)	...
				Deferred revenue & deposits	1,214,000	1,384,000	Earnings per share-disp of discontinued opers	\$0.99	\$0.00	...
				Lease liability current	462,000	1,252,000	Earnings per share-total discontinued opers	\$0.99	\$0.00	...
				Total current liabilities	9,720,000	12,064,000	Earnings per share from continuing
				Deferred income tax liabilities	249,000	...				
				Deferred tax liabilities	...	233,000				
				Lease liability non-current	1,217,000	385,000				
				Capitalized Lease Obligations - Long-Term	421,000	...				
				Total liabilities	11,607,000	12,682,000				
				Class A common stock	49,000	49,000				
				Class B common stock	386,000	385,000				
				Additional paid-in capital	356,666,000	354,999,000				

operations	\$(1.59)	\$(2.37)	...
Earns per share-disp of discount opers - diluted	\$0.99	\$0.00	...
Earning per share-total discount opers - diluted	\$0.99	\$0.00	...
Income tax expense	3,675
Total number of employees	8

[Ⓜ] Restated to reflect correction of errors; [Ⓜ] Reclassified to conform with 2022 presentation; [Ⓜ] As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
		(revised)
Cash & cash equivalents	15,111,450	11,782,172
Prepaid expenses & deposits	988,126	2,435,079
Other receivables	1,027,815	2,402,004
Total current assets	17,127,391	16,619,255
Total non-current assets	...	17,802,929
Total assets	17,127,391	34,422,184
Related party payable	1,329,655	...
Current liabilities of discontinued operations	...	5,260,616
Total current liabilities	3,074,848	7,781,809
Lease liability, net of current portion	...	7,039,338
Total non-current liabilities	...	7,039,338
Total liabilities	3,074,848	14,821,147
Common stock	8,891	8,406
Additional paid-in capital	450,329,515	447,641,680
Retained earnings (accumulated deficit)	(436,285,863)	(428,049,049)
Total stockholders' equity (deficit)	14,052,543	19,601,037
Total Equity	14,052,543	...

Recent Dividends:

1. Marker Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Marker Therapeutics Inc common.

No dividends paid.

MCGRATH RENTCORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	[Ⓜ] 2022	2021
		(revised)	(revised)
Rental	474,336,000	389,663,000	390,013,000
Rental related services	138,160,000	94,963,000	98,061,000
Sales	207,165,000	147,720,000	125,235,000
Other revenues	12,181,000	3,319,000	3,524,000
Total revenues	831,842,000	635,665,000	616,833,000
Depreciation of rental equipment	88,912,000	80,425,000	91,887,000
Rental related services	96,628,000	68,846,000	74,256,000
Other direct costs of rental operations	114,942,000	104,358,000	91,069,000
Cost of sales	137,727,000	91,828,000	78,600,000
Total costs of revenues	438,209,000	345,457,000	335,812,000
Gross profit	393,633,000	290,208,000	281,021,000
Selling & administrative expenses	207,539,000	142,914,000	148,600,000
Income (loss) from operations	189,712,000	147,294,000	132,421,000
Interest expense	40,560,000	12,230,000	10,455,000
Foreign currency exchange gain (loss)	310,000	(378,000)	(210,000)
Income (loss) before provision (benefit) for income taxes - U.S.	121,660,000

Income (loss) before provision (benefit) for income taxes - foreign	96,000
Income (loss) before provision (benefit) for income taxes	149,462,000	134,686,000	121,756,000
Current provision (benefit) for income taxes - U.S. federal	(1,692,000)
Current provision (benefit) for income taxes - state	5,360,000
Current provision (benefit) for income taxes - foreign	2,035,000
Total current provision (benefit) for income taxes	5,703,000
Deferred provision (benefit) for income taxes - U.S. federal	23,433,000
Deferred provision (benefit) for income taxes - state	2,896,000
Deferred provision (benefit) for income taxes - foreign	19,000
Total deferred provision (benefit) for income taxes	26,348,000
Provision (benefit) for income taxes	37,610,000	31,377,000	32,051,000
Income from continuing operations	111,852,000	103,309,000	...
Net income (loss)	174,621,000	115,138,000	89,705,000
Weighted average shares outstanding - basic	24,469,000	24,353,000	24,220,000
Weighted average shares outstanding - diluted	24,529,000	24,519,000	24,515,000
Year end shares outstanding	24,496,000	24,388,000	24,260,000
Income (loss) per share from continuing operations - basic	\$4.57	\$4.24	...
Net income (loss) per share - basic	\$7.14	\$4.73	\$3.70
Income (loss) per share from continuing operations - diluted	\$4.56	\$4.21	...
Net income (loss) per share - diluted	\$7.12	\$4.70	\$3.66
Cash dividends declared per share	\$1.86	\$1.82	\$1.74
Full-Time Employees (Period End)	1,204
Total number of employees	1,204	...	1,184
Number of common stockholders	45	...	[Ⓜ] 43
Number of street stockholders	[Ⓜ] 500
Income from discontinued operations before provision for income taxes	1,709,000	15,334,000	...
Provision for income taxes from discontinued

operations	(453,000)	(3,505,000)	...
Sale of Discontinued Operations - Net - Gain/Loss	61,513,000
Income from discontinued operations	62,769,000	11,829,000	...
Earnings per share-total discontinued opers	\$2.57	\$0.49	...
Earning per share-total discount opers - diluted	\$2.56	\$0.48	...
Other Operating Income/Expense	(3,618,000)
Sale of Tangible & Intangible Fixed Assets - Gain/Loss	3,618,000

[Ⓜ] Restated to reflect discontinued operations; [Ⓜ] Approximately; [Ⓜ] As of February 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
		(revised)
Cash	877,000	957,000
Accounts receivable, gross	230,169,000	192,323,000
Less allowance for doubtful accounts	2,801,000	2,300,000
Reported Net Trade/Accounts Receivable	227,368,000	...
Accounts receivable, net	...	190,023,000
Relocatable modular buildings	...	1,123,268,000
Electronic test equipment	377,587,000	398,267,000
Liquid & solid containment tanks & boxes	...	308,396,000
Less accumulated depreciation	575,480,000	701,877,000
Land	75,143,000	...
Land improvements	65,931,000	61,487,000
Buildings	35,360,000	34,082,000
Furniture, office equipment & software	...	37,379,000
Vehicles & machinery	...	47,324,000
Machinery & service equipment	35,233,000	...
Furniture	30,039,000	...
Less accumulated depreciation	87,399,000	102,977,000
Construction in progress	14,807,000	1,199,000
Property, plant & equipment, net	169,114,000	143,945,000
Prepaid expenses & other assets	102,789,000	71,429,000
Intangible assets, net	64,588,000	41,131,000
Goodwill	323,224,000	132,305,000
SubTotal	1,904,803,000	...
SubTotal - Balancing value	1,291,093,000	...
Portable storage containers	236,123,000	...
Total assets	2,217,283,000	1,707,844,000
Unsecured revolving lines of credit	...	313,775,000
Senior notes	762,975,000	100,000,000
Less: unamortized debt issuance cost	762,975,000	(33,000)
Notes payable	...	413,742,000
Accounts payable & accrued liabilities	167,523,000	160,829,000
Deferred Income - Balancing value	70,728,000	...
Deferred income	111,428,000	82,417,000
Deferred income taxes, net	241,555,000	246,911,000
Deferred Tax Credit-Liability	292,837,000	...
Deferred Tax (Debit)-Liability	(51,282,000)	...
Contract Liabilities -

Long-Term - Advance Consideration & Progress		
Billings in Excess of Unbilled Revenue	40,700,000	...
Total liabilities	1,283,481,000	903,899,000
Common stock	111,122,000	110,080,000
Retained earnings	822,796,000	693,943,000
Accumulated other comprehensive income (loss)	(116,000)	(78,000)
Total shareholders' equity	933,802,000	803,945,000
Rep Total Equity & Minority Interest	933,802,000	...

Deferred expense	305,000	92,000	...
Consolidated Net Income Net (Loss)			
Income Attributable to Noncontrolling	6,024,000
Income tax expense (benefit)	888,000	586,000	5,096,000
Consolidated net income (loss)	6,024,000	9,089,000	18,202,000
Less: consolidated net income (loss) attributable to noncontrolling interest in variable interest entity	114,000	(604,000)	(757,000)
Consolidated net income (loss) attributable to controlling interest	6,138,000	...	17,445,000
Preferred stock dividends	2,027,000
Income (loss) available to common shareholders	...	8,485,000	15,418,000
Weighted average shares outstanding - basic	6,512,000	6,585,000	6,703,000
Weighted average shares outstanding - diluted	8,264,000	8,694,000	9,631,000
Year end shares outstanding	6,517,965	6,503,924	6,545,089

Property & equipment, total cost	258,903,000	252,297,000
Accumulated depreciation	106,306,000	91,134,000
Property & equipment, net	152,597,000	161,163,000
Goodwill	205,703,000	177,552,000
Intangible assets	7,580,000	6,132,000
Operating lease right-of-use assets, net	399,156,000	379,343,000
Long-term investments	...	1,786,000
Deposits & other assets	17,733,000	18,229,000
Total assets	816,905,000	791,318,000
Trade accounts payable	21,958,000	28,445,000
Current portion of long-term debt	20,365,000	14,041,000
Current portion of operating lease obligations payable	28,091,000	25,841,000
Short-term borrowings	26,257,000	31,848,000
Accrued payroll & related payroll taxes	1,199,000	14,207,000
Accrued interest expense	4,454,000	...
Accrued impairment charges	...	6,899,000
Other accrued liabilities	...	1,391,000
Sales Tax	3,270,000	3,329,000
Payroll and related payroll taxes	12,850,000	...
Total current liabilities	118,444,000	126,001,000
Unearned vendor allowances	2,301,000	1,154,000
Operating lease obligations payable	376,946,000	359,318,000
Other long-term liabilities	17,093,000	16,720,000
Deferred income taxes	15,803,000	15,821,000
Total liabilities	694,865,000	...
Convertible preferred stock	15,000	14,000
Common stock	65,000	66,000
Paid in Capital	33,577,000	29,117,000
Comprehensive Income - Accumulated	6,342,000	...
Accumulated other comprehensive income	...	8,959,000
Retained Earnings	81,144,000	...
Retained earnings (accumulated deficit)	...	77,992,000
Total stockholders' equity (deficit)	121,143,000	116,148,000
Non-controlling interests	897,000	1,049,000
Total equity (deficit)	122,040,000	117,197,000

**Recent Dividends:
1. McGrath RentCorp common.**

ExDate	Amt	Declared	Record	Payable
01/14/2021	0.42	12/10/2020	01/15/2021	01/29/2021
04/14/2021	0.43	02/23/2021	04/15/2021	04/30/2021
07/15/2021	0.43	06/09/2021	07/16/2021	07/30/2021
10/14/2021	0.43	09/16/2021	10/15/2021	10/29/2021
01/13/2022	0.43	12/09/2021	01/17/2022	01/31/2022
04/13/2022	0.46	02/23/2022	04/15/2022	04/29/2022
07/14/2022	0.46	06/08/2022	07/15/2022	07/29/2022
10/14/2022	0.46	09/15/2022	10/17/2022	10/31/2022
01/13/2023	0.46	12/08/2022	01/17/2023	01/31/2023
04/13/2023	0.47	02/22/2023	04/14/2023	04/28/2023
07/14/2023	0.47	06/07/2023	07/17/2023	07/31/2023
10/16/2023	0.47	09/15/2023	10/17/2023	10/31/2023
01/16/2024	0.47	12/07/2023	01/17/2024	01/31/2024

**Annual Dividends:
1. McGrath RentCorp common.**

2021	1.73	2022	1.80	2023	1.85
2024	0.47				

**MERITAGE HOSPITALITY GROUP INC
Annual Report
Consolidated Income Statement, Years Ended (\$):**

	12/31/23	01/01/23	01/02/22
Occupancy fee expenses	...	77,942,000	...
Food & beverage revenue	672,494,000	626,043,000	577,127,000
Total revenue	672,494,000	626,043,000	...
Food & beverages	184,247,000	172,001,000	150,774,000
Labor & related expenses	213,808,000	201,852,000	183,396,000
Occupancy	86,806,000	...	76,467,000
Advertising	26,273,000	24,442,000	22,295,000
Franchise fee	25,439,000	...	21,841,000
Other operating expenses	62,750,000	56,143,000	51,761,000
Operating expenses - General & administrative	32,012,000	30,809,000	32,225,000
Preopening, acquisition & closing expenses	3,989,000
Preopening & acquisition expenses	4,809,000	7,645,000	...
Depreciation & amortization	18,552,000	17,418,000	16,306,000
Income (loss) from operations	17,798,000	13,973,000	18,073,000
Interest expense - swap	(1,036,000)
Interest expense	11,939,000	8,156,000	7,745,000
Other income (expense)	1,053,000	3,858,000	11,934,000
Total other income (expense)	(10,886,000)	(4,298,000)	5,225,000
Income (loss) before income taxes	6,912,000	9,675,000	23,298,000
Current income tax expense (benefit)	583,000	494,000	1,036,000
Deferred income tax expense (benefit)	4,060,000

Income (loss) per share - continuing operations - basic	\$0.61
Net earnings (loss) per share - basic	\$0.61	\$1.29	\$2.30
Incomes (loss) per share - continuing operations - diluted	\$0.56
Net earnings (loss) per share - diluted	\$0.56	\$0.98	\$1.81
Dividends per common share	\$0.18	\$0.30	\$0.32
Number of full time employees	2,800	2,600	2,000
Number of part time employees	...	8,400	9,000
Total number of employees	2,800	11,000	11,000
Number of common stockholders	56	56	59
Number of preferred B stockholders	18	18	22
Number of preferred C stockholders	7	7	7
Number of preferred D stockholders	24	24	24
Number of preferred E stockholders	13	13	14
□ Approximately			

Consolidated Balance Sheet, Years Ended (\$):

	12/31/23	01/01/23
Cash	19,434,000	35,372,000
Receivables	2,412,000	368,000
Inventories	5,189,000	4,754,000
Prepaid expenses & other current assets	7,101,000	6,619,000
Total current assets	34,136,000	47,113,000
Land & improvements	29,201,000	34,505,000
Buildings & improvements	112,817,000	98,403,000
Leasehold improvements	24,099,000	23,230,000
Construction in progress	11,875,000	23,660,000
Buildings and improvements	80,911,000	72,499,000

**Recent Dividends:
1. Meritage Hospitality Group Inc series B nonvoting convertible cumulative preferred.**

No dividends paid.

2. Meritage Hospitality Group Inc series A convertible cumulative preferred.

No dividends paid.

3. Meritage Hospitality Group Inc series C nonvoting convertible preferred.

ExDate	Amt	Declared	Record	Payable
03/12/2021	0.08	03/02/2021	03/15/2021	03/26/2021
06/14/2021	0.08	05/18/2021	06/15/2021	07/01/2021
09/14/2021	0.08	08/17/2021	09/15/2021	10/01/2021
12/14/2021	0.08	11/09/2021	12/15/2021	01/01/2022
06/14/2022	0.12	05/17/2022	06/15/2022	07/01/2022
09/14/2022	0.12	08/08/2022	09/15/2022	10/01/2022
12/23/2022	0.06	12/14/2022	12/27/2022	01/12/2023
06/14/2023	0.03	05/16/2023	06/15/2023	07/01/2023
09/14/2023	0.09	08/15/2023	09/15/2023	10/01/2023
12/14/2023	0.06	11/07/2023	12/15/2023	01/01/2024

4. Meritage Hospitality Group Inc common.

No dividends paid.

5. Meritage Hospitality Group Inc series D convertible preferred shares.

No dividends paid.

6. Meritage Hospitality Group Inc series E convertible preferred shares.

No dividends paid.

Annual Dividends:

1. Meritage Hospitality Group Inc series B nonvoting convertible cumulative preferred.

No dividends paid.

2. Meritage Hospitality Group Inc series A convertible cumulative preferred.

No dividends paid.

3. Meritage Hospitality Group Inc series C nonvoting convertible preferred.

2021.....	0.24	2022.....	0.32	2023.....	0.18
2024.....	0.06				

4. Meritage Hospitality Group Inc common.

No dividends paid.

5. Meritage Hospitality Group Inc series D convertible preferred shares.

No dividends paid.

6. Meritage Hospitality Group Inc series E convertible preferred shares.

No dividends paid.

**MICROVAST HOLDINGS INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Total revenues	306,617,000
Revenues	306,617,000	204,495,000	151,976,000
Cost of revenues	249,390,000	195,422,000	194,719,000
Gross profit (loss)	57,227,000	9,073,000	(42,743,000)
General & administrative expenses	97,291,000	104,572,000	101,632,000
Research & development	45,004,000	43,508,000	34,385,000
Selling & marketing expenses	23,614,000	22,611,000	21,431,000
Total operating expenses	...	170,691,000	157,448,000
Subsidy income	1,953,000	1,672,000	6,127,000
Income (loss) from operations	(106,729,000)	(159,946,000)	(194,064,000)
Interest income	3,609,000
Interest expense	2,628,000	3,323,000	5,411,000
Loss on changes in fair value of Bridge notes	9,861,000
Gain on change in fair value of warrant liability	59,000	979,000	2,469,000
Other income (expense), net	(713,000)	944,000	(62,000)
Income (loss) before provision for income taxes - domestic (USA)	...	(116,353,000)	(98,821,000)
Income (loss) before provision for income taxes - foreign	...	(41,814,000)	(107,662,000)
Income (loss) before provision for income taxes	(106,402,000)	(158,167,000)	(206,483,000)
Current provision for federal income taxes	...	33,000	...
Income Taxes - Total - Current	10,000
Provision for income taxes	10,000	33,000	...
Net income (loss)	(106,412,000)	(158,200,000)	(206,483,000)
Less: net loss attributable to noncontrolling interest	76,000
Net loss attributable to Microvast Holding, Inc.	(106,336,000)	...	(206,483,000)
Less: accretion of series C1 preferred	...	2,257,000	...
Less: accretion of series C2 preferred	...	5,132,000	...
Less: accretion of series D1 preferred	10,708,000

Less: accretion for non-controlling interests	9,523,000
Net income (loss) to common stock shareholders of Microvast Holding, Inc.	...	(158,200,000)	(234,103,000)
Weighted average shares outstanding - basic	310,909,379	303,279,188	185,896,482
Weighted average shares outstanding - diluted	310,909,379	303,279,188	185,896,482
Year end shares outstanding	315,006,942	307,628,511	298,843,016
Net income (loss) per share - basic	\$(0.34)	\$(0.52)	\$(1.26)
Net income (loss) per share - diluted	\$(0.34)	\$(0.52)	\$(1.26)
Number of full time employees	2,006	1,535	1,359
Number of part time employees	...	730	794
Total number of employees	2,006
Number of common stockholders	102	127	113
Foreign currency translation adjustments	...	(24,782,000)	(655,000)
Earnings per share from continuing operations	\$(0.34)
Earnings per share from continuing operations	\$(0.34)
Cost of revenues	249,390,000
Income tax expense	10,000

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of March 10, 2023; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	44,541,000	231,420,000
Restricted cash, current	...	70,732,000
Short-term investments	5,634,000	25,070,000
Account receivables, gross	143,288,000	123,711,000
Allowance for doubtful accounts	4,571,000	4,407,000
Account receivables, net	138,717,000	119,304,000
Notes receivable	23,736,000	2,196,000
Work in process	86,379,000	48,747,000
Raw materials	35,867,000	29,331,000
Finished goods	27,503,000	6,174,000
Inventories	149,749,000	84,252,000
Advances to supplier	5,800,000	5,075,000
Prepaid expenses	3,972,000	3,374,000
VAT receivables	14,279,000	2,408,000
Deposits	950,000	925,000
Other receivables	751,000	311,000
Prepaid expenses & other current assets	25,752,000	12,093,000
Restricted cash	37,477,000	...
Total current assets	425,606,000	545,067,000
Restricted cash, non-current	6,171,000	465,000
Machinery & equipment	204,599,000	140,160,000
Buildings	144,497,000	44,680,000
Leasehold improvements	32,808,000	28,625,000
Fixtures & electronic equipment	19,132,000	16,193,000
Motor vehicles	6,027,000	10,842,000
Property, plant & equipment, gross	407,063,000	240,500,000
Less: Accumulated depreciation	108,309,000	100,902,000
Construction in progress	321,913,000	195,542,000
Property, plant & equipment, net	620,667,000	335,140,000
Land use right, net	11,984,000	12,639,000
Acquired intangible

assets, net	3,136,000	1,636,000
Operating lease right-of-use assets	19,507,000	16,368,000
Other non-current assets	9,661,000	73,642,000
Land use rights - Accumulated Amortization & Impairment	(2,727,000)	...
Land use rights, net - Balancing value	14,711,000	...
Total assets	1,096,732,000	984,957,000
Accounts payable	112,618,000	44,985,000
Notes payable	63,374,000	68,441,000
Product warranty	13,738,000	13,044,000
Payables for purchase of property, plant & equipment	...	29,183,000
Other current liabilities	14,312,000	8,608,000
Accrued payroll & welfare	8,089,000	4,716,000
Accrued expenses	6,224,000	2,641,000
Interest payable	41,000	298,000
Operating lease liabilities	2,413,000	1,934,000
Other tax payable	96,350,000	6,296,000
Accrued expenses & other current liabilities	148,284,000	66,720,000
Advance from customers	43,087,000	54,207,000
Short-term bank borrowings	...	17,398,000
Income taxes payable	655,000	658,000
Bonds payable	35,392,000	...
Promissory note - related party	7,117,000	...
Total current liabilities	403,410,000	252,409,000
Long term bank borrowings	43,761,000	28,997,000
Long-term bonds payable	43,157,000	43,888,000
Warrant liability	67,000	126,000
Share-based compensation liability	199,000	131,000
Operating lease liabilities	17,087,000	14,347,000
Product warranty - non-current	21,479,000	29,016,000
Deferred subsidy income - non-current	3,382,000	3,066,000
Other non-current liabilities	24,861,000	32,082,000
Total liabilities	532,542,000	371,980,000
Common stock	32,000	31,000
Additional paid in capital	1,481,241,000	1,416,160,000
Statutory reserves	6,032,000	6,032,000
Accumulated deficit	(897,501,000)	...
Retained earnings (accumulated deficit)	...	(791,165,000)
Accumulated other comprehensive income (loss)	(25,614,000)	(18,081,000)
Total stockholder's equity	564,190,000	612,977,000
Total Equity	564,190,000	...

Recent Dividends:

1. Microvast Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Microvast Holdings Inc common.

No dividends paid.

MILLERKNOLL INC

Earnings, 9 mos. to (Consol. - \$000):

	03/02/24	03/04/23
Total Revenues	2,739,500	...
Net Sales	2,739,500	3,130,400
Cost & expenses	2,596,000	3,019,700
Operating income	143,500	110,700
Interest expense	57,400	54,100
Other income (expense), net	2,000	(1,700)
Equity earnings	300	(200)
Net before taxes	92,900	56,900
Income taxes	19,000	11,100
Net income	73,600	46,000
Earnings common share		
Primary	\$0.98	\$0.56

Fully Diluted Common Shares:	\$0.97	\$0.56	
Full Diluted Year-end	74,616	76,036	71,736

MOLECULAR TEMPLATES INC

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development revenue	52,625
Research & development revenue, related party	13,136
Research & development revenue, other	...	19,754	25,561
Grant revenue	4,681
Total revenue	57,306	19,754	38,697
Research & development expenses	48,875	82,425	84,665
General & administrative expenses	18,897	26,200	34,106
Total operating expenses	67,772	108,625	118,771
Income (loss) from operations	(10,466)	(88,871)	(80,074)
Interest & other income, net	1,208	988	434
Interest & other expense, net	2,654	4,782	3,369
Loss on extinguishment of debt	1,795
Other income (expense), net	2,457
Income (loss) before provision for income taxes	(8,135)	(92,665)	(83,009)
Provision (benefit) for income taxes	(11)	53	...
Net income (loss)	(8,124)	(92,718)	(83,009)
Net income (loss) attributable to common stockholders	...	(92,718)	(83,009)
Weighted average shares outstanding - basic	4,501	3,756	3,687
Weighted average shares outstanding - diluted	4,501	3,756	3,687
Year end shares outstanding	5,374	3,757	3,754
Net income (loss) per share - basic	\$(1.80)	\$(24.75)	\$(22.50)
Net income (loss) per share - diluted	\$(1.80)	\$(24.75)	\$(22.50)
Number of full time employees	62	...	261
Total number of employees	62
Number of common stockholders	...	56,351,647	56,305,049
Loss on disposal of property and equipment	(475)
Basic EPS Excluding ExtraOrdinary Items	\$(1.80)
Diluted EPS Excluding ExtraOrd Items	\$(1.80)

Ⓛ Adjusted for 1-for-15 stock split, August 14, 2023; Ⓜ As is; Ⓨ Approximately; Ⓩ As of March 27, 2023; ⓐ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	11,523	32,190

Marketable securities, current	...	28,859	...
Prepaid expenses	2,195	3,459	...
Grants revenue receivable	250
Other current assets	2,804	3,790	...
Total current assets	16,772	68,298	...
Operating lease right-of-use assets	9,161	11,132	...
Laboratory equipment	20,695	21,831	...
Leasehold improvements	12,974	12,971	...
Furniture & fixtures	518	518	...
Computer & office equipment	254
Computer & equipment	34,441	658	...
Property & equipment, gross	...	35,978	...
Less: accumulated depreciation	27,048	21,346	...
Property & equipment, net	7,393	14,632	...
Other assets	2,057	3,486	...
Total assets	35,383	97,548	...
Accounts payable	1,523	504	...
Accrued general & administrative	225	855	...
Accrued clinical trial related costs	3,574	1,327	...
Accrued non-clinical research & manufacturing operations	404	1,779	...
Accrued payroll related	60	4,828	...
Other accrued expenses	16	34	...
Deferred revenue, current	9,031	45,573	...
Other current liabilities	2,488	2,182	...
Operating Lease Liabilities - Current
Portion/Short-Term Total current liabilities	2,488	57,082	...
Deferred revenue, long-term	...	5,904	...
Long-term debt, net	...	36,168	...
Operating lease liabilities	9,742	12,231	...
Other liabilities, related party	2,702
Other liabilities	1,406	1,295	...
Total liabilities	31,171	112,680	...
Common stock	5	56	...
Additional paid-in capital	457,099	429,646	...
Accumulated other comprehensive income (loss)	...	(66)	...
Retained earnings (accumulated deficit)	...	(444,768)	...
Accumulated deficit	(452,892)
Total stockholders' equity (deficit)	4,212	(15,132)	...
Total Equity	4,212

Recent Dividends:

- 1. Molecular Templates Inc series B redeemable convertible preferred.**
No dividends paid.
- 2. Molecular Templates Inc common.**
No dividends paid.
- 3. Molecular Templates Inc series A convertible preferred.**
No dividends paid.
- 4. Molecular Templates Inc series A redeemable convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. Molecular Templates Inc series B redeemable convertible preferred.**
No dividends paid.
- 2. Molecular Templates Inc common.**
No dividends paid.
- 3. Molecular Templates Inc series A convertible preferred.**
No dividends paid.
- 4. Molecular Templates Inc series A redeemable convertible preferred.**
No dividends paid.

MONTANA TECHNOLOGIES CORP

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
General & administrative expenses	5,889,740	887,745	372,924
General & administrative expenses - related party	240,000	240,000	20,000
Franchise tax expenses	200,000	215,408	152,195
Loss from operations	(6,329,740)	(1,343,153)	(545,119)
Income from investments held in trust account	205,275	4,187,504	895
Net income (loss) before income taxes	3,001,713	2,844,351	(544,224)
Current income tax provision (benefit) - federal	1,758,720	802,367	...
Deferred income tax provision (benefit) - federal	(427,576)	(205,053)	(114,287)
Deferred income tax provision (benefit) - state	(266,934)	205,053	114,287
Income Taxes - Other - Deferred/Current	694,510
Income tax expense	1,758,720	802,367	...
Net income (loss)	1,242,993	2,041,984	(544,224)
Weighted average class A common stock outstanding - basic	...	28,750,000	1,822,183
Weighted average class B common stock outstanding - basic	...	7,187,500	6,309,419
Weighted average shares outstanding - basic	25,897,368
Weighted average class A common stock outstanding - diluted	...	28,750,000	1,822,183
Weighted average class B common stock outstanding - diluted	...	7,187,500	6,309,419
Weighted average shares outstanding - diluted	25,897,368
Year end shares outstanding	17,795,678	35,937,500	35,937,500
Net income (loss) per class A common share - basic	...	\$0.06	\$(0.07)
Net income (loss) per class B common share - basic	...	\$0.06	\$(0.07)
Net income (loss) per share - basic	\$0.05
Net income (loss) per class A common share - diluted	...	\$0.06	\$(0.07)
Net income (loss) per class B common share - diluted	...	\$0.60	\$(0.07)
Net income (loss) per share - diluted	\$0.05
Number of part time employees	...	4	3
Number of common stockholders	5	4	4
Income from investments held in Trust Account	9,126,178

Ⓛ From March 23, 2021 (inception); Ⓜ Reclassified to conform with 2022 presentation; Ⓨ Shares increased due to the effect of

class A common stock subject to possible redemption; [¶] As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	59,167	1,287,986
Prepaid expenses	...	284,405
Total current assets	59,167	1,572,391
Investments held in trust account	114,641,527	294,395,846
Total assets	114,700,694	295,968,237
Accounts payable	695,515	267,297
Accrued expenses	5,737,714	660,491
Income taxes payable	...	802,367
Franchise tax payable	171,836	72,289
Franchise tax payable	124,250	...
Excise tax payable	1,881,321	...
Advance from related party	900,000	...
Total current liabilities	9,510,636	1,802,444
Deferred underwriting commissions	6,037,500	10,062,500
Total liabilities	15,548,136	11,864,944
Class A common stock subject to possible redemption	...	293,293,429
Class B common stock	114,128,755	719
Retained earnings (accumulated deficit)	(14,976,916)	(9,190,855)
Common stock value	719	...
Total stockholders' (deficit)	99,152,558	(9,190,136)
Total Equity	99,152,558	...

Recent Dividends:

1. **Montana Technologies Corp class B common.**
No dividends paid.
2. **Montana Technologies Corp class A common subject to possible redemption.**
No dividends paid.

Annual Dividends:

1. **Montana Technologies Corp class B common.**
No dividends paid.
2. **Montana Technologies Corp class A common subject to possible redemption.**
No dividends paid.

MSP RECOVERY INCORPORATION

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Operating & formation costs	476,492,000	266,929,000	3,785,303
Income (loss) from operations	(559,870,000)	(331,478,000)	(3,785,303)
Interest earned on marketable securities held in trust account	15,188
Transactions costs associated with the initial public offering	...	(63,067,000)	...
Change in fair value of warrant liabilities	4,604,000	(12,483,000)	6,976,750
Interest expense	289,169,000	121,011,000	...
Other income (expense), net	9,290,000	...	6,991,938
Claims recovery income	7,207,000	4,878,000	...
Claims recovery service income	498,000	18,542,000	...
Net loss attributable to non-controlling members	778,797,000	394,488,000	...
Net Income After Extraordinary Items applicable to Common	(56,348,000)	(7,417,000)	...
Net income (loss)	(835,145,000)	(401,905,000)	3,206,635
Total revenues	7,705,000	23,420,000	...

Weighted average shares outstanding per class A common stock - basic	946,000
Weighted average shares outstanding per class B common stock - basic	230,000
Cost of claim recoveries	2,145,000	2,054,000	...
Weighted average shares outstanding per class A common stock - diluted	946,000
Professional fees legal	22,766,000	18,497,000	...
General and administrative	26,508,000	23,959,000	...
Professional fees legal	34,401,000	43,035,000	...
Weighted average shares outstanding per class B common stock - diluted	230,000
Year end shares outstanding	138,837,375	3,223,714,367	1,176,000
Net earnings (loss) per class A common stock - basic	\$2.75
Net earnings (loss) per class B common stock - basic	\$2.75
Net earnings (loss) per class A common stock - diluted	\$2.75
Net earnings (loss) per class B common stock - diluted	\$2.75
Full-Time Employees (Period End)	88	100	...
Total number of employees	88	100	3
Number of unit holders	9
Number of class A common stockholders	1
Income from cont operations before income tax	(835,145,000)	(401,905,000)	...
Depreciation and amortization	263,000	424,000	...
Total operating expenses	567,575,000	354,898,000	...
Shares used to calculate Basic EPS - Total	8,914,761	61,825,105	...
Shares used to calculate Diluted EPS - Total	8,914,761	61,825,105	...
EPS - Basic - including Extraordinary Items
Applicable to Common - Total	\$(6.32)	\$(0.12)	...
EPS - Diluted - including Extraordinary Items
Applicable to Common - Total	\$(6.32)	\$(0.12)	...
Allowance for credit losses	5,000,000
Common Shareholders - Number	82

[¶] Adjusted for 1-for-25 stock split, October 13, 2023; [¶] As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Restricted cash	...	11,420,000
Cash and cash equivalents	11,633,000	3,661,000
Affiliate receivable	1,188,000	2,425,000

Prepaid expenses and other current assets	8,908,000	27,656,000
Accounts receivable	217,000	6,195,000
Total current assets	21,946,000	51,357,000
Office and computer equipment	434,000	430,000
Leasehold improvements	113,000	113,000
Internally developed software	5,789,000	4,050,000
Other software	67,000	68,000
Property, Plant & Equipment - Gross - Total	6,403,000	4,661,000
accumulated depreciation and amortization of software	1,492,000	1,229,000
Property, plant and equipment, net	4,911,000	3,432,000
Intangible assets, net	3,132,796,000	3,363,156,000
Right-of-use assets	342,000	...
Total assets	3,159,995,000	3,417,945,000
Accounts payable & accrued expenses	6,244,000	8,422,000
Affiliate payable	19,822,000	19,822,000
Commission payable	821,000	545,000
Derivative Liability	37,000	9,613,000
Warrant Liability	268,000	5,311,000
Other Current Liabilities	19,314,000	72,002,000
Total current liabilities	46,506,000	115,715,000
Claims financing obligation and notes payable	548,276,000	198,489,000
Loan from related parties	130,709,000	125,759,000
Lease liabilities	235,000	...
Interest payable	73,839,000	2,765,000
Guaranty Obligation	941,301,000	787,945,000
Total liabilities	1,740,866,000	1,230,673,000
Class A common stock	1,000	1,807,000
Class B common stock	...	7,000
Additional paid-in capital	357,928,000	136,760,000
Accumulated deficit	(85,551,000)	...
Retained earnings (accumulated deficit)	...	(29,203,000)
Class V	12,000	315,000
Total stockholders' equity (deficit)	272,390,000	109,686,000
Non-controlling interest	1,146,739,000	2,077,586,000
Total Equity	1,419,129,000	2,187,272,000

Recent Dividends:

1. **MSP Recovery Incorporation class B common.**
No dividends paid.
2. **MSP Recovery Incorporation class A common subject to possible redemption.**
No dividends paid.
3. **MSP Recovery Incorporation class A common.**
No dividends paid.
4. **MSP Recovery Incorporation class V common.**
No dividends paid.

Annual Dividends:

1. **MSP Recovery Incorporation class B common.**
No dividends paid.
2. **MSP Recovery Incorporation class A common subject to possible redemption.**
No dividends paid.
3. **MSP Recovery Incorporation class A common.**
No dividends paid.
4. **MSP Recovery Incorporation class V common.**
No dividends paid.

NCINO INC (NEW)

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2024	2023	2022 (revised)
Subscription revenues	409,479	344,752	224,854
Professional services revenues	67,064
Professional services & other revenues	...	63,563	49,011
Total revenues	476,543	408,315	273,865

Weighted average shares outstanding - diluted	12,589,698	3,034,022	4,466,682
Year end shares outstanding	25,240,051	11,077,394	8,685,093
Net income (loss) per common share - basic	\$(0.21)	\$(0.51)	\$(0.16)
Net income (loss) per common share - diluted	\$(0.21)	\$(0.51)	\$(0.16)
Total number of employees	...	1	1
Number of common stockholders	1,417	49	28
Total other income (expense)	20,475

¹ Shares increased due to the effect of shares issued on conversion of convertible notes; ² Shares increased due to the effect of issuance of common stock

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	...	1,007,018
Prepaid expenses	541,034	4,829
Cash and cash equivalents	9,744,392	...
Total current assets	10,285,426	1,011,847
Equity investment	...	156,805
Mineral property interests	780,395	720,395
Investment in equity security	56,105	...
Total assets	11,121,926	1,889,047
Trade payables	...	802,648
Accrued liabilities	...	41,800
Accounts payable & accrued liabilities	846,307	844,448
Related party advances	...	477,031
Related party payable	460,000	...
Notes & advances payable	...	515
Total current liabilities	1,306,307	1,321,994
Total liabilities	1,306,307	1,321,994
Common stock	2,523	1,107
Additional paid in capital	14,957,547	3,073,447
Retained earnings (accumulated deficit)	(5,162,451)	(2,507,501)
Obligation to issue shares	18,000	...
Total stockholders' equity (deficit)	9,815,619	567,053
Total Equity	9,815,619	...

Recent Dividends:

1. Nevada Canyon Gold Corp common.

No dividends paid.

Annual Dividends:

1. Nevada Canyon Gold Corp common.

No dividends paid.

NEW PROVIDENCE ACQUISITION CORP II

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	¹ 2021 (revised)
Formation & operating costs	1,326,228	1,256,508	466,240
Income (loss) from operations	(1,326,228)	(1,256,508)	(466,240)
Interest earned on marketable securities held in trust account	5,889,542	3,364,235	20,868
Unrealized gain (loss) on marketable securities held in trust account	...	219,567	(27,975)
Other income (expense), net	5,889,542	3,583,802	(7,107)
Income (loss) before provision for income taxes	4,563,314	2,327,294	(473,347)

Current provision for federal income taxes	...	537,174	...
Deferred provision (benefit) for federal income taxes	...	(47,617)	...
Change in valuation allowance	244,767	196,479	...
Current	1,354,823
Deferred	(393,629)
Provision for income taxes	1,205,961	686,036	...
Net income (loss)	3,357,353	1,641,258	(473,347)
Weighted average class A common shares outstanding - basic	...	25,000,000	3,757,225
Weighted average class B common shares outstanding - basic	...	6,250,000	5,718,931
Weighted average class A common shares outstanding - diluted	...	25,000,000	3,757,225
Weighted average class B common shares outstanding - diluted	...	6,250,000	5,718,931
Weighted average shares outstanding - diluted	18,599,816
Year end shares outstanding	11,517,875	31,250,000	² 31,250,000
Net income (loss) per class A common share - basic	...	\$0.05	\$(0.05)
Net income (loss) per class B common share - basic	...	\$0.05	\$(0.05)
Net income (loss) per class A common share - diluted	...	\$0.05	\$(0.05)
Net income (loss) per class B common share - diluted	...	\$0.05	\$(0.05)
Number of part time employees	...	3	...
Full-Time Employees (Period End)	3
Total number of employees	3	...	3
Number of class A ordinary stockholders	...	¹ 1	¹ 1
Number of class B ordinary stockholders	...	⁶ 6	⁶ 6
EPS - Basic - including Extraordinary Items
Applicable to Common - Total	\$0.18
EPS - Diluted - including Extraordinary Items
Applicable to Common - Total	\$0.18
Income Taxes - Total	1,205,961
Common Shareholders - Number	7

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to issuance of class B common stock; ³ As of March 24, 2023; ⁴ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
--	------	------

Cash in Hand & with Banks	56,867	...
Cash	...	339,663
Prepaid expenses	13,080	285,490
Prepaid income taxes	...	125,826
Total current assets	69,947	750,979
Marketable securities held in trust account	56,981,202	257,913,695
Total assets	57,051,149	258,664,674
Accrued expenses	...	614,155
Accrued offering costs	...	524,918
Accounts payable and accrued expenses	1,295,810	...
Income Taxes Payable	209,997	...
Excise taxes payable	2,054,788	...
Total current liabilities	3,850,595	1,139,073
Deferred tax liability	...	148,862
Promissory note - related party	290,000	...
Deferred underwriting payable	8,750,000	8,750,000
Total liabilities	12,600,595	10,037,935
Class A common stock subject to possible redemption	...	257,577,578
Class B common stock	325	625
Accumulated deficit	(12,171,761)	...
Retained earnings (accumulated deficit)	...	(8,951,464)
Class A common stock	56,621,690	...
Common Stock - Issued & Paid	300	...
Total stockholders' equity (deficit)	44,450,554	(8,950,839)
Total Equity	44,450,554	...

Recent Dividends:

1. New Providence Acquisition Corp II class B common.

No dividends paid.

2. New Providence Acquisition Corp II class A common subject to possible redemption.

No dividends paid.

3. New Providence Acquisition Corp II class A common.

No dividends paid.

Annual Dividends:

1. New Providence Acquisition Corp II class B common.

No dividends paid.

2. New Providence Acquisition Corp II class A common subject to possible redemption.

No dividends paid.

3. New Providence Acquisition Corp II class A common.

No dividends paid.

NORTHERN TECHNOLOGIES INTERNATIONAL CORP. Earnings, 6 mos. to (Consol. - \$):

	02/29/24	02/28/23
Total Revenues	41,024,213	...
Net Sales	...	38,223,591
Cost & expenses	37,441,509	36,106,708
Operating income	3,582,704	2,116,883
Interest income	75,652	9,619
Interest expense	188,896	206,475
Net before taxes	3,469,460	1,920,027
Income taxes	515,991	292,528
Net income	2,953,469	1,627,499
Earnings common share		
Primary	\$0.28	\$0.15
Fully Diluted	\$0.27	\$0.14
Common Shares:		
Full Diluted	9,715,121	9,745,166
Year-end	9,427,598	9,366,357

NRX PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	¹ 2021 (revised)
--	------	------	-----------------------------

Research & development	13,371,000	17,027,000	20,257,000
General & administrative	14,216,000	27,308,000	74,944,000
Settlement expense	21,366,000
Reimbursement of expenses from

Automobiles	3,449	2,839
Construction in progress	65,643	...
Property & equipment, gross	454,264	326,333
Less: accumulated depreciation	184,201	...
Less: accumulated depreciation & amortization	...	150,386
Property & equipment, net	270,063	175,947
Operating lease right-of-use assets	475,526	436,326
Goodwill	444,850	444,850
Trade name	230,559	230,559
Other assets	2,168	2,118
Total assets	2,294,594	2,044,096
Current portion of long-term debt	639	430
Accounts payable	128,097	90,204
Income taxes payable	14,744	3,056
Current portion of operating lease liabilities	89,176	88,636
Compensation & benefits	20,535	14,751
Deferred revenue	12,809	10,657
Insurance	9,671	9,141
Advertising	1,780	6,582
Sales & use taxes	10,234	6,567
Real estate related	4,680	6,283
Freight	4,359	2,641
Other accrued expenses	...	20,337
Accrued expenses and other	82,895	...
Other	18,827	...
Accrued expenses & other current liabilities	...	76,959
Total current liabilities	315,551	259,285
Long-term debt	1,022	858
Deferred income taxes	71,877	70,632
Long-term operating lease liabilities	397,912	351,251
Other long-term liabilities	...	1
Total liabilities	786,362	682,027
Common stock	67	67
Additional paid-in capital	694,959	677,694
Retained earnings (accumulated deficit)	1,167,951	986,512
Treasury - common stock, at cost	354,745	302,204
Total stockholders' equity (deficit)	1,508,232	1,362,069
Total Equity	1,508,232	...

Recent Dividends:
1. Ollie's Bargain Outlet Holdings Inc common.
 No dividends paid.
Annual Dividends:
1. Ollie's Bargain Outlet Holdings Inc common.
 No dividends paid.

OMEGA THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31
(\$000):

	2023	2022	2021 (revised)
Total revenues	3,094
Collaboration revenue from related party	3,094	2,073	144
Research & development expenses	...	79,996	47,865
General & administrative expenses	26,186	21,821	16,603
Related party expense, net	77,169	3,022	1,708
Total operating expenses	(103,355)	(104,839)	(66,176)
Income (loss) from			

operations	(100,261)	(102,766)	(66,032)
Interest income (expense), net	2,810	222	(910)
Change in fair value of warrant liability	(1,310)
Other expenses, net	(23)	157	28
Total other income (expense), net	2,833	65	(2,248)
Net income (loss)	(97,428)	(102,701)	(68,280)
Net income (loss) attributable to common stockholders	...	(102,701)	(68,280)
Weighted average shares outstanding - basic	54,011	47,881	22,404
Weighted average shares outstanding - diluted	54,011	47,881	22,404
Year end shares outstanding	55,145	48,073	47,793
Net earnings (loss) per share - basic	\$(1.80)	\$(2.14)	\$(3.05)
Net earnings (loss) per share - diluted	\$(1.80)	\$(2.14)	\$(3.05)
Number of full time employees	93	116	79
Number of part time employees	1	1	1
Number of common stockholders	79	79	62
Income from cont operations before income tax	(97,428)
Total number of employees	94

Reclassified to conform with 2022 presentation; Shares increased due to the issuance of common shares from initial public offering, options exercised and conversion of redeemable convertible preferred shares; As is; Approximately; As of February 24, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	68,443	70,615
Marketable securities	4,986	54,063
Accounts receivable, due from related party	1,006	618
Prepaid clinical expenses	...	5,232
Prepaid research & development	1,609	2,072
Prepaid rent	...	1,857
Other receivables	855	1,180
Prepaid insurance	...	1,020
Prepaid other	431	776
Prepaid software	...	157
Prepaid expenses & other current assets	10,324	12,294
Software	303	...
Facilities	1,242	...
Insurance	716	...
Clinical development	5,168	...
Accounts receivable	5,125	...
Total current assets	89,884	137,590
Lab equipment	1,636	6,121
Leasehold improvements	1,290	1,378
Furniture & fixtures	...	1,093
Construction in process	588	827
Computer equipment	1,226	190
Lab equipment	6,633	...
Total property & equipment, gross	11,373	9,609
Less: accumulated depreciation	6,062	5,414
Property & equipment, net	5,311	4,195
Operating lease right-of-use assets, net	108,736	3,668
Restricted cash	341	341
Other assets	94	204
Total assets	204,366	145,998
Accounts payable	1,620	3,107

Employees related expenses	4,482	4,368
Accrued manufacturing costs	547	4,303
Accrued research costs	...	3,876
Accrued professional & consulting fees	716	743
Other accrued expenses	...	429
Accrued interest	...	122
Research costs	1,395	...
Accrued expenses	7,914	13,841
Other current liabilities	1,972	159
Lease liabilities, current	11,300	1,524
Long-term debt, current portion	4,000	3,333
Interest	147	...
Other Current Liabilities	627	...
Total current liabilities	26,806	21,964
Lease liabilities, non-current	98,243	1,120
Long-term debt, net	14,885	16,603
Other liabilities	6,416	340
Total liabilities	146,350	40,027
Common stock	55	48
Additional paid-in capital	392,609	343,608
Accumulated other comprehensive income (loss)	(14)	(479)
Retained earnings (accumulated deficit)	(334,634)	(237,206)
Total stockholders' equity (deficit)	58,016	105,971
Total Equity	58,016	...

Recent Dividends:
1. Omega Therapeutics Inc common.
 No dividends paid.
Annual Dividends:
1. Omega Therapeutics Inc common.
 No dividends paid.

OMEROS CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31
(\$000):

	2023	2022	2021 (revised)
Research & development expenses	114,870	112,721	118,775
Selling, general & administrative expenses	49,660	50,668	54,842
Total costs & expenses	164,530	163,389	173,617
Income (loss) from operations	(164,530)	(163,389)	(173,617)
Interest expense	30,844	22,702	19,669
Interest & other income	...	4,062	1,740
Other income (expense)	16,342
Gain (loss) on early extinguishment of debt	4,112
Income (loss) from continuing operations before income tax expense (benefit)	(174,920)	(182,029)	(191,546)
Net income (loss) from continuing operations	(174,920)	(182,029)	(191,546)
Net income from discontinued operations, net of tax	57,107	229,446	385,781
Net income (loss)	(117,813)	47,417	194,235
Weighted average shares outstanding - basic	62,739	62,737	62,344

Weighted average shares outstanding				professional fees	3,539	4,425	(expense)	(18,466)	(21,489)	207,701
- diluted	62,739	62,737	62,344	Accrued contract research & development	6,223	3,209	Income (loss) before income taxes	(214,606)	(195,909)	18,209
Year end shares outstanding	61,129	62,829	62,629	Other accrued expenses	31,868	673	Current state income taxes			
Net income (loss) per share from continuing operations - basic	\$(2.79)	\$(2.90)	\$(3.07)	Accrued expenses		30,551	expense (benefit)	800	800	800
Earnings per share-inc from discontinued oper	\$0.91			Current portion of unsecured convertible senior notes, net		94,381	Current Tax - Total	800		
Net income (loss) per share from discontinued operations - basic	\$0.91	\$3.66	\$6.19	Current portion of OMIDRIA royalty obligation	8,576	1,152	Income tax expense (benefit)	800	800	800
Net income (loss) per share - basic	\$(1.88)	\$0.76	\$3.12	Current portion of lease liabilities		4,310	Net income (loss)	(215,406)	(196,709)	17,409
Net income (loss) per share from continuing operations - diluted	\$(2.79)	\$(2.90)	\$(3.07)	Interest payable	4,242		Weighted average shares outstanding - basic	21,948,091	21,948,091	21,600,189
Earn per share-inc from discount ops	\$0.91			Current portion of lease liabilities	5,160		Weighted average shares outstanding - diluted	21,948,091	21,948,091	23,708,115
- diluted	\$0.91	\$3.66	\$6.19	Operating Lease Liabilities - Current			Year end shares outstanding	21,948,091	21,948,091	21,948,091
Net income (loss) per share - diluted	\$(1.88)	\$0.76	\$3.12	Portion/Short-Term Total current liabilities	53,316	136,383	Net income (loss) per share - basic	\$(0.01)	\$(0.01)	\$0.00
Number of full time employees	198	2196	2213	Lease obligation, net of current portion	719		Net income (loss) per share - diluted	\$(0.01)	\$(0.01)	\$0.00
Number of common stockholders	84	284	285	Lease liabilities, non-current	18,143	22,426	Number of full time employees	6	6	6
Total number of employees	198			Notes payable	213,155		Total number of employees	6		
				Unsecured convertible senior notes, net		220,906	Number of common stockholders	46	46	46
				OMIDRIA royalty obligation	116,550	125,126	Basic EPS Excluding ExtraOrdinary Items	\$(0.01)		
				Other accrued liabilities - noncurrent	2,088	444	Diluted EPS			
				Common stock	611	628	Excluding ExtraOrd Items	\$(0.01)		
				Additional paid-in capital	727,936	720,773				
				Accumulated deficit	(753,530)					
				Retained earnings (accumulated deficit)		(635,717)				
				Total shareholders' equity (deficit)	(24,983)	85,684				
				Total Equity	(24,983)					
				Operating Lease Liabilities	17,424					

¹ Reclassified to conform with 2022 presentation; ² As is; ³ As of March 8, 2023; ⁴ As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	7,105	11,009
Short-term investments	164,743	183,909
OMIDRIA contract royalty asset, short-term	29,373	28,797
Trade receivables, net	6,724	212,966
Sublease & other receivables	1,372	255
Receivables, net	8,096	213,221
Prepaid expense & other assets	8,581	6,300
Total current assets	217,898	443,236
OMIDRIA contract royalty asset	138,736	123,425
Equipment under finance leases	6,929	6,204
Laboratory equipment	3,525	3,135
Computer equipment	1,113	1,076
Office equipment & furniture	624	625
Total property & equipment, cost	12,191	11,040
Less accumulated depreciation & amortization	10,241	9,548
Property & equipment, net	1,950	1,492
Right of use assets	18,631	21,762
Restricted investments		1,054
Restricted cash & investments	1,054	
Total assets	378,269	590,969
Accounts payable	7,712	5,989
Accrued employee compensation	7,380	6,665
Accrued clinical trials	316	5,536
Interest payable	10,168	5,172
Income taxes payable		4,871
Accrued consulting &		

Recent Dividends:

1. Omeros Corp common.

No dividends paid.

Annual Dividends:

1. Omeros Corp common.

No dividends paid.

OMNITEK ENGINEERING CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Revenues	1,055,314	1,070,787	1,097,467
Total revenues	1,055,314		
Cost of goods sold	644,660	649,427	621,659
Total cost of goods sold		649,427	621,659
Gross margin	410,654	421,360	475,808
General & administrative expenses	537,473	526,836	600,169
Research & development expenses	67,576	66,444	63,829
Depreciation & amortization expenses	1,745	2,500	1,302
Total operating expenses	606,794	595,780	665,300
Income (loss) from operations	(196,140)	(174,420)	(189,492)
Other income (expense)			32,100
Forgiveness of debt			200,321
Interest expense	23,343	21,489	24,720
Impairment of investments	(88,945)		
Reversal of allowance for obsolete inventory	84,068		
Total other income			
Cash	73,703	56,379	
Accounts receivable, net	12,233	10,180	
Accounts receivable - related parties	1,304	2,252	
Raw materials	799,642	836,833	
Finished goods	494,074	634,275	
Allowance for obsolete inventory		927,755	
Inventory Net - Balancing value	(922,878)		
Inventories, net	370,838	543,353	
Deposits	24,443	7,657	
Total current assets	482,521	619,821	
Production equipment	68,456	68,456	
Leasehold improvements	4,689	4,689	
Less: accumulated depreciation	67,478	65,733	
Property & equipment, net	5,667	7,412	
Operating lease - right-of-use asset	345,459	472,342	
Long-term deposit	13,514	13,514	
Total assets	847,161	1,113,089	
Accounts payable & accrued expenses	323,236	353,591	
Accrued management compensation	635,158	635,158	
Accounts payable - related parties	131,285	127,192	
Notes payable - related parties, current portion	37,940	15,000	
Convertible notes payable - related party	10,000	32,827	
Customer deposits	310,025	231,418	
Operating lease liabilities - current	131,868	118,756	
Total current liabilities	1,579,512	1,513,942	
Loans payable - small business administration ("SBA"), net of current portion	199,000	199,000	
Operating lease liabilities - long-term	254,339	386,207	
Total long-term liabilities	453,339	585,207	

¹ Reclassified to conform with 2022 presentation; ² Approximately; ³ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	73,703	56,379
Accounts receivable, net	12,233	10,180
Accounts receivable - related parties	1,304	2,252
Raw materials	799,642	836,833
Finished goods	494,074	634,275
Allowance for obsolete inventory		927,755
Inventory Net - Balancing value	(922,878)	
Inventories, net	370,838	543,353
Deposits	24,443	7,657
Total current assets	482,521	619,821
Production equipment	68,456	68,456
Leasehold improvements	4,689	4,689
Less: accumulated depreciation	67,478	65,733
Property & equipment, net	5,667	7,412
Operating lease - right-of-use asset	345,459	472,342
Long-term deposit	13,514	13,514
Total assets	847,161	1,113,089
Accounts payable & accrued expenses	323,236	353,591
Accrued management compensation	635,158	635,158
Accounts payable - related parties	131,285	127,192
Notes payable - related parties, current portion	37,940	15,000
Convertible notes payable - related party	10,000	32,827
Customer deposits	310,025	231,418
Operating lease liabilities - current	131,868	118,756
Total current liabilities	1,579,512	1,513,942
Loans payable - small business administration ("SBA"), net of current portion	199,000	199,000
Operating lease liabilities - long-term	254,339	386,207
Total long-term liabilities	453,339	585,207

Total liabilities	2,032,851	2,099,149
Share capital	8,607,086	...
Common stock	...	8,607,086
Additional paid-in capital	12,067,571	12,051,795
Accumulated deficit	(21,860,347)	...
Retained earnings (accumulated deficit)	...	(21,644,941)
Total stockholders' equity (deficit)	(1,185,690)	(986,060)
Total Equity	(1,185,690)	...

Net income (loss) per common share - diluted	\$(3.30)	Ⓔ\$(15.60)	\$(14.82)
Number of full time employees	102	Ⓔ118	Ⓔ231
Number of part time employees	2	Ⓔ1	Ⓔ20
Number of temporary employees	Ⓔ1
Total number of employees	104	Ⓔ119	Ⓔ252
Number of common stockholders	42	Ⓔ36	Ⓔ34

Accumulated deficit	(470,661)	...
Retained earnings (accumulated deficit)	...	(442,741)
Total stockholders' equity (deficit)	14,271	5,677
Total Equity	14,271	...

Recent Dividends:

1. OmniTek Engineering Corp common.

No dividends paid.

Annual Dividends:

1. OmniTek Engineering Corp common.

No dividends paid.

ONTRAK INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	Ⓔ2021 (revised)
Revenue	12,743
Cost of revenue	3,943	7,461	31,214
Gross profit	8,800	7,053	52,919
Research & development expense	6,626	10,974	18,279
Sales & marketing expense	3,580	5,006	9,895
General & administrative expense	19,269	34,256	43,774
Restructuring, severance & related costs	457	934	8,952
Total operating expenses	29,932	51,170	80,900
Operating income (loss)	(21,132)	(44,117)	(27,981)
Other income (expense), net	334	(3,461)	(1,013)
Contractual interest expense, net	7,202	...	7,997
Income (loss) before income taxes	(28,000)	(51,485)	(36,991)
Current state income taxes	(80)	88	153
Total current taxes	(80)	88	153
Income tax expense (benefit)	(80)	88	153
Net income (loss)	(27,920)	(51,573)	(37,144)
Dividends on preferred stock - declared & undeclared	8,954	8,954	8,954
Net income (loss) attributable to common stockholders	(36,874)	(60,527)	(46,098)
Weighted average shares outstanding - basic	11,159	Ⓔ3,878	3,109
Weighted average shares outstanding - diluted	11,159	Ⓔ3,878	3,109
Year end shares outstanding	38,467	Ⓔ4,528	3,448
Income (loss) per share from continuing operations - basic	\$(3.30)
Net income (loss) per common share - basic	\$(3.30)	Ⓔ\$(15.60)	\$(14.82)
Income (loss) per share from continuing operations - diluted	\$(3.30)

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	...	5,032
Cash, cash equivalents & restricted cash	9,701	...
Restricted cash - current	...	4,477
Unbilled receivables	207	453
Deferred costs - current	128	156
Prepaid expenses & other current assets	2,743	3,168
Total current assets	12,779	14,259
Software	4,575	6,882
Computers & equipment	416	466
Right-of-use assets - finance lease	5,350	375
Leasehold improvements	...	17
Furniture & equipment	59	...
ROU assets - finance lease	300	...
Subtotal property & equipment	...	7,740
Less accumulated depreciation	4,437	...
Less: accumulated depreciation & amortization	...	5,242
Property & equipment, net	913	2,498
Restricted cash - long term	...	204
Deferred commissions	147	...
Goodwill	5,713	5,713
Intangible assets, net	99	1,125
Other assets	...	1,326
Operating lease right-of-use assets	195	632
Total assets	19,846	25,757
Accounts payable	563	1,927
Accrued compensation & benefits	442	1,987
Deferred revenue	97	326
Current portion of operating lease liabilities	56	653
Other accrued liabilities	2,784	4,576
Accrued claims payable	2,784	...
Total current liabilities	3,942	9,469
Long-term operating lease liabilities	166	546
Total liabilities	5,575	20,080
Common stock, \$0.0001 par value; 500,000,000 shares authorized; 15,889,171 and 9,214,743 shares issued and outstanding at 31, 2017 and 31, 2016, respectively	6	...
Common stock	...	3
Additional paid-in capital	484,926	448,415

Recent Dividends:

1. Ontrak Inc common.

No dividends paid.

2. Ontrak Inc 9.50% series A cumulative perpetual preferred.

ExDate	Amt	Declared	Record	Payable
02/11/2021	0.59	02/05/2021	02/15/2021	02/28/2021
05/13/2021	0.59	05/05/2021	05/15/2021	05/28/2021
08/12/2021	0.59	08/04/2021	08/15/2021	08/31/2021
11/12/2021	0.59	11/03/2021	11/15/2021	11/30/2021
02/14/2022	0.59	02/03/2022	02/15/2022	02/28/2022

Annual Dividends:

1. Ontrak Inc common.

No dividends paid.

2. Ontrak Inc 9.50% series A cumulative perpetual preferred.

2021.....2.38 2022.....0.59

ORTHOFIX MEDICAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Total revenues	746,641
Product sales	693,345
Marketing service fees	53,296
Net sales	746,641	460,713	464,479
Cost of sales	260,368	123,544	114,914
Gross profit (loss)	486,273	337,169	349,565
Sales & marketing	385,736	228,810	221,318
General & administrative	144,659	79,966	69,353
Research & development	80,231	49,065	49,621
Acquisition-related amortization & remeasurement	14,757	(7,404)	17,588
Changes in fair value of contingent consideration	(2,700)
Amortization of acquired intangibles	17,408
Acquired in-process Research and development	49
Operating income (loss)	(139,110)	(13,268)	(8,315)
Interest income (expense), net	(8,631)	(1,288)	(1,837)
Other income (expense), net	(938)	(3,150)	(3,343)
Income (loss) before income taxes	...	(22,318)	(5,987)
- U.S.	...	(22,318)	(5,987)
Income (loss) before income taxes - non-U.S.	...	4,612	(7,508)
Income (loss) before income taxes	(148,679)	(17,706)	(13,495)
Domestic Current	17
Current U.S. income tax expense (benefit)	...	1,151	(607)
Domestic Deferred	1,160
Deferred U.S. income tax expense (benefit)	...	67	24,292
Current non-U.S. income tax expense (benefit)	2,120	578	1,009
Deferred non-U.S.

income tax expense (benefit)	(581)	247	190	finance lease liability	708	652	Net change in unrealized appreciation (depreciation) on investments - non-affiliate, non-control investments	6,198,413	(109,479,985)	37,699,436
Income tax expense (benefit)	2,716	2,043	24,884	Accrued expenses	12,189	9,611	Net change in unrealized appreciation (depreciation) on investments - affiliated investments	926,274	3,577,327	772,491
Income before minority interests	(151,395)	Salaries, bonuses, commissions & related taxes payable	38,826	18,531	Total net change in unrealized appreciation (depreciation) on investments	7,124,687	(105,902,658)	38,471,927
Net income (loss)	(151,395)	(19,749)	(38,379)	Accrued distributor commissions	22,602	10,483	Net realized gains (losses) - non-affiliated, non-control investments	(17,056,245)	(339,819)	(14,987,438)
Weighted average shares outstanding - basic	36,729	20,054	19,691	Accrued legal & settlement expenses	12,077	3,891	Net realized gains (losses) - extinguishment of debt	(190,353)
Weighted average shares outstanding - diluted	36,729	20,054	19,691	Contingent consideration liability	...	1,000	Total net realized gains (losses)	(17,246,598)	(339,819)	(14,987,438)
Year end shares outstanding	37,165	20,162	19,837	Short-term operating lease liability	3,477	1,638	Net realized & unrealized gain (loss)	(10,121,911)
Net income (loss) per share from continuing operations - basic	\$(4.12)	Non-income taxes payable	7,585	6,586	Net increase (decrease) in net assets from operations	17,238,028	(85,554,899)	39,584,684
Net income (loss) per common share - basic	\$(4.12)	\$(0.98)	\$(1.95)	Other payables	8,152	3,634	Weighted average common shares outstanding - basic	53,919,104	49,757,122	49,624,851
Net income (loss) per share from continuing operations - diluted	\$(4.12)	Total current liabilities	165,223	83,624	Weighted average common shares outstanding - diluted	53,919,104	49,757,122	49,624,851
Net income (loss) per common share - diluted	\$(4.12)	\$(0.98)	\$(1.95)	Long-term portion of finance lease liability	18,532	19,239	Year end shares outstanding	59,300,472	49,844,796	49,690,059
Full-Time Employees (Period End)	1,634	Total long-term debt	93,107	...	Net investment income (loss) per common share - basic	\$0.51	\$0.42	\$0.32
Total number of employees	1,634	1,092	1,087	Other long-term liabilities	49,723	18,906	Net investment income (loss) per common share - diluted	\$0.51	\$0.42	\$0.32
Number of common stockholders	456	493	265	Total liabilities	326,585	121,769	Net increase (decrease) in net assets resulting from operations per common share - basic	\$0.32	\$(1.72)	\$0.80
Foreign currency translation adjustments	...	(1,771)	...	Common Sahare Capital	3,717	...	Net increase (decrease) in net assets resulting from operations per common share - diluted	\$0.32	\$(1.72)	\$0.80
				Common shares	...	2,016	Distributions per common share	\$0.54	\$0.42	\$0.42
				Additional paid-in capital	746,450	334,969	Number of common stockholders	125	129	141
				Retained earnings (accumulated deficit)	(150,144)	1,251	Dividends Per Share - Special - Gross - by Period End Date	\$0.12
				Currency translation adjustments	(1,065)	(2,482)	Full-Time Employees (Period End)	0
				Neo Medical convertible loan	...	1,005	Total number of employees	0
				Other investments	...	101				
				Accumulated other comprehensive income (loss)	(1,293)	(1,376)				
				Total shareholders' equity (deficit)	598,730	336,860				
				Rep Total Equity & Minority Interest	598,730	...				

¹ As is; ² As of March 1, 2023; ³ As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$'000):
2023 2022

Cash & cash equivalents	33,107	50,700
Restricted cash	4,650	...
Trade accounts receivable, gross	135,228	89,276
Less allowance for doubtful accounts	7,130	6,419
Trade accounts receivable, net	128,098	...
Accounts receivable, net	...	82,857
Raw materials	28,390	17,035
Work-in-process	53,510	19,243
Finished products	140,266	63,872
Field or consignment inventories	222,166	100,150
Prepaid expenses & other current assets	32,422	22,283
Total current assets	420,443	255,990
Buildings	4,103	3,867
Plant & equipment	70,252	48,358
Instrumentation	154,192	92,607
Plant, equipment & instrumentation	11,010	...
Computer software	43,040	40,685
Furniture & fixtures	...	7,917
Construction in progress	41,751	4,515
Finance lease assets	23,337	23,276
Property, plant & equipment, gross	347,685	221,225
Less: accumulated depreciation	188,625	162,996
Property, plant & equipment, net	159,060	58,229
Intangible assets, net	117,490	47,388
Goodwill	194,934	71,317
Other long-term assets	33,388	25,705
Total assets	925,315	458,629
Current portion of long-term debt	1,250	...
Accounts payable	58,357	27,598
Current portion of		

Recent Dividends:

1. Orthofix Medical Inc common.

No dividends paid.

Annual Dividends:

1. Orthofix Medical Inc common.

No dividends paid.

OXFORD SQUARE CAPITAL CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Excise tax	1,423,686
Transfer Agent and Custodian Fees	246,562
Interest income - debt investments	33,592,166	25,234,315	17,440,229
Income from securitization vehicles & investments	16,796,699	17,093,203	18,691,631
Other income	1,435,316	790,594	1,043,153
Total investment income	51,824,181	43,118,112	37,175,013
Interest expense	10,825,877	12,354,392	10,495,897
Base fee	3,705,387	5,903,986	6,287,173
Professional fees	1,426,098	1,393,116	1,910,390
Compensation expense	825,226	915,583	723,931
Director's fees	429,500	417,500	490,500
Insurance expenses	329,892	378,804	422,805
Transfer agent & custodian fees	4,613,664	231,241	222,581
Excise tax	1,423,686
General & administrative expenses	638,350	835,912	521,541
Total expenses before incentive fees	20,758,855	22,430,534	21,074,818
Total expenses	24,464,242	22,430,534	21,074,818
Net investment income (loss)	27,359,939	20,687,578	16,100,195

Net change in unrealized appreciation (depreciation) on investments - non-affiliate, non-control investments	6,198,413	(109,479,985)	37,699,436
Net change in unrealized appreciation (depreciation) on investments - affiliated investments	926,274	3,577,327	772,491
Total net change in unrealized appreciation (depreciation) on investments	7,124,687	(105,902,658)	38,471,927
Net realized gains (losses) - non-affiliated, non-control investments	(17,056,245)	(339,819)	(14,987,438)
Net realized gains (losses) - extinguishment of debt	(190,353)
Total net realized gains (losses)	(17,246,598)	(339,819)	(14,987,438)
Net realized & unrealized gain (loss)	(10,121,911)
Net increase (decrease) in net assets from operations	17,238,028	(85,554,899)	39,584,684
Weighted average common shares outstanding - basic	53,919,104	49,757,122	49,624,851
Weighted average common shares outstanding - diluted	53,919,104	49,757,122	49,624,851
Year end shares outstanding	59,300,472	49,844,796	49,690,059
Net investment income (loss) per common share - basic	\$0.51	\$0.42	\$0.32
Net investment income (loss) per common share - diluted	\$0.51	\$0.42	\$0.32
Net increase (decrease) in net assets resulting from operations per common share - basic	\$0.32	\$(1.72)	\$0.80
Net increase (decrease) in net assets resulting from operations per common share - diluted	\$0.32	\$(1.72)	\$0.80
Distributions per common share	\$0.54	\$0.42	\$0.42
Number of common stockholders	125	129	141
Dividends Per Share - Special - Gross - by Period End Date	\$0.12
Full-Time Employees (Period End)	0
Total number of employees	0

¹ As of March 17, 2023; ² As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):
2023 2022

Non-affiliated or

non-control investments	261,614,335 [□]	310,347,097	01/13/2023	0.04
Affiliated investments	5,276,092 [□]	4,349,818	02/13/2023	0.04
Cash	1,160,664	1,673,650	03/16/2023	0.04
Cash equivalents	4,579,889	7,345,514	04/13/2023	0.04
Cash & cash equivalents	5,740,553	9,019,164	05/16/2023	0.04
Interest & distributions receivable	3,976,408	3,492,716	06/15/2023	0.04
Other assets	1,060,384	785,640	07/14/2023	0.04
Stockholders' equity	151,308,625	...	08/16/2023	0.04
Total assets	277,667,772	327,994,435	09/14/2023	0.04
Notes payable - 6.50% unsecured notes, net of deferred issuance costs	...	63,964,568 [□]	09/14/2023	0.12
Notes payable - 6.25% unsecured notes, net of deferred issuance costs	44,247,141 [□]	44,013,984 [□]	10/16/2023	0.04
Notes payable - 5.50% unsecured notes, net of deferred issuance costs	...	78,346,238 [□]	11/15/2023	0.04
Notes payable - credit facility, net of deferred issuance costs	78,731,781	...	12/14/2023	0.04
Base fee & net investment income incentive fee payable to affiliate	1,012,389	1,323,573	01/16/2024	0.04
Accrued interest payable	1,204,487	1,216,109	02/14/2024	0.04
Accrued expenses	1,163,349	458,001	03/14/2024	0.04
Total liabilities	126,359,147	189,322,473	03/14/2024	0.04
Common stock	593,005	498,447	01/13/2023	0.04
Capital in excess of par value	458,121,381	434,737,950	02/13/2023	0.04
Distributable ordinary income	...	30,254,968	02/20/2022	0.04
Distributable long-term capital gains (capital loss carry forward)	...	(103,955,360)	02/20/2022	0.04
Unrealized appreciation (depreciation) on investments	...	(221,821,951)	02/20/2022	0.04
Other timing differences	...	(1,042,092)	02/20/2022	0.04
Total distributable earnings (accumulated losses)	(307,405,761)	(296,564,435)	02/20/2022	0.04
Total net assets	\$151,308,625.00	\$138,671,962.00	02/20/2022	0.04
Net asset value per common share	\$2.55	\$2.78	02/20/2022	0.04
Total Equity	151,308,625	...	02/20/2022	0.04

[□] Cost - non-affiliated or non-control investments: \$495,000,997; [□] Cost - affiliated investments: \$16,836,822; [□] Net of deferred issuance costs - notes payable - 6.50% unsecured notes: \$405,657; [□] Net of deferred issuance costs - notes payable - 6.25% unsecured notes: \$776,766; [□] Net of deferred issuance costs - notes payable - 5.50% unsecured notes: \$2,153,762

**Recent Dividends:
1. Oxford Square Capital Corp common.**

ExDate	Amt	Declared	Record	Payable
01/14/2021	0.04	10/22/2020	01/15/2021	01/29/2021
02/11/2021	0.04	10/22/2020	02/12/2021	02/26/2021
03/16/2021	0.04	10/22/2020	03/17/2021	03/31/2021
04/15/2021	0.04	02/23/2021	04/16/2021	04/30/2021
05/13/2021	0.04	02/23/2021	05/14/2021	05/28/2021
06/15/2021	0.04	02/23/2021	06/16/2021	06/30/2021
07/15/2021	0.04	04/22/2021	07/16/2021	07/30/2021
08/16/2021	0.04	04/22/2021	08/17/2021	08/31/2021
09/15/2021	0.04	04/22/2021	09/16/2021	09/30/2021
10/14/2021	0.04	07/22/2021	10/15/2021	10/29/2021
11/15/2021	0.04	07/22/2021	11/16/2021	11/30/2021
12/16/2021	0.04	07/22/2021	12/17/2021	12/31/2021
01/13/2022	0.04	10/22/2021	01/17/2022	01/31/2022
02/11/2022	0.04	10/22/2021	02/14/2022	02/28/2022
03/16/2022	0.04	10/22/2021	03/17/2022	03/31/2022
04/13/2022	0.04	03/01/2022	04/15/2022	04/29/2022
05/16/2022	0.04	03/01/2022	05/17/2022	05/31/2022
06/15/2022	0.04	03/01/2022	06/16/2022	06/30/2022
07/14/2022	0.04	04/21/2022	07/15/2022	07/29/2022
08/16/2022	0.04	04/21/2022	08/17/2022	08/31/2022
09/15/2022	0.04	04/21/2022	09/16/2022	09/30/2022
10/14/2022	0.04	07/21/2022	10/17/2022	10/31/2022
11/15/2022	0.04	07/21/2022	11/16/2022	11/30/2022
12/15/2022	0.04	07/21/2022	12/16/2022	12/30/2022

**Annual Dividends:
1. Oxford Square Capital Corp common.**

2021	0.42	2022	0.42	2023	0.54
2024	0.11				

**PAPAYA GROWTH OPPORTUNITY CORP I
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
General & administrative expenses	1,907,007	1,928,794	32,172
Franchise tax	200,000	200,000	800
Total expenses	2,107,007	2,128,794	32,972
Interest earned on investments held in trust account	5,608,405	497,081	...
Unrealized gain on investments held in trust account	479,857	3,821,190	...
Total other income	6,088,262	4,318,271	...
Income (loss) before provision for income taxes	3,981,255	2,189,477	(32,972)
Current federal income taxes	...	57,000	...
Current state income taxes	...	27,000	...
Deferred expense (benefit)	...	555,020	(6,924)
Change in valuation allowance	6,924
Income tax expense	1,553,174	639,020	...
Net income (loss)	2,428,081	1,550,457	(32,972)
Weighted average shares outstanding - basic	21,415,804
Weighted average class A common shares outstanding - basic	...	28,630,352	...
Weighted average class B common shares outstanding - basic	...	7,528,875	7,528,875
Weighted average shares outstanding - diluted	21,415,804
Weighted average class A common shares outstanding - diluted	...	28,630,352	...
Weighted average class B common shares outstanding - diluted	...	7,528,875	7,528,875
Year end shares outstanding	11,197,582 [□]	37,644,375	7,528,875
Net income (loss) per share - basic	\$0.11
Net income (loss) per class A common share - basic	...	\$1.19	...
Net income (loss) per class B common share - basic	...	\$0.04	\$0.00

Net income (loss) per share - diluted	\$0.11
Net income (loss) per class A common share - diluted	...	\$1.19	...
Net income (loss) per class B common share - diluted	...	\$0.04	\$0.00
Total number of employees	...	3	3
Number of unitholders	...	4 [□]	...
Number of class A common stockholders	...	1 [□]	1 [□]
Common Shareholders - Number	6

[□] From October 8, 2021 (inception); [□] Reclassified to conform with 2022 presentation; [□] Shares increased due to the effect class A common stock subject to redemption; [□] As of March 6, 2023; [□] As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	2,013	320,067
Prepaid expenses & other assets	43,677	216,608
Advance taxes paid	41,000	41,000
Interest income receivable	53,054	...
Total current assets	139,744	577,675
Investments held in trust account	24,976,375	297,568,272
Deferred tax asset	542,806	...
Total assets	25,658,925	298,145,947
Accounts payable & accrued expenses	480,958	223,640
Accrued offering costs	2,770,478	...
Note payable - related party	2,624,070	...
Due to affiliate	174,000	14,500
State franchise tax payable	40,200	200,800
State income tax payable	...	27,000
Deferred underwriting fees payable	15,125,000	15,125,000
Total current liabilities	21,214,706	15,590,940
Deferred tax liability	...	555,020
Total liabilities	21,214,706	16,145,960
Class A common stock subject to possible redemption	...	293,250,000
Class A common stock	753	137
Class B common stock	137	753
Accumulated deficit	(20,533,046)	...
Retained earnings (accumulated deficit)	...	(11,250,903)
Common Stock - Issued & Paid	24,976,375	...
Total stockholders' equity (deficit)	4,444,219	(11,250,013)
Total Equity	4,444,219	...

Recent Dividends:

- 1. Papaya Growth Opportunity Corp I class B common.**
No dividends paid.
 - 2. Papaya Growth Opportunity Corp I class A common.**
No dividends paid.
 - 3. Papaya Growth Opportunity Corp I class A common subject to possible redemption.**
No dividends paid.
- Annual Dividends:**
- 1. Papaya Growth Opportunity Corp I class B common.**
No dividends paid.
 - 2. Papaya Growth Opportunity Corp I class A common.**
No dividends paid.
 - 3. Papaya Growth Opportunity Corp I class A common subject to possible redemption.**
No dividends paid.

PAYCHEX INC

Earnings, 9 mos. to (Consol. - \$000):

	02/29/24	02/28/23	Total Current Tax	25,936	Trade name	1,025,000	1,025,000
Total Revenues	3,983,200	3,777,500	Total Deferred Tax	(53,549)	Other long-term assets	205,694	176,806
Cost & expenses	2,290,900	2,197,700	Income tax expense				Total assets	5,363,152	6,612,829
Operating income	1,692,300	1,579,800	(benefit)	(27,613)	35,347	53,473	Accounts payable & book overdrafts	485,131	381,213
Other income (expense), net	600	1,800	Income (loss) from equity method				Accrued compensation & related taxes	55,358	44,724
Net before taxes	1,726,200	1,584,600	investees	16,188	12,976	10,883	Self-insurance reserves	101,265	27,175
Income taxes	415,700	377,700	Net income (loss)	(1,280,210)	89,910	159,805	Accrued paid time-off	...	18,030
Net income	1,310,500	1,206,900	Net loss attributable to noncontrolling interest		891	4,612	Accrued salaries & employee benefits	...	89,929
Earnings common share			Net income (loss) attributable to class A & B-1 common stockholders	(1,280,210)	90,801	164,417	Accrued capital expenditures	18,888	29,051
Primary	\$3.64	\$3.35	Weighted average class A & B-1 common shares outstanding - basic	267,549	265,522	264,261	Accrued real estate taxes	26,996	26,485
Fully Diluted	\$3.62	\$3.33	Weighted average class A & B-1 common shares outstanding - diluted	267,549	265,951	265,338	Accrued advertising	15,079	24,020
Common Shares:			Year end shares outstanding	306,738	303,920	302,769	Deferred revenues	33,523	23,045
Full Diluted	362,200	362,300	Net earnings (loss) per class A & B-1 common share - basic	\$(4.78)	\$0.34	\$0.62	Sales taxes payable	21,241	22,950
Year-end	360,000	360,500	Net earnings (loss) per class A & B-1 common share - diluted	\$(4.78)	\$0.34	\$0.62	Other accrued expenses & liabilities	200,278	92,005
PENNANTPARK INVESTMENT CORPORATION			Full-Time Employees (Period End)	29,000	Current portion of operating lease liabilities	310,507	309,766
Earnings, 3 mos. to Dec 31(Consol. - \$):			Total number of employees	29,000	29,000	28,495	Current portion of long-term debt & other lease liabilities	15,962	22,794
	2023	2022	Number of class A common stockholders	...	64	38	Self-insurance reserves	18,911	...
Total Revenues	34,336,000	...	Number of class B-1 common stockholders	...	1	1	Accrued real estate taxes	28,843	...
Cost & expenses	18,678,000	19,630,000	Number of class B-2 common stockholders	...	2	2	Capitalized Leases - Current Portion	15,962	...
Net income	15,658,000	10,333,000	Foreign currency translation adjustments	...	194	(963)	Total current liabilities	1,113,143	1,021,258
Earnings common share			Goodwill impairment	1,222,524	Senior secured credit facilities, net, excluding current portion	...	1,628,331
Primary	\$0.16	\$0.16	Common Shareholders - Number	92	Senior notes, net	1,576,223	...
Fully Diluted	\$0.16	\$0.16	Consolidated Balance Sheet, Years Ended (\$000):				Operating lease liabilities, excluding current portion	1,116,615	1,148,155
Common Shares:				02/03/24	01/28/23	01/29/22 (revised)	Deferred taxes, net	251,629	303,121
Full Diluted	65,224,500	65,224,500	Cash & cash equivalents	125,428	201,901	...	Self-insurance reserves	...	52,780
Year-end	65,224,500	65,224,500	Receivables, gross	46,175	50,532	...	Finance leases	...	23,642
Consolidated Balance Sheet Items, as of (\$):			Allowance for credit losses	1,806	952	...	Other liabilities	...	54,065
Assets:		2023	Receivables	44,369	49,580	...	Other long-term liabilities	121,113	130,487
Cash & equivalents	36,893,000	...	Merchandise inventories, net	684,502	652,430	...	Total liabilities	4,178,723	4,231,352
Current assets	52,339,000	...	Other prepaid expenses	58,615	Class A common stock	231	228
Total assets	1,267,238,000	...	Prepaid expenses	...	51,274	...	Class B-1 common stock	38	38
Liabilities:			Other current assets	38,830	60,809	...	Additional paid-in-capital (Accumulated deficit)	2,229,582	2,152,342
Current liabilities	72,746,000	...	Total current assets	951,744	1,015,994	...	retained earnings	(1,047,243)	...
Long-term debt	695,350,000	...	Equipment	978,242	885,370	...	Retained earnings (accumulated deficit)	...	232,967
Stockholders' equity	499,142,000	...	Leasehold improvements	753,160	686,888	...	Derivatives	1,821	(2,053)
Net current assets	(20,407,000)	...	Furniture & fixtures	...	398,187	...	Foreign currency adjustment	...	(2,044)
PETCO HEALTH & WELLNESS CO INC			Buildings & related improvements	428,561	16,696	...	Accumulated comprehensive income (loss)	...	(4,098)
Annual Report			Land	236	418	...	Total stockholders' equity	1,184,429	2,381,477
Consolidated Income Statement, Years Ended (\$000):			Buildings and related improvements	12,816	Total equity	1,184,429	2,381,477
	02/03/24	01/28/23	Fixed assets, gross	2,173,015	1,987,559	...	For 52 weeks, As reported by the Company		
Total revenues	6,255,284	...	Less: accumulated depreciation	1,356,648	1,184,232	...	Recent Dividends:		
Total net sales	6,255,284	...	Fixed assets, net	816,367	803,327	...	1. Petco Health & Wellness Co Inc class B-2 common.		
Net sales	6,035,967	5,807,149	Operating lease right-of-use assets	1,384,050	1,397,761	...	No dividends paid.		
Gross profit	2,353,835	2,427,107	Goodwill	980,297	2,193,941	...	2. Petco Health & Wellness Co Inc class B-1 common.		
Selling, general & administrative expenses	2,311,625	2,201,548				...	No dividends paid.		
Cost of sales	3,901,449	3,608,860				...	3. Petco Health & Wellness Co Inc class A common.		
Operating income (loss)	(1,180,314)	225,559				...	No dividends paid.		
Interest income	3,405	1,032				...	Annual Dividends:		
Interest expense	150,909	101,643				...	1. Petco Health & Wellness Co Inc class B-2 common.		
Gain (loss) on extinguishment & modification of debt	(920)	No dividends paid.		
Other non-operating income	4,727	(12,667)				...	2. Petco Health & Wellness Co Inc class B-1 common.		
Income (loss) before income taxes & income (loss) from equity method investees	(1,324,011)	112,281				...	No dividends paid.		
Current income tax expense (benefit) - federal	23,321	23,141				...	3. Petco Health & Wellness Co Inc class A common.		
Current income tax expense (benefit) - state	2,615	13,099				...	No dividends paid.		
Total current income tax expense (benefit)	...	36,240				...	Annual Dividends:		
Deferred income tax expense (benefit) - federal	(41,684)	4,649				...	1. Petco Health & Wellness Co Inc class B-2 common.		
Deferred income tax expense (benefit) - state	(11,865)	(5,542)				...	No dividends paid.		
Total deferred income tax expense (benefit)	...	(893)				...	2. Petco Health & Wellness Co Inc class B-1 common.		
						...	No dividends paid.		
						...	3. Petco Health & Wellness Co Inc class A common.		
						...	No dividends paid.		
						...	PLBY GROUP INC		
						...	Annual Report		
						...	Consolidated Income Statement, Years Ended Dec. 31 (\$):		
						...	2023		
						...	01/2022 (revised)		
						...	02/2021 (revised)		

Income (loss) from operations.....	(43,736)	(62,308)	(39,376)	Construction in progress.....	70	533		02/29/24	02/28/23
Impairment charges.....		10,844		Leasehold improvements.....	11,945	22,955		184,685	164,226
Gain (loss) on disposal of assets.....	1,145	(510)	(26)	Software.....	432	442		132,290	115,027
Gain (loss) from changes in fair value.....				Laboratory equipment.....	15,856	23,459		Operating income.....	35,006
Gain on deconsolidation of subsidiary.....				Office equipment.....	1,399	1,594		Interest expense.....	7,344
Income (loss) from equity method investment.....	(4,931)	(1,579)		Furniture & fixtures.....	2,124	2,295		Foreign currency.....	(331)
Interest expense.....	2,230	1,111		Total property, equipment & software.....	31,826	51,278		Net before taxes.....	27,607
Interest income.....	7,686	3,473		Less: accumulated depreciation & amortization.....	25,488	31,088		Income taxes.....	4,968
(Loss) gain on disposal of assets.....	(461)	(30)		Property, equipment, & software - net.....	6,338	20,190		Net income	22,639
Total other income (expense), net.....	1,209	(10,601)		Intangible assets - net.....	400	1,348		Earnings common share:	
Net income (loss)	(61,319)	(111,637)	(30,602)	Right-of-use assets - net.....	8,263	2,974		Primary.....	\$0.52
Weighted average shares outstanding - basic.....	¹ 3,841	2,930	1,956	Investment in equity securities.....	3,206	2,576		Fully Diluted.....	\$0.51
Weighted average shares outstanding - diluted.....	¹ 3,841	2,930	1,956	Equity method investment.....		2,172		Common Shares:	
Year end shares outstanding.....	¹ 4,164	3,699	2,030	Note receivable - net.....	4,990	7,234		Full Diluted.....	44,826
Net earnings (loss) per share - basic.....	² \$(15.96)	\$(38.10)	\$(15.60)	Other assets.....	225	2,570		Year-end.....	43,689
Net earnings (loss) per share - diluted.....	² \$(15.96)	\$(38.10)	\$(15.60)	Total assets.....	159,781	238,169		Consolidated Balance Sheet Items, as of (\$'000):	
Number of full time employees.....	109		³ 198	Accounts payable.....	2,968	1,225		Assets:	2024
Number of common stockholders.....	25		⁴ 29	Accrued compensation.....	4,978	6,259		Cash & equivalents.....	133,222
Income from cont operations before income tax.....	(42,527)	(72,909)		Accrued clinical research & development expenses.....		3,206		Current assets.....	297,256
Income from continuing operations.....	(42,527)	(72,909)		Accrued research & development expenses.....	1,557			Net property & equip.....	14,081
Sale of discontinued Operations - Net - Gain/Loss.....	8,446			Deferred revenue.....	12,035	46,192		Total assets.....	1,547,769
Discontinued operations.....	(18,792)	(38,728)		Lease liabilities.....	1,133	2,037		Liabilities:	
Earnings per share from continuing operations.....	⁵ \$(11.07)	\$(24.88)		Other current liabilities.....	2,391	745		Current liabilities.....	312,208
Earnings per share-discontinued opers.....	⁶ \$(4.89)	\$(13.22)		Loan payablenet.....	22,412			Long-term debt.....	691,262
Earnings per share from continuing operations.....	⁵ \$(11.07)	\$(24.88)		Current liabilities of discontinued operations.....	2,513			Stockholders' equity.....	461,743
Earning per share-total discount opers - diluted.....	⁶ \$(4.89)	\$(13.22)		Total current liabilities.....	49,987	59,664		Net current assets.....	(14,952)
Discontinued Operations - Net of Taxes.....	(27,238)	(38,728)		Deferred revenue.....	73,082	82,872			
Total number of employees.....	109			Lease liabilities.....	7,723	2,776			
				Long term debt - net.....		22,223			
				Contract liabilities.....	10,000	10,000			
				Other noncurrent liabilities.....		201			

Recent Dividends:**1. Precision Biosciences Inc common.**

No dividends paid.

Annual Dividends:**1. Precision Biosciences Inc common.**

No dividends paid.

PRICESMART INC**Earnings, 6 mos. to (Consol. - \$'000):**

	02/29/24	02/28/23	
Total Revenues.....	2,458,425	2,196,995	
Cost & expenses.....	2,336,594	2,087,668	
Operating income.....	121,831	109,327	
Interest income.....	6,091	3,099	
Interest expense.....	(9,162)	(5,563)	
Other income (expense), net.....	(1,072)	(9,910)	
Gains or losses.....	(1,072)		
Equity earnings.....	(79)	73	
Net before taxes.....	112,651	96,953	
Income taxes.....	35,412	32,628	
Net income	77,318	64,252	
Balance for common.....	76,425	63,625	
Earnings common share:			
Primary.....	\$2.54	\$2.07	
Fully Diluted.....	\$2.54	\$2.07	
Common Shares:			
Full Diluted.....	30,095	30,740	
Year-end.....	30,656	31,001	

PROGRESS SOFTWARE CORP**Earnings, 3 mos. to (Consol. - \$'000):**

	02/29/24	02/28/23	
Total Revenues.....	184,685	164,226	
Cost & expenses.....	132,290	115,027	
Operating income.....	35,006	35,588	
Interest expense.....	7,344	5,848	
Foreign currency.....		(331)	
Net before taxes.....	27,607	29,924	
Income taxes.....	4,968	6,250	
Net income	22,639	23,674	
Earnings common share:			
Primary.....	\$0.52	\$0.55	
Fully Diluted.....	\$0.51	\$0.53	
Common Shares:			
Full Diluted.....	44,826	44,353	
Year-end.....	43,689	43,307	

Consolidated Balance Sheet Items, as of (\$'000):

	2023	2022	2021
Assets:			
Cash & equivalents.....			133,222
Current assets.....			297,256
Net property & equip.....			14,081
Total assets.....			1,547,769
Liabilities:			
Current liabilities.....			312,208
Long-term debt.....			691,262
Stockholders' equity.....			461,743
Net current assets.....			(14,952)

PROTAGENIC THERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$'000):**

	2023	2022	2021
Research & development expense.....	3,319,867	1,589,239	1,136,790
General & administrative expense.....	1,207,107	1,968,549	3,003,623
Total operating & administrative expenses.....	4,526,974	3,557,788	4,140,413
Income (loss) from operations.....	(4,526,974)	(3,557,788)	(4,140,413)
Interest income.....	264,476	185,790	33,207
Interest expense.....	107,682	137,456	496,912
Realize gain (loss) on foreign exchange transactions.....	(630,317)		
Realized gain (loss) on marketable securities.....		(46,051)	(2,486)
Change in fair value of derivative liability.....			83,670
Total other income (expenses).....	(473,523)	2,283	(382,521)
Income (loss) before income taxes - domestic.....		(3,522,834)	(4,522,862)
Income (loss) before income taxes - foreign.....		(32,671)	(72)
Income (loss) before tax.....	(5,000,497)	(3,555,505)	(4,522,934)
Net income (loss)	(5,000,497)	(3,555,505)	(4,522,934)
Weighted average shares outstanding - basic.....	4,344,580	4,317,875	⁷ 3,685,206
Weighted average shares outstanding - diluted.....	4,344,580	4,317,875	⁷ 3,685,206
Year end shares outstanding.....	4,435,132	4,321,315	⁸ 4,302,403
Income (loss) per share-continuing operations - basic.....	\$(1.15)		
Net income (loss) per common share - basic.....	\$(1.15)	\$(0.82)	⁹ \$(1.24)
Income (loss) per share-continuing operations - diluted.....	\$(1.15)		
Net income (loss).....			

¹ Restated to reflect correction of errors; ² Reclassified to conform with 2022 presentation; ³ Adjusted for 1-for-30 stock split February 14, 2024; ⁴ As Is; ⁵ Approximately; ⁶ As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$'000):

	2023	2022	
Cash & cash equivalents.....	116,678	189,576	
Accounts receivable.....	901	720	
Prepaid expenses.....	5,977	7,552	
Other current assets.....	419	1,257	
Convertible note receivable.....	11,897		
Assets held for sale.....	487		
Total current assets.....	136,359	199,105	

per common share - diluted	\$(1.15)	\$(0.82)	[Ⓜ] \$(1.24)
Number of part time employees	2	2	2
Total number of employees	2
Number of common stockholders	3,000	[Ⓜ] 3,000	[Ⓜ] 3,000
Number of series B preferred stockholders	...	[Ⓜ] 0	[Ⓜ] 0

[Ⓜ] Adjusted for 1-for-4 stock split, March 23, 2023; [Ⓜ] Shares increased due to exercise of options and warrants, issuance of shares and warrants from offering, conversion of preferred stock, notes and interest and issuance of stock for underwriter; [Ⓜ] Approximately; [Ⓜ] As of March 31, 2023; [Ⓜ] As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022	
Cash in Hand & with Banks	1,287,893	...	
Cash	...	215,189	
Marketable securities, current	2,768,119	7,763,517	
Prepaid expenses	144,025	56,939	
Total current assets	4,200,037	8,035,645	
Equipment - net	123,332	1,775	
Total assets	4,323,369	8,037,420	
Research & development	498,366	...	
Legal	6,334	...	
Accounts payable & accrued expenses	655,252	669,704	
Accounts payable & accrued expenses - related party	36,750	...	
Accounts payable & accrued expenses - related party	...	105,928	
Payment-in-kind ("PIK") convertible notes payable, net of debt discount	...	150,591	
Payment-in-kind ("PIK") convertible notes payable, net of debt discount - related parties	...	193,639	
Accrued expenses	113,802	...	
Total current liabilities	655,252	1,119,862	
Total liabilities	655,252	1,119,862	
Common stock, \$0.001 par value, 100,000,000 shares authorized, 8,307,915 shares issued and outstanding at September 30, 2016, 7,612,838 shares issued and 6,612,838 shares outstanding at December 31, 2015	444	...	
Common stock	...	434	
Additional paid-in-capital	34,559,091	33,371,406	
Accumulated deficit	(30,777,872)	...	
Retained earnings (accumulated deficit)	...	(25,777,375)	
Accumulated other comprehensive income (loss)	(113,546)	(676,907)	
Total stockholders' equity (deficit)	3,668,117	6,917,558	
Total shareholders' equity (deficit)	3,668,117	...	

Recent Dividends:
1. Protagenic Therapeutics Inc series B convertible preferred.
 No dividends paid.
2. Protagenic Therapeutics Inc common.
 No dividends paid.
3. Protagenic Therapeutics Inc series A convertible preferred.

No dividends paid.
Annual Dividends:
1. Protagenic Therapeutics Inc series B convertible preferred.
 No dividends paid.
2. Protagenic Therapeutics Inc common.
 No dividends paid.
3. Protagenic Therapeutics Inc series A convertible preferred.
 No dividends paid.

QT IMAGING HOLDINGS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[Ⓜ] 2021 (revised)
General & administrative expenses	4,927,599	4,279,100	1,081,298
Income (loss) from operations	(4,927,599)	(4,279,100)	(1,081,298)
Other income (expense)	14,953	384,108	(30,627)
Interest expense	219,686	23,098	...
Interest income on cash & marketable securities held in trust account	1,526,860	1,630,398	5,978
Income (loss) before provision for income taxes - domestic	...	(2,287,692)	(1,105,947)
Income (loss) before provision for income taxes	(3,605,472)	(2,287,692)	(1,105,947)
Current federal provision for income taxes	...	342,216	1,255
Current state & local provision for income taxes	...	144,399	528
Provision for income taxes	419,119	486,615	1,783
Net income (loss)	(4,024,591)	(2,774,307)	(1,107,730)
Net income (loss) attributable to common stock subject to possible redemption	...	(1,143,783)	(4,195)
Net income (loss) attributable to common stockholders	...	(3,918,090)	(1,111,925)
Weighted average common shares outstanding subject to possible redemption - basic	...	17,954,419	6,296,830
Weighted average shares common outstanding - basic	...	6,540,000	8,185,533
Weighted average shares outstanding - basic	9,560,634
Weighted average common shares outstanding subject to possible redemption - diluted	...	17,954,419	6,296,830
Weighted average shares common outstanding - diluted	...	6,540,000	8,185,533
Weighted average shares outstanding - diluted	9,560,634
Year end shares outstanding	8,659,978	[Ⓜ] 10,559,050	29,545,000
Net income (loss) per common share subject to possible redemption - basic	...	\$0.06	\$0.00
Net income (loss) per common share - basic	...	\$(0.60)	\$(0.14)

Earnings (loss) per share - basic	\$(0.42)
Net income (loss) per common share subject to possible redemption - diluted	...	\$0.06	\$0.00
Net income (loss) per common share - diluted	...	\$(0.60)	\$(0.14)
Earnings (loss) per share - diluted	\$(0.42)
Total number of employees	3
Number of part time employees	...	3	...
Number of unitholders	[Ⓜ] 2
Number of common stockholders	624	[Ⓜ] 4	[Ⓜ] 4

[Ⓜ] From January 19, 2021 (date of inception); [Ⓜ] Reclassified to conform with 2022 presentation; [Ⓜ] Shares decreased due to the effect of redemption of shares; [Ⓜ] As of March 29, 2022; [Ⓜ] As of March 29, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	2,438	78,196
Prepaid expenses & other current assets	94,008	172,508
Total current assets	96,446	250,704
Cash & marketable securities held in trust account	23,302,116	41,561,656
Interest receivable on cash & marketable securities held in the trust account	...	133,211
Total assets	23,398,562	41,945,571
Related party loan	1,610,875	...
Accounts payable	767,615	195,064
Accrued legal fees	3,500,000	2,157,037
Payable to related parties	...	781,561
Note payable to related party	1,564,673	603,880
Note payable to related party at fair value	1,506,389	257,492
Accrued liabilities	893,830	103,344
Other current liabilities	79,162	88,021
Deferred underwriting fee payable - current	2,760,000	...
Total current liabilities	12,682,544	4,186,399
Warrant liability	7,950	31,800
Deferred underwriting fee payable	...	9,200,000
Total liabilities	12,690,494	13,418,199
Common stock subject to possible redemption	23,222,954	41,606,846
Common Stock - Issued & Paid	655	...
Common stock	...	655
Additional paid-in capital	4,589,179	...
Retained earnings (accumulated deficit)	(17,104,720)	(13,080,129)
Total stockholder's equity (deficit)	(12,514,886)	(13,079,474)
Total Equity	(12,514,886)	...

Recent Dividends:
1. QT Imaging Holdings Inc common.
 No dividends paid.
Annual Dividends:
1. QT Imaging Holdings Inc common.
 No dividends paid.
QUINCE THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)				02/29/24	02/28/23
Research & development	9,447	25,178	60,795	Australia research & development refundable tax credit	1,003		1,293,956	1,354,683
General & administrative expenses	17,695	26,012	29,523	Prepaid research & development expenses	1,088		1,343,661	1,362,452
Goodwill impairment charge		825		Other current assets	276		Operating income	(49,705)
Fair value adjustment for contingent consideration	(1,578)			Prepaid expenses & other current assets	2,381	3,567	Interest expense	10,613
Total operating expenses	34,620	52,015	90,318	Total current assets	77,440	93,748	Other income (expense), net	(432)
Income (loss) from operations	(34,620)	(52,015)	(90,318)	Computer equipment	36	18	Net before taxes	(60,750)
Interest income, net	3,478	1,068	620	Lab equipment	486	415	Income taxes	(8,975)
Other expense, net	102	997	247	Finance lease right of use assets	153	124	Income contin. oper.	(51,775)
Net income (loss) before income tax expense (benefit) - U.S.	(27,375)	(48,191)	(87,907)	Leasehold improvement	36	21	Income discont. oper.	(33)
Net income (loss) before income tax expense (benefit) - international	(4,207)	(3,753)	(2,038)	Less: accumulated depreciation	507		Net income	(51,808)
Net income (loss) before income tax expense (benefit)	(31,582)	(51,944)	(89,945)	Less: accumulated amortization & depreciation		185	Earnings common share	
Income Taxes - Foreign - Current	61			Computer Software & Equipment - Tangible Assets - Gross	30		Primary	\$(1.83)
Income Taxes - Total - Current	61			Property & equipment, net	234	393	Fully Diluted	\$(1.83)
Income Taxes - Foreign - Deferred	(10)			Operating lease right-of-use assets, net	385	291	Common Shares:	
Income Taxes - Domestic - Deferred	(248)			Long term investments		3,578	Full Diluted	28,337
Income Taxes - Total - Deferred	(258)			Intangible asset	63,672	5,900	Year-end	27,982
Income tax (benefit)	(197)	(284)		Other assets	8,456			27,455
Net income (loss)	(31,385)	(51,660)	(89,945)	Goodwill	17,625			
Weighted average shares outstanding - basic	37,237	33,497	29,719	Equity investment in Lighthouse, Inc	78			
Weighted average shares outstanding - diluted	37,237	33,497	29,719	Assets Held for Sale	10			
Year end shares outstanding	42,973	36,136	30,074	Total assets	167,900	103,910		
Net earnings (loss) per share - basic	\$(0.84)	\$(1.54)	\$(3.03)	Accounts payable	2,033	570		
Net earnings (loss) per share - diluted	\$(0.84)	\$(1.54)	\$(3.03)	Personnel expenses	3,436	1,130		
Number of full time employees	32			Professional fees	211	234		
Total number of employees	32	21	55	Research & development expenses	564	497		
Number of common stockholders	50	62	15	Current portion of operating lease liabilities	64	377		
Foreign currency translation adjustments		248	20	Current portion of finance lease liability		76		
Intangible asset impairment charge	5,900			Other accrued expenses & other current liabilities		185		
Fair value adjustment for long-term debt	(338)			Accrued expenses & other current liabilities		2,499		
				Accrued interest payable	257			
				Personnel expenses	2,340			
				Short-term contingent consideration	4,103			
				Total current liabilities	9,572	3,069		
				Long-term operating lease liabilities	321			
				Deferred tax liabilities	5,304	248		
				Long-term debt	13,429			
				Long-term contingent consideration	53,603			
				Other long-term liabilities	587			
				Total liabilities	82,816	3,317		
				Common stock	43	36		
				Additional paid-in capital	401,638	389,105		
				Accumulated other comprehensive income (loss)	3,047	(289)		
				Accumulated deficit	(319,644)			
				Retained earnings (accumulated deficit)		(288,259)		
				Total stockholders' equity	85,084	100,593		
				Total Equity	85,084			

[□] Reclassified to conform with 2022 presentation; [□] Shares increased due to the effect issuance of shares for exercise of stock options and vesting of restricted stock units and acquisition of Novosteo, Inc.; [□] As is; [□] As of March 3, 2023; [□] As of February 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	20,752	44,579
Short-term investments	54,307	45,602
Prepaid expenses	223	
Prepaid insurance		977

Recent Dividends:

1. Quince Therapeutics Inc common.
No dividends paid.

Annual Dividends:

1. Quince Therapeutics Inc common.
No dividends paid.

RADIUS RECYCLING INC

Earnings, 6 mos. to (Consol. - \$000):

	2023	2022	2021
Total Revenues	54,807,348	113,322,999	90,621,570
Cost & expenses	48,894,945	47,926,077	35,081,922
Operating income	103,702,293	161,249,076	125,703,492
Interest expense		(161,249,076)	(125,703,492)
Other income (expense), net	5,151,704		
Net before taxes		6,351,606	
Income taxes		2,659,424	1,199,077
Income contin. oper.		3,823,234	(585,522)
Income discont. oper.		(4,064,391)	(4,220,255)
Net income		4,910,547	4,205,253
Earnings common share		(98,791,746)	(157,043,823)
Primary		30,099,203	29,628,664
Fully Diluted		30,099,203	29,628,664
Common Shares:		30,099,203	30,099,203
Full Diluted		129	136
Year-end		136	154

RELMADA THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Research & development expenses			
General & administrative expenses			
Total operating expenses			
Income (loss) from operations			
Interest income, net			
Gain on settlement of fees			
Interest or investment income, net			
Realized gain (loss) on short-term investments			
Unrealized gain (loss) on short-term investments			
Total other income (expenses), net			
Net income (loss)			
Weighted average shares outstanding - basic			
Weighted average shares outstanding - diluted			
Year end shares outstanding			
Net earnings (loss) per common share - basic			
Net earnings (loss) per common share - diluted			
Number of full time employees			
Total number of employees			
Number of common stockholders			
Operating income			
Income from cont operations before income tax			

[□] Shares increased due to the effect of equity offering, ATM offering, warrant exercised and option exercised; [□] As of March 20, 2023; [□] As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	4,091,568	5,395,905

Short-term investments	92,232,292	142,926,781
Other receivables	...	512,432
Insurance	...	313,200
Research & development	...	3,619,800
Other prepaid expenses	1,185,057	102,200
Prepaid expenses	...	4,035,186
Total current assets	97,508,917	152,870,304
Other assets	43,125	34,875
Total assets	97,552,042	152,905,179
Accounts payable	3,506,009	5,261,936
Research & development	5,394,700	5,809,800
Professional fees	174,000	116,500
Accrued bonus	2,632,400	492,100
Accrued vacation	372,200	529,800
Other accrued expenses	...	258,700
Other	115,500	...
Accrued expenses -
Balancing value	(9)	...
Accrued expenses	8,688,791	7,206,941
Total current liabilities	12,194,800	12,468,877
Total liabilities	12,194,800	12,468,877
Common stock	30,099	30,099
Additional paid-in capital	646,229,824	602,517,138
Retained earnings (accumulated deficit)	(560,902,681)	(462,110,935)
Total stockholders' equity (deficit)	85,357,242	140,436,302
Total Equity	85,357,242	...

□ Rounding difference, breakdown taken from the notes

Recent Dividends:

1. **Relmada Therapeutics Inc class A convertible preferred.**
No dividends paid.
2. **Relmada Therapeutics Inc common.**
No dividends paid.

Annual Dividends:

1. **Relmada Therapeutics Inc class A convertible preferred.**
No dividends paid.
2. **Relmada Therapeutics Inc common.**
No dividends paid.

RENEO PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development	56,613	37,705	28,169
General & administrative expenses	26,440	16,143	11,649
Total operating expenses	83,053	53,848	39,818
Income (loss) from operations	(83,053)	(53,848)	(39,818)
Other income	5,665	1,893	48
Net income (loss)	(77,388)	(51,955)	(39,770)
Weighted average shares outstanding - basic	30,676	24,496	18,143
Weighted average shares outstanding - diluted	30,676	24,496	18,143
Year end shares outstanding	33,421	24,700	24,455
Net earnings (loss) per share - basic	\$(2.52)	\$(2.12)	\$(2.19)
Net earnings (loss) per share - diluted	\$(2.52)	\$(2.12)	\$(2.19)
Number of full time employees	8	36	20
Number of part time employees	...	12	12
Total number of employees	8	48	32
Number of common stockholders	184	25	30
Income from cont operations before income tax	(77,388)

□ Shares increased due to the effect issuance of shares for conversion preferred stock, stock in public offering, stock option exercised and employee stock purchase plan; □ As is; □ As of March 21, 2023; □ Approximately; □ As of March 17, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	27,632	19,927
Short-term investments	75,331	81,246
Prepaid expenses & other current assets	3,659	5,180
Total current assets	106,622	106,353
Computer, software & office equipment	254	300
Leasehold improvements	...	255
Computer, software and office equipment	254	...
Property, plant & equipment, gross	...	555
Less: accumulated depreciation & amortization	120	102
Property & equipment, net	134	453
Right-of-use assets	599	1,292
Other non-current assets	81	84
Total assets	107,436	108,182
Accounts payable	8,717	1,893
Accrued clinical & regulatory	...	1,872
Accrued contract manufacturing cost	...	1,583
Accrued compensation	3,948	807
Accrued research & development-other	...	565
Accrued expenses - Balancing value	5,181	...
Accrued expenses	9,129	4,827
Operating lease liabilities, current portion	331	404
Total current liabilities	18,177	7,124
Operating lease liabilities, less current portion	642	1,059
Performance award	7	29
Total liabilities	18,826	8,212
Common stock	3	3
Additional paid-in capital	307,073	236,693
Retained earnings (accumulated deficit)	(218,474)	(136,683)
Accumulated other comprehensive income (loss)	8	(43)
Total stockholders' equity (deficit)	88,610	99,970
Total Equity	88,610	...

Recent Dividends:

1. **Renoo Pharmaceuticals Inc common.**
No dividends paid.

Annual Dividends:

1. **Renoo Pharmaceuticals Inc common.**
No dividends paid.

RENT THE RUNWAY INC

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2024	2023	2022 (revised)
Marketing	31,200
Subscription & reserve rental revenue	264,900	268,600	185,800
Other revenue	33,300	27,800	17,500
Total revenue, net	298,200	296,400	203,300
Fulfillment expense	...	92,200	61,900
Technology expense	...	55,400	45,300
Marketing expense	...	35,100	26,500
General & administrative expense	101,600	109,000	104,400

Rental product depreciation & revenue share	92,500	84,200	71,700
Other depreciation & amortization expense	14,700	16,400	19,400
Restructuring charges	2,000	2,400	...
Loss on asset impairment related to restructuring	1,100	5,300	...
Total costs & expenses	378,200	400,000	329,200
Operating income (loss)	(80,000)	(103,600)	(125,900)
Interest income (expense), net	(33,700)	(36,800)	(53,000)
Gain (loss) on warrant liability revaluation, net	(24,900)
Gain (loss) on debt extinguishment, net	(12,200)
Other income (expense), net	700	1,500	3,900
Net income (loss) before income tax expense (benefit) - domestic	...	(139,500)	(212,600)
Net income (loss) before income tax expense (benefit) - foreign	...	600	500
Net income (loss) before income tax expense (benefit)	(113,000)	(138,900)	(212,100)
Deferred foreign income taxes (benefit)	...	(200)	(300)
Total deferred income taxes (benefit)	...	(200)	(300)
Income tax expense (benefit)	200	(200)	(300)
Net income (loss)	(113,200)	(138,700)	(211,800)
Weighted average shares outstanding - basic	3,418	3,213	1,244
Weighted average shares outstanding - diluted	3,418	3,213	1,244
Year end shares outstanding	3,546	3,251	3,152
Net income (loss) per share - basic	\$(33.12)	\$(43.20)	\$(170.20)
Net income (loss) per share - diluted	\$(33.12)	\$(43.20)	\$(170.20)
Number of full time employees	938	880	958
Number of part time employees	166	135	138
Number of class A common stockholders	...	177	291
Number of class B common stockholders	...	7	7
Fulfillment	86,000
Technology	49,100
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(33.12)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(33.12)
Common Shareholders - Number	166
Total number of employees	1,104

□ Adjusted for 1-for-20 stock split, April 3, 2024; □ Shares increased due to issuance of stock under incentive plan and as part

of IPO, conversion of redeemable preferred stock, and exercise of warrants; [□] As is; [□] Approximately; [□] As of April 7, 2023; [□] As of April 11, 2022

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2024	2023
Cash & cash equivalents	84,000	154,500
Restricted cash, current	5,200	3,100
Prepaid expenses & other current assets	13,000	14,500
Total current assets	102,200	172,100
Restricted cash	4,800	6,000
Rental product, net	...	78,700
Leasehold improvements	54,500	53,800
Machinery & equipment	46,800	45,900
Reusable packaging	2,900	3,500
Computer hardware	4,500	4,500
Furniture & fixtures	4,000	3,900
Financing lease right-of-use ("ROU") assets	2,600	2,200
Fixed assets, gross	...	113,800
Less accumulated depreciation	79,600	69,100
Fixed assets, net - Balancing value	94,000	...
Fixed assets, net	35,700	44,700
Intangible assets, net	3,400	4,100
Operating lease right-of-use assets	33,900	26,700
Other assets	4,500	3,900
Total assets	278,500	336,200
Accounts payable	5,800	12,400
Accrued operating & general expenses	7,600	6,000
Revenue share payable	6,000	5,300
Accrued interest	21,700	5,100
Accrued payroll related expenses	4,500	4,700
Short-term financing	1,200	...
Sales & other taxes	1,900	2,700
Gift card liability	500	600
Accrued expenses & other current liabilities	...	24,400
Deferred revenue	10,900	12,000
Customer credit liabilities	6,300	6,800
Operating lease liabilities	3,400	4,400
Total current liabilities	48,100	60,000
Facilities	...	271,600
Add: payment-in-kind interest	...	17,800
Less: unamortized debt discount	...	(16,900)
Long-term debt, net	306,700	272,500
Operating lease liabilities	45,300	38,300
Other liabilities	700	700
Total liabilities	400,800	371,500
Class A common stock	3	100
Additional paid-in capital	930,800	904,500
Accumulated deficit	(1,053,100)	...
Retained earnings (accumulated deficit)	...	(939,900)
Class B common stock, \$0001 par value; 50,000,000 shares authorized as of 31, 2022 and 31, 2022; 3,056,086 and 2,932,739 shares issued and outstanding as of 31, 2022 and 31, 2022, respectively	0	...
Total stockholders' equity (deficit)	(122,300)	(35,300)
Total Equity	(122,300)	...

Recent Dividends:

1. Rent The Runway Inc class B common.
No dividends paid.

2. Rent The Runway Inc class A common.

No dividends paid.

Annual Dividends:

1. Rent The Runway Inc class B common.

No dividends paid.

2. Rent The Runway Inc class A common.

No dividends paid.

RESOURCES CONNECTION INC

Earnings, 9 mos. to (Consol. - \$000):

	02/24/24	02/25/23
Total Revenues	484,603	591,194
Cost & expenses	460,632	529,060
Operating income	17,491	55,739
Interest expense	(830)	662
Other income (expense), net	6	381
Net before taxes	18,327	55,458
Income taxes	7,765	12,867
Net income	10,562	42,591
Earnings common share		
Primary	\$0.32	\$1.27
Fully Diluted	\$0.31	\$1.24
Common Shares:		
Full Diluted	33,906	34,245
Year-end	33,808	33,625

RICHARDSON ELECTRONICS LTD

Earnings, 9 mos. to (Consol. - \$000):

	03/02/24	02/25/23
Total Revenues	149,086	...
Net Sales	149,086	203,826
Cost & expenses	148,624	180,235
Operating income	296	23,591
Other income (expense), net	(43)	29
Foreign currency	(305)	...
Net before taxes	296	23,494
Income taxes	116	5,281
Net income	180	18,213
Earnings common share		
Primary	\$0.01	\$1.33
Fully Diluted	\$0.01	\$1.27
Common Shares:		
Full Diluted	14,532	12,524
Year-end	14,279	14,137

RISE GOLD CORP

Earnings, 6 mos. to Jan 31 (Consol. - \$):

	2024	2023
Cost & expenses	2,057,244	1,418,524
Operating income	(1,985,950)	(1,418,524)
Other income (expense), net	89,232	(727,492)
Foreign currency	(7,899)	...
Net income	(1,975,911)	(2,146,016)
Earnings common share		
Primary	\$(0.05)	\$(0.04)
Fully Diluted	\$(0.05)	\$(0.04)
Common Shares:		
Full Diluted	42,499,527	32,837,257
Year-end	45,740,341	37,236,864

ROSS STORES INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	02/03/24	01/28/23	01/29/22
Sales	...	18,695,829	18,916,244
Sales Costs and Expenses	20,376,941
Gross operating revenues	20,376,941
Cost of goods sold	14,801,601	13,946,230	13,708,907
Selling, general & administrative	3,267,677	2,759,268	2,874,469
Interest on long-term debt	...	84,558	88,286
Interest expense on short-term debt	84,596
Other interest expense	1,599	1,668	1,351
Capitalized interest	12,106	5,678	14,476
Interest income	238,207	77,706	833
Interest income (expense), net	164,118	(2,842)	(74,328)
Total costs &			

expenses	17,905,160	16,708,340	16,657,704
Earnings (loss) before taxes	2,471,781	1,987,489	2,258,540
Current federal income taxes expense (benefit)	532,913	338,479	442,152
Current state income taxes expense (benefit)	85,169	57,552	78,024
Total current income taxes expense (benefit)	618,082	396,031	520,176
Deferred federal income taxes expense (benefit)	(16,265)	74,062	21,103
Deferred state income taxes expense (benefit)	(4,556)	5,355	(5,328)
Total deferred income taxes expense (benefit)	(20,821)	79,417	15,775
Provision (benefits) for taxes on earnings	597,261	475,448	535,951
Net earnings (loss)	1,874,520	1,512,041	1,722,589

Weighted average shares outstanding - basic	335,187	343,452	351,496
Weighted average shares outstanding - diluted	337,433	345,222	353,734
Year end shares outstanding	335,172	342,753	351,720
Earnings (loss) per share - continuing operations - basic	\$5.59
Net earnings (loss) per share - basic	\$5.59	\$4.40	\$4.90
Earnings (loss) per share - continuing operations - diluted	\$5.56
Net earnings (loss) per share - diluted	\$5.56	\$4.38	\$4.87
Dividends per common share	\$1.34	\$1.24	\$1.14
Number of full time employees	108,000
Total number of employees	108,000	^{□□} 101,000	^{□□} 100,000
Number of common stockholders	1,234	^{□□} 1,217	^{□□} 1,198

[□] As is; [□] Approximately; [□] As of March 6, 2023; [□] As of March 7, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	02/03/24	01/28/23
Cash & cash equivalents	4,872,446	4,551,876
Accounts receivable	130,766	145,694
Merchandise inventory	2,192,220	2,023,495
Prepaid expenses & other current assets	...	183,654
Prepaid expenses and other	202,706	...
Total current assets	7,398,138	6,904,719
Land & buildings	1,486,557	1,495,006
Fixtures & equipment	4,220,221	3,961,733
Leasehold improvements	1,577,102	1,433,647
Construction-in-progress	628,730	319,319
Property & equipment, gross	7,912,610	7,209,705
Less accumulated depreciation & amortization	4,380,709	4,028,178
Property & equipment, net	3,531,901	3,181,527
Operating lease assets	3,126,841	3,098,134
Deferred compensation	165,582	155,496
Restricted cash & cash equivalents	48,506	47,688
Other long-term assets	29,141	28,899
Other long-term assets	243,229	232,083
Total assets	14,300,109	13,416,463

Accounts payable	1,955,850	2,009,924
Accrued expenses & other current liabilities	...	638,561
Current operating lease liabilities	683,625	655,976
Accrued payroll & benefits	548,371	279,710
Income taxes payable	76,370	52,075
Current portion of long-term debt	249,713	...
Accrued expenses and other	671,867	...
Total current liabilities	4,185,796	3,636,246
Senior notes	...	2,456,510
Long-term debt	2,211,017	2,456,510
Non-current operating lease liabilities	2,603,349	2,593,961
Income taxes	...	57,409
Deferred compensation	...	155,496
Other long-term liabilities	232,383	11,199
Deferred income taxes	196,238	217,059
Common stock	3,352	3,428
Additional paid-in capital	1,952,625	1,820,249
Treasury stock	633,318	584,750
Retained Earnings	3,548,667	...
Retained earnings (accumulated deficit)	...	3,049,656
Total stockholders' equity	4,871,326	4,288,583
Total Equity	4,871,326	...

Recent Dividends:

1. Ross Stores Inc common.

ExDate	Amt	Declared	Record	Payable
03/15/2021	0.28	03/02/2021	03/16/2021	03/31/2021
06/07/2021	0.28	05/19/2021	06/08/2021	06/30/2021
09/03/2021	0.28	08/18/2021	09/07/2021	09/30/2021
12/06/2021	0.28	11/17/2021	12/07/2021	12/31/2021
03/14/2022	0.31	03/01/2022	03/15/2022	03/31/2022
06/06/2022	0.31	05/18/2022	06/07/2022	06/30/2022
09/02/2022	0.31	08/17/2022	09/06/2022	09/30/2022
12/05/2022	0.31	11/16/2022	12/06/2022	12/30/2022
03/13/2023	0.34	02/28/2023	03/14/2023	03/31/2023
06/05/2023	0.34	05/17/2023	06/06/2023	06/30/2023
09/01/2023	0.34	08/16/2023	09/05/2023	09/29/2023
12/04/2023	0.34	11/15/2023	12/05/2023	12/29/2023
03/14/2024	0.37	03/05/2024	03/15/2024	03/29/2024

Annual Dividends:

1. Ross Stores Inc common.

2021	1.14	2022	1.24	2023	1.34
2024	0.37				

ROTH CH ACQUISITION V CO

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
General & administrative expenses	1,764,792	541,229	166,644
Income (loss) from operations	(1,764,792)	(541,229)	(166,644)
Interest earned on marketable securities held in trust account	2,967,733	1,684,555	...
Change in fair value of due to non-redeeming stockholders	(480,000)
Other income	2,487,733	1,684,555	...
Income (loss) before provision for income taxes	722,941	1,143,326	(166,644)
Current federal income tax provision (benefit)	810,659	421,211	...
Deferred federal income tax

provision (benefit)	(456,612)	(75,979)	(34,995)
Deferred state & local income tax provision (benefit)	(151,769)	(36,886)	...
Change in valuation allowance	603,381	112,865	34,995
Income Taxes - Other	5,000
Provision for income taxes	810,659	421,211	...
Net income (loss)	(87,718)	722,115	(166,644)
Accretion of redeemable common stock to redemption amount	...	1,084,374	3,350,220
Net income (loss) including accretion of temporary equity to redemption value	...	(362,259)	(3,516,864)
Weighted average common stock subject to possible redemption shares outstanding - basic	...	11,500,000	882,192
Weighted average non-redeemable common stock shares outstanding - basic	...	3,336,500	2,564,170
Weighted average shares outstanding - basic	9,515,117
Weighted average common stock subject to possible redemption shares outstanding - diluted	...	11,500,000	882,192
Weighted average non-redeemable common stock shares outstanding - diluted	...	3,336,500	2,564,170
Weighted average shares outstanding - diluted	9,515,117
Year end shares outstanding	4,919,297	14,836,500	14,836,500
Net income (loss) per common stock subject to possible redemption share - basic	...	\$0.07	\$2.78
Net income (loss) per non-redeemable common stock share - basic	...	\$(0.02)	\$(1.02)
Net income (loss) per common stock subject to possible redemption share - diluted	...	\$0.07	\$2.78
Net income (loss) per non-redeemable common stock share - diluted	...	\$(0.02)	\$(1.02)
Number of part time employees	...	7	...
Total number of employees	7
Number of common stockholders	15	15	15
EPS - Basic - including Extraordinary Items
Applicable to Common - Total	\$(0.01)
EPS - Diluted - including Extraordinary Items
Applicable to Common - Total	\$(0.01)

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	200,059	687,471
Prepaid expenses	62,174	150,250
Cash & marketable securities held in trust account	16,978,160	118,377,460
Total current assets	17,240,393	119,215,181
Total assets	17,240,393	119,215,181
Accrued expenses	1,099,863	224,719
Income taxes payable	142,500	421,211
Promissory note related party	416,841	...
Excise taxes payable	1,029,003	...
Total current liabilities	2,688,207	645,930
Common stock subject to possible redemption	16,949,887	117,809,374
Common stock	334	334
Additional paid-in capital	...	205,072
Accumulated earnings (deficit)	(2,398,035)	554,471
Total stockholders' equity (deficit)	(2,397,701)	759,877

Recent Dividends:

- 1. Roth CH Acquisition V Co common.**
No dividends paid.
 - 2. Roth CH Acquisition V Co common, subject to possible conversion/tender.**
No dividends paid.
- Annual Dividends:**
- 1. Roth CH Acquisition V Co common.**
No dividends paid.
 - 2. Roth CH Acquisition V Co common, subject to possible conversion/tender.**
No dividends paid.

RUMBLE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Revenues	80,963,451	39,384,284	...
Cost of service (content, hosting & other)	146,156,734	43,745,518	...
General & administrative expenses	37,125,296	16,086,254	2,756,496
Administrative expenses - related party	102,143
Research & development expenses	15,721,663	6,342,851	...
Sales & marketing expenses	13,427,021	6,137,860	...
Amortization & depreciation expenses	4,850,812	1,556,056	...
Franchise tax expense	201,515
Total expenses	216,510,463	74,984,595	...
Income (loss) from operations	(135,547,012)	(35,600,311)	(3,060,154)
Interest income on investments held in trust account	13,594,463	3,019,456	23,016
Changes in fair value of warrant liability	2,365,895	21,010,500	(10,418,045)
Changes in fair value of FPS liability	(4,452,968)
Income (loss) before income taxes	(119,712,165)	(11,619,422)	...
Deferred tax recovery	(3,291,703)
Income tax recovery (expense)	...	(215,428)	...
Income tax

Reclassified to conform with 2022 presentation; As of March 29, 2023; As of March 28, 2022

(recovery) expenses ..	(3,291,703)	(215,428)	...
Net income (loss)	(116,420,462)	(11,403,994)	(17,908,151)
Weighted average shares outstanding - basic	201,442,321	242,443,272	...
Weighted average class A public shares outstanding - basic	25,643,836
Weighted average class A private placement shares outstanding - basic	598,356
Weighted average class B shares outstanding - basic	7,500,000
Weighted average shares outstanding - diluted	201,442,321	242,443,272	...
Weighted average class A public shares outstanding - diluted	25,643,836
Weighted average class A private placement shares outstanding - diluted	598,356
Year end shares outstanding	386,062,724	384,912,380	38,200,000
Earnings (loss) per share - basic	\$(0.58)	\$(0.05)	...
Earnings (loss) per class A public share - basic	\$(0.53)
Earnings (loss) per class A private placement share - basic	\$(0.53)
Earnings per class B common share - basic	\$(0.53)
Earnings (loss) per share - diluted	\$(0.58)	\$(0.05)	...
Earnings (loss) per class A public share - diluted	\$(0.53)
Earnings (loss) per class A private placement share - diluted	\$(0.53)
Earnings per class B common share - diluted	\$(0.53)
Number of full time employees	158
Total number of employees	158	...	3
Number of units stockholder	2
Number of class A common stockholders	1
Number of class B common stockholders	115	...	3
Number of warrants stockholders	1
Other income (expense)	(125,511)	(49,067)	...
Acquisition-related transaction costs	1,151,318	1,116,056	...
Changes in fair value of contingent consideration	1,922,381
Depreciation of capital assets	987,014	...
Amortization of intangible assets	569,042	...

□ Restated to reflect correction of errors; □ 2021 & prior financials for the company prior to reverse recapitalization with CF

Acquisition Corp. VI ("CFVI")

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
		(revised)
Cash & cash equivalents	218,338,658	337,169,279
Marketable securities	1,135,200	1,100,000
Accounts receivable, net	5,440,447	4,748,189
Prepaid expenses & other current assets	9,342,691
Prepaid expenses and other	13,090,072	...
Total current assets	238,004,377	352,360,159
Prepaid expenses & other, long term	547,589
Computer hardware	21,969,345	8,866,157
Furniture & fixtures	121,077	100,921
Leasehold improvements	1,911,901	921,570
Capital asset, gross	24,002,323	9,888,648
Accumulated depreciation	4,312,336	1,044,416
Capital assets	19,689,987	8,844,232
Right-of-use assets - Gross	3,833,184	...
Accumulated Depreciation of Right-of-use assets	1,359,281	...
Right-of-use assets	2,473,903	1,356,454
Intangibles assets	23,262,428	3,211,305
Goodwill	10,655,391	662,899
Other non-current assets	1,626,802	...
Total assets	295,712,888	366,982,638
Accounts payable & accrued liabilities	24,713,203	14,324,696
Deferred revenue	7,003,891	1,040,619
Lease liabilities	975,844	583,186
Income taxes payable	934
Accrued expenses	0
Contingent consideration	863,643	...
Total current liabilities	33,556,581	15,949,435
Warrant liability	10,062,500
Lease liabilities, long-term	1,630,837	835,924
FPS liability	7,696,605	...
Other liability	500,000	500,000
Contingent consideration, net of current portion	705,717	...
Total liabilities	44,089,740	27,347,859
Class A common stock subject to possible redemption	0
Common shares	768,523	768,357
Retained earnings (deficit)	(145,203,163)	(28,782,701)
Additional paid-in capital	396,057,788	367,649,123
Total stockholder's equity (deficit)	251,623,148	339,634,779
Total Equity	251,623,148	...

Recent Dividends:

1. Rumble Inc class A common subject to possible redemption. No dividends paid.

2. Rumble Inc class A common. No dividends paid.

3. Rumble Inc class A common (new). No dividends paid.

4. Rumble Inc class D common. No dividends paid.

5. Rumble Inc class C common. No dividends paid.

6. Rumble Inc class B common. No dividends paid.

Annual Dividends: 1. Rumble Inc class A common subject to possible redemption. No dividends paid.

2. Rumble Inc class A common. No dividends paid.

3. Rumble Inc class A common (new). No dividends paid.

4. Rumble Inc class D common. No dividends paid.

5. Rumble Inc class C common. No dividends paid.

6. Rumble Inc class B common. No dividends paid.

6. Rumble Inc class B common.

No dividends paid.

SAB BIOTHERAPEUTICS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021
			(revised)
Grant revenue	23,904,181	60,876,078
Total revenue	2,238,991	23,904,181	60,876,078
Research & development	16,515,005	36,438,513	57,183,589
General & administrative	23,799,306	16,383,285	17,085,692
Total operating expenses	40,314,311	52,821,798	74,269,281
Income (loss) from operations	(38,075,320)	(28,917,617)	(13,393,203)
Changes in fair value of warrant liabilities	(4,823,237)	10,399,200	(4,151,068)
Gain on debt extinguishment of paycheck protection program SBA loan	665,596
Other income	435,089	33,754	5,488
Interest expense	315,284	301,584	294,459
Interest income	584,966	71,072	23,115
Total other income (expense)	(4,118,466)	10,202,442	(3,751,328)
Income (loss) before income taxes ..	(42,193,786)	(18,715,175)	(17,144,531)
Income tax expense (benefit)	25,629	...
Net income (loss)	(42,193,786)	(18,740,804)	(17,144,531)
Net income (loss) per share attributable to the Company's shareholders	(18,740,804)	(17,144,531)
Weighted average shares outstanding - basic	5,521,487	□4,352,497	2,733,918
Weighted average shares outstanding - diluted	5,521,487	□4,352,497	2,733,918
Year end shares outstanding	9,225,494	□5,039,426	4,348,728
Net earnings (loss) per common share - basic	\$(7.64)	□\$(4.30)	\$(6.30)
Net earnings (loss) per common share - diluted	\$(7.64)	□\$(4.30)	\$(6.30)
Number of full time employees	57	56	139
Total number of employees	57
Number of common stockholders	260	□246	□202
SubTotal	2,238,991

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1- for -10 stock split, January 5, 2024; □ As of March 28, 2023; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	56,566,066	15,046,894
Accounts receivable, net	5,556,577
Prepaid expenses and other current assets	2,340,797	...
Prepaid expenses	1,493,982
Total current assets	58,906,863	22,097,453
Long-term prepaid insurance	350,230	467,694
Operating lease right-of-use assets	1,277,982	1,192,054
Financing lease right-of-use assets	3,669,659	3,896,873
Laboratory equipment	9,415,210	9,000,114
Animal facility	8,357,667	8,357,667
Animal facility equipment	1,137,666	1,141,213

Construction-in-progress	308,317	
Leasehold improvements	9,296,344	9,296,343
Vehicles	192,683	
Office furniture & equipment	1,233,038	1,233,038
Less: accumulated depreciation & amortization	9,911,859	6,278,522
Property, Plant & Equipment - Gross - Total	208,453	
Property, Plant & Equipment - Gross - Total	29,648,378	
Equipment, net	19,736,519	23,250,853
Total assets	83,941,253	50,904,927
Accounts payable	945,927	3,679,116
Notes payable - current portion		772,665
Operating lease liabilities, current portion	669,946	490,794
Finance lease liabilities, current portion	132,004	132,788
Deferred grant income	1,322,410	
Accrued vacation	656,132	511,849
Accrued payroll	412,943	357,390
Accrued construction-in-progress		85,767
Accrued consulting		186,833
Accrued clinical trial expense		355,479
Accrued outside laboratory services		1,106,903
Accrued bonus & severance		950,324
Accrued contract manufacturing		25,129
Accrued legal		856,505
Accrued financing fees payable		4,910,500
Accrued franchise tax payable	40,000	50,000
Accrued interest	77,995	8,192
Other accrued expenses	149,924	513,110
Accrued expenses & other current liabilities	5,355,187	9,917,981
Notes payable	1,050,849	
Accrued expenses and other current liabilities - Balancing value	6,692,181	
Total current liabilities	10,813,317	14,993,344
Operating lease liabilities, noncurrent	635,777	361,225
Finance lease liabilities, noncurrent	3,418,483	3,629,642
Warrant liabilities	11,774,235	320,930
Convertible debt		541,644
Total liabilities	26,641,812	19,846,785
Common stock	929	5,094
Treasury stock, at cost	5,521,246	5,521,246
Additional paid-in capital	152,856,874	84,444,049
Retained earnings (accumulated deficit)	(90,063,541)	(47,869,755)
Preferred Stock	5	
Comprehensive Income - Accumulated	26,420	
Total stockholders' equity (deficit)	57,299,441	31,058,142
Total Equity	57,299,441	

Recent Dividends:
1. SAB Biotherapeutics Inc common.
 No dividends paid.
Annual Dividends:
1. SAB Biotherapeutics Inc common.
 No dividends paid.

SAGA COMMUNICATIONS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Net operating revenue	112,773	114,893	108,343
Station operating expense	90,199	87,537	83,245
Corporate general & administrative expense	10,966	14,300	10,040
Other operating expense (income), net	120	(14)	7
Total operating expenses	111,285	101,823	93,292
Operating income (loss)	1,488	13,070	15,051
Interest expense	173	130	284
Interest income	1,441	410	16
Other income (expense)	119	652	634
Income (loss) before income tax expense (benefit)	12,875	14,002	15,417
Current federal income tax provision (benefit)	2,240	2,800	3,080
Current state income tax provision (benefit)	750	1,065	985
Income tax provision (benefit) - current	2,990	3,865	4,065
Income tax provision (benefit) - deferred	385	935	195
Net income	9,500	9,202	11,157
Income tax provision (benefit) available to common stockholders	9,351	9,062	10,967
Weighted average shares outstanding - basic	6,045	5,973	5,917
Weighted average shares outstanding - diluted	6,045	5,973	5,917
Year end shares outstanding	6,253	6,113	6,042
Earning (loss) per share from continuing operations - basic	\$1.55		
Earnings (loss) per share - basic	\$1.55	\$1.52	\$1.85
Earning (loss) per share from continuing operations - diluted	\$1.55		
Earnings (loss) per share - diluted	\$1.55	\$1.52	\$1.85
Special DPS - by Period End Date - Gross	\$2.00		
Common DPS - by Period End Date - Gross	\$1.00		
Dividends declared per share		\$4.86	\$0.98
Number of full time employees	589	585	570
Number of part time employees	244	225	227
Total number of employees	833		
Number of class A common stockholders	168	174	166

Net operating revenue	112,773	114,893	108,343
Station operating expense	90,199	87,537	83,245
Corporate general & administrative expense	10,966	14,300	10,040
Other operating expense (income), net	120	(14)	7
Total operating expenses	111,285	101,823	93,292
Operating income (loss)	1,488	13,070	15,051
Interest expense	173	130	284
Interest income	1,441	410	16
Other income (expense)	119	652	634
Income (loss) before income tax expense (benefit)	12,875	14,002	15,417
Current federal income tax provision (benefit)	2,240	2,800	3,080
Current state income tax provision (benefit)	750	1,065	985
Income tax provision (benefit) - current	2,990	3,865	4,065
Income tax provision (benefit) - deferred	385	935	195
Net income	9,500	9,202	11,157
Income tax provision (benefit) available to common stockholders	9,351	9,062	10,967
Weighted average shares outstanding - basic	6,045	5,973	5,917
Weighted average shares outstanding - diluted	6,045	5,973	5,917
Year end shares outstanding	6,253	6,113	6,042
Earning (loss) per share from continuing operations - basic	\$1.55		
Earnings (loss) per share - basic	\$1.55	\$1.52	\$1.85
Earning (loss) per share from continuing operations - diluted	\$1.55		
Earnings (loss) per share - diluted	\$1.55	\$1.52	\$1.85
Special DPS - by Period End Date - Gross	\$2.00		
Common DPS - by Period End Date - Gross	\$1.00		
Dividends declared per share		\$4.86	\$0.98
Number of full time employees	589	585	570
Number of part time employees	244	225	227
Total number of employees	833		
Number of class A common stockholders	168	174	166

Number of class B common stockholders □□1
 □ As is; □ Approximately; □ As of March 3, 2023; □ As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	29,582	36,802
Short-term investments	10,595	10,123
Accounts receivable, gross	17,791	17,959
Less: allowance	618	519
Accounts receivable, less allowance	17,173	
Accounts receivable		17,440
Prepaid expenses & other current assets	2,451	2,479
Barter transactions	843	1,015
Total current assets	60,644	67,859
Land & land improvements	15,239	15,259
Buildings	40,460	40,823
Towers & antennae	148,265	26,992
Equipment	54,747	52,459
Furniture, fixtures & leasehold improvements	7,907	7,741
Vehicles	2,767	2,780
Towers and Antennas	27,145	
Property & equipment		146,054
Less accumulated depreciation	96,860	92,856
Net property & equipment	51,405	53,198
Broadcast licenses, net	90,240	90,307
Goodwill	19,236	19,236
Other intangibles, right of use assets, deferred costs & investments, net	10,688	10,153
Total assets	232,213	240,753
Accounts payable	2,802	2,654
Accrued payroll & payroll taxes	5,318	5,623
Dividend payable	12,505	13,754
Other accrued expenses	6,480	6,359
Barter transactions	924	987
Total current liabilities	28,029	29,377
Deferred income taxes	26,122	25,737
Other liabilities	7,513	7,110
Total liabilities	61,664	62,224
Class A common stock	80	78
Additional paid-in capital	72,593	71,664
Retained earnings	134,771	
Retained earnings (accumulated deficit)		143,896
Treasury stock	36,895	37,109
Total shareholders' equity	170,549	178,529
Total Equity	170,549	

□ Net of accumulated amortization - other intangibles, right of use assets, deferred costs & investments: \$15,944,000

Recent Dividends:
1. Saga Communications Inc class A common.
 No dividends paid.
2. Saga Communications Inc class B common.
 No dividends paid.
Annual Dividends:
1. Saga Communications Inc class A common.
 No dividends paid.
2. Saga Communications Inc class B common.
 No dividends paid.

SAKER AVIATION SERVICES, INC.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
REVENUE	8,837,614		
Revenue	8,837,614	7,598,597	2,400,316
Cost of revenue	2,556,394	2,985,281	575,362
Gross profit (loss)	6,281,220	4,613,316	1,824,954
Selling, general & administrative			

expenses	2,768,310	3,880,902	1,384,408	equipment	424,242	413,574	fair value adjustment	(3,166)	22,301	30,365																																																																																										
Operating income (loss)	3,512,910	732,414	440,546	Leasehold improvements	2,753,074	2,740,750	Derivative liability fair value adjustment	(154)	1,316	1,170																																																																																										
Bad debt recovery	(212,000)	(125,000)	...	Property & equipment, gross	3,177,316	3,154,324	Total other income (expense)	(5,490)	18,248	24,884																																																																																										
Life insurance proceeds, former president	...	500,000	...	Less: accumulated depreciation & amortization	3,127,876	3,111,462	Income (loss) before taxes	67,179	(67,509)	(35,954)																																																																																										
Gain on extinguishment of debt - PPP loan	304,833	Property & equipment, net	49,440	42,862	Income Taxes -US	138																																																																																										
Interest income	220,098	3,302	3,780	Total assets	10,610,638	6,912,925	Current income tax expense (benefit) - U.S.	...	(4,700)	(4,188)																																																																																										
REALIZED GAIN ON INVESTMENTS	8,479	Accounts payable & accrued expenses	705,133	...	Current income tax expense - Non-U.S.	1,100																																																																																										
Total other income (expense)	440,577	628,302	308,613	Total current liabilities	2,291,671	1,130,400	Total current income taxes	...	(4,700)	(3,088)																																																																																										
Income tax expense (benefit)	1,507,043	300,000	150,000	Total liabilities	2,291,671	1,130,400	Income tax expense (benefit)	138	(4,700)	(3,088)																																																																																										
Income (loss) from discontinued operations	...	(65,413)	179,125	Common stock	29,577	29,290	Net income (loss)	67,041	(62,809)	(32,866)																																																																																										
Gain on sale of assets from discontinued operations	...	431,318	...	Additional paid-in capital	19,902,505	19,812,794	Weighted average shares outstanding - basic	47,853	42,614	26,385																																																																																										
Income tax expense	...	(180,000)	(52,100)	Accumulated deficit	(11,613,115)	...	Weighted average shares outstanding - diluted	48,391	42,614	26,385																																																																																										
Income from discontinued operations, net of income taxes	...	185,905	127,025	Retained earnings (accumulated deficit)	...	(14,059,559)	Year end shares outstanding	37,208	32,682	28,705																																																																																										
Net income (loss)	2,446,444	1,246,621	726,184	Total stockholders' equity (deficit)	8,318,967	5,782,525	Net earnings (loss) per share from continuing operations - basic	\$1.40																																																																																										
Weighted average shares outstanding - basic	976,782	976,048	1,023,709	Total equity	8,318,967	...	Net earnings (loss) per share - basic	\$1.40	\$(1.47)	\$(1.25)																																																																																										
Weighted average shares outstanding - diluted	989,686	987,149	1,026,729				Net earnings (loss) per share from continuing operations - diluted	\$1.39																																																																																										
Year end shares outstanding	985,888	976,330	975,074				Net earnings (loss) per share - diluted	\$1.39	\$(1.47)	\$(1.25)																																																																																										
Income (loss) per share from continuing operations - basic	\$2.50				Number of full time employees	36	56	56																																																																																										
Income (loss) per share from total discontinued operations - basic	\$0.00				Number of common stockholders	43	50	51																																																																																										
Net income (loss) per share - basic	\$2.50	\$1.28	\$0.71																																																																																																	
Income (loss) per share from continuing operations - diluted	\$2.47																																																																																																	
Income (loss) per share from total discontinued operations - diluted	\$0.00																																																																																																	
Net income (loss) per share - diluted	\$2.47	\$1.26	\$0.71																																																																																																	
Number of full time employees	11	12	...																																																																																																	
Number of part time employees	...	1	...																																																																																																	
Total number of employees	11	13	...																																																																																																	
Number of common stockholders	475	156	...																																																																																																	
<p>¹ Restated to reflect the discontinued operation of FBO Air Garden City, Inc.; ² Approximately; ³ As of March 31, 2023</p> <p>Consolidated Balance Sheet, Years Ended Dec. 31 (\$):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> </tr> </thead> <tbody> <tr> <td>Cash & restricted cash</td> <td>6,931,709</td> <td>5,977,157</td> </tr> <tr> <td>Accounts receivable</td> <td>294,521</td> <td>244,543</td> </tr> <tr> <td>Non-compete receivable</td> <td>...</td> <td>160,000</td> </tr> <tr> <td>Other inventory</td> <td>1,142</td> <td>...</td> </tr> <tr> <td>Inventories</td> <td>...</td> <td>13,551</td> </tr> <tr> <td>Income tax receivable</td> <td>44,899</td> <td>119,899</td> </tr> <tr> <td>Prepaid expenses</td> <td>745,606</td> <td>354,913</td> </tr> <tr> <td>Investments</td> <td>2,543,321</td> <td>...</td> </tr> <tr> <td>Total current assets</td> <td>10,561,198</td> <td>6,870,063</td> </tr> </tbody> </table>					2023	2022	Cash & restricted cash	6,931,709	5,977,157	Accounts receivable	294,521	244,543	Non-compete receivable	...	160,000	Other inventory	1,142	...	Inventories	...	13,551	Income tax receivable	44,899	119,899	Prepaid expenses	745,606	354,913	Investments	2,543,321	...	Total current assets	10,561,198	6,870,063	<p>SCYNEXT, INC.</p> <p>Annual Report</p> <p>Consolidated Income Statement, Years Ended Dec. 31 (\$000):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> <th>2021 (revised)</th> </tr> </thead> <tbody> <tr> <td>Product revenue, net</td> <td>1,044</td> <td>4,988</td> <td>1,113</td> </tr> <tr> <td>License agreement revenue</td> <td>139,097</td> <td>103</td> <td>12,050</td> </tr> <tr> <td>Total revenue</td> <td>140,141</td> <td>5,091</td> <td>13,163</td> </tr> <tr> <td>Cost of product revenue</td> <td>15,624</td> <td>628</td> <td>312</td> </tr> <tr> <td>Research & development</td> <td>30,928</td> <td>27,259</td> <td>23,773</td> </tr> <tr> <td>Selling, general & administrative</td> <td>20,920</td> <td>62,961</td> <td>49,916</td> </tr> <tr> <td>Total operating expenses</td> <td>67,472</td> <td>90,848</td> <td>74,001</td> </tr> <tr> <td>Income (loss) from operations</td> <td>72,669</td> <td>(85,757)</td> <td>(60,838)</td> </tr> <tr> <td>Gain (loss) on extinguishment of debt</td> <td>...</td> <td>...</td> <td>(2,725)</td> </tr> <tr> <td>Amortization of debt issuance costs & discount</td> <td>2,994</td> <td>1,589</td> <td>1,303</td> </tr> <tr> <td>Interest income</td> <td>3,954</td> <td>1,415</td> <td>24</td> </tr> <tr> <td>Interest expense</td> <td>3,130</td> <td>5,198</td> <td>2,660</td> </tr> <tr> <td>Other income</td> <td>...</td> <td>3</td> <td>13</td> </tr> <tr> <td>Warrant liabilities</td> <td>...</td> <td>...</td> <td>...</td> </tr> </tbody> </table>								2023	2022	2021 (revised)	Product revenue, net	1,044	4,988	1,113	License agreement revenue	139,097	103	12,050	Total revenue	140,141	5,091	13,163	Cost of product revenue	15,624	628	312	Research & development	30,928	27,259	23,773	Selling, general & administrative	20,920	62,961	49,916	Total operating expenses	67,472	90,848	74,001	Income (loss) from operations	72,669	(85,757)	(60,838)	Gain (loss) on extinguishment of debt	(2,725)	Amortization of debt issuance costs & discount	2,994	1,589	1,303	Interest income	3,954	1,415	24	Interest expense	3,130	5,198	2,660	Other income	...	3	13	Warrant liabilities
	2023	2022																																																																																																		
Cash & restricted cash	6,931,709	5,977,157																																																																																																		
Accounts receivable	294,521	244,543																																																																																																		
Non-compete receivable	...	160,000																																																																																																		
Other inventory	1,142	...																																																																																																		
Inventories	...	13,551																																																																																																		
Income tax receivable	44,899	119,899																																																																																																		
Prepaid expenses	745,606	354,913																																																																																																		
Investments	2,543,321	...																																																																																																		
Total current assets	10,561,198	6,870,063																																																																																																		
	2023	2022	2021 (revised)																																																																																																	
Product revenue, net	1,044	4,988	1,113																																																																																																	
License agreement revenue	139,097	103	12,050																																																																																																	
Total revenue	140,141	5,091	13,163																																																																																																	
Cost of product revenue	15,624	628	312																																																																																																	
Research & development	30,928	27,259	23,773																																																																																																	
Selling, general & administrative	20,920	62,961	49,916																																																																																																	
Total operating expenses	67,472	90,848	74,001																																																																																																	
Income (loss) from operations	72,669	(85,757)	(60,838)																																																																																																	
Gain (loss) on extinguishment of debt	(2,725)																																																																																																	
Amortization of debt issuance costs & discount	2,994	1,589	1,303																																																																																																	
Interest income	3,954	1,415	24																																																																																																	
Interest expense	3,130	5,198	2,660																																																																																																	
Other income	...	3	13																																																																																																	
Warrant liabilities																																																																																																	
				<p>Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> </tr> </thead> <tbody> <tr> <td>Cash & cash equivalents</td> <td>34,050</td> <td>45,814</td> </tr> <tr> <td>Short-term investments</td> <td>40,312</td> <td>27,689</td> </tr> <tr> <td>Prepaid research & development services</td> <td>196</td> <td>635</td> </tr> <tr> <td>Prepaid insurance</td> <td>264</td> <td>622</td> </tr> <tr> <td>Other prepaid expenses</td> <td>182</td> <td>1,184</td> </tr> <tr> <td>Other current assets</td> <td>4,906</td> <td>62</td> </tr> <tr> <td>Accounts receivable, net</td> <td>...</td> <td>2,101</td> </tr> <tr> <td>Inventory, net</td> <td>...</td> <td>899</td> </tr> <tr> <td>Restricted cash</td> <td>380</td> <td>55</td> </tr> <tr> <td>License agreement receivable</td> <td>2,463</td> <td>...</td> </tr> <tr> <td>Prepaid expenses and other current assets</td> <td>5,548</td> <td>...</td> </tr> <tr> <td>Total current assets</td> <td>102,116</td> <td>79,061</td> </tr> <tr> <td>Other assets</td> <td>...</td> <td>5,511</td> </tr> <tr> <td>Deferred offering costs</td> <td>175</td> <td>73</td> </tr> <tr> <td>Restricted cash</td> <td>163</td> <td>163</td> </tr> <tr> <td>Intangible assets, net</td> <td>...</td> <td>408</td> </tr> <tr> <td>Operating lease right-of-use asset</td> <td>2,364</td> <td>2,594</td> </tr> <tr> <td>Investments</td> <td>23,594</td> <td>...</td> </tr> <tr> <td>Total assets</td> <td>128,412</td> <td>87,810</td> </tr> <tr> <td>Accounts payable</td> <td>7,149</td> <td>5,937</td> </tr> <tr> <td>Accrued research & development expenses</td> <td>2,830</td> <td>786</td> </tr> <tr> <td>Accrued employee bonus compensation</td> <td>1,692</td> <td>1,628</td> </tr> <tr> <td>Other accrued expenses</td> <td>940</td> <td>1,313</td> </tr> </tbody> </table>								2023	2022	Cash & cash equivalents	34,050	45,814	Short-term investments	40,312	27,689	Prepaid research & development services	196	635	Prepaid insurance	264	622	Other prepaid expenses	182	1,184	Other current assets	4,906	62	Accounts receivable, net	...	2,101	Inventory, net	...	899	Restricted cash	380	55	License agreement receivable	2,463	...	Prepaid expenses and other current assets	5,548	...	Total current assets	102,116	79,061	Other assets	...	5,511	Deferred offering costs	175	73	Restricted cash	163	163	Intangible assets, net	...	408	Operating lease right-of-use asset	2,364	2,594	Investments	23,594	...	Total assets	128,412	87,810	Accounts payable	7,149	5,937	Accrued research & development expenses	2,830	786	Accrued employee bonus compensation	1,692	1,628	Other accrued expenses	940	1,313																		
	2023	2022																																																																																																		
Cash & cash equivalents	34,050	45,814																																																																																																		
Short-term investments	40,312	27,689																																																																																																		
Prepaid research & development services	196	635																																																																																																		
Prepaid insurance	264	622																																																																																																		
Other prepaid expenses	182	1,184																																																																																																		
Other current assets	4,906	62																																																																																																		
Accounts receivable, net	...	2,101																																																																																																		
Inventory, net	...	899																																																																																																		
Restricted cash	380	55																																																																																																		
License agreement receivable	2,463	...																																																																																																		
Prepaid expenses and other current assets	5,548	...																																																																																																		
Total current assets	102,116	79,061																																																																																																		
Other assets	...	5,511																																																																																																		
Deferred offering costs	175	73																																																																																																		
Restricted cash	163	163																																																																																																		
Intangible assets, net	...	408																																																																																																		
Operating lease right-of-use asset	2,364	2,594																																																																																																		
Investments	23,594	...																																																																																																		
Total assets	128,412	87,810																																																																																																		
Accounts payable	7,149	5,937																																																																																																		
Accrued research & development expenses	2,830	786																																																																																																		
Accrued employee bonus compensation	1,692	1,628																																																																																																		
Other accrued expenses	940	1,313																																																																																																		

Accrued severance	688	Interest income	3,051	5,801	1,469	adjustments	499	...
Accrued co-pay rebates	595	Gain (loss) on				Comprehensive			
Accrued other rebates	618	written-down of fixed				(loss) income			
Accrued expenses -			assets	3,929	attributable to			
Balancing value	2,033	...	Interest expense	94,233	common stockholders (1,098,383)
Other liabilities,			Non-operating				Amortization of			
current portion	130	5,771	expense, net	542	1,331	989	debt discount and			
Deferred revenue, current			Income (loss)				issuance costs	7,320
portion	1,189	...	before income taxes				Write-off of			
Operating lease			- domestic	(59,961)	(16,593)	deferred financing			
liability, current			Income before				costs and debt			
portion	340	282	income taxes -				discount	4,446
Total current liabilities	16,303	17,618	foreign	138,428	155,662				
Other liabilities	21,680	...	Income (loss)							
Deferred revenue,			before taxes &							
non-current	2,727	...	equity in net gains							
Warrant liabilities	18,644	(losses) of equity							
Convertible debt &			method investments ..	(1,041,555)	78,467	139,069				
derivative liability	12,159	11,001	Federal income tax							
Loan payable	34,393	provision (benefit)							
Operating lease liability			- current	1,758	8,291	1,078	Cash & cash equivalents	128,585	235,510	
.....	2,581	2,921	State income tax				Accounts receivable,			
Total liabilities	55,450	84,577	provision - current ...	1	17	211	gross	138,483	165,576	
Common stock	40	36	Foreign income tax				Less: allowances	4,161	3,881	
Additional paid-in			provision - current ...	8,750	24,231	16,374	Accounts receivable, net	134,322	161,695	
capital	428,169	425,485	Total income tax				Raw materials	46,425	...	
Retained earnings			provision - current ...	10,509	32,539	17,663	Raw materials &			
(accumulated deficit)	(355,247)	(422,288)	Federal income tax				electronic components	76,919	
Total stockholders'			provision (benefit)				Work in progress	69,404	88,764	
equity (deficit)	72,962	3,233	- deferred	50,938	(23,730)	(1,797)	Finished goods	29,163	42,021	
Total Equity	72,962	...	State income tax				Inventories	144,992	207,704	
			provision (benefit)				Prepaid taxes	11,969	6,243	
			- deferred	51	(28)	...	Other current assets	114,329	111,634	
			Foreign income tax				Total current assets	534,197	722,786	
			provision (benefit)				Land	13,577	13,577	
			- deferred	(10,979)	8,563	(327)	Buildings	49,897	46,596	
			Total income tax				Leasehold improvements	13,742	13,980	
			provision (benefit)				Machinery & equipment	271,215	250,838	
			- deferred	40,010	(15,195)	(2,124)	Computer hardware &			
			Provision for				software	75,224	
			income taxes				Furniture & office			
			(benefit)	50,519	17,344	15,539	equipment	7,753	8,174	
			Net income before				Construction in progress	4,676	18,882	
			equity in net gains				Computer Software &			
			(losses) of equity				Equipment - Tangible			
			method investments ..	(1,092,074)	61,123	123,530	Assets - Gross	76,483	...	
			Equity in net gains				Property, plant &			
			(losses) of equity				equipment, gross	437,343	427,271	
			method investments ..	45	249	2,115	Less: accumulated			
			Net income (loss) ...	(1,092,029)	61,372	125,645	depreciation &			
			Net loss				amortization	283,725	257,978	
			attributable to				Property, plant &			
			noncontrolling				equipment, net	153,618	169,293	
			interest	(1)	8	19	Deferred tax assets	18,014	63,783	
			Net income				Goodwill	541,227	1,281,703	
			attributable to				Other intangible assets,			
			common stockholders	(1,092,030)	61,380	125,664	net	35,566	215,102	
			Weighted average				Other assets	91,113	116,961	
			shares outstanding				Total assets	1,373,735	2,569,628	
			- basic	64,127	63,770	64,662	Accounts payable	45,051	100,676	
			Weighted average				Accrued warranty			
			shares outstanding				allowance	172,105	...	
			- diluted	64,127	64,013	65,565	Accrued compensation	21,456	69,654	
			Year end shares				Deferred revenue	19,092	26,775	
			outstanding	64,416	63,871	64,099	Refund liabilities	32,527	
			Earnings per share				Lease liabilities	6,560	6,209	
			from continuing				Deferred compensation	28,756	4,714	
			operations - basic	\$(17.03)	Accrued professional fees	6,095	11,452	
			Net earnings (loss)				Inventory commitment			
			per share - basic	\$(17.03)	\$0.96	\$1.94	reserve	12,637	
			Earnings per share				Accrued R&D expenses	1,924	6,806	
			- continuing				Accrued inventory	12,894	6,700	
			operations -				Accrued royalties	23,488	
			diluted	\$(17.03)	Income taxes payable	8,522	
			Net earnings (loss)				Accrued environment			
			per share - diluted	\$(17.03)	\$0.96	\$1.92	reserve	541	1,152	
			Number of full time				Accrued taxes	2,924	...	
			employees	1,917	2,248	2,439	Accrued restructuring	4,039	
			Total number of				Other accrued liabilities	38,400	
			employees	1,917	Current portion of			
			Number of common				long-term debt	43,104	
			stockholders	171	171	165	Accrued Expense-other	39,053	...	
			Foreign currency				Accrued Liabilities -			
			translation				Balancing value	10,552	...	
							Deferred compensation	7,412	...	
							Royalties	8,569	...	

^[1] Reclassified to conform with 2022 presentation; ^[2] As is; ^[3] As of March 24, 2023; ^[4] As of March 11, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	01/28/24	01/29/23	01/30/22 (revised)						
Cash & cash equivalents	128,585	235,510							
Accounts receivable, gross	138,483	165,576							
Less: allowances	4,161	3,881							
Accounts receivable, net	134,322	161,695							
Raw materials	46,425	...							
Raw materials & electronic components	76,919							
Work in progress	69,404	88,764							
Finished goods	29,163	42,021							
Inventories	144,992	207,704							
Prepaid taxes	11,969	6,243							
Other current assets	114,329	111,634							
Total current assets	534,197	722,786							
Land	13,577	13,577							
Buildings	49,897	46,596							
Leasehold improvements	13,742	13,980							
Machinery & equipment	271,215	250,838							
Computer hardware & software	75,224							
Furniture & office equipment	7,753	8,174							
Construction in progress	4,676	18,882							
Computer Software & Equipment - Tangible Assets - Gross	76,483	...							
Property, plant & equipment, gross	437,343	427,271							
Less: accumulated depreciation & amortization	283,725	257,978							
Property, plant & equipment, net	153,618	169,293							
Deferred tax assets	18,014	63,783							
Goodwill	541,227	1,281,703							
Other intangible assets, net	35,566	215,102							
Other assets	91,113	116,961							
Total assets	1,373,735	2,569,628							
Accounts payable	45,051	100,676							
Accrued warranty allowance	172,105	...							
Accrued compensation	21,456	69,654							
Deferred revenue	19,092	26,775							
Refund liabilities	32,527							
Lease liabilities	6,560	6,209							
Deferred compensation	28,756	4,714							
Accrued professional fees	6,095	11,452							
Inventory commitment reserve	12,637							
Accrued R&D expenses	1,924	6,806							
Accrued inventory	12,894	6,700							
Accrued royalties	23,488							
Income taxes payable	8,522							
Accrued environment reserve	541	1,152							
Accrued taxes	2,924	...							
Accrued restructuring	4,039							
Other accrued liabilities	38,400							
Current portion of long-term debt	43,104							
Accrued Expense-other	39,053	...							
Accrued Liabilities - Balancing value	10,552	...							
Deferred compensation	7,412	...							
Royalties	8,569	...							

Restructuring	6,277	...
Total current liabilities	217,156	396,855
Deferred tax liabilities	829	5,065
Revolving loans	...	150,000
Term loans	...	895,000
Senior notes	1,371,039	319,500
Total debt	...	1,364,500
Current portion	...	(43,104)
Debt issuance costs	...	(24,430)
Long term debt, less current portion	...	1,296,966
Other long-term liabilities	91,961	114,707
Common stock	785	785
Treasury stock, at cost	556,888	577,907
Additional paid-in capital	485,452	471,374
Retained earnings (accumulated deficit)	(233,790)	858,240
Defined benefit plan	(1,120)	(221)
Foreign currency hedge	81	558
Interest rate hedge	5,571	(286)
Available-for-sale securities	2,527	2,527
Currency translation adjustment	(10,052)	782
Accumulated other comprehensive income (loss)	(2,993)	3,360
Total stockholders' equity	(307,434)	755,852
Noncontrolling interest	184	183
Total equity	(307,250)	756,035

Recent Dividends:**1. Semtech Corp. common.**

No dividends paid.

Annual Dividends:**1. Semtech Corp. common.**

No dividends paid.

SHARECARE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
			(revised)
Revenue	445,251,000
Revenues	445,251,000	442,415,000	412,815,000
Costs of revenue (exclusive of depreciation & amortization below)	254,545,000	238,293,000	203,218,000
Sales & marketing	57,420,000	55,870,000	51,407,000
Product & technology	70,046,000	70,527,000	74,438,000
General & administrative expenses	138,008,000	171,811,000	136,594,000
Depreciation & amortization	61,207,000	45,256,000	32,601,000
Total costs & operating expenses	(581,226,000)	581,757,000	498,258,000
Income (loss) from operations	(135,975,000)	(139,342,000)	(85,443,000)
Interest income	...	1,867,000	96,000
Interest expense	1,760,000	2,431,000	27,662,000
Loss on extinguishment of debt	(1,148,000)
Other income (expense)	1,218,000	20,215,000	27,007,000
Other income - interest earned on trust account	6,296,000
Re-measurement of contingent consideration	1,484,000
Re-measurement of warrant liabilities	2,037,000
Other income (expense) - Balancing value	(2,303,000)
Total other income (expense)	5,754,000	19,651,000	(1,707,000)

Income before income taxes - Domestic	...	(120,766,000)	(91,261,000)
Income before income taxes - Foreign	...	1,075,000	4,111,000
Income (loss) before income tax benefit (expense) & income (loss) from equity method investment	(130,221,000)	(119,691,000)	(87,150,000)
Current foreign income tax benefit (expense)	(31,000)	(47,000)	133,000
Current federal income tax benefit (expense)	...	56,000	...
Current state income tax benefit (expense)	9,000	12,000	42,000
Total current income tax benefit (expense)	(22,000)	21,000	175,000
Deferred foreign income tax benefit (expense)	11,000	764,000	(84,000)
Deferred federal income tax benefit (expense)	(213,000)	(308,000)	(1,469,000)
Deferred state income tax benefit (expense)	15,000	(683,000)	(643,000)
Total deferred income tax benefit (expense)	(187,000)	(227,000)	(2,196,000)
Income tax benefit (expense)	(209,000)	(206,000)	(2,021,000)
Net income (loss)	(130,012,000)	(119,485,000)	(85,129,000)
Net income (loss) attributable to noncontrolling interest in subsidiaries	1,514,000	778,000	129,000
Net income (loss) attributable to Sharecare, Inc.	(128,498,000)	(118,707,000)	(85,000,000)
Weighted average shares outstanding - basic	352,076,785	348,103,491	281,026,365
Weighted average shares outstanding - diluted	352,076,785	348,103,491	281,026,365
Year end shares outstanding	353,430,357	354,463,620	345,788,707
Net earnings (loss) per share - basic	\$(0.36)	\$(0.34)	\$(0.30)
Net earnings (loss) per share - diluted	\$(0.36)	\$(0.34)	\$(0.30)
Full-Time Employees (Period End)	3,352
Total number of employees	3,352	3,485	3,279
Number of class A common stockholders	183	193	265
Number of preferred stockholders	...	1	...
Foreign currency translation adjustments	...	(611,000)	...
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(0.36)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(0.36)

[□] Approximately; [□] As of March 24, 2023; [□] As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	128,187,000	182,508,000
Accounts receivable, gross	136,717,000	124,074,000
Less: allowance for doubtful accounts	8,544,000	7,197,000
Accounts receivable, net	128,173,000	116,877,000
Other receivables	2,262,000	4,114,000
Prepaid expenses	6,007,000	12,612,000
Other current assets	3,178,000	4,515,000
Total current assets	267,807,000	320,626,000
Computer hardware	9,408,000	10,171,000
Furniture or fixtures	...	1,345,000
Leasehold improvements	2,771,000	2,204,000
Other property, plant & equipment	1,666,000	...
Property & equipment, gross	13,845,000	13,720,000
Less: accumulated depreciation	10,470,000	8,638,000
Property & equipment, net	3,375,000	5,082,000
Security deposits	...	572,000
Foreign tax credits	...	1,811,000
Acquisition related assets	...	1,770,000
Operating lease right-of-use assets, net	...	7,755,000
Related party contract asset	...	5,802,000
Other assets	...	2,652,000
Other long-term assets	13,863,000	20,362,000
Intangible assets, net	136,552,000	163,114,000
Goodwill	192,037,000	191,817,000
Total assets	613,634,000	701,001,000
Accounts payable	45,388,000	8,838,000
Accrued expenses	...	18,526,000
Accrued compensation	16,235,000	23,762,000
Accrued media costs	...	4,515,000
Accrued taxes	1,837,000	1,602,000
Operating lease liabilities, current	1,826,000	2,941,000
Contract liabilities due to a related party, current	17,496,000	10,000,000
Accrued expenses due to a related party	...	18,011,000
Accrued other	28,312,000	2,270,000
Accrued expenses & other current liabilities	65,706,000	81,627,000
Deferred revenue	5,517,000	9,032,000
Contract liabilities, current	...	1,535,000
Total current liabilities	116,611,000	101,032,000
Warrant liabilities	403,000	2,441,000
Long-term debt	519,000	...
Other long-term liabilities	8,032,000	16,723,000
Total liabilities	125,565,000	120,196,000
Series A redeemable convertible preferred stock	...	58,205,000
Common stock	35,000	35,000
Additional paid-in capital	1,157,737,000	1,120,024,000
Accumulated other comprehensive income (loss)	(2,263,000)	(2,794,000)
Accumulated deficit	(725,373,000)	...
Retained earnings (accumulated deficit)	...	(595,820,000)
Series A redeemable convertible preferred stock, \$0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of \$50,000 as of 31, 2023 and 2022	58,205,000	...
Total Sharecare, Inc. stockholders' equity	488,341,000	521,445,000

Noncontrolling interest in subsidiaries	(272,000)	1,155,000	employees	2,300	2,500	2,600	07/02/2021	0.14	06/14/2021	07/06/2021	07/19/2021
Total stockholders' equity (deficit)	488,069,000	522,600,000	Number of part time employees	3,000	3,000	3,200	After 2-for-1 split:		Declared	Record	Payable

Recent Dividends:

1. **Sharecare Inc series A redeemable convertible preferred.**
No dividends paid.
2. **Sharecare Inc common.**
No dividends paid.
3. **Sharecare Inc class A common.**
No dividends paid.
4. **Sharecare Inc class B common.**
No dividends paid.

Annual Dividends:

1. **Sharecare Inc series A redeemable convertible preferred.**
No dividends paid.
2. **Sharecare Inc common.**
No dividends paid.
3. **Sharecare Inc class A common.**
No dividends paid.
4. **Sharecare Inc class B common.**
No dividends paid.

SHOE CARNIVAL, INC.

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	02/03/24	01/28/23	01/29/22 (revised)
Net sales	1,175,882	1,262,235	1,330,394
Cost of sales (including buying, distribution & occupancy costs)	754,492	794,071	803,607
Gross profit (loss)	421,390	468,164	526,787
Selling, general & administrative expenses	327,885	321,720	319,133
Operating income (loss)	93,505	146,444	207,654
Interest income	2,917	972	24
Interest expense	282	294	478
Income (loss) before income taxes	96,140	147,122	207,200
Current federal provision (benefit) for income taxes	13,290	15,542	38,576
Current state provision (benefit) for income taxes	2,623	4,919	8,076
Current Puerto Rico provision (benefit) for income taxes	1,382	2,050	2,730
Total current provision (benefit) for income taxes	17,295	22,511	49,382
Deferred federal provision (benefit) for income taxes	4,862	11,712	1,296
Deferred state provision (benefit) for income taxes	21	1,878	390
Total deferred provision (benefit) for income taxes	4,883	13,590	1,686
Valuation allowance	614	953	1,251
Income tax expense (benefit)	22,792	37,054	52,319
Net income (loss)	73,348	110,068	154,881
Weighted average shares outstanding - basic	27,231	27,543	28,233
Weighted average shares outstanding - diluted	27,407	27,812	28,596
Year end shares outstanding	27,130	27,165	28,166
Net income (loss) per share - basic	\$2.69	\$4.00	\$5.49
Net income (loss) per share - diluted	\$2.68	\$3.96	\$5.42
Dividends per common share	\$0.44	\$0.36	\$0.28
Number of full time			

Reclassified to conform with 2023 presentation; As is; As of March 17, 2023; As of March 21, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	02/03/24	01/28/23
Cash & cash equivalents	99,000	51,372
Marketable securities	12,247	11,601
Accounts receivable	2,593	3,052
Merchandise inventories	346,442	390,390
Other current assets	21,056	13,308
Total current assets	481,338	469,723
Land	1,564	1,564
Buildings	7,690	7,670
Furniture, fixtures & equipment	227,749	202,790
Leasehold improvements	188,946	163,929
Total property & equipment - gross	425,949	375,953
Less accumulated depreciation & amortization	257,336	234,518
Property & equipment - net	168,613	141,435
Other noncurrent assets	13,600	15,388
Operating lease right-of-use assets	333,851	318,612
Intangible assets	32,600	32,600
Goodwill	12,023	12,023
Total assets	1,042,025	989,781
Accounts payable	58,274	78,850
Employee compensation & benefits	6,033	8,474
Current portion of non-qualified deferred compensation		1,514
Self-insurance reserves	1,954	1,721
Gift cards		2,399
Sales & use tax	2,344	2,416
Other accrued & other liabilities		3,757
Current portion of operating lease liabilities	52,981	58,154
Other	6,289	
Total current liabilities	127,875	157,285
Long-term portion of operating lease liabilities	301,355	285,074
Deferred income taxes	17,341	11,844
Deferred compensation	11,639	9,840
Other liabilities	426	170
Total liabilities	458,636	464,213
Common stock	410	410
Additional paid-in capital	83,738	83,423
Retained earnings (accumulated deficit)	714,647	653,450
Treasury stock, at cost	215,406	211,715
Total shareholders' equity (deficit)	583,389	525,568
Total Equity	583,389	

Recent Dividends:

1. **Shoe Carnival, Inc. common.**

ExDate	Amt	Declared	Record	Payable
01/08/2021	0.09	12/17/2020	01/11/2021	01/25/2021
04/01/2021	0.14	03/18/2021	04/05/2021	04/19/2021

Annual Dividends:

1. **Shoe Carnival, Inc. common.**

2021	0.37
After 2-for-1 split:	
2021	0.21
2022	0.34
2023	0.41
2024	0.26

SILVER SPIKE INVESTMENT CORP

Annual Report

Consolidated Income Statement, Years Ended (\$):

	12/31/23	12/31/22	03/31/22
Non-controlled or non-affiliate investment income	11,736,649	3,626,792	10,073
Non-controlled or non-affiliate investment income: fee income	196,251	410,000	
Total investment income	11,932,900	4,036,792	10,073
Legal expenses	343,824	484,412	34,069
Management fee	1,013,764	336,432	
Transaction expenses related to the Loan Portfolio			
Acquisition	711,264		
Audit expense	499,698	210,284	40,000
Administrator fees	335,253	171,494	47,151
Insurance expense	269,719	228,288	46,488
Director expenses	200,955	99,845	
Valuation fees	115,985		
Other expense	85,953	122,070	6,808
Professional fees		70,264	34,920
Custodian fees	48,000	36,150	36,000
Excise tax expense	10,655	80,566	
Organizational expenses			328,002
Professional fees	70,150		
Income-based incentive fees	1,511,253		
Capital gains incentive fees	87,583		
Total expenses	5,304,056	1,839,805	573,438
Net investment income (loss)	6,628,844	2,196,987	(563,365)
Net realized gain (loss) from investments - non-controlled or non-affiliate investments	(210,767)		
Net realized gain (loss)	(210,767)		
Net change in unrealized appreciation (depreciation) on investments - non-controlled or non-affiliate investments	922,031	(273,348)	
Net change in unrealized appreciation (depreciation) on			

investments	922,031	(273,348)	...
Net increase (decrease) in net assets resulting from operations	7,340,108	1,923,639	(563,365)
Weighted average shares outstanding - basic	6,214,682	6,214,672	877,409
Weighted average shares outstanding - diluted	6,214,682	6,214,672	877,409
Year end shares outstanding	6,214,941	6,214,672	6,214,672
Net investment income (loss) per share - basic	\$1.07	\$0.35	\$(0.64)
Net increase (decrease) in net assets resulting from operations per share - basic	\$1.18	\$0.31	\$(0.64)
Net investment income (loss) per share - diluted	\$1.07	\$0.35	\$(0.64)
Net increase (decrease) in net assets resulting from operations per share - diluted	\$1.18	\$0.31	\$(0.64)
Number of common stockholders	3	2	2

□ From April 1, 2022; □ Approximately; □ As of March 24, 2023; □ As of June 27, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Non-control or non-affiliate investments at fair value	54,120,000	50,254,550
Cash & cash equivalents	32,611,635	35,125,320
Interest receivable	1,755,360	1,559,081
Prepaid expenses	39,276	32,323
Other assets	50,000	...
Total assets	88,576,271	86,971,274
Management fee payable	257,121	170,965
Excise tax payable	10,655	80,566
Administrator fees payable	86,463	57,306
Audit fees payable	123,998	50,000
Legal fees payable	84,824	42,215
Director's fee payable	94,760	32,049
Professional fees payable	17,233	28,744
Due to affiliate	...	37
Other payables	13,822	33,663
Income-based incentive fees payable	1,511,253	...
Distributions payable	2	...
Capital gains incentive fees payable	87,583	...
Valuation fees payable	24,675	...
Transaction fees payable related to the Loan	711,264	...
Total liabilities	3,023,653	495,545
Common stock	62,149	62,147
Additional paid-in capital	85,041,203	84,917,788
Distributable earnings (accumulated losses)	449,266	1,495,794
Total net assets (liabilities)	...	86,475,729
Net asset (liability) value per share	...	\$13.91
Total net assets	85,552,618	...
Total Equity	85,552,618	...

□ Amortized cost - non-control or non-affiliate investments at fair value: \$50,527,898

Recent Dividends:

1. Silver Spike Investment Corp common.
No dividends paid.

Annual Dividends:		
1. Silver Spike Investment Corp common.		
No dividends paid.		
SIMULATIONS PLUS INC		
Earnings, 6 mos. to (Consol. - \$):		
	02/29/24	02/28/23
Total Revenues	32,805,000	27,714,000
Cost & expenses	27,403,000	22,802,000
Operating income	5,402,000	4,912,000
Interest income	2,640,000	1,756,000
Other income (expense), net	(330,000)	...
Foreign currency	(54,000)	18,000
Net before taxes	7,658,000	6,686,000
Income taxes	1,684,000	...
Net income	5,974,000	5,419,000
Balance for common	...	5,419,000
Earnings common share		
Primary	\$0.30	\$0.27
Fully Diluted	\$0.29	\$0.26
Common Shares:		
Full Diluted	20,288,000	20,657,000
Year-end	19,983,703	19,930,623

SMARTKEM INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenue	27,000
Revenue	27,000	40,000	18,000
Cost of revenue	23,000
Cost of revenue	23,000	33,000	8,000
Gross profit	4,000	7,000	10,000
Other operating income	836,000	1,172,000	1,285,000
Research & development	5,556,000	5,802,000	8,199,000
Salaries & benefits	5,366,000
Rent & property tax expense	24,000
Insurance expense	486,000
Utilities	4,000
Sales & marketing	749,000
Legal & professional fees	1,132,000
Other selling, general, & administrative expenses	5,188,000	...	308,000
Selling, general & administrative expense	...	5,071,000	8,069,000
Transaction expenses	1,329,000
Loss on foreign currency transactions	(87,000)
Total operating expenses	...	10,873,000	17,597,000
Income (loss) from operations	(9,991,000)	(9,694,000)	(16,302,000)
(Loss) on foreign currency transactions	1,213,000	(1,782,000)	(808,000)
Other income	(198,000)
Interest expense	19,000
Interest income	12,000	5,000	3,000
Change in fair value of the warrant liability	465,000
Total non-operating income (expense)	1,492,000	(1,777,000)	(824,000)
Income (loss) before income taxes
- United States	...	584,000	(5,039,000)
Income (loss) before income taxes - Foreign	...	(12,055,000)	(12,087,000)
Income (loss) before income taxes	(8,499,000)	(11,471,000)	(17,126,000)
Current state income tax expense	...	2,000	...
Current foreign

income tax expense	...	22,000	...
Total current income tax expense	...	24,000	...
Income tax expense	...	24,000	...
Net income (loss)	(8,499,000)	(11,495,000)	(17,126,000)
Weighted average shares outstanding - basic	1,344,892	824,623	720,954
Weighted average shares outstanding - dilutive	1,344,892	824,623	720,954
Year end shares outstanding	889,668	771,000	730,123
Net income (loss) per common share - basic	\$(6.32)	\$(14.00)	\$(23.80)
Net income (loss) per common share - dilutive	\$(6.32)	\$(14.00)	\$(23.80)
Number of full time employees	29	50	41
Number of part time employees	2	5	3
Total number of employees	31	55	44
Number of common stockholders	...	102	139

□ Adjusted for 1-for-35 stock split, September 21, 2023; □ Shares increased due to the effect of exercise of stock-option, repurchase of common stock, reverse capitalization, common shares to vendor and warrant in private placement; □ As of March 24, 2023; □ As of March 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	8,836,000	4,235,000
Accounts receivable, net	268,000	30,000
Research & development tax credit receivable	610,000	1,121,000
Prepaid service charges & property taxes	...	55,000
Prepaid utilities	...	51,000
Prepaid insurance	...	358,000
Prepaid administrative expenses	...	35,000
Prepaid technical fees	...	22,000
Prepaid consulting fees	...	304,000
Value added tax receivable	...	195,000
Other receivable & other prepaid expenses	...	36,000
Prepaid expenses & other current assets	811,000	1,056,000
Total current assets	10,525,000	6,442,000
Plant & equipment	1,584,000	1,478,000
Furniture & fixtures	...	218,000
Computer hardware & software	108,000	24,000
Computer hardware and software	24,000	...
Property, plant & equipment, gross	1,716,000	1,720,000
Accumulated depreciation	1,261,000	1,118,000
Property, plant & equipment, net	455,000	602,000
Right-of-use assets, net	285,000	475,000
Other assets, non-current	7,000	6,000
Total assets	11,272,000	7,525,000
Accounts payable	355,000	230,000
Accrued expenses - lab refurbishments	...	117,000
Accrued expenses - technical fees	...	130,000
Accrued expenses - variable rent & utilities	...	15,000
Accrued expenses - audit & accounting fees	...	128,000
Other accrued expenses	1,178,000	80,000
Credit card liabilities	...	20,000
Payroll & social security liabilities	375,000	211,000

Accounts payable & accrued expenses	931,000
Income taxes payable	22,000
Lease liabilities, current	230,000
Other current liabilities	360,000
Accrued expenses - Balancing value	448,000
Total current liabilities	1,768,000
Non-current lease liabilities	19,000
Warrant liability	1,372,000
Total liabilities	3,159,000
Common shares	3,000
Additional paid-in capital	104,757,000
Accumulated other comprehensive income (loss)	(1,578,000)
Retained earnings (accumulated deficit)	(95,066,000)
Total shareholders' equity (deficit)	8,113,000
Total Equity	8,113,000

investment in hotel properties, net	12,201,461
Gain (loss) on disposal of assets	4,700
Corporate general & administrative expenses	7,078,222
Net operating income (loss)	18,925,431
Interest expense	17,588,091
Interest income	802,183
Gain (loss) on early extinguishment of debt	275,494
Unrealized gain (loss) on hedging activities	(737,682)
PPP loan forgiveness	456,388
Gain (loss) on sale of hotel properties	30,053,977
Gain (loss) on involuntary conversion of assets	1,763,320
Impairment of note receivable	(1,371,041)
Net income (loss) before income taxes	3,504,764
Current state income tax provision (benefit)	(304,947)
Total current income tax provision (benefit)	(304,947)
Deferred federal income tax provision (benefit)	(1,559,177)
Deferred state income tax provision (benefit)	(254,558)
Total deferred income tax provision (benefit)	(1,813,735)
Change in deferred tax valuation allowance	1,813,735
Net income (loss)	3,809,711
Less: net loss (income) attributable to the noncontrolling interest	131,710
Net income (loss) attributable to the company	3,941,421
Undeclared distributions to preferred stockholders	7,977,250
Gain on extinguishment of preferred stock	(64,518)
Net income (loss) attributable to common stockholders	(4,035,829)
Weighted average shares outstanding - basic	18,843,032
Weighted average shares outstanding - diluted	18,843,032
Year end shares outstanding	19,696,805
Earnings (loss) per share - continuing operations - basic	\$(0.22)
Net earnings (loss) per share - basic	\$(0.22)
Earnings (loss) per	

share - continuing operations - diluted	\$(0.22)
Net earnings (loss) per share - diluted	\$(0.22)
Number of full time employees	9
Total number of employees	9
Number of common stockholders	85
Dividends per common share	\$0.52
Dividends Per Share - Common - Gross - by Period End Date	\$2.00
Dividends Per Share - Common - Gross - by Period End Date	\$1.97
Dividends Per Share - Special - Gross - by Period End Date	\$0.50
Dividends Per Share - Special - Gross - by Period End Date	\$0.49
Dividends Per Share - Special - Gross - by Period End Date	\$2.06

Recent Dividends:

1. SmartKem Inc common.

No dividends paid.

2. SmartKem Inc preferred.

No dividends paid.

Annual Dividends:

1. SmartKem Inc common.

No dividends paid.

2. SmartKem Inc preferred.

No dividends paid.

OTHERLY HOTELS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Rooms department	26,177,539		
Food and beverage department	24,211,133		
Other operating departments	9,031,960		
Rooms department	114,748,834	109,553,906	88,625,659
Food & beverage department	35,231,959	29,556,213	15,829,487
Other operating departments	23,857,264	26,967,185	23,132,778
Total revenue	173,838,057	166,077,304	127,587,924
Hotel operating expenses - rooms department	25,782,888	22,688,063	
Hotel operating expenses - food & beverage department	19,724,225	10,297,461	
Hotel operating expenses - other operating departments	9,296,056	8,607,594	
Sales & marketing	15,062,397	11,684,933	
General & administrative	13,436,054	10,533,201	
Repair & maintenance	8,723,144	7,362,334	
Utilities	5,649,716	5,309,637	
Property taxes	5,254,075	6,131,271	
Management fees, including incentive	4,377,814	3,620,071	
Franchise fees	4,059,709	3,321,352	
Insurance	4,082,551	3,596,153	
Information & telecommunications	3,378,716	3,048,495	
Other indirect hotel operating expenses	787,391	492,798	
Indirect hotel operating expenses	69,629,724	64,811,567	55,100,245
Depreciation & amortization expenses	18,788,748	18,650,336	19,909,226
Impairment of			

Reclassified to conform with 2022 presentation; Approximately; As of March 1, 2023; As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Land & land improvements	61,114,486	60,934,859
Buildings & improvements	418,833,706	412,717,919
Right of use assets	4,733,406	5,199,845
Furniture, fixtures & equipment	51,501,629	51,292,107
Less: accumulated depreciation & impairment	181,264,121	165,074,005
Investment in hotel properties, net	354,919,106	365,070,725
Cash & cash equivalents	17,101,993	21,918,680
Restricted cash	9,134,347	5,422,950
Accounts receivable, net	5,945,724	5,844,904
Prepaid expenses, inventory & other assets	6,342,310	8,311,862
Total assets	393,443,480	406,569,121
Mortgage loans, net		320,482,103
Loans payable	315,989,194	
Unsecured notes, net	1,536,809	2,545,975
Accounts payable & accrued liabilities	23,315,677	25,704,835
Advance deposits	2,614,981	2,233,013
Dividends & distributions payable	2,088,160	4,082,472
Total liabilities	345,544,821	355,048,398
Series B cumulative redeemable perpetual preferred stock	14,641	14,641
Series C cumulative redeemable perpetual preferred stock	13,461	13,461
Series D cumulative redeemable perpetual preferred stock	11,631	11,631
Common stock	196,968	189,515
Additional paid-in capital	175,779,222	175,611,370
Unearned employee stock option plan ("ESOP") shares	1,764,507	2,601,134
Distributions in excess of retained earnings (accumulated deficit)	(125,021,013)	(120,985,183)
Total Sotherly Hotels Inc. stockholders' equity (deficit)	49,230,403	52,254,301
Noncontrolling interest	(1,331,744)	(733,578)
Total equity (deficit)	47,898,659	51,520,723

Recent Dividends:

1. Sotherly Hotels Inc 8.0% series B cumulative redeemable perpetual preferred.

ExDate	Amt	Declared	Record	Payable
02/27/2023	0.52	01/24/2023	02/28/2023	03/15/2023
05/30/2023	0.52	04/24/2023	05/31/2023	06/15/2023
06/29/2023	0.52	05/30/2023	06/30/2023	07/14/2023
08/30/2023	0.52	08/01/2023	08/31/2023	09/15/2023
11/29/2023	0.52	10/31/2023	11/30/2023	12/15/2023
02/28/2024	0.52	01/30/2024	02/29/2024	03/15/2024

2. Sotherly Hotels Inc series A cumulative redeemable preferred.

ExDate	Amt	Declared	Record	Payable
02/27/2023	0.50	01/24/2023	02/28/2023	03/15/2023
05/30/2023	0.50	04/24/2023	05/31/2023	06/15/2023
06/29/2023	0.50	05/30/2023	06/30/2023	07/14/2023
08/30/2023	0.50	08/01/2023	08/31/2023	09/15/2023
11/29/2023	0.50	10/31/2023	11/30/2023	12/15/2023
02/28/2024	0.50	01/30/2024	02/29/2024	03/15/2024

3. Sotherly Hotels Inc 7.875% series C cumulative redeemable perpetual preferred.

No dividends paid.

4. Sotherly Hotels Inc common.

No dividends paid.

5. Sotherly Hotels Inc 8.25% series D cumulative redeemable perpetual preferred.

No dividends paid.

Annual Dividends:

1. Sotherly Hotels Inc 8.0% series B cumulative redeemable perpetual preferred.

2023.....2.58 2024.....0.52

2. Sotherly Hotels Inc series A cumulative redeemable preferred.

2023.....2.50 2024.....0.50

3. Sotherly Hotels Inc 7.875% series C cumulative redeemable perpetual preferred.

No dividends paid.

4. Sotherly Hotels Inc common.

No dividends paid.

5. Sotherly Hotels Inc 8.25% series D cumulative redeemable perpetual preferred.

No dividends paid.

SPORTSMAN'S WAREHOUSE HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	01/28/23	01/29/22	01/30/21 (revised)
Net sales	1,399,515	1,506,072	1,451,767
Cost of goods sold	939,275	1,015,775	975,313
Gross profit (loss)	460,240	490,297	476,454
Selling, general, & administrative expenses	402,177	399,678	353,706
Income (loss) from operations	58,063	90,619	122,748
Bargain purchase gain	2,218
Merger termination payment	...	(55,000)	...
Interest expense	4,195	1,380	3,506
Income (loss) before income taxes	53,868	144,239	121,460
Current federal income tax provision (benefit)	6,853	23,107	24,023
Current state income tax provision (benefit)	2,737	7,312	6,991
Total current income tax provision (benefit)	9,590	30,419	31,014
Deferred federal income tax provision (benefit)	3,602	5,133	(390)
Deferred state income tax provision (benefit)	158	217	(544)
Total deferred			

income tax provision (benefit)	3,760	5,350	(934)
Income tax expense (benefit)	13,350	35,769	30,080
Net income (loss)	40,518	108,470	91,380
Weighted average shares outstanding - basic	40,489	43,827	43,525
Weighted average shares outstanding - diluted	40,719	44,543	44,430
Year end shares outstanding	37,541	43,880	43,623
Net income (loss) per share - basic	\$1.00	\$2.47	\$2.10
Net income (loss) per share - diluted	\$1.00	\$2.44	\$2.06
Number of full time employees	3,000	3,300	3,000
Number of part time employees	3,700	4,400	4,000
Total number of employees	6,700	7,700	7,000
Number of common stockholders	211	165	167

□ As is; □ Approximately; □ As of March 31, 2023; □ As of March 8, 2022; □ As of March 1, 2021

Consolidated Balance Sheet, Years Ended (\$000):

	01/28/23	01/29/22
Cash & cash equivalents	2,389	57,018
Accounts receivable, net	2,053	1,937
Merchandise inventory, gross	408,564	394,965
Less: reserves for shrinkage, damaged, or obsolescence	9,436	8,405
Merchandise inventories	399,128	386,560
Prepaid expenses & other current assets	22,326	21,955
Total current assets	425,896	467,470
Operating lease right of use asset	268,593	243,047
Furniture, fixtures, & equipment	138,004	115,597
Leasehold improvements	170,494	143,064
Construction in progress	20,875	5,007
Total property & equipment, gross	329,373	263,668
Less: accumulated depreciation & amortization	166,787	135,364
Property & equipment, net	162,586	128,304
Goodwill	1,496	1,496
Definite lived intangibles, net	389	264
Total assets	858,960	840,581
Accounts payable	61,948	58,916
Book overdraft	20,723	16,252
Unearned revenue	41,203	42,058
Accrued payroll & related expenses	15,820	26,309
Sales & use tax payable	5,896	8,788
Accrued construction costs	1,469	416
Other accrued expenses	14,865	15,189
Accrued expenses	99,976	109,012
Income taxes payable	932	9,500
Operating lease liability, current	45,465	40,924
Revolving line of credit	87,503	66,054
Total current liabilities	295,824	284,406
Deferred income taxes	9,544	5,779
Operating lease liability, noncurrent	260,479	236,227
Total long-term liabilities	270,023	242,006
Total liabilities	565,847	526,412
Common stock	375	439
Additional paid-in capital	79,743	90,851

Retained earnings (accumulated deficit)	212,995	222,879
Total stockholders' equity (deficit)	293,113	314,169

Recent Dividends:

1. Sportsman's Warehouse Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Sportsman's Warehouse Holdings Inc common.

No dividends paid.

STAR EQUITY HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022 (revised)	2021 (revised)
Healthcare revenue	58,556,000
Construction revenue	48,003,000
Revenue from contract with customer	45,785,000	57,149,000	...
Total revenues	45,785,000	57,149,000	106,559,000
Cost of revenues - healthcare	228,000	290,000	46,097,000
Cost of revenues - construction	44,995,000
Cost of revenues - investments	227,000
Construction	33,631,000	44,489,000	...
Total cost of revenues	33,859,000	44,779,000	91,319,000
Gross profit (loss)	11,926,000	12,370,000	15,240,000
Selling, general & administrative expenses	14,538,000	14,195,000	22,595,000
Amortization of intangible assets	1,734,000	1,719,000	1,728,000
Goodwill impairment	3,359,000
Gain on sale of MD Office Solutions	847,000
Total operating expenses	16,272,000	15,914,000	26,835,000
Net income (loss) from continuing operations	(4,346,000)	(3,544,000)	(11,595,000)
Other income (expense), net	852,000	(1,336,000)	(550,000)
Interest income (expense), net	973,000	(564,000)	(905,000)
Gain on forgiveness of Paycheck Protection Program loans	4,179,000
Total other income (expense), net	1,825,000	(1,900,000)	2,724,000
Income (loss) from continuing operations before income taxes	(2,521,000)	(5,444,000)	(8,871,000)
Current federal provision (benefit) for income taxes	4,000
Current state provision (benefit) for income taxes	20,000
Total current provision (benefit) for income taxes	24,000
Deferred federal provision (benefit) for income taxes	(312,000)	37,000	6,000
Deferred state provision (benefit) for income taxes	(302,000)	346,000	30,000
Total deferred provision (benefit) for income taxes	(614,000)	383,000	36,000
Income tax provision (benefit)	(614,000)	383,000	60,000
Income (loss) from continuing operations, net of			

tax	(1,907,000)	(5,827,000)	(8,931,000)
Income (loss) from discontinuing operations before income taxes	27,732,000	367,000	...
Discontinued Operations - Tax Impacts - Current Income/Expense	(693,000)	208,000	...
Income (loss) from discontinued operations, net of tax	27,039,000	575,000	5,948,000
Net income (loss)	25,132,000	(5,252,000)	(2,983,000)
Deemed dividend on series A perpetual preferred stock	1,916,000	1,916,000	1,906,000
Net income (loss) attributable to common stockholders	23,216,000	(7,168,000)	(4,889,000)
Weighted average shares outstanding - basic	15,638,000	14,751,000	5,085,000
Weighted average shares outstanding - diluted	15,638,000	14,751,000	5,085,000
Year end shares outstanding	15,826,217	15,177,919	5,805,916
Income (loss) from continuing operations per share - basic	\$(0.24)	\$(0.40)	\$(1.76)
Income (loss) from discontinued operations per share - basic	\$1.73	\$0.04	\$1.17
Net income (loss) per share - basic	\$1.48	\$(0.49)	\$(0.59)
Income (loss) from continuing operations per share - diluted	\$(0.24)	\$(0.40)	\$(1.76)
Income (loss) from discontinued operations per share - diluted	\$1.73	\$0.04	\$1.17
Net income (loss) per share - diluted	\$1.48	\$(0.49)	\$(0.59)
Dividends declared per common share	\$1.00	\$0.25	...
Number of full time employees	171
Total number of employees	171	...	458
Number of common stockholders	168	...	159
Earning per share-total discount opers - diluted	\$1.73	\$0.04	...
Earnings per share-total discontinued opers	\$1.73	\$0.04	...

¹ Restated to reflect discontinued operations; ² Reclassified to conform with 2022 presentation; ³ Approximately; ⁴ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022 (revised)
Cash & cash equivalents	18,326,000	4,665,000
Investments in equity securities	4,838,000	3,490,000
Lumber derivative contracts	19,000	...
Accounts receivable, gross	...	18,470,000
Less allowance for doubtful accounts	191,000	714,000
Accounts receivable, Net - Balancing value	6,195,000	...
Accounts receivable, net	6,004,000	17,756,000
Raw materials	1,394,000	6,330,000
Work-in-process	410,000	2,567,000
Finished goods	1,616,000	1,946,000

Total inventories	3,420,000	10,843,000
Less reserve for excess & obsolete inventories	...	216,000
Inventories, net	...	10,627,000
Restricted cash	620,000	142,000
Other current assets	1,180,000	2,587,000
Notes Receivables	399,000	...
Total current assets	34,806,000	39,267,000
Land	1,353,000	805,000
Buildings & leasehold improvements	...	4,843,000
Machinery & equipment	3,511,000	24,648,000
Computer hardware & software	...	2,465,000
Leasehold improvements	5,123,000	...
Gross property & equipment	9,987,000	32,761,000
Accumulated depreciation	2,159,000	24,413,000
Property & equipment, net	7,828,000	8,348,000
Operating lease right-of-use assets, net	1,470,000	4,482,000
Intangible assets, net	12,518,000	13,352,000
Goodwill	4,438,000	6,046,000
Other assets	9,000	1,807,000
Cost method investment	6,000,000	...
Notes receivable	8,427,000	...
Total assets	75,496,000	73,302,000
Accounts payable	1,571,000	3,430,000
Accrued compensation	1,772,000	3,701,000
Accrued warranty	44,000	291,000
Lumber derivative contracts	...	104,000
Deferred revenue	1,377,000	3,376,000
Short-term debt	2,019,000	11,682,000
Operating lease liabilities	403,000	1,427,000
Finance lease liabilities	42,000	397,000
Professional fees	108,000	913,000
Sales & property taxes payable	...	764,000
Radiopharmaceuticals & consumable medical supplies	...	353,000
Facilities & related costs	...	217,000
Outside services & consulting	279,000	235,000
Other accrued liabilities	552,000	655,000
Accrued liabilities	1,506,000	3,137,000
Earn-out Provision	169,000	...
Taxes Payable related to Digrad Sale	398,000	...
Total current liabilities	8,734,000	27,545,000
Deferred tax liabilities	318,000	176,000
Operating lease liabilities, net of current portion	1,102,000	3,141,000
Finance lease liabilities, net of current portion	43,000	386,000
Other liabilities	...	299,000
Total liabilities	10,197,000	31,547,000
Series A preferred stock	18,988,000	18,988,000
Common stock	2,000	1,000
Treasury stock, at cost	5,728,000	5,728,000
Additional paid-in capital	160,126,000	161,715,000
Retained earnings (accumulated deficit)	(108,089,000)	(133,221,000)
Total stockholders' equity (deficit)	65,299,000	41,755,000
Total Equity	65,299,000	...

Recent Dividends:
1. Star Equity Holdings Inc common.
 No dividends paid.
2. Star Equity Holdings Inc 10% series A cumulative perpetual preferred.
 No dividends paid.
Annual Dividends:
1. Star Equity Holdings Inc common.
 No dividends paid.

2. Star Equity Holdings Inc 10% series A cumulative perpetual preferred.
 No dividends paid.

SUTRO BIOPHARMA INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Revenue	153,731
Revenue	153,731	67,772	61,880
Research & development	180,425	137,171	104,400
General & administrative expenses	62,584	59,544	56,004
Total operating expenses	243,009	196,715	160,404
Income (loss) from operations	(89,278)	(128,943)	(98,524)
Interest income	14,510	3,455	577
Unrealized gain (loss) on equity securities	(12,570)	12,130	(4,454)
Interest & other income (expense), net	(11,180)	(3,346)	(3,137)
Income (loss) before provision for income taxes	(88,601)	(116,704)	(105,538)
Current provision (benefit) for state income taxes	603
Current provision (benefit) for foreign income taxes	943	2,500	...
Income Taxes - Domestic - Current	16,646
Income Taxes - Total - Current	18,192
Provision for income taxes	18,192	2,500	...
Net income (loss)	(106,793)	(119,204)	(105,538)
Weighted average shares outstanding - basic	60,164	50,739	46,119
Weighted average shares outstanding - diluted	60,164	50,739	46,119
Year end shares outstanding	61,010	57,500	46,327
Net earnings (loss) per share - basic	\$(1.78)	\$(2.35)	\$(2.29)
Net earnings (loss) per share - diluted	\$(1.78)	\$(2.35)	\$(2.29)
Number of full time employees	302	278	239
Number of common stockholders	69	72	77
Unrealized gain (loss) on equity securities	9,917
Total number of employees	302

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect of exercise of stock option, issuance of common stock under employee stock purchase plan and in connection with at-the-market sale and vesting of stock units; ³ As is; ⁴ As of March 27, 2023; ⁵ Approximately; ⁶ As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	69,268	47,254
Marketable securities	264,413	255,090
Investment in equity securities	41,937	32,020
Accounts receivable	36,078	7,122
Prepaid expenses & other current assets	9,846	11,667

service fees	4,587	3,972	Net revenue	136,223	110,121	97,434	Total number of employees	752	□719	□684
Accrued telecommunications & hosting	3,101	2,006	Cost of sales	118,975	95,268	82,928	Number of common stockholders	554	□□573	□□584
Accrued income taxes payable	338	803	Cost of sales	118,975	95,268	82,928	Total net revenue	136,223
Accrued series B preferred dividend	2,129	2,298	Gross profit	17,248	14,853	14,506	Foreign currency translation adjustments	...	982	...
Accrued operating lease liabilities	5,838	5,497	Selling, general & administrative expenses	16,279	14,489	12,596	□ As is; □ As of March 1, 2023; □ As of March 10, 2022			
Accrued third party tech services	278	1,226	Operating income (loss)	969	364	1,910	Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			
Accrued 2021 8.375% senior notes - interest	...	1,969	Interest expense, net	777	1,110	868	2023 2022			
Accrued other expenses	...	10,510	Other income (expense), net	(1,125)	(800)	(645)	Cash & cash equivalents	7,881	21,648	
Accrued other	1,796	...	Forgiveness of paycheck protection program ("PPP") loan & related interest	3,599	Commercial accounts receivable	8,929	8,139	
Accrued expenses - Balancing value	1,969	...	Income (loss) before income taxes - domestic	(3,527)	(4,661)	408	Less: allowance for doubtful accounts - accounts receivable	306	75	
Accrued Sales and Use Tax	1,090	...	Income (loss) before income taxes - foreign	2,594	3,115	3,588	Accounts receivable, net	...	8,064	
Accrued expenses	39,127	52,115	Income (loss) before income taxes	(933)	(1,546)	3,996	Raw materials	67,962	36,612	
Deferred revenues, current	1,095	13,859	Current income tax expense (benefit) - federal	...	0	0	Work in process	9,027	6,585	
Lease liabilities, current	562	...	Current income tax expense (benefit) - state	10	3	6	Finished goods	1,974	802	
Total current liabilities	47,697	80,183	Current income tax expense (benefit) - foreign	599	616	52	Less: reserve for excess & obsolete inventory	1,649	1,866	
Long-term debt, net of debt issuance costs	136,215	134,584	Total current income tax expense (benefit)	609	619	58	Inventory, net	77,314	42,133	
Deferred tax liabilities	3,207	466	Deferred income tax expense (benefit) - federal	...	0	0	Prepaid expenses	1,405	1,810	
Deferred revenues, non-current	...	324	Deferred income tax expense (benefit) - state	...	0	0	Contract assets	4,638	2,393	
Leases, non-current	23,593	29,637	Deferred income tax expense (benefit) - foreign	54	329	1,015	Other current assets	3,700	3,930	
Other non-current liabilities	1,691	3,933	Total deferred income tax expense (benefit)	54	329	1,015	Total current assets	103,867	79,978	
Total liabilities	212,403	249,127	Income tax expense (benefit)	54	329	1,015	Land & land improvements	43	43	
Series B non-convertible perpetual preferred stock	58,802	68,348	Net income (loss)	(1,596)	(2,494)	2,923	Buildings & building improvements	8,507	8,044	
Redeemable noncontrolling interest	12,500	12,500	Less distributed & undistributed earnings allocable to restricted award holders	...	0	12	Machinery, equipment, furniture & fixtures	84,001	66,037	
Common stock	1	9	Net income (loss) allocable to common stockholders	(1,596)	(2,494)	2,911	Construction in progress	863	2,048	
Additional paid-in capital	483,527	488,848	Weighted average shares outstanding - basic	21,876	21,729	21,585	Machinery, Equipment, furniture and fixtures	74,588	...	
Foreign currency	...	(40,611)	Weighted average shares outstanding - diluted	21,876	21,729	23,001	Property, plant & equipment, gross	...	76,172	
Unrealized gain (loss) on intercompany foreign currency transactions	...	(3,520)	Year end shares outstanding	22,460	22,176	21,865	Less: accumulated depreciation - property, plant & equipment	66,868	60,640	
Unrealized holding gains (loss) on available-for-sale securities	18,399	...	Earnings (loss) per share from continuing operations - basic	\$(0.07)	Property, plant & equipment, net	17,133	15,532	
Foreign Currency Translation adjustments	(44,131)	...	Net income (loss) per share - basic	\$(0.07)	\$(0.11)	\$0.14	Operating lease right-of-use assets	3,309	4,251	
Accumulated other comprehensive income (loss)	(25,732)	(44,131)	Earnings (loss) per share from continuing operations - diluted	\$(0.07)	Long term spare parts	...	497	
Retained earnings (accumulated deficit)	(431,164)	(376,629)	Net income (loss) per share - diluted	\$(0.07)	\$(0.11)	\$0.13	Long term deposits	...	280	
Total stockholders' equity (deficiency)	26,632	68,097	Number of full time employees	752	Pension asset	...	645	
Recent Dividends:										
1. Synchronoss Technologies Inc common.										
No dividends paid.										
2. Synchronoss Technologies Inc series B non-convertible perpetual preferred.										
No dividends paid.										
3. Synchronoss Technologies Inc series A convertible participating perpetual preferred.										
No dividends paid.										
Annual Dividends:										
1. Synchronoss Technologies Inc common.										
No dividends paid.										
2. Synchronoss Technologies Inc series B non-convertible perpetual preferred.										
No dividends paid.										
3. Synchronoss Technologies Inc series A convertible participating perpetual preferred.										
No dividends paid.										
SYPRIS SOLUTIONS, INC.										
Annual Report										
Consolidated Income Statement, Years Ended Dec. 31 (\$000):										
	2023	2022	2021 (revised)				Operating lease liabilities, current portion	1,068	1,168	
							Income, Property and Other Taxes	300	...	
							Finance lease obligations, current portion	1,327	1,102	
							Equipment financing obligations, current portion	618	398	
							Note payable - related party, current portion	...	2,500	
							Working capital line of credit	500	...	
							Total current liabilities	86,482	56,122	

Operating lease obligations, net of current portion	2,642	3,710	Weighted average shares outstanding - basic	28,326	12,632	26,253	Long-Term Debt excluding Capitalized Leases	6,667	...
Finance lease obligations, net of current portion	1,852	2,536	Weighted average shares outstanding - diluted	28,326	12,632	26,253	Total current liabilities	36,681	30,778
Equipment financing obligations, net of current portion	1,333	738	Year end shares outstanding	26,449	20,263	26,202	Operating lease obligation, net of current portion	18,528	20,851
Note payable - related party	...	4,000	Net earnings (loss) per share - basic	\$(5.81)	\$(7.49)	\$(13.84)	Warrant liability	61,747	24,472
Less unamortized debt issuance & modification costs	6,484	(11)	Net earnings (loss) per share - diluted	\$(5.81)	\$(7.49)	\$(13.84)	Debt, net of debt discount, long term	34,556	40,649
Note payable - related party	...	3,989	Number of full time employees	68	117	124	Common stock	26	20
Noncurrent pension liability	3,823	4,332	Number of part time employees	...	1	...	Additional paid-in capital	739,443	685,847
Deferred gain from sale leaseback	407	660	Number of common stockholders	73	76	33	Accumulated other comprehensive gain (loss)	...	102
Contract liabilities - long term	3,799	12,482	Income from cont operations before income tax	(164,574)	Retained earnings (accumulated deficit)	(722,807)	(558,233)
Other liabilities	8,082	...	Earnings per share from continuing operations	\$(5.81)	Total stockholders' equity (deficit)	16,662	127,736
Total liabilities	106,875	84,569	Earnings per share from continuing operations	\$(5.81)	Total Equity	16,662	...
Common stock	224	221	Total number of employees	68	Recent Dividends:		
Additional paid-in capital	156,242	155,535	□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-10 stock split, September 19, 2022; □ Shares increased due to the effect of issuance of shares in private placement, issuance of shares in merger, issuance of shares under employee stock purchase plan and vesting of restricted stock unit; □ As is; □ Approximately; □ As of February 27, 2023; □ As of March 11, 2022				1. Syros Pharmaceuticals Inc common. No dividends paid.		
Accumulated deficit	(116,932)	...	Annual Dividends:						
Retained earnings (accumulated deficit)	...	(115,336)	1. Syros Pharmaceuticals Inc common. No dividends paid.						
Foreign currency translation adjustments, net of tax	(7,869)	(10,458)	T2 BIOSYSTEMS INC						
Employee benefit related adjustments - U.S., net of tax	(9,281)	(10,488)	Annual Report						
Employee benefit related adjustments - Mexico, net of tax	83	101	Consolidated Income Statement, Years Ended Dec. 31						
Accumulated other comprehensive income (loss)	(17,067)	(20,845)	(\$000):			2023	2022	2021 (revised)	
Total stockholders' equity	22,467	19,575	Cash & cash equivalents	139,526	167,467	6,770	11,259	16,646	
Rep Total Equity & Minority Interest	22,467	...	Marketable securities	...	34,837	Product revenue	
Recent Dividends:			Contract assets	...	1,694	Contribution revenue	423	11,046	
1. Sypris Solutions, Inc. common. No dividends paid.			Prepaid expenses & other current assets	5,454	7,394	Total revenue	7,193	22,305	
Annual Dividends:			Total current assets	144,980	211,392	Cost of product revenue	15,363	21,101	
1. Sypris Solutions, Inc. common. No dividends paid.			Laboratory equipment	...	9,140	Research & development expense	14,153	25,775	
SYROS PHARMACEUTICALS INC			Computer equipment	2,200	2,036	Selling, general & administrative expense	24,830	30,625	
Annual Report			Furniture & fixtures	1,075	1,075	Total costs & expenses	56,857	77,501	
Consolidated Income Statement, Years Ended Dec. 31			Leasehold improvements	11,657	11,657	Impairment of property and equipment	
(\$000):			Property & equipment, gross	14,932	23,908	Income (loss) from operations	(49,664)	(55,196)	
Revenue	9,936	...	Less: accumulated depreciation	7,634	12,555	Interest income	...	8	
Revenue	9,936	14,880	Property & equipment, net	7,298	11,353	Interest expense to related party	5,343	...	
Research & development expenses	108,153	111,944	Other long-term assets	1,592	5,348	Interest expense	...	6,084	
General & administrative expenses	28,282	29,299	Restricted cash	2,119	3,086	Change in fair value of derivative instrument	...	(1,088)	
Transaction related expenses	...	9,510	Right-of-use asset - operating lease	12,185	13,231	Change in fair value of warrant liability	5,891	326	
Restructuring	2,489	...	Right-of-use assets - financing leases	...	76	Other income	(495)	125	
Total operating expenses	138,924	150,753	Total assets	168,174	244,486	Other expense	...	15	
Income (loss) from operations	(128,988)	(135,873)	Accounts payable	11,544	6,411	Other losses	...	79	
Interest income	6,816	2,132	External research & preclinical development	8,001	8,219	Change in fair value of derivative related to Term Loan with related party	(466)	...	
Interest expense	5,127	4,134	Employee compensation & benefits	6,993	8,529	Total other income (expense)	(413)	(6,807)	
Change in fair value of warrant liabilities	(37,275)	43,221	Professional fees	1,015	1,164	Net income (loss)	(50,077)	(62,003)	
Net income (loss)	(164,574)	(94,654)	Facilities & other accrued expenses	...	54	Deemed dividend on series A redeemable convertible preferred stock	...	330	
Net income (loss) applicable to common stockholders	...	(94,654)	Facilities and other accrued expenses	16,146	17,966	Net income (loss) attributable to common stockholders	(50,077)	(62,333)	
			Deferred revenue, current portion	...	4,330	Weighted average shares outstanding - basis	2,610	2,610	
			Financing & capital lease obligations, current portion	...	65	Weighted average shares outstanding	...	51	
			Operating lease obligation, current portion	2,324	2,006	Current Portion of	...	32	

- diluted	2,610	□51	□32
Year end shares outstanding	4,058	□□77	□33
Net earnings (loss) per share - basic	\$(19.19)	□\$(1,222.00)	□\$(1,550.00)
Net earnings (loss) per share - diluted	\$(19.19)	□\$(1,222.00)	□\$(1,550.00)
Number of full time employees	113	□158	□182
Number of common stockholders	13	□□14	□□11
Income from cont operations before income tax	(50,077)
Earnings per share from continuing operations	\$(19.19)
Earnings per share from continuing operations	\$(19.19)
Total number of employees	113

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-100 stock split, October 13, 2023; □ Adjusted for 1-for-50 stock split, October 13, 2022; □ Shares increased due to the effect of issuance of common stock from vesting of stock, exercise of stock options and, employee stock purchase plan, from secondary offering and split adjustment; □ As is; □ As of March 27, 2023; □ As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	15,689	10,329
Accounts receivable	1,420	2,163
Raw materials	1,497	2,004
Work-in-process	1,441	1,176
Finished goods	1,881	1,105
Inventories	4,819	4,285
Prepaid expenses & other current assets	3,261	2,582
Total current assets	25,189	19,359
Office & computer equipment	778	757
Software	...	783
Laboratory equipment	5,104	5,570
Furniture	198	197
Manufacturing equipment	1,109	1,454
Manufacturing tooling & molds	371	494
T2-owned instruments & components	...	4,052
Leased T2-owned instruments	1,059	1,014
Leasehold improvements	3,608	3,784
Construction in progress	23	685
Machinery equipment	710	...
Construction in progress - instruments	3,549	...
Property & equipment, gross	16,509	18,790
Less accumulated depreciation & amortization	14,851	14,257
Property & equipment, net	1,658	4,533
Operating lease right-of-use assets	7,395	8,741
Restricted cash	551	1,551
Other assets	4	143
Total assets	34,797	34,327
Accounts payable	1,527	1,296
Accrued payroll & compensation	2,705	2,930
Accrued research & development expenses	4,905	1,097
Accrued professional services	554	1,626
Accrued interest	285	1,009
Other accrued expenses	522	607
Accrued final fee	4,807	...
Operating lease liability	1,616	1,352

Warrant liability	...	39
Deferred revenue	224	172
Derivative liability	235	...
Accrued interest	839	...
Derivative liability related to Term Loan	1,554	...
Notes payable to related party	41,284	...
Total current liabilities	56,152	10,128
Notes payable	...	49,651
Operating lease liabilities, net of current portion	6,598	8,214
Deferred revenue, net of current portion	83	52
Derivative liability	...	1,088
Accrued interest on term loan	...	4,849
Total liabilities	62,833	73,982
Common stock	4	8
Additional paid-in capital	556,256	494,556
Accumulated deficit	(584,296)	...
Retained earnings (accumulated deficit)	...	(534,219)
Total stockholders' equity (deficit)	(28,036)	(39,655)
Total Equity	(28,036)	...

Recent Dividends:

1. T2 Biosystems Inc common.
No dividends paid.
Annual Dividends:
1. T2 Biosystems Inc common.
No dividends paid.

TFF PHARMACEUTICALS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Grant revenue	...	495,805	88,161
Research & development	12,061,422	18,496,340	21,300,865
General & administrative	10,567,111	13,796,255	10,573,954
Total operating expenses	22,628,533	32,292,595	31,874,819
Income (loss) from operations	(21,894,662)	(31,796,790)	(31,786,658)
Other income	696,714
Revenue	733,871
Total revenues	733,871
Interest income	266,188	26,728	51,232
Change in fair value of note receivable	385,243
Net income before Tax	(21,243,231)
Total other income (expense)	651,431	26,728	747,946
Net income (loss)	(21,243,231)	(31,770,062)	(31,038,712)
Net income (loss) applicable to common stock	...	(31,770,062)	(31,038,712)
Weighted average shares outstanding - basic	1,792,551	□1,199,191	992,839
Weighted average shares outstanding - diluted	1,792,551	□1,199,191	992,839
Year end shares outstanding	2,370,000	□□1,447,723	1,014,871
Net earning (loss) per share - basic	\$(11.85)	□\$(26.50)	\$(31.25)
Net earning (loss) per share - diluted	\$(11.85)	□\$(26.50)	\$(31.25)
Full-Time Employees (Period End)	19
Total number of employees	19	15	...
Number of common stockholders	6	□6	□7

Foreign currency translation adjustments	...	(90,374)	2,617
--	-----	----------	-------

□ Adjusted for 1-for-25 stock split, December 19, 2023; □ Shares increased due to the effect of sales of common stock through the at-the-market offering, sales of common stock and warrants through public offering, and stock for stock option exercises; □ As of March 21, 2023; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	5,478,113	16,612,315
Research & development tax incentive receivable	433,852	186,507
Prepaid assets & other current assets	1,678,353	2,226,344
Total current assets	7,590,318	19,025,166
Operating lease right-of-use asset, net	119,529	196,044
Property & equipment, net	1,999,781	3,078,342
Other assets	7,688	7,688
Note receivable - Augmenta	2,310,000	...
Note receivable - Augmenta Bioworks, Inc.	...	1,812,975
Total assets	12,027,316	24,120,215
Accounts payable	958,442	919,607
Accrued compensation	568,689	4,430
Deferred research grant revenue	101,000	126,000
Current portion of operating lease liability	83,512	80,625
Accrued liabilities	1,285,586	...
Accrued liabilities - Balancing value	716,897	...
Total current liabilities	2,428,540	1,130,662
Operating lease liability, net of current portion	31,742	110,094
Total liabilities	2,460,282	1,240,756
Common stock	2,370	36,193
Additional paid-in capital	128,044,509	120,070,983
Accumulated other comprehensive income (loss)	(148,192)	(139,295)
Accumulated deficit	(118,331,653)	...
Retained earnings (accumulated deficit)	...	(97,088,422)
Total stockholders' equity (deficit)	9,567,034	22,879,459
Total Equity	9,567,034	...

Recent Dividends:

1. TFF Pharmaceuticals Inc common.
No dividends paid.
Annual Dividends:
1. TFF Pharmaceuticals Inc common.
No dividends paid.

THERAPEUTICSMD INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021 (revised)
Product revenue, net	1,302,000
License revenue	...	69,963,000	2,573,000
Total revenue, net	1,302,000	69,963,000	2,573,000
Cost of revenue	...	1,397,000	1,402,000
Gross profit	1,302,000	68,566,000	1,171,000
General & administration expense	8,903,000	57,903,000	80,748,000
Restructuring expense	...	9,472,000	...
Depreciation & amortization	922,000
Total operating expense	9,825,000	67,375,000	80,748,000
Income (loss) from operations	(8,523,000)	1,191,000	(79,577,000)

Other income (expense), net	781,000	(117,000)	272,000	proceeding costs	253,000	2,334,000	Income (loss) from operations	(43,954)	(37,708)	(19,004)
Total other income (expense), net	781,000	(117,000)	272,000	Other prepaid costs	1,448,000	...	Change in fair value of anti-dilution right liability	(682)
Income (loss) from continuing operations before income taxes	(7,742,000)	1,074,000	(79,305,000)	Other prepaid & other current assets	2,533,000	Change in fair value of preferred stock tranche liability	(9,928)
Provision (benefit) for income taxes	(43,000)	0	...	Prepaid & other current assets	4,035,000	6,034,000	Other income	22	2,553	5
Net income (loss) from continuing operations	(7,699,000)	1,074,000	(79,305,000)	Current assets of discontinued operations	344,000	...	Interest Income	13,108
Income discontinued operations	(2,579,000)	Computer software	375,000	375,000	Total other income (expense), net	13,130	2,553	(10,605)
Income (loss) from discontinued operations, net of income taxes	110,923,000	(93,110,000)	Equipment	1,167,000	...	Net income (loss)	(30,824)	(35,155)	(29,609)
Net income (loss) from discontinued operations	(2,579,000)	Leasehold improvements	49,000	49,000	Weighted average shares outstanding			
Net income (loss) from discontinued operations	(10,278,000)	111,997,000	(172,415,000)	Property & equipment, gross	2,522,000	2,523,000	- basic	39,645	13,426	[Ⓐ] 4,043
Weighted average shares outstanding				Less accumulated depreciation	2,522,000	2,445,000	Weighted average shares outstanding			
- basic	10,441,000	9,028,000	[Ⓐ] 7,960,000	Fixed assets, net	78,000	- diluted	39,645	13,426	[Ⓐ] 4,043
Weighted average shares outstanding - diluted	10,441,000	9,366,000	[Ⓐ] 7,960,000	License rights & other intangible assets, net	6,098,000	6,943,000	Year end shares outstanding	40,105	[Ⓒ] 39,377	[Ⓐ] 4,237
Year end shares outstanding	11,532,000	9,498,000	[Ⓐ] [Ⓒ] 8,598,000	Right-of-use asset	6,873,000	7,580,000	Net income (loss) per share - basic	\$(0.78)	\$(2.62)	[Ⓐ] \$(7.32)
Earnings (loss) per share from continuing operations - basic	\$(0.74)	\$0.12	\$(9.96)	Royalty receivable, long term	18,484,000	20,253,000	Net income (loss) per share - diluted	\$(0.78)	\$(2.62)	[Ⓐ] \$(7.32)
Earnings per share-inc from discontinued oper	\$(0.25)	Other non-current assets	58,000	253,000	Number of full time employees	30	[Ⓐ] 28	[Ⓐ] [Ⓒ] 16
Earnings (loss) per share from discontinued operations - basic	\$(0.25)	\$12.29	\$(11.70)	Total assets	43,309,000	90,458,000	Number of common stockholders	8	[Ⓐ] [Ⓒ] 24	[Ⓐ] [Ⓒ] 11
Net earnings (loss) per share - basic	\$(0.98)	\$12.41	[Ⓐ] \$(21.66)	Accounts payable	27,000	2,162,000	Income from cont operations before income tax	(30,824)
Earnings (loss) per share from continuing operations - diluted	\$(0.74)	\$0.11	\$(9.96)	Payroll & related costs	762,000	8,748,000	Total number of employees	30
Earn per share-inc from discount ops - diluted	\$(0.25)	Accrued contract termination costs	4,700,000				
Earnings (loss) per share from discontinued operations - diluted	\$(0.25)	\$11.84	\$(11.70)	Research & development expenses	978,000				
Net earnings (loss) per share - diluted	\$(0.98)	\$11.96	[Ⓐ] \$(21.66)	Professional fees	489,000	415,000				
Number of full time employees	1	1	...	Operating lease liabilities	1,473,000	1,390,000				
Total number of employees	1	Prepaid royalty	1,011,000				
Number of common stockholders	80	[Ⓐ] 40,366	...	Other accrued expenses & other current liabilities	409,000	1,604,000				
				Accrued expenses & other current liabilities	3,133,000	18,846,000				
				Liabilities of discontinued operations-current	3,694,000	25,831,000				
				Total current liabilities	6,854,000	46,839,000				
				Operating lease liabilities, non-current	6,532,000	7,369,000				
				Other non-current liabilities	636,000	1,107,000				
				Total liabilities	14,022,000	55,315,000	Cash & cash equivalents	269,070	288,877	
				Common stock	11,000	9,000	Prepaid expenses & other current assets	3,376	3,958	
				Additional paid in capital	978,917,000	974,497,000	Total current assets	272,446	292,835	
				Retained earnings (accumulated deficit)	(949,641,000)	(939,363,000)	Restricted cash	453	441	
				Total stockholders' equity (deficit)	29,287,000	35,143,000	Construction in progress	16	
				Total Equity	29,287,000	...	Computer equipment	20	
							Leasehold Improvements -			
							Gross	109	...	
							Office furniture - Other			
							- Gross	44	...	
							Computer Equipment -			
							Tangible Assets - Gross	51	...	
							Property, plant & equipment, gross	204	36	
							Less: accumulated depreciation	35	1	
							Property & equipment, net	169	35	
							Right of use asset	3,763	4,327	
							Other assets	880	1,037	
							Total assets	277,711	298,675	
							Accounts payable	1,838	2,087	
							Accrued research & development expenses	1,444	
							Accrued professional fees	339	
							Accrued employee compensation & related benefits	2,232	1,165	
							Other accrued expenses & other current liabilities	233	
							Accrued expenses & other current liabilities & other	563	3,181	
							Operating lease liability, current	745	385	
							Other Current Liabilities	40	...	

[Ⓐ] Restated to reflect discontinued operations of vitaCare Prescription Services, Inc. and ANNOVERA; [Ⓑ] Adjusted for 1-for-50 stock split, May 9, 2022; [Ⓒ] Shares increased due to the effect of shares issued for sale of common stock, net of cost; [Ⓓ] As of February 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022				
Cash and cash equivalents	4,327,000	...	Research & development expenses	23,964	24,407	15,748
Cash	38,067,000	General & administrative expenses	19,990	13,301	3,256
Restricted cash	11,250,000	Total operating expenses	43,954	37,708	19,004
Royalty receivable, current portion	3,090,000	...				
Capitalized legal	2,334,000	...				
Prepaid insurance	1,167,000				
Paragraph IV legal				

Recent Dividends:
1. TherapeuticsMD Inc class B preferred.
No dividends paid.
2. TherapeuticsMD Inc common.
No dividends paid.
Annual Dividends:
1. TherapeuticsMD Inc class B preferred.
No dividends paid.
2. TherapeuticsMD Inc common.
No dividends paid.

**THIRD HARMONIC BIO INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	[Ⓐ] 2021 (revised)
Research & development expenses	23,964	24,407	15,748
General & administrative expenses	19,990	13,301	3,256
Total operating expenses	43,954	37,708	19,004
Income (loss) from operations	(43,954)	(37,708)	(19,004)
Change in fair value of anti-dilution right liability	(682)
Change in fair value of preferred stock tranche liability	(9,928)
Other income	22	2,553	5
Interest Income	13,108
Total other income (expense), net	13,130	2,553	(10,605)
Net income (loss)	(30,824)	(35,155)	(29,609)
Weighted average shares outstanding			
- basic	39,645	13,426	[Ⓐ] 4,043
Weighted average shares outstanding			
- diluted	39,645	13,426	[Ⓐ] 4,043
Year end shares outstanding	40,105	[Ⓒ] 39,377	[Ⓐ] 4,237
Net income (loss) per share - basic	\$(0.78)	\$(2.62)	[Ⓐ] \$(7.32)
Net income (loss) per share - diluted	\$(0.78)	\$(2.62)	[Ⓐ] \$(7.32)
Number of full time employees	30	[Ⓐ] 28	[Ⓐ] [Ⓒ] 16
Number of common stockholders	8	[Ⓐ] [Ⓒ] 24	[Ⓐ] [Ⓒ] 11
Income from cont operations before income tax	(30,824)
Total number of employees	30

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	269,070	288,877
Prepaid expenses & other current assets	3,376	3,958
Total current assets	272,446	292,835
Restricted cash	453	441
Construction in progress	16
Computer equipment	20
Leasehold Improvements -		
Gross	109	...
Office furniture - Other		
- Gross	44	...
Computer Equipment -		
Tangible Assets - Gross	51	...
Property, plant & equipment, gross	204	36
Less: accumulated depreciation	35	1
Property & equipment, net	169	35
Right of use asset	3,763	4,327
Other assets	880	1,037
Total assets	277,711	298,675
Accounts payable	1,838	2,087
Accrued research & development expenses	1,444
Accrued professional fees	339
Accrued employee compensation & related benefits	2,232	1,165
Other accrued expenses & other current liabilities	233
Accrued expenses & other current liabilities & other	563	3,181
Operating lease liability, current	745	385
Other Current Liabilities	40	...

Accrued expenses and other current liabilities			
- Balancing value	2,835
Total current liabilities	5,418	5,653	...
Operating lease liability, noncurrent	3,208	3,954	...
Total liabilities	8,626	9,607	...
Common stock	4	4	...
Additional paid-in capital	383,301	372,460	...
Retained earnings (accumulated deficit)	(114,220)	(83,396)	...
Total stockholders' equity (deficit)	269,085	289,068	...
Total Equity	269,085

Recent Dividends:

1. Third Harmonic Bio Inc common.

No dividends paid.

Annual Dividends:

1. Third Harmonic Bio Inc common.

No dividends paid.

THUNDER BRIDGE CAPITAL PARTNERS IV INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
		(revised)	(revised)
Formation costs & other operating expenses	1,389,821	3,075,258	905,815
Income (loss) from operations	(1,389,821)	(3,075,258)	(905,815)
Interest income	6,158,350	3,409,917	7,854
Change in fair value of warrant liability	537,211	3,202,088	732,055
Income (loss) before income taxes	5,305,740	3,536,747	(165,906)
Provision for income taxes	1,210,504	674,439	...
Net income (loss)	4,095,236	2,862,308	(165,906)
Weighted average class A shares outstanding - basic	12,262,874
Weighted average class B shares outstanding - basic	5,741,402
Weighted average shares outstanding - basic	19,953,105	30,214,036	...
Weighted average class A shares outstanding - diluted	12,262,874
Weighted average class B shares outstanding - diluted	5,741,402
Weighted average shares outstanding - diluted	19,953,105	30,214,036	...
Year end shares outstanding	10,078,337	30,214,035	30,214,036
Net earnings (loss) per share - basic	\$0.21	\$0.09	...
Earnings (loss) per class A share - basic	\$(0.01)
Earnings (loss) per class B share - basic	\$(0.01)
Net earnings (loss) per share - diluted	\$0.21	\$0.09	...
Earnings (loss) per class A share - diluted	\$(0.01)
Earnings (loss) per class B share - diluted	\$(0.01)
Total number of employees	2
Number of class A common stockholders	4	...	1

☐ Restated to reflect correction of errors; ☑ From January 7, 2021 (inception); ☒ Reclassified to conform with 2022 presentation; ☓ As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
		(revised)
Cash	13,002	32,022
Prepaid expenses	5,002	121,217
Total current assets	18,004	153,239
Cash & marketable securities held in trust account	37,273,384	239,770,045
Total assets	37,291,388	239,923,284
Accounts payable & accrued expenses	1,664,765	2,126,638
Income taxes payable	2,070,896	...
Promissory note payable - related party, at fair value	781,000	206,000
Excise taxes payable	1,460,954	674,439
Total current liabilities	5,977,615	3,007,077
Warrant liability	390,110	927,321
Deferred underwriting fee payable	8,278,474	8,278,474
Total liabilities	14,646,199	12,212,872
Class A common stock	37,025,930	591
Class B common stock	656	239,406,682
Accumulated deficit	(14,381,397)	(11,696,926)
Common stock value	...	65
Total stockholders' equity (deficit)	22,645,189	227,710,412
Total Equity	22,645,189	227,710,412

Recent Dividends:

1. Thunder Bridge Capital Partners IV Inc subject to possible redemption.

No dividends paid.

2. Thunder Bridge Capital Partners IV Inc class B common.

No dividends paid.

3. Thunder Bridge Capital Partners IV Inc class A common.

No dividends paid.

Annual Dividends:

1. Thunder Bridge Capital Partners IV Inc subject to possible redemption.

No dividends paid.

2. Thunder Bridge Capital Partners IV Inc class B common.

No dividends paid.

3. Thunder Bridge Capital Partners IV Inc class A common.

No dividends paid.

TILRAY BRANDS INC

Earnings, 9 mos. to (Consol. - \$000):

	02/29/24	02/28/23
Total Revenues	559,060	442,936
Net Sales	559,060	...
Cost & expenses	651,579	1,650,769
Operating income	(158,219)	(1,279,705)
Interest expense	26,977	8,560
Other income (expense), net	(10,792)	(21,079)
Gains or losses	(11,969)	(2,529)
Foreign currency	1,941	(26,621)
Net before taxes	(206,016)	(1,338,494)
Income taxes	1,013	(15,313)
Net income	(207,029)	(1,323,181)
Earnings common share		
Primary	\$(0.29)	\$(2.20)
Fully Diluted	\$(0.29)	\$(2.20)
Common Shares:		
Full Diluted	725,347	597,830
Year-end	774,028	617,857

TITAN MACHINERY, INC.

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$):

	2024	2023	2022
			(revised)
Revenue - equipment	1,711,559,000	1,291,684,000	...
Revenue - parts	327,196,000	266,916,000	...
Revenue - service	129,803,000	115,641,000	...
Revenue - rental & other	44,973,000	40,748,000	37,665,000
Equipment	2,145,316,000
Parts	410,841,000

Service	157,315,000
Total revenue	2,758,445,000	2,209,306,000	1,711,906,000
Cost of revenue - equipment	1,864,558,000	1,477,539,000	1,130,205,000
Cost of revenue - parts	279,921,000	220,418,000	186,324,000
Cost of revenue - service	53,981,000	46,208,000	38,771,000
Cost of revenue - rental & other	28,631,000	25,302,000	23,882,000
Total cost of revenue	2,227,091,000	1,769,467,000	1,379,182,000
Gross profit	531,354,000	439,839,000	332,724,000
Operating expenses	362,509,000	301,516,000	241,044,000
Impairment of intangible & long-lived assets	1,498,000
Income (loss) from operations	168,845,000	138,323,000	90,182,000
Interest income & other income (expense)	3,300,000	3,862,000	2,431,000
Floorplan interest expense	...	1,875,000	1,175,000
Subordinated debt interest expense	13,802,000
Other interest expense	7,303,000	5,069,000	4,537,000
Income (loss) before income taxes - United States	130,438,000	115,044,000	74,349,000
Income (loss) before income taxes - foreign	20,602,000	20,197,000	12,552,000
Income (loss) before income taxes	151,040,000	135,241,000	86,901,000
Current federal income taxes	24,074,000	15,943,000	10,348,000
Current state income taxes	7,020,000	5,776,000	3,316,000
Current foreign income taxes	4,595,000	4,015,000	2,875,000
Total currently payable	35,689,000	25,734,000	16,539,000
Deferred federal income taxes	2,280,000	6,310,000	3,978,000
Deferred state income taxes	266,000	1,210,000	772,000
Deferred foreign income taxes	364,000	119,000	(435,000)
Deferred income taxes (benefit)	2,910,000	7,639,000	4,315,000
Provision for (benefit from) income taxes	38,599,000	33,373,000	20,854,000
Net income (loss)	112,441,000	101,868,000	66,047,000
Allocated to participating securities	1,519,000	1,295,000	977,000
Net income (loss) attributable to Titan Machinery Inc. common stockholders	110,922,000	100,573,000	65,070,000
Weighted average shares outstanding - basic	22,493,000	22,373,000	22,238,000
Weighted average shares outstanding - diluted	22,499,000	22,380,000	22,248,000
Year end shares outstanding	22,848,138	22,697,761	22,587,859
Income (loss) per share from continuing operations - basic	\$4.93
Net income (loss) per share - basic	\$4.93	\$4.50	\$2.93
Income (loss) per share from continuing operations - diluted	\$4.93
Net income (loss)

per share - diluted	\$4.93	\$4.49	\$2.92	accumulated amortization	53,356,000	18,411,000	Operating income (loss)	(118,380,000)	(112,091,000)	(92,312,000)
Number of full time employees	3,338	2,700	2,288	Other noncurrent assets	1,783,000	1,178,000	Other income	1,722,000
Number of part time employees	266	186	148	Total non-current assets	473,246,000	319,445,000	Interest income, net	...	1,873,000	25,000
Number of common stockholders	695	580	575	Total assets	1,992,261,000	1,188,695,000	Net income (loss)	(116,658,000)	(110,218,000)	(92,287,000)
Foreign currency translation adjustments	(2,847,000)	Accounts payable	43,846,000	40,834,000	Preferred stock deemed dividend	...	6,659,000	...
Total number of employees	3,604	Floorplan payable	...	258,372,000	Net income (loss) available to common stockholders	(116,658,000)	(116,877,000)	(92,287,000)
				Senior convertible notes	893,846,000	...	Weighted average shares outstanding			
				Current maturities of long-term debt	13,706,000	7,241,000	- basic	17,039,309	5,718,249	1,821,969
				Current maturities of operating leases	10,751,000	9,855,000	Weighted average shares outstanding			
				Deferred revenue	115,852,000	119,845,000	- diluted	17,039,309	5,718,249	1,821,969
				Accrued compensation	43,375,000	39,026,000	Year end shares outstanding	58,614,593	12,236,585	2,502,124
				Accrued sales, payroll, real estate & value added taxes	...	7,357,000	Net income (loss) per common share - basic	\$(6.85)	\$(20.44)	\$(50.63)
				Accrued sales & payroll taxes	8,075,000	...	Net income (loss) per common share - diluted	\$(6.85)	\$(20.44)	\$(50.63)
				Accrued interest	5,212,000	487,000	Number of full time employees	...	117	73
				Accrued insurance	...	4,291,000	Number of common stockholders	228	231	233
				Lease residual value guarantees	...	193,000	Foreign currency translation adjustments	(75,000)	(30,000)	...
				Finance lease liabilities	...	577,000	Income from cont operations before income tax	(116,658,000)
				Other accrued expenses & other current liabilities	17,738,000	6,228,000	Earnings per share from continuing operations	\$(6.85)
				Accrued expenses & other current liabilities	74,400,000	58,159,000	Earnings per share from continuing operations	\$(6.85)
				Income taxes payable	...	3,845,000				
				Total current liabilities	1,152,401,000	498,151,000				
				Operating lease liabilities	50,964,000	48,513,000				
				Secured mortgage loans	...	68,689,000				
				Sale-leaseback financing obligations	...	11,252,000				
				Secured vehicle loans	...	12,659,000				
				Other long-term debt	...	4,591,000				
				Less: current maturities	...	7,241,000				
				Subordinated Debentures	106,407,000	...				
				Deferred income taxes	22,607,000	9,563,000				
				Other long-term liabilities	2,240,000	6,212,000				
				Total long-term liabilities	182,218,000	154,238,000				
				Common stock	228	...				
				Additional paid-in capital	258,657,000	256,541,000				
				Retained earnings (accumulated deficit)	397,225,000	284,784,000				
				Foreign currency translation adjustment	(951,000)	(7,730,000)				
				Net investment hedging instruments, unrealized gain	2,711,000	2,711,000				
				Accumulated other comprehensive income (loss)	1,760,000	(5,019,000)				
				Total stockholders' equity	657,642,000	536,306,000				
				Total stockholders' equity	657,642,000	536,306,000				

¹ Approximately; ² As of March 24, 2023; ³ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Jan. 31 (\$):

	2024	2023
Cash	38,066,000	43,913,000
Accounts receivable, gross	156,695,000	...
Less: allowance for doubtful accounts	3,038,000	...
Trade & unbilled receivables from contracts with customers - trade receivables due from customers	...	47,298,000
Trade & unbilled receivables from contracts with customers - unbilled receivables	...	19,764,000
Trade & unbilled receivables from contracts with customers - less allowance for expected credit losses	...	3,080,000
Trade accounts - due from finance companies	...	11,212,000
Trade & unbilled receivables from rental contracts - trade receivables	...	3,629,000
Trade & unbilled receivables from rental contracts - unbilled receivables	...	776,000
Trade & unbilled receivables from rental contracts - less allowance for expected credit losses	...	360,000
Other receivables - due from manufacturers	...	15,007,000
Other receivables	...	1,598,000
Receivables, net	153,657,000	95,844,000
New equipment	745,445,000	369,828,000
Used equipment	347,041,000	164,761,000
Parts & attachments	203,124,000	164,553,000
Work in process	7,420,000	4,797,000
Inventories	1,303,030,000	703,939,000
Prepaid expenses & other current assets	...	25,554,000
Prepaid expenses and other	24,262,000	...
Total current assets	1,519,015,000	869,250,000
Rental fleet equipment	79,308,000	75,386,000
Machinery & equipment	31,760,000	27,220,000
Vehicles	103,765,000	80,122,000
Furniture & fixtures	...	53,937,000
Land, buildings & leasehold improvements	57,935,000	140,773,000
Land, buildings, and leasehold improvements	204,992,000	...
Property & equipment, gross	477,760,000	377,438,000
Less: accumulated depreciation	178,986,000	159,656,000
Property & equipment, net	298,774,000	217,782,000
Operating lease assets	54,699,000	50,206,000
Deferred income taxes	529,000	1,246,000
Goodwill	64,105,000	30,622,000
Intangible assets, net of

Recent Dividends:

1. Titan Machinery, Inc. common.

No dividends paid.

Annual Dividends:

1. Titan Machinery, Inc. common.

No dividends paid.

TONIX PHARMACEUTICALS HOLDING CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	¹ 2021
Revenue Sales of Goods & Services	7,768,000
Cost of sales	4,741,000
Research & development	86,655,000	81,876,000	68,838,000
General & administrative	34,752,000	30,215,000	23,474,000
Total costs & expenses	112,091,000	92,312,000	...
Total cost & expenses	126,148,000

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	24,948,000	120,229,000
Contract-related	...	8,043,000
Prepaid insurance	...	1,275,000
Other prepaid expenses & other current assets	...	1,230,000
Prepaid expenses & other current assets	9,181,000	10,548,000
Inventory	13,639,000	...
Raw Materials	3,611,000	...
Work-in-process	2,539,000	...
Finished Goods	7,510,000	...
Inventory reserves	(21,000)	...
Total current assets	47,768,000	130,777,000
Land	8,011,000	8,011,000
Land improvements	326,000	79,000
Building	66,749,000	65,644,000
Office furniture & equipment	2,366,000	1,893,000
Laboratory equipment	21,904,000	18,440,000
Leasehold improvements	34,000	34,000
Construction in progress	...	1,366,000
Property & equipment, gross	99,390,000	95,467,000
Less: accumulated depreciation & amortization - property & equipment	5,362,000	1,653,000

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-6.25 stock split, May 10, 2023; ³ Adjusted for 1-for-32 stock split, May 17, 2022; ⁴ Shares increased due to the effect of issuance of common stock under at-the-market offering, purchase agreement and employee stock purchase plan; ⁵ Shares increased due to the effect of issuance of common stock for transactional expenses, exercise of warrants, acquisition of license, employee stock purchase plan and purchase agreements; ⁶ As of March 13, 2023; ⁷ As of March 14, 2022; ⁸ As of March 10, 2023; ⁹ As of March 11, 2022

Property & equipment, net.....	94,028,000	93,814,000	operations before income taxes - United States	9,636,000	3,723,000	operations - diluted	\$0.80	\$0.53	\$0.07
Operating lease right-to-use assets	824,000	715,000	Income (loss) from continuing operations before income taxes - foreign	322,000	(1,030,000)	Earn per share-inc from discount opers - diluted	\$0.03
Goodwill	965,000	...	Income from continuing operations before income taxes	17,113,000	9,958,000	2,693,000	Income (loss) per share from discontinued operations - diluted	\$0.03
Intangible asset	9,743,000	...	Federal income tax expense (benefit) - current	1,772,000	593,000	Net income (loss) per share - diluted	\$0.83	\$0.53	\$0.07
Other non-current assets	1,129,000	384,000	Federal income tax expense (benefit) - deferred	528,000	493,000	Number of full time employees	223	237	214
Total assets	154,457,000	225,690,000	State income tax expense - current	376,000	197,000	Total number of employees	223
Accounts payable	3,782,000	8,068,000	State income tax expense (benefit) - deferred	221,000	219,000	Number of common stockholders	175	...	176
Contract-related	2,980,000	3,273,000	Foreign income tax expense - current	348,000	183,000	Foreign currency translation adjustments	(1,112,000)	...
Compensation & compensation-related expenses	4,361,000	3,645,000	Foreign income tax expense - current	25,000	93,000	☐ Approximately; ☒ As of March 16, 2022 Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
Construction in progress	2,103,000	deferred	2023	2022		
Professional fees & other current liabilities	659,000	Federal Current Tax ..	3,267,000	(revised)			
Accrued expenses & other current liabilities	743,000	9,680,000	State Current Tax ..	664,000	Cash & cash equivalents	15,713,000	18,693,000	
Lease liability, short term	270,000	432,000	Foreign Current Tax ..	1,126,000	Accounts receivable, gross	14,449,000	15,288,000	
Accrued interest, related party	12,482,000	...	Federal Deferred Tax	7,000	Less: allowance for doubtful accounts	1,484,000	1,468,000	
Professional fees and other	1,398,000	...	State Deferred Tax ..	72,000	Accounts receivable, net	12,965,000	13,820,000	
Term loan payable, short term	2,350,000	...	Current Tax - Total ..	5,057,000	Prepaid income taxes	629,000	1,778,000	
Upsher Smith obligation	3,000,000	...	Deferred Tax - Foreign	(31,000)	Prepaid expenses	1,084,000	764,000	
Total current liabilities	18,884,000	18,180,000	Deferred Tax - Foreign	Notes receivable - current	232,000	
Lease liability, long-term	632,000	328,000	Total	48,000	Deposits	286,000	153,000	
Term loan payable, long term	6,561,000	...	Income tax expense (benefit)	5,105,000	3,270,000	1,778,000	Other current assets	90,000	140,000	
Series C Warrant Liabilities	14,595,000	...	Income (loss) from continuing operations	12,008,000	6,688,000	915,000	Assets from discontinued operations	1,000	11,000	
Series D Warrant Liabilities	8,260,000	...	Income (loss) from discontinued operations, net of tax	(59,000)	(13,000)	Prepaid expenses and other	1,460,000	1,289,000	
Total liabilities	48,932,000	18,508,000	Net income (loss) attributable to non-controlling interest	(102,000)	5,000	9,000	Total current assets	30,768,000	35,591,000	
Common stock	59,000	76,000	Travelzoo	12,366,000	6,634,000	911,000	Deposits & other assets	1,115,000	5,094,000	
Additional paid in capital	706,356,000	677,311,000	Weighted average shares outstanding - basic	14,897,000	12,372,000	11,646,000	Deferred tax assets	3,196,000	3,222,000	
Accumulated deficit	(600,658,000)	...	Weighted average shares outstanding - diluted	14,964,000	12,561,000	12,991,000	Restricted cash	675,000	675,000	
Retained earnings (accumulated deficit)	(470,038,000)	Year end shares outstanding	13,575,000	15,704,000	12,056,000	Operating lease right-of-use assets	6,015,000	7,440,000	
Accumulated other comprehensive income (loss)	(232,000)	(167,000)	Income (loss) per share from continuing operations - basic	\$0.80	\$0.54	\$0.08	Office equipment & office furniture	2,141,000	5,005,000	
Total stockholders' equity (deficiency)	105,525,000	207,182,000	Income (loss) per share from discontinued operations - basic	\$0.03	Capitalized internal-use software & website development	45,000	1,728,000	
Total Equity	105,525,000	...	Net income (loss) attributable to non-controlling interest	(102,000)	5,000	9,000	Leasehold improvements	804,000	2,414,000	
Recent Dividends:										
1. Tonix Pharmaceuticals Holding Corp common.										
No dividends paid.										
2. Tonix Pharmaceuticals Holding Corp series A convertible preferred.										
No dividends paid.										
Annual Dividends:										
1. Tonix Pharmaceuticals Holding Corp common.										
No dividends paid.										
2. Tonix Pharmaceuticals Holding Corp series A convertible preferred.										
No dividends paid.										
TRAVELZOO										
Annual Report										
Consolidated Income Statement, Years Ended Dec. 31 (\$):										
	2023	2022	2021							
		(revised)	(revised)							
Revenues	84,477,000							
Revenues	84,477,000	70,599,000	62,712,000							
Cost of revenues	10,934,000	10,003,000	11,388,000							
Gross profit	73,543,000	60,596,000	51,324,000							
Sales & marketing	37,774,000	33,072,000	30,294,000							
Product development	2,113,000	2,064,000	2,590,000							
General & administrative	18,084,000	17,903,000	19,753,000							
Total operating expenses	57,971,000	53,039,000	52,637,000							
Operating income (loss)	15,572,000	7,557,000	(1,313,000)							
Other income (loss), net	1,541,000	2,401,000	4,006,000							
Income from continuing operations before income taxes							
Income from discontinued operations, net of income taxes	460,000	...							
Net income (loss)	12,468,000	6,629,000	902,000						
Net income (loss) attributable to non-controlling interest	(102,000)	5,000	9,000						
Net income (loss) attributable to Travelzoo	12,366,000	6,634,000	911,000						
Weighted average shares outstanding - basic	14,897,000	12,372,000	11,646,000						
Weighted average shares outstanding - diluted	14,964,000	12,561,000	12,991,000						
Year end shares outstanding	13,575,000	15,704,000	12,056,000						
Income (loss) per share from continuing operations - basic	\$0.80	\$0.54	\$0.08						
Earnings per share-inc from discontinued oper	\$0.03						
Income (loss) per share from discontinued operations - basic	\$0.03						
Net income (loss) per share - basic	\$0.83	\$0.54	\$0.08						
Income (loss) per share from continuing operations						
Income (loss) per share from discontinued operations						

Long-term operating lease liabilities	6,717,000	8,326,000
Other long-term liabilities	4,681,000	1,569,000
Total liabilities	46,499,000	58,423,000
Common stock	136,000	165,000
Treasury stock, at cost	...	7,130,000
Additional paid-in capital	439,000	23,274,000
Tax indemnification	(9,537,000)	(9,537,000)
Note receivable from shareholder	(1,753,000)	(4,753,000)
Retained earnings (accumulated deficit)	19,508,000	7,142,000
Accumulated other comprehensive income (loss)	(4,607,000)	(4,905,000)
Total stockholders' equity (deficit)	4,186,000	4,256,000
Non-controlling interest	4,697,000	4,595,000
Total Equity	8,883,000	8,851,000

Recent Dividends:**1. Travelzoo common.**

No dividends paid.

Annual Dividends:**1. Travelzoo common.**

No dividends paid.

ULTA BEAUTY INC**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	02/03/24	01/28/23	01/29/22 (revised)
Net sales	11,207,303	10,208,580	8,630,889
Cost of sales	6,826,203	6,164,070	5,262,335
Gross profit (loss)	4,381,100	4,044,510	3,368,554
Selling, general & administrative expenses	2,694,561	2,395,299	2,061,545
Pre-opening expenses	8,510	10,601	9,517
Operating income (loss)	1,678,029	1,638,610	1,297,492
Interest income (expense), net	17,622	4,934	(1,663)
Income (loss) before income taxes	1,695,651	1,643,544	1,295,829
Current federal provision (benefit) for income taxes	...	315,763	280,300
Current state provision (benefit) for income taxes	...	69,719	55,358
Total current provision (benefit) for income taxes	374,071	385,482	335,658
Deferred federal provision (benefit) for income taxes	27,391	11,800	(22,936)
Deferred state provision (benefit) for income taxes	3,184	3,854	(2,730)
Total deferred provision (benefit) for income taxes	30,575	15,654	(25,666)
Income tax expense (benefit)	404,646	401,136	309,992
Net income (loss)	1,291,005	1,242,408	985,837
Weighted average shares outstanding - basic	49,304	51,403	54,482
Weighted average shares outstanding - diluted	49,596	51,738	54,841
Year end shares outstanding	48,324	50,364	52,311
Net income (loss) per common share - basic	\$26.18	\$24.17	\$18.09
Net income (loss) per common share - diluted	\$26.03	\$24.01	\$17.98
Number of full time			

employees	20,000	18,500	16,500
Number of part time employees	36,000	34,500	24,000
Total number of employees	56,000
Number of common stockholders	27	27	31
Total Revenue	11,207,303
Basic EPS Excluding ExtraOrdinary Items	\$26.18
Diluted EPS Excluding ExtraOrd Items	\$26.03

Reclassified to conform with 2022 presentation; As is; Approximately; As of March 20, 2023; As of March 21, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	02/03/24	01/28/23
Cash	677,004	...
Cash and Cash Equivalents - Balancing value	89,590	...
Cash & cash equivalents	766,594	737,877
Receivables, gross	208,574	200,498
Reserve for doubtful accounts	635	1,076
Receivables, net	207,939	199,422
Merchandise inventories, net	1,742,136	1,603,451
Prepaid expenses & other current assets	115,598	130,246
Prepaid income taxes	4,251	38,308
Total current assets	2,836,518	2,709,304
Equipment & fixtures	1,297,428	1,147,870
Leasehold improvements	928,900	855,695
Electronic equipment & software	774,441	663,497
Construction-in-progress	193,260	196,117
Property & equipment, gross	3,194,029	2,863,179
Less: accumulated depreciation & amortization	2,011,694	1,853,906
Property & equipment, net	1,182,335	1,009,273
Operating lease assets	1,574,530	1,561,263
Goodwill	10,870	10,870
Other intangible assets, net	...	1,312
Deferred compensation plan assets	43,516	35,382
Other long-term assets	58,732	43,007
Developed Technology	510	...
Total assets	5,707,011	5,370,411
Accounts payable	544,001	559,527
Accrued payroll, bonus, & employee benefits	150,880	183,828
Accrued advertising	33,875	40,580
Accrued taxes	56,790	58,850
Accrued capital expenditures	42,257	55,438
Other accrued liabilities	98,666	105,582
Deferred revenue	436,591	394,677
Accrued income taxes	11,310	...
Current operating lease liabilities	283,821	283,293
Total current liabilities	1,658,191	1,681,775
Non-current operating lease liabilities	1,627,271	1,619,883
Deferred income taxes	85,921	55,346
Other long-term liabilities	56,300	53,596
Total liabilities	3,427,683	3,410,600
Common stock	491	511
Treasury stock-common, at cost	83,032	60,470
Additional paid-in capital	1,075,104	1,023,997
Retained earnings (accumulated deficit)	1,286,765	995,773
Total stockholders' equity	2,279,328	1,959,811
Total Equity	2,279,328	...

Recent Dividends:**1. Ulta Beauty Inc common.**

No dividends paid.

Annual Dividends:**1. Ulta Beauty Inc common.**

No dividends paid.

UNITED AIRLINES HOLDINGS INC**Earnings, 3 mos. to Mar 31 (Consol. - \$000):**

	2024	2023
Total Revenues	12,539,000	11,429,000
Cost & expenses	11,732,000	10,817,000
Deprec., depl. & amort.	708,000	655,000
Operating income	99,000	(43,000)
Interest income	177,000	170,000
Other income (expense), net	(10,000)	41,000
Gains or losses	(37,000)	24,000
Net before taxes	(164,000)	(256,000)
Income taxes	(40,000)	(62,000)
Net income	(124,000)	(194,000)
Balance for common	...	(194,000)
Earnings common share		
Primary	\$(0.38)	\$(0.59)
Fully Diluted	\$(0.38)	\$(0.59)
Common Shares:		
Full Diluted	328,300	327,400
Year-end	328,803	327,969

Consolidated Balance Sheet Items, as of (\$000):

	2024
Assets:	
Cash & equivalents	8,401,000
Inventories	1,675,000
Current assets	18,696,000
Net property & equip.	40,470,000
Total assets	71,902,000
Liabilities:	
Current liabilities	24,764,000
Long-term debt	23,137,000
Stockholders' equity	9,188,000
Net current assets	(6,068,000)

UNITED HEALTH PRODUCTS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Revenues	...	37,500	59
Cost of sales	...	18,644	25
Gross profit (loss)	...	18,856	34
Selling, general & administrative expenses	1,827,729	2,196,331	29,563,211
Research & development expenses	598,810	624,564	237,458
Total operating expenses	2,426,539	2,820,895	29,800,669
Income (loss) from operations	(2,426,539)	(2,802,039)	(29,800,635)
Interest expense	40,512	17,022	226,139
Interest expense - related party	75,684	61,823	392,112
Other income	...	1,402,981	304,273
Gain (loss) on settlement of debt	(80,532)	(209,598)	(434,570)
Net Income before Tax	(2,623,267)
Total other income (expense)	(196,728)	1,114,538	(748,548)
Net income (loss)	(2,623,267)	(1,687,501)	(30,549,183)
Weighted average shares outstanding - basic	239,080,282	229,718,142	225,741,684
Weighted average shares outstanding - diluted	239,080,282	229,718,142	225,741,684
Year end shares outstanding	244,783,222	230,871,034	228,667,229
Net income (loss) per common share - basic	\$(0.01)	\$(0.01)	\$(0.14)
Net income (loss) per common share - diluted	\$(0.01)	\$(0.01)	\$(0.14)

Number of full time employees.....	...	207	207
Number of common stockholders.....	401	204	213
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$(0.01)
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$(0.01)

	2023	2022	2021
Net sales	10,885,154	12,698,503	13,929,629
Total revenues	10,885,154
Cost of sales	5,479,566	5,996,376	5,747,931
Operating expenses ..	2,078,564	2,174,127	2,035,970
Research & development	463,992	490,770	478,642
Total costs & expenses	8,022,122	8,661,273	8,262,543
Income (loss) from operations	2,863,032	4,037,230	5,667,086
Dividend income	306,651
Investment income	236,695	233,857
Net gain (loss) on marketable securities	81,095	(1,046,245)	(23,018)
Total other income (loss)	387,746	(809,550)	210,839
Income (loss) before provision for income taxes	3,250,778	3,227,680	5,877,925
Current income taxes provision (benefit) - federal	609,006	850,344	1,287,749
Current income taxes provision (benefit) - state	788	1,590	96
Total current income taxes provision (benefit) ..	609,794	851,934	1,287,845
Deferred income taxes provision (benefit) ..	59,614	(193,766)	(68,462)
Total deferred income taxes provision (benefit) ..	59,614	(193,766)	(68,462)
Provision (benefit) for income taxes	669,408	658,168	1,219,383
Net income (loss)	2,581,370	2,569,512	4,658,542
Weighted average shares outstanding - basic	4,594,319	4,594,319	4,594,319
Weighted average shares outstanding - diluted	4,594,319	4,594,319	4,594,319
Year end shares outstanding	4,594,319	4,594,319	4,594,319
Earnings (loss) per share - continued operations - basic	\$0.56
Net earnings (loss) per common share - basic	\$0.56	\$0.56	\$1.01
Earnings per share from continuing operations - basic	\$0.56
Net earnings (loss) per common share - diluted	\$0.56	\$0.56	\$1.01
Dividends per common share	\$0.35	\$0.68	\$1.13
Number of full time employees	25	23	22
Number of part time employees	3	1	2
Total number of employees	28	24	24
Number of common stockholders	355	371	385

Accounts & notes receivable	1,566,839	...
Raw materials	476,501	601,125
Work in process	92,089	16,520
Finished products	654,916	1,054,367
Inventories (net)	1,223,506	1,672,012
Prepaid expenses & other current assets	191,708	201,846
Prepaid income taxes	176,220	185,228
Total current assets	12,252,713	9,970,630
Deferred income taxes, net	50,930	110,544
Land	69,000	69,000
Factory equipment & fixtures	4,669,936	4,585,055
Building & improvements	2,976,577	2,895,742
Total property, plant & equipment	7,715,513	7,549,797
Less accumulated depreciation	7,096,318	6,990,636
Total property, plant & equipment, net	619,195	559,161
Total assets	12,922,838	10,640,335
Accounts payable	134,449	30,415
Accrued bonuses	187,002	175,496
Accrued distribution fees	407,133	395,536
Payroll & related expenses	96,157	53,475
Company 401(k) contribution	109,000	94,326
Accrued annual report expenses	81,725	68,349
Accrued audit fee	66,500
Accrued reserve for outdated material	369,154
Accrued sales rebates	80,926
Other accrued expenses	18,294
Deferred revenue	15,498	...
Dividends payable	21,265	21,220
Other	30,930	...
Audit fee	71,000	...
Sales rebates	132,250	...
Accrued Expenses - Balancing value	247,847	...
Total current liabilities	1,534,256	1,373,691
Common stock	459,432	459,432
Retained earnings (accumulated deficit)	10,929,150	8,807,212
Total stockholders' equity	11,388,582	9,266,644
Total Equity	11,388,582	...

[¶] Shares increased due to the effect of stock issued for litigation settlement, settle accrued liabilities and related party advances, services, compensation and conversion of notes payable and interest; [¶] As of March 27, 2023; [¶] As of March 31, 2022; [¶] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	95,420	13,377
Finished goods	33,598	34,730
Inventory	33,598	34,730
Prepaid & other current assets	22,804	22,932
Total current assets	151,822	71,039
Deferred offering costs	21,051	243,039
Patents, net	32,400	36,450
Operating lease right-of-use asset	76,520	...
Security deposit	2,850	...
Total assets	284,643	350,528
Accounts payable & accrued expenses	987,567	1,255,232
Accrued liabilities - related parties	226,475	172,579
Accrued litigation settlement	300,000
Promissory note payable	9,136
Loans payable - related parties	4,000
Convertible notes payable, net of debt discount	207,500	196,177
Convertible loans payable - related parties, net of debt discount	478,331
Short term loans	500,000	...
Operating lease liability - current	28,838	...
Total current liabilities	2,415,455
Operating lease liability - long-term	48,489	...
Total liabilities	2,415,455
Common stock	244,783	230,871
Subscription receivable	(50,550)
Additional paid-in capital	74,740,201	71,830,695
Accumulated Deficit	(76,699,210)	...
Retained earnings (accumulated deficit)	(74,075,943)
Total stockholders' equity (deficiency)	(1,714,226)	(2,064,927)
Total Equity	(1,714,226)	...

Recent Dividends:

1. United Health Products Inc series A convertible preferred.

No dividends paid.

2. United Health Products Inc common.

No dividends paid.

Annual Dividends:

1. United Health Products Inc series A convertible preferred.

No dividends paid.

2. United Health Products Inc common.

No dividends paid.

UNITED-GUARDIAN, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

[¶] As of March 1, 2023; [¶] As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Demand deposits	333,275
U.S. treasury bills	497,177
Cash & cash equivalents	8,243,122	830,452
Marketable securities	851,318	5,653,516
Accounts receivable, gross	1,583,511	1,447,639
Less: allowance for doubtful accounts	16,672	20,063
Accounts receivable, net	1,427,576

Recent Dividends:

1. United-Guardian, Inc. common.

ExDate	Amt	Declared	Record	Payable
05/27/2021	0.48	05/18/2021	05/31/2021	06/07/2021
11/26/2021	0.65	11/16/2021	11/29/2021	12/07/2021
05/20/2022	0.37	05/12/2022	05/23/2022	06/01/2022
11/25/2022	0.31	11/15/2022	11/28/2022	12/07/2022
07/25/2023	0.10	07/12/2023	07/26/2023	08/02/2023
02/09/2024	0.25	02/02/2024	02/12/2024	02/20/2024

Annual Dividends:

1. United-Guardian, Inc. common.

2021.....	1.13	2022.....	0.68	2023.....	0.10
2024.....	0.25				

UNITY BIOTECHNOLOGY INC

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022 (revised)	2021 (revised)
Collaboration revenue	236	...
Licensing revenue - related party	236	4,784
Research & development expenses	20,099	36,859	38,393
General & administrative			

expenses	18,966	20,949	23,056
Impairment of long-lived assets	5,602
Total operating expenses	61,449
Income (loss) from operations	(44,667)	(57,572)	(56,665)
Interest income (expense)	100
Interest expense	2,452	3,558	3,177
Other income (expense), net	(1,830)	(1,402)	(983)
Net income (loss)	(39,860)	(44,469)	(60,725)
Weighted average shares outstanding - basic	14,774	9,494	5,582
Weighted average shares outstanding - diluted	14,774	9,494	5,582
Year end shares outstanding	16,785	14,215	6,299
Net earnings (loss) per share - basic	\$(2.70)	\$(4.68)	\$(10.88)
Net earnings (loss) per share - diluted	\$(2.70)	\$(4.68)	\$(10.88)
Full-Time Employees (Period End)	19
Total number of employees	19	...	65
Number of common stockholders	45	...	54
Interest income	2,874	1,220	...
Net Income before Tax	(39,860)	(44,469)	...
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(2.70)	\$(4.68)	...
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(2.70)	\$(4.68)	...
Gain (loss) on warrant liability	6,215	16,843	...

Restated to reflect correction of errors; Reclassified to conform with 2022 presentation; Adjusted for 1-for-10 stock split, October 20, 2022; As is; As of March 1, 2022

Accrued & other current liabilities	4,619	5,334	...
Current portion of long-term debt	...	9,476	...
Total current liabilities	7,840	19,620	...
Operating lease liability, net of current portion	23,539	26,991	...
Long-term debt, net	...	10,891	...
Other long-term liabilities	5,913	10,764	...
Total liabilities	37,292	68,266	...
Common stock	2	1	...
Additional paid-in capital	512,773	500,827	...
Accumulated other comprehensive gain (loss)	(24)	(251)	...
Accumulated deficit	(484,353)	(444,493)	...
Total stockholders' equity (deficit)	28,398	56,084	...
Total Equity	28,398	56,084	...

Reclassified to conform with 2022 presentation; As is

share - continuing operations - basic	\$0.54
Net earnings (loss) per share - basic	\$0.54	\$(0.90)	\$(0.09)
Income (loss) per share - continuing operations - diluted	\$0.53
Net earnings (loss) per share - diluted	\$0.53	\$(0.90)	\$(0.09)
Full-Time Employees (Period End)	678
Total number of employees	678	622	558
Number of common stockholders	87	89	91
Income from cont operations before income tax	5,308

Reclassified to conform with 2022 presentation; As is
Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash	394	2,019
Accounts receivable, gross	39,068	31,161
Less: allowance for doubtful accounts	34	201
Accounts receivable	39,034	30,960
Raw materials & starting stock	...	14,890
Semi-finished & finished steel products	117,039	129,534
Operating materials	15,124	13,220
Semi-finished steel products	15,967	...
Inventory reserves	3,430	3,451
Inventory, net	...	154,193
Other current assets	11,693	10,392
Total current assets	195,821	197,564
Land & land improvements	8,130	8,090
Buildings	53,807	53,334
Machinery & equipment	325,023	315,165
Construction in progress	15,649	12,602
Gross property, plant & equipment	402,609	389,191
Accumulated depreciation - property, plant & equipment	242,973	225,701
Property, plant & equipment, net	159,636	163,490
Deferred income tax assets	...	143
Other long-term assets	1,233	2,137
Total assets	356,690	363,334
Accounts payable	34,855	38,179
Accrued employment costs	6,492	2,790
Current portion of long-term debt - Balancing value	2,386	...
Current portion of long-term debt	3,733	3,419
Other current liabilities	829	1,112
Capital Leases- Current obligation	1,347	...
Total current liabilities	45,909	45,500
Term loan	...	11,786
Revolving credit facility	...	79,545
Capital Leases obligation	5,161	...
Finance leases	...	6,663
Sale & leaseback financing liability	...	1,804
Less current portion of long-term debt	...	3,419
Less: deferred financing costs	76,685	(1,364)
Long-term debt	...	95,015
Deferred income tax liabilities	2	...
Other long-term liabilities	2,891	3,066
Total liabilities	130,648	143,581
Common stock	9	9

Reclassified to conform with 2022 presentation; As is

Recent Dividends:
1. Unity Biotechnology Inc common.
No dividends paid.

Annual Dividends:
1. Unity Biotechnology Inc common.
No dividends paid.

UNIVERSAL STAINLESS & ALLOY PRODUCTS, INC.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Conversion services and other sales	4,762
Specialty alloys	213,077
Premium alloys	68,104
Net sales	285,943	202,114	155,934
Cost of products sold	244,404	187,927	147,963
Gross margin	41,539	14,187	7,971
Selling, general & administrative expenses	27,783	21,180	20,243
Operating income (loss)	13,756	(6,993)	(12,272)
Interest expense & other financing costs	8,414
Interest expense	...	4,388	2,214
Gain on extinguishment of debt	10,000
Other income (expense), net	(34)	684	445
Income (loss) before income taxes	...	(10,697)	(4,041)
Current federal income tax provision (benefit)	177	(1)	...
Current state income tax provision (benefit)	8	5	5
Deferred federal income tax provision (benefit)	309	(2,566)	(3,376)
Deferred state income tax provision (benefit)	(96)	(62)	88
Provision for income taxes	398	(2,624)	(3,283)
Net income (loss)	4,910	(8,073)	(758)
Weighted average shares outstanding - basic	9,086	8,972	8,908
Weighted average shares outstanding - diluted	9,279	8,972	8,908
Year end shares outstanding	9,185	9,050	8,938
Income (loss) per

Additional paid-in capital	98,637	97,002
Accumulated other comprehensive income (loss)	(123)	133
Retained earnings	127,519	...
Retained earnings (accumulated deficit)	...	122,609
Total stockholders' equity	226,042	219,753
Total Equity	226,042	...

Recent Dividends:

1. Universal Stainless & Alloy Products, Inc. common.

No dividends paid.

Annual Dividends:

1. Universal Stainless & Alloy Products, Inc. common.

No dividends paid.

USIO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Service revenues	82,591,109
Revenues	82,591,109	69,428,285	61,942,316
Cost of services	63,992,417	54,835,069	46,309,706
Gross profit	18,598,692	14,593,216	15,632,610
Stock-based compensation	2,222,969	2,072,041	1,489,976
Other expenses	16,216,690	15,000,487	11,654,340
Depreciation & amortization	2,081,533	2,735,118	2,643,675
Total operating expenses	20,521,192	19,807,646	15,787,991
Operating income (loss)	(1,922,500)	(5,214,430)	(155,381)
Interest income	1,695,122	15,237	7,643
Interest expense	5,202	4,051	4,314
Other income (expense), net	50,000	...	279
Total other income (expense), net	1,739,920	11,186	3,608
Income (loss) before income taxes	(182,580)	(5,203,244)	(151,773)
Current state income tax provision	292,524	280,000	279,861
Current income tax provision	292,524	280,000	279,861
State income tax expense	...	280,000	279,861
Deferred federal income tax provision (benefit)	(110,000)
Federal income tax (benefit)	(110,000)
Income taxes	292,524	280,000	169,861
Net income (loss)	(475,104)	(5,483,244)	(321,634)
Weighted average shares outstanding - basic	20,105,968	20,379,386	20,028,850
Weighted average shares outstanding - diluted	20,105,968	20,379,386	20,028,850
Year end shares outstanding	26,332,523	25,097,963	25,473,453
Income (loss) per share - continuing operations - basic	\$(0.02)
Net income (loss) per share - basic	\$(0.02)	\$(0.27)	\$(0.02)
Income (loss) per share - continuing operations - diluted	\$(0.02)
Net income (loss) per share - diluted	\$(0.02)	\$(0.27)	\$(0.02)
Number of full time employees	126	117	108
Total number of employees	126
Number of common stockholders	3,377	3,548	143

As of March 3, 2023; As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	7,155,687	5,709,117
Accounts receivable, gross	5,883,138	4,690,640
Less: allowance for doubtful accounts	319,000	319,000
Accounts receivable, net	5,564,138	4,371,640
Settlement processing assets	44,899,603	49,737,068
Prepaid card load assets	31,578,973	20,170,761
Customer deposits	1,865,731	1,554,122
Inventory	422,808	507,355
Prepaid expenses & other current assets	444,071	450,389
Current assets before merchant reserves	...	82,500,452
Merchant reserves	...	4,909,501
Restricted cash	5,310,095	...
Total current assets	97,241,106	87,409,953
Software	7,688,476	7,053,905
Equipment	3,542,707	2,530,498
Furniture & fixtures	818,522	818,522
Leasehold improvements	207,624	207,624
Total property & equipment	12,257,329	10,610,549
Less: accumulated depreciation	8,597,237	7,387,732
Property & equipment, net	3,660,092	3,222,816
Intangibles, net	1,753,333	2,625,360
Deferred tax asset	1,504,000	1,504,000
Operating lease right-of-use assets	2,420,782	2,795,483
Other assets	355,357	355,357
Total assets	106,934,670	97,912,969
Accounts payable	1,031,141	858,622
Accrued commissions	2,433,353	1,479,580
Reserve for processing losses	826,528	755,494
Other accrued expenses	246,444	821,167
Accrued taxes	294,953	320,854
Accrued salaries	...	344,013
Customer deposits	1,865,731	...
Operating lease liabilities, current portion	633,616	617,319
Equipment loan, current portion	107,270	56,429
Settlement processing obligations	44,899,603	49,737,068
Prepaid card load obligations	31,578,973	20,170,761
Customer deposits	...	1,554,122
Current liabilities before merchant reserve obligations	...	76,715,429
Merchant reserve obligations	5,310,095	4,909,501
Total current liabilities	89,227,707	81,624,930
Equipment loan, non-current portion	718,980	14,994
Operating lease liabilities, non-current portion	1,919,144	2,338,947
Total liabilities	91,865,831	83,978,871
Common stock	197,087	195,471
Additional paid-in capital	97,479,830	94,048,603
Treasury stock, at cost	4,362,150	3,749,027
Deferred compensation	6,907,775	5,697,900
Retained earnings (accumulated deficit)	(71,338,153)	(70,863,049)
Total stockholders' equity (deficit)	15,068,839	13,934,098
Total Equity	15,068,839	...

As reported by the Company

Recent Dividends:

1. Usio Inc common.

No dividends paid.

Annual Dividends:

1. Usio Inc common.

No dividends paid.

UTAH MEDICAL PRODUCTS, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Total revenues	50,224,000
Sales, net	50,224,000	52,281,000	49,054,000
Cost of goods sold	20,186,000	20,085,000	18,137,000
Gross profit	30,038,000	32,196,000	30,917,000
Sales & marketing expense	...	1,507,000	1,414,000
Research & development expense	560,000	493,000	526,000
General & administrative expense	11,016,000	10,406,000	10,097,000
Selling, general & administrative expense	1,685,000
Operating income	16,777,000	19,790,000	18,880,000
Dividend & interest income	3,036,000	661,000	166,000
Royalty income	20,000	20,000	15,000
Other income (expense), net	256,000	188,000	...
Income (loss) before provision for income taxes - domestic	11,170,000	12,475,000	12,004,000
Income (loss) before provision for income taxes - foreign	8,919,000	8,184,000	7,057,000
Income (loss) before provision for income taxes	20,089,000	20,659,000	19,061,000
Current provision for income taxes	4,075,000	4,632,000	3,983,000
Deferred provision (benefit) for income taxes	(621,000)	(446,000)	290,000
Provision for income taxes	3,454,000	4,186,000	4,273,000
Net income (loss)	16,635,000	16,473,000	14,788,000
Weighted average shares outstanding - basic	3,629,000	3,637,000	3,647,000
Weighted average shares outstanding - diluted	3,637,000	3,643,000	3,660,000
Year end shares outstanding	3,630,000	3,627,767	3,655,000
Earnings per share - continuing operations - basic	\$4.58
Earnings per share - continuing operations - diluted	\$4.57
Net earnings (loss) per common share - basic	\$4.58	\$4.53	\$4.05
Net earnings (loss) per common share - diluted	\$4.57	\$4.52	\$4.04
Dividends per common share	\$1.19	\$0.87	\$3.14
Number of full time employees	169	186	178
Number of part time employees	21	68	51
Total number of employees	190
Number of beneficial stockholders	2,000	2,000	2,000
Foreign currency translation adjustments	...	(2,986,000)	(773)

□ Approximately; □ As of March 5, 2023; □ As of March 6, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash	75,052,000	
Accounts receivable	3,488,000	5,720,000
Accrued interest & other receivables	54,000	51,000
Less: allowance for doubtful accounts	151,000	182,000
Finished products		1,896,000
Work-in-process	1,503,000	1,193,000
Raw materials	6,394,000	5,725,000
Finished goods	1,685,000	
Inventories	9,582,000	8,814,000
Prepaid expenses & other current assets	428,000	515,000
Cash & Investments	92,868,000	
Total current assets	106,269,000	89,919,000
Land	1,638,000	1,593,000
Buildings & improvements	13,907,000	13,601,000
Furniture, equipment & tooling	17,315,000	17,068,000
Construction-in-progress	1,413,000	906,000
Total property & equipment, gross	34,273,000	33,168,000
Less: accumulated depreciation	23,722,000	22,944,000
Property & equipment, net	10,551,000	10,224,000
Goodwill	13,692,000	13,354,000
Other intangible assets		52,755,000
Other intangible assets - accumulated amortization		42,378,000
Other intangible assets, net	4,946,000	10,377,000
Total assets	135,458,000	123,874,000
Accounts payable	769,000	1,218,000
Income taxes payable	327,000	
Income taxes payable (receivable)		337,000
Payroll & payroll taxes	1,294,000	1,318,000
Reserve for litigation costs	257,000	204,000
Other accrued expenses		2,883,000
Other	2,063,000	
Other - Balancing value	2,016,000	
Accrued expenses	3,941,000	
Operating Lease Liabilities - Current		
Portion/Short-Term	47,000	
Total current liabilities	4,710,000	5,960,000
Long term lease liability	295,000	341,000
Long term income tax payable (REPAT tax)	698,000	1,256,000
Deferred tax liability - intangible assets	1,120,000	1,514,000
Deferred income taxes	322,000	549,000
Total liabilities	7,145,000	9,620,000
Common stock	36,000	36,000
Accumulated other comprehensive income (loss)	(10,658,000)	(12,039,000)
Additional paid-in capital	594,000	251,000
Retained earnings	138,341,000	126,006,000
Total stockholders' equity	128,313,000	114,254,000
Total Equity	128,313,000	

Recent Dividends:				
1. Utah Medical Products, Inc. common.				
ExDate	Amt	Declared	Record	Payable
12/14/2020	0.28	11/03/2020	12/15/2020	01/05/2021
03/16/2021	0.28	02/09/2021	03/17/2021	04/02/2021
06/14/2021	0.28	05/11/2021	06/15/2021	07/06/2021
09/15/2021	0.28	08/03/2021	09/16/2021	10/05/2021
12/14/2021	2.00	11/02/2021	12/15/2021	12/29/2021
03/17/2022	0.29	02/08/2022	03/18/2022	04/05/2022
06/16/2022	0.29	05/10/2022	06/17/2022	07/06/2022
09/15/2022	0.29	08/02/2022	09/16/2022	10/05/2022
12/15/2022	0.29	11/01/2022	12/16/2022	01/04/2023

03/16/2023	0.29	02/07/2023	03/17/2023	04/04/2023
06/15/2023	0.29	05/08/2023	06/16/2023	07/06/2023
09/14/2023	0.29	08/01/2023	09/15/2023	10/03/2023
12/14/2023	0.30	10/31/2023	12/15/2023	01/03/2024
03/14/2024	0.30	02/06/2024	03/15/2024	04/03/2024

Annual Dividends:			
1. Utah Medical Products, Inc. common.			
2021	3.14	2022	0.87
2023		2024	0.60
2023		2024	1.18

VAXXINITY INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Revenue			66
Cost of revenue			1,937
Gross profit (loss)			(1,871)
Research & development expenses	35,899	47,627	71,379
General & administrative expenses	22,386	28,352	51,825
Total operating expenses	58,285	75,979	123,204
Income (loss) from operations	(58,285)	(75,979)	(125,075)
Interest & other expense	696	514	840
Interest & other income	2,090	1,259	9
Change in fair value of convertible notes			(2,667)
Change in fair value of simple agreement for future equity			(8,365)
Change in fair value of warrant liability			(214)
Gain (loss) on foreign currency translation, net	(43)	12	(23)
Other other income (expense)	1,351	757	(12,100)
Income (loss) before income taxes - domestic entities		(69,943)	(128,538)
Income (loss) before income taxes - entities outside the U.S.		(5,477)	(8,636)
Income (loss) before income taxes	(56,934)	(75,222)	(137,175)
Net income (loss)	(56,934)	(75,222)	(137,175)
Weighted average shares outstanding - basic	126,509	125,939	76,587
Weighted average shares outstanding - diluted	126,509	125,939	76,587
Year end shares outstanding	126,747	126,057	125,392
Net income (loss) per share - basic	\$(0.45)	\$(0.60)	\$(1.79)
Net income (loss) per share - diluted	\$(0.45)	\$(0.60)	\$(1.79)
Number of full time employees	57	87	89
Number of part time employees	8	2	
Number of class A common stockholders		81	135
Number of class B common stockholders		4	4
EPS - Basic - excluding Extraordinary Items			
Applicable to			

Common - Total	EPS - Diluted - excluding Extraordinary Items	Applicable to	Common - Total	Common Shareholders - Number	Total number of employees
\$(0.45)			74		65
\$(0.45)					

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of issuance of common stock upon exercise of stock options, vesting of restricted stock, stock grant, IPO, exercise of warrants and conversion of series A and B; □ As Is; □ As of March 15, 2023; □ Approximately; □ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	4,931	33,475
Short-term investments	25,464	53,352
Restricted cash	105	1,095
Amounts due from related parties	414	414
Clinical prepayments		2,679
Prepaid insurance		1,870
Prepaid materials & supplies	1,235	248
Deposits	241	232
Other prepaid expenses & other current assets		522
Prepaid expenses & other current assets	2,316	5,551
Other Current Assets	840	
Total current assets	33,230	93,887
Airplane	11,983	11,983
Laboratory & computer equipment	16,948	3,146
Leasehold improvements	576	403
Software	426	415
Vehicles	87	87
Facilities, furniture & fixtures	99	37
Construction in progress	128	65
Laboratory and computer equipment	3,649	
Total property & equipment, gross		16,136
Less: accumulated depreciation	5,867	3,624
Property & equipment, net	11,081	12,512
Total assets	44,311	106,399
Accounts payable	1,783	5,295
Amounts due to related parties	10,575	12,772
Accrued bonuses	1,558	2,568
Accrued external research & development		6,904
Accrued professional fees & other		1,722
Accrued interest	21	176
Accrued expenses & other current liabilities	1,762	11,370
Notes payable	406	391
Notes payable to related party	1,500	1,113
Accrued expenses and other current liabilities - Balancing value	3,341	
Total current liabilities	17,605	30,941
Convertible notes payable	3,735	
Notes payable, net of current portion	9,527	9,933
Notes payable to related party, net of current portion		3,112
Accrued tax provision	35	236
Other long-term liabilities	35	236
Total liabilities	30,902	44,222
Class A common stock	278	278
Additional paid-in capital	374,760	366,799

Operating lease liabilities	2,436	2,645	derivative financial instruments, net				continuing operations - basic	\$0.28	\$(0.09)	\$(0.07)
Accrued clinical & drug manufacturing expenses	...	4,334	Change in fair value of future tranche right			(14,374)	Net income (loss) per share - basic	\$0.28	\$(0.09)	\$(0.07)
Accrued payroll	3,932	3,217	Other income (expense), net	(3,523)	(1,471)	5,435	Income (loss) per share from continuing operations - diluted	\$0.28	\$(0.09)	\$(0.07)
Related party payable	...	2,780	Total other income (expense), net	(6,913)	(2,594)	(7,339)	Net income (loss) per share - diluted	\$0.28	\$(0.09)	\$(0.07)
Accrued legal fees	...	338	Income (loss) before provision for income taxes - domestic			(6,676)	Number of full time employees	3,700
Accrued expenses & other current liabilities	4,817	295	Income (loss) before provision for income taxes - foreign			61,438	Total number of employees	3,700	□□4,300	□□4,400
Accrued expenses & other current liabilities	8,749	10,964	Income (loss) from continuing operations before provision for income taxes	61,272	54,762	39,504	Number of common stockholders	1,500	□□1,614	□□□1,625
Total current liabilities	22,303	25,600	Current provision for (benefit from) income taxes - federal	20,128	30,637	3,215	Foreign currency translation adjustments		(35,545)	...
Long-term debt	49,877	24,810	Current provision for (benefit from) income taxes - state	2,784	2,733	1,121	Comprehensive (loss) income attributable to Verint Systems Inc	49,747
Operating lease liabilities, noncurrent	1,395	3,831	Deferred provision for (benefit from) income taxes - federal	(17,086)	(8,010)	6,714				
Accrued & other noncurrent liabilities	286	286	Deferred provision for (benefit from) income taxes - state	(133)	(699)	255				
Total liabilities	...	54,527	Deferred provision for (benefit from) income taxes - foreign	(420)	(835)	(18,292)				
Class A common stock	44	28	Total deferred provision for (benefit from) income taxes	(17,639)	(9,544)	(11,323)				
Additional paid-in capital	410,492	290,216	Provision for net income (loss) from continuing operations	21,638	39,103	23,853				
Accumulated other comprehensive income (loss)	251	(224)	Net income (loss) attributable to noncontrolling interests from continuing operations	39,634	15,659	15,651				
Retained earnings (accumulated deficit)	(309,102)	(213,112)	Net income (loss) attributable to Verint Systems Inc	17,810	14,898	14,413				
Total stockholders' equity (deficit)	101,685	76,908	Dividends on preferred stock	20,800	20,800	18,922				
Total Equity	101,685	...	Net income (loss) attributable to Verint Systems Inc common shares	...	(5,902)	(4,509)				

Recent Dividends:
1. Vera Therapeutics Inc class B non-voting common.
 No dividends paid.
2. Vera Therapeutics Inc class A common.
 No dividends paid.
Annual Dividends:
1. Vera Therapeutics Inc class B non-voting common.
 No dividends paid.
2. Vera Therapeutics Inc class A common.
 No dividends paid.

VERINT SYSTEMS INC Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2024	2023	2022 (revised)
Product revenue	211,139
Revenue - recurring	...	685,537	633,129
Revenue - nonrecurring	...	216,708	241,380
Nonrecurring Revenue	699,248
Total revenue	910,387	902,245	874,509
Recurring	107,110
Cost of revenue - recurring	...	162,347	156,569
Cost of revenue - nonrecurring	...	119,530	124,226
Service costs	162,868
Amortization of acquired technology	7,134	13,191	17,777
Total cost of revenue	277,112	295,068	298,572
Gross profit	633,275	607,177	575,937
Research & development, net	133,804	130,644	123,291
Selling, general & administrative	405,915	392,939	376,808
Amortization of other acquired intangible assets	25,371	26,238	28,995
Total operating expenses	565,090	549,821	529,094
Operating income (loss)	68,185	57,356	46,843
Interest income	6,944	3,301	233
Interest expense	10,334	7,877	10,325
Gains (losses) on early retirements of debt	(2,474)
Foreign exchange gains (losses), net	(439)	3,453	(1,644)
Gain (losses) on			

	2024	2023
Cash & bank time deposits	155,504	134,289
Money market funds	85,647	96,941
Commercial paper	...	50,869
U.S Treasury Bills	249	...
Cash & cash equivalents	241,400	282,099
Bank time deposits	...	697
Short-term investments	686	697
Accounts receivable, gross	191,661	189,714
Less: allowance for doubtful accounts	1,200	1,300
Accounts receivable, net of allowance for doubtful accounts	190,461	...
Accounts receivable, net	...	188,414
Contract assets, net	66,913	60,444
Raw materials	4,402	3,325
Work-in-process	69	40
Finished goods	9,738	9,263
Inventories	14,209	12,628
Prepaid expenses & other current assets	59,505	75,374
Total current assets	573,174	619,656
Land & buildings	...	820
Land	779	...
Leasehold improvements	11,837	15,026
Software	56,203	73,569
Equipment, furniture & other property & equipment	...	41,966
Equipment, furniture, and other	28,505	...
Total cost	97,324	131,381
Less: accumulated depreciation & amortization	49,620	66,571
Property & equipment, net	47,704	64,810
Operating lease right-of-use assets	30,118	37,649
Goodwill	1,352,715	1,347,213
Intangible assets, net	57,466	85,272
Long-term deferred income taxes	25,697	10,719
Capitalized software development costs, net	...	23,527
Long-term contract assets, net	...	37,950
Long-term deferred cost of revenue	...	4,951
Comverse Technology, Inc. litigation settlement indemnification asset

□ As is; □ Approximately; □ As of March 15, 2023; □ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2024	2023
Cash & bank time deposits	155,504	134,289
Money market funds	85,647	96,941
Commercial paper	...	50,869
U.S Treasury Bills	249	...
Cash & cash equivalents	241,400	282,099
Bank time deposits	...	697
Short-term investments	686	697
Accounts receivable, gross	191,661	189,714
Less: allowance for doubtful accounts	1,200	1,300
Accounts receivable, net of allowance for doubtful accounts	190,461	...
Accounts receivable, net	...	188,414
Contract assets, net	66,913	60,444
Raw materials	4,402	3,325
Work-in-process	69	40
Finished goods	9,738	9,263
Inventories	14,209	12,628
Prepaid expenses & other current assets	59,505	75,374
Total current assets	573,174	619,656
Land & buildings	...	820
Land	779	...
Leasehold improvements	11,837	15,026
Software	56,203	73,569
Equipment, furniture & other property & equipment	...	41,966
Equipment, furniture, and other	28,505	...
Total cost	97,324	131,381
Less: accumulated depreciation & amortization	49,620	66,571
Property & equipment, net	47,704	64,810
Operating lease right-of-use assets	30,118	37,649
Goodwill	1,352,715	1,347,213
Intangible assets, net	57,466	85,272
Long-term deferred income taxes	25,697	10,719
Capitalized software development costs, net	...	23,527
Long-term contract assets, net	...	37,950
Long-term deferred cost of revenue	...	4,951
Comverse Technology, Inc. litigation settlement indemnification asset

Accounts payable	32,756	36,738
Accrued media payments	93,896	102,064
Client advances	15,452	19,042
Contingent consideration, current	1,000	8,067
Other accrued liabilities	27,095	27,412
Deferred revenue	12,813	...
Senior Secured Term Loan, current portion	5,813	...
Operating Lease Liabilities - Current
Portion/Short-Term	2,348	...
Other accrued liabilities - Balancing value	24,747	...
Total current liabilities	188,825	193,323
Convertible senior notes, non-current	89,572	137,767
Contingent consideration, non-current	633	...
Other non-current liabilities	13,625	13,811
Senior Secured Term Loan, non-current	45,012	...
Total liabilities	337,667	344,901
Common stock	38	36
Additional paid-in capital	468,015	451,162
Accumulated deficit	(429,896)	...
Retained earnings (accumulated deficit)	...	(371,271)
Accumulated other comprehensive income (loss)	(10)	(76)
Total stockholders' equity (deficit)	38,147	79,851
Total Equity	38,147	...

Recent Dividends:

1. Veritone Inc common.
No dividends paid.

Annual Dividends:

1. Veritone Inc common.
No dividends paid.

VIGIL NEUROSCIENCE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development	60,934	47,444	32,330
General & administrative	27,932	21,440	10,079
Total operating expenses	88,866	68,884	42,409
Income (loss) from operations	(88,866)	(68,884)	(42,409)
Change in fair value of the related party antidilution obligation	(836)
Change in fair value of series A preferred stock tranche obligation	(28)
Interest income, net	6,241	623	3
Other income (expense), net	(13)	(44)	(13)
Net Income before Tax	(82,638)
Total other income (expense), net	6,228	579	(874)
Net income (loss)	(82,638)	(68,305)	(43,283)
Net income (loss) attributable to common stockholders	...	(68,305)	(43,283)
Weighted average shares outstanding - basic	38,712	31,685	1,532
Weighted average shares outstanding

- diluted	38,712	31,685	1,532
Year end shares outstanding	35,885	35,620	1,725
Net income (loss) per share - basic	\$(2.13)	\$(2.16)	\$(28.26)
Net income (loss) per share - diluted	\$(2.13)	\$(2.16)	\$(28.26)
Number of full time employees	...	56	41
Number of part time employees	11
Number of common stockholders	12	15	32

□ Reclassified to conform with 2022 presentation; □ Includes related party amounts - research & development: \$295,000; □ Includes related party amounts - research & development: \$2,672,000; □ Shares increased due to the effect of conversion of convertible preferred stock to common stock upon closing of initial public offering, issuance of common stock from IPO and from PIPE; □ As is; □ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	51,992	186,605
Research & development	...	6,670
Construction related prepaid assets	...	3,769
Business insurance	...	133
Other prepaid expenses & other current assets	...	628
Prepaid expenses & other current assets	3,967	11,200
Marketable securities	65,948	...
Total current assets	121,907	197,805
Computer software & equipment	138	16
Furniture & fixtures	...	104
Lab equipment	...	192
Leasehold improvements	233	...
Construction in progress	...	944
Computer Software & Equipment	71	...
Lab equipment- Gross	1,753	...
Total property & equipment, gross	2,195	1,256
Less: accumulated depreciation	450	72
Property & equipment, net	1,745	1,184
Operating lease right-of-use assets	16,147	141
Financing lease right-of-use assets	49	70
Restricted cash	927	927
Other assets	83	266
Total assets	140,858	200,393
Accounts payable	1,946	1,942
Accrued Payroll	4,208	...
Accrued payroll & employee related	...	3,512
Accrued research & development	...	2,894
Accrued construction related	...	1,416
Accrued professional fees	...	986
Other accrued expenses & other current liabilities	...	386
Accrued expenses & other current liabilities	8,810	9,194
Operating lease liabilities	905	153
Financing lease liabilities	...	23
Accrued expenses and other current liabilities - Balancing value	4,602	...
Total current liabilities	11,661	11,312
Operating lease liabilities, net of current portion	12,945	...
Total liabilities	24,606	11,312

Common stock	4	4
Additional paid-in capital	339,025	329,211
Retained earnings (accumulated deficit)	(222,772)	(140,134)
Accumulated other comprehensive loss	(5)	...
Total stockholders' equity (deficit)	116,252	189,081
Total Equity	116,252	...

□ Includes related party amounts - accrued expenses & other current liabilities: \$78,000

Recent Dividends:

1. Vigil Neuroscience Inc common.
No dividends paid.

Annual Dividends:

1. Vigil Neuroscience Inc common.
No dividends paid.

VIRCO MANUFACTURING CORP.

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2024	2023 (revised)	2022 (revised)
Net sales	269,117	231,064	184,828
Costs of goods sold	153,059	145,723	123,899
Gross profit	116,058	85,341	60,929
Selling, general & administrative expenses	84,181	74,697	61,265
Operating income (loss)	31,877	10,644	(336)
Pension expense	(1,008)	(816)	(2,197)
Interest expense, net	2,679	1,979	1,195
Income (loss) before income taxes	29,240	8,043	(3,728)
Current income tax expense (benefit) - federal	5,567	82	...
Current state income tax expense (benefit)	963	125	92
Total current income tax expense (benefit)	6,530	207	92
Deferred federal income tax expense (benefit)	301	1,524	(731)
Deferred state income tax expense (benefit)	1,112	311	(256)
Total deferred income tax expense (benefit)	1,413	1,835	(987)
Change in valuation allowance	(613)	(10,546)	12,303
Income tax expense (benefit)	7,330	(8,504)	11,408
Net income (loss)	21,910	16,547	(15,136)
Weighted average shares outstanding - basic	16,295	16,142	15,954
Weighted average shares outstanding - diluted	16,388	16,192	15,954
Year end shares outstanding	16,347	16,211	16,102
Income (loss) per share from continuing operations - basic	\$1.34	\$1.03	...
Net income (loss) per common share - basic	\$1.34	\$1.03	\$(0.95)
Income (loss) per share from continuing operations - diluted	\$1.34	\$1.02	...
Net income (loss) per common share -

diluted	\$1.34	\$1.02	\$(0.95)	Common stock	164	162	integration expense	14,557	13,169	8,835
Number of full time employees	776	...	815	Additional paid-in capital	121,373	120,890	Gain (loss) on disposal of property, plant & equipment	(1,153)	(935)	(243)
Total number of employees	776	Accumulated deficit	(29,048)	...	Total operating expenses	160,287	144,089	137,584
Number of common stockholders	140	...	160	Retained earnings (accumulated deficit)	...	(50,631)	Income (loss) from operations	(20,429)	8,676	7,839
Number of beneficiary stockholders	1,260	Accumulated other comprehensive income (loss)	(1,310)	(2,360)	Other income (expense), net	(1,446)	1,146	34
Total revenues	...	231,064	...	Total stockholders' equity (deficit)	91,179	68,061	Term loan facility	...	3,642	...
Unrealized gain on investment in trust account	1,050	194	...	Total Equity	91,179	...	Prior term loan facility	...	14,735	22,959

Reclassified to conform 2024 presentation; Approximately;

As of April 22, 2022

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2024	2023	(revised)
Cash	5,286	1,057	
Trade accounts receivables, gross	23,361	18,635	
Less: allowance for doubtful accounts	200	200	
Trade accounts receivables, net	23,161	18,435	
Other receivables	20	68	
Income tax receivable	...	19	
Finished goods	18,861	25,740	
Work in process	25,047	25,303	
Raw materials	14,463	16,363	
Inventories	58,371	67,406	
Prepaid expenses & other current assets	2,188	2,083	
Total current assets	89,026	89,068	
Land	3,731	3,731	
Land improvements	...	686	
Land & land improvements	694	...	
Buildings & building improvements	51,576	51,310	
Machinery & equipment	114,400	113,662	
Leasehold improvements	523	983	
Total property, plant & equipment	170,924	170,372	
Less accumulated depreciation & amortization	136,356	135,810	
Net property, plant & equipment	34,568	34,562	
Operating lease right-of-use assets	6,508	10,120	
Deferred income tax assets, net	6,634	7,800	
Other assets	9,709	8,576	
Total assets	146,445	150,126	
Accounts payable	12,945	19,448	
Accrued compensation & employee benefits	10,880	9,554	
Income tax payable	145	...	
Current portion of long-term debt	248	7,360	
Current portion operating lease liability	5,744	5,082	
Other accrued liabilities	8,570	7,081	
Total current liabilities	38,532	48,525	
Accrued self-insurance	650	1,050	
Accrued retirement benefits	9,429	10,676	
Income tax payable	128	79	
Revolving credit line	...	17,122	
Other debt	...	4,622	
Derivative instrument	4,136	...	
Less current portion	...	7,360	
Long-term debt, less current portion	...	14,384	
Operating lease liability, less current portion	1,829	6,796	
Other long-term liabilities	562	555	
Total non-current liabilities	16,734	33,540	

Recent Dividends:

1. Virco Manufacturing Corp. common.

ExDate	Amt	Declared	Record	Payable
12/21/2023	0.02	12/08/2023	12/22/2023	01/10/2024
03/06/2024	0.02	02/27/2024	03/07/2024	04/10/2024

Annual Dividends:

1. Virco Manufacturing Corp. common.

2024.....0.04

WALGREENS BOOTS ALLIANCE INC

Earnings, 6 mos. to (Consol. - \$000):

	02/29/24	02/28/23
Total Revenues	73,760,000	73,760,000
Net Sales	73,760,000	68,244,000
Cost & expenses	86,969,000	74,198,000
Operating income	(13,209,000)	(5,954,000)
Interest expense	237,000	252,000
Other income (expense), net	(25,000)	1,544,000
Equity earnings	(16,000)	(13,000)
Net before taxes	(13,472,000)	...
Income taxes	(856,000)	...
Net income	(12,600,000)	(3,272,000)
Earnings common share		
Primary	\$(6.93)	\$(3.50)
Fully Diluted	\$(6.93)	\$(3.50)
Common Shares:		
Full Diluted	862,800	863,100
Year-end	862,713	862,796

WD-40 CO

Earnings, 6 mos. to (Consol. - \$000):

	02/29/24	02/28/23
Total Revenues	279,521	279,521
Net Sales	279,521	255,086
Cost & expenses	233,893	213,751
Operating income	45,125	40,832
Interest income	140	95
Interest expense	2,154	2,671
Other income (expense), net	(233)	315
Net before taxes	42,878	38,571
Income taxes	9,860	8,048
Net income	33,018	30,523
Balance for common	32,896	30,398
Earnings common share		
Primary	\$2.43	\$2.24
Fully Diluted	\$2.42	\$2.23
Common Shares:		
Full Diluted	13,583	13,608
Year-end	13,555	13,578

WESTROCK COFFEE CO

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021
			(revised)
Product revenues	864,714
Net sales	864,714	867,872	698,144
Product costs of sales	724,856
Total costs of sales	724,856	715,107	552,721
Gross profit (loss)	139,858	152,765	145,423
Selling, general & administrative expense	144,577	129,985	128,506
Acquisition, restructuring &			

Income tax expense	14,557	13,169	8,835
Gain (loss) on disposal of property, plant & equipment	(1,153)	(935)	(243)
Total operating expenses	160,287	144,089	137,584
Income (loss) from operations	(20,429)	8,676	7,839
Other income (expense), net	(1,446)	1,146	34
Term loan facility	...	3,642	...
Prior term loan facility	...	14,735	22,959
Prior term loan facility early termination fee	...	1,580	...
Prior ABL facility	...	2,414	1,980
Short-term related party debt	...	428	1,393
Subordinated related party debt	...	642	1,237
International trade finance lines	...	3,465	568
International notes payable	...	681	316
Other interest expense	...	1,593	479
Total cash interest	...	29,180	28,932
Amortization of deferred financing costs	...	1,726	1,840
Write-off of deferred financing costs	...	4,296	...
Payments-in-kind interest	...	295	1,777
Total non-cash interest	...	6,317	3,617
Interest expense	29,157	35,497	32,549
Change in fair value of warrant liabilities	10,207	(29,675)	...
Income (loss) before income taxes	...	(51,607)	(28,573)
- U.S.	...	(51,607)	(28,573)
Income (loss) before income taxes - international	...	(3,743)	3,897
Income (loss) before income taxes	(40,825)	(55,350)	(24,676)
Current state income tax expense (benefit)	266	529	179
Current foreign income tax expense (benefit)	(112)	1,619	(99)
Total current income tax expense (benefit)	154	2,148	80
Deferred federal income tax expense (benefit)	(7,365)	173	(4,617)
Deferred state income tax expense (benefit)	236	81	(901)
Deferred foreign income tax expense (benefit)	617	(2,291)	2,070
Total deferred income tax expense (benefit)	(6,512)	(2,037)	(3,448)
Income tax expense (benefit)	(6,358)	111	(3,368)
Net income (loss)	(34,567)	(55,461)	(21,308)
Net income (loss) attributable to noncontrolling interest	(15)	276	(639)
Net income (loss) attributable to unitholders	...	(55,185)	(21,947)
Accretion of convertible			

preferred stock.....	...	1,316	...	Property, plant & equipment, gross	427,299	252,208	Total Revenues	2023	2022
Loss on extinguishment of Redeemable Common Equivalent Preferred Units, net.....	...	2,870	...	Less: accumulated depreciation	83,261	67,002	Net Sales	649,748	640,149
Common equivalent preferred dividends	4,380	...	Property, plant & equipment, net	344,038	185,206	Cost & expenses	663,809	632,507
Accumulating preferred dividends	161	13,882	24,208	Goodwill	116,111	113,999	Operating income	(14,061)	7,642
Net income (loss) attributable to common unitholders	(34,743)	(77,633)	(46,155)	Intangible assets, net	122,945	130,886	Other income (expense), net	17,510	(4,430)
Weighted average units outstanding - basic	80,684	48,444	34,472	Other long-term assets	7,769	18,023	Equity earnings	80
Weighted average units outstanding - diluted	80,684	48,444	34,472	Operating lease right-of-use assets	67,601	...	Net before taxes	(17,767)	(27,053)
Year end units outstanding	88,051	[Ⓜ] 75,020	34,523	Total assets	971,514	746,213	Income taxes	(3,331)	(3,511)
Net earnings (loss) per common unit - basic	\$(0.43)	\$(1.60)	\$(1.34)	Current maturities of long-term debt	9,811	11,504	Net income	(14,516)	(23,542)
Net earnings (loss) per common unit - diluted	\$(0.43)	\$(1.60)	\$(1.34)	Short-term debt	43,694	42,905	Balance for common	(14,780)	(44,717)
Full-Time Employees (Period End)	1,399	Accounts payable	69,106	116,675	Earnings common share		
Total number of employees	1,399	[Ⓜ] 1,327	[Ⓜ] 1,200	Derivative liabilities	3,731	7,592	Primary	\$(0.19)	\$(1.12)
Number of common stockholders	22	[Ⓜ] 81	...	Accrued expenses & other current liabilities	30,408	37,459	Fully Diluted	\$(0.19)	\$(1.12)
Equity in (earnings) loss from unconsolidated entities	(100)	Supply chain finance program	78,076	...	Common Shares:		
Income tax expense (benefit)	(6,358)	Operating Lease Liabilities - Current Portion/Short-Term	4,809	...	Full Diluted	78,203	39,819

[Ⓜ] Reclassified to conform with 2022 presentation; [Ⓜ] Shares increased due to the effect of issuance of common shares upon closing of de-SPAC merger transaction, issuance of common shares related to PIPE financing; [Ⓜ] As is; [Ⓜ] Approximately; [Ⓜ] As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	37,196	16,838
Restricted cash	644	9,567
Accounts receivable, gross	101,773	104,662
Less: allowance for credit losses	2,915	3,023
Accounts & Notes Receivable - Trade - Net	99,158	...
Accounts receivable	101,639
Raw materials	78,882	66,925
Finished goods	26,857	21,232
Green coffee	44,182	57,679
Inventories - Balancing value	149,921	...
Inventories	145,836
Derivative assets	13,658	15,053
Prepaid expenses & other current assets	300	9,166
Prepaid expenses and other current assets	12,473	...
Total current assets	313,050	298,099
Land	8,778	9,052
Buildings	35,911	44,425
Leasehold improvements	9,800	1,651
Plant equipment	128,639	107,885
Vehicles & transportation equipment	648	700
IT systems	8,909	3,053
Furniture & fixtures	3,294	3,529
Customer beverage equipment	22,931	21,930
Lease right-of-use assets	81	36
Construction in progress & equipment deposits	208,308	59,947

Recent Dividends:
1. Westrock Coffee Co common. No dividends paid.

2. Westrock Coffee Co series A preferred. No dividends paid.

Annual Dividends:
1. Westrock Coffee Co common. No dividends paid.

2. Westrock Coffee Co series A preferred. No dividends paid.

WESTROCK COFFEE CO Earnings, 9 mos. to Sep 30 (Consol. - \$000):

Operating lease liabilities	583,558	459,548	Total liabilities	219,680	175,000
Series A convertible preferred shares	274,936	Term loan	175,000
Additional paid-in capital	471,666	342,664	International trade finance lines	42,905
Retained earnings (accumulated deficit)	(362,624)	(328,042)	International notes payable	1,750
Common stock	880	750	Other loans	25
Cash flow hedge changes in fair value gain (loss)	(6,355)	Total debt	219,680
Foreign currency translation gain (loss)	252	Unamortized debt costs	(2,769)
Accumulated other comprehensive income (loss)	3,818	(6,103)	Less: current maturities of long-term debt	11,504
Preferred Stock - Redeemable - Convertible	274,216	...	Short-term debt	42,905
Total unitholders' equity (deficit) attributable to Westrock Coffee Holdings, LLC	387,956	9,269	Long-term debt, net	223,092	162,502
Noncontrolling interest	2,460	Deferred income taxes	10,847	14,355
Total unitholders' equity (deficit)	387,956	11,729	Warrant liabilities	44,801	55,521

XILIO THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Research & development	52,136	59,201	51,188
General & administrative	26,997	29,948	23,856
Total operating expenses	79,133	89,149	75,044
Income (loss) from operations	(79,133)	(89,149)	(75,044)
Other income (expense), net	2,729	927	(756)
Net Income before Tax	(76,404)
Tax
Total other income (expense), net	2,729	927	(756)
Net income (loss)	(76,404)	(88,222)	(75,800)
Weighted average shares outstanding - basic	27,496	27,392	5,606
Weighted average shares outstanding - diluted	27,496	27,392	5,606
Year end shares outstanding	27,608	27,425	[Ⓜ] 27,358
Net income (loss) per share - basic	\$(2.78)	\$(3.22)	\$(13.52)
Net income (loss) per share - diluted	\$(2.78)	\$(3.22)	\$(13.52)
Number of full time employees	[Ⓜ] 89	[Ⓜ] 74
Number of common stockholders	35	[Ⓜ] 58	[Ⓜ] 89

[Ⓜ] Shares increased due to the effect of conversion of convertible preferred stock into common stock upon initial public offering, issuance of common stock upon initial public offering, vesting of restri; [Ⓜ] As is; [Ⓜ] As of February 15, 2023; [Ⓜ] As of February 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	44,704	120,385
Prepaid expenses & other current assets	3,423	4,111
Total current assets	48,127	124,496
Restricted cash	1,587	1,562
Laboratory equipment	5,815	5,587
Computers & software	183	228
Furniture & fixtures	681	636
Leasehold improvements	5,124	5,124
Construction in process	98
Property & equipment, gross	11,803	11,673
Less: accumulated depreciation	5,861	4,418
Property & equipment, net	5,942	7,255
Operating lease right-of-use asset	5,125	5,585
Other non-current assets	145	267

Total assets	60,926	139,165	for income taxes	(75,822,000)	(73,317,000)	23,403,000	Total assets	93,684,000	189,936,000
Accounts payable	1,050	3,125	Current state				Accounts payable	2,756,000	2,896,000
External research & development		3,178	income tax expense				Convertible debt, current		26,849,000
Personnel related		5,413	(benefit)	21,000	8,000	2,000	Derivative liabilities		405,000
Professional & consulting fees		1,536	Total current				Accrued expenses & other		7,782,000
Other accrued expenses	10,497	200	income tax expense				current liabilities		721,000
Accrued expenses		10,327	(benefit)	21,000	8,000	2,000	Customer deposits		1,099,000
Operating lease liability, current		918	Provision for				Warranty liability		303,000
Notes payable, current		6,667	income taxes	21,000	8,000	2,000	Equipment notes payable		2,065,000
Other current liabilities		82	Net income (loss)	(75,843,000)	(73,325,000)	23,401,000	Short-term insurance		1,530,000
Capitalized Leases - Current Portion		48	Net income (loss)				financing notes		2,116,000
Total current liabilities	15,957	21,119	attributable to				Operating lease		15,616,000
Notes payable, net of current portion		3,165	common stockholders		(73,325,000)	23,401,000	liabilities, current		45,766,000
Operating lease liability, net of current portion		8,142	Weighted average				Finance lease		19,920,000
Other liabilities, long-term		45	shares outstanding				liabilities, current		564,000
Total liabilities	24,099	33,518	- basic	5,785,126	5,508,433	3,518,933	non-current		661,000
Common units		3	- Weighted average				Earn-out interest		784,000
Common stock		3	shares outstanding				liability		942,000
Additional paid-in capital	362,336	354,752	- diluted	5,785,126	5,812,733	3,592,867	Common stock warrant		5,174,000
Accumulated deficit	(325,512)		Year end shares				liability		4,100,000
Retained earnings (accumulated deficit)		(249,108)	outstanding	5,941,000	5,627,233	5,437,900	Other non-current		11,000,000
Total stockholders' equity (deficit)	36,827	105,647	Net earnings (loss)				liabilities	8,561,000	77,861,000
Total stockholders equity	36,827		per share - basic	\$(13.11)	\$(13.20)	\$6.60	Total liabilities	48,488,000	17,000
			Net earnings (loss)				Additional paid-in capital	198,456,000	190,215,000
			per share - diluted	\$(13.11)	\$(13.20)	\$6.60	Retained earnings (accumulated deficit)	(153,261,000)	(77,418,000)
			Number of full time employees	161	272	289	Accumulated other comprehensive income (loss)		(739,000)
			Total number of employees	161			Total stockholders' equity (deficit)	45,196,000	112,075,000
			Number of class A common stockholders	55	61	82	Total Equity	45,196,000	

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	11,640,000	35,631,000
Restricted cash		3,044,000
Accounts receivable, gross		8,277,000
Less: allowance for doubtful accounts		39,000
Accounts receivable, net	15,142,000	8,238,000
Marketable debt securities, available-for-sale - short-term		50,648,000
Raw materials	30,357,000	40,271,000
Work in process	3,033,000	4,618,000
Finished goods	4,453,000	12,651,000
Inventories, net	37,843,000	57,540,000
Prepaid inventories	4,541,000	2,372,000
Prepaid expenses and other current assets		1,589,000
Financed insurance premiums	1,310,000	2,289,000
Deposits	811,000	
Assets held for sale	408,000	1,850,000
Prepaid expenses & other current assets	7,070,000	8,100,000
Total current assets	71,695,000	163,201,000
Equipment	7,629,000	7,595,000
Finance lease assets	7,974,000	9,283,000
Furniture & fixtures	173,000	173,000
Company vehicles	2,102,000	1,389,000
Leasehold improvements	1,401,000	1,401,000
Computers, software & related equipment		2,865,000
Construction in progress	292,000	346,000
Computer Software & Equipment - Tangible		
Assets - Gross	3,091,000	
Property & equipment, gross	22,662,000	23,052,000
Less: accumulated depreciation	8,002,000	4,471,000
Property & equipment, net	14,660,000	18,581,000
Operating lease right-of-use assets, net	4,991,000	6,555,000
Other non-current assets	2,338,000	1,599,000

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-30 stock split, December 7, 2023; □ As of March 23, 2023; □ As of March 23, 2022

Recent Dividends:

1. Xilio Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Xilio Therapeutics Inc common.

No dividends paid.

XOS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Total product revenue	44,523,000		
Revenues	44,523,000	36,376,000	5,048,000
Cost of goods sold	45,813,000	66,405,000	7,410,000
Gross profit (loss)	(1,290,000)	(30,029,000)	(2,362,000)
General & administrative expenses	37,698,000	41,093,000	27,197,000
Research & development	19,589,000	30,679,000	20,077,000
Sales & marketing	6,388,000	9,547,000	3,519,000
Total operating expenses	63,675,000	81,319,000	50,793,000
Income (loss) from operations	(64,965,000)	(111,348,000)	(53,155,000)
Other income (expense), net	(12,047,000)	(4,835,000)	38,000
Change in fair value of derivative instruments	671,000	14,184,000	18,498,000
Change in fair value of earn-out interests liability	519,000	28,682,000	72,505,000
Write off of subscription receivable			(379,000)
Realized gain (loss) on debt extinguishment			(14,104,000)
Income (loss) before provision for income taxes - United States	(73,317,000)		23,403,000
Income (loss) before provision			

Recent Dividends:

1. Xos Inc class B ordinary.

No dividends paid.

2. Xos Inc common.

No dividends paid.

3. Xos Inc class A ordinary.

No dividends paid.

Annual Dividends:

1. Xos Inc class B ordinary.

No dividends paid.

2. Xos Inc common.

No dividends paid.

3. Xos Inc class A ordinary.

No dividends paid.

XTANT MEDICAL HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Orthopedic product sales	91,303,000	57,958,000	55,146,000
Other revenue		11,000	117,000
Total revenue	91,303,000	57,969,000	55,263,000
Cost of sales	35,836,000	25,832,000	22,773,000
Gross profit	55,467,000	32,137,000	32,490,000
General & administrative expenses	25,850,000	15,462,000	14,449,000
Sales & marketing expenses	38,439,000	22,515,000	21,025,000
Research & development expenses	1,336,000	915,000	870,000
Income (loss) from operations	(10,158,000)	(6,755,000)	(3,854,000)
Interest expense	2,938,000	1,692,000	995,000
Interest income	149,000	31,000	
Write-off of debt			

related costs	(11,694,000)		
Other income (expense)	(49,000)		
Unrealized foreign currency translation gain	265,000		
Total other income (expense)	9,121,000	(1,661,000)	(995,000)
Net income (loss) from operations before provision (benefit) for income taxes - U.S.		(8,416,000)	(4,849,000)
Net income (loss) from operations before provision (benefit) for income taxes	(1,037,000)	(8,416,000)	(4,849,000)
Current federal provision (benefit) for income taxes			(51,000)
Current state provision (benefit) for income taxes	93,000	69,000	51,000
Foreign	111,000		
Current benefit (provision) for income taxes	204,000	69,000	
Deferred federal income taxes	(1,422,000)		
Deferred state income taxes	(479,000)		
Deferred benefit (provision) for income taxes	(1,901,000)		
Provision (benefit) for income taxes current & deferred	(1,697,000)	69,000	
Net income (loss)	660,000	(8,485,000)	(4,849,000)
Weighted average shares outstanding - basic	119,093,687	94,085,197	85,456,175
Weighted average shares outstanding - diluted	126,793,318	94,085,197	85,456,175
Year end shares outstanding	130,180,031	108,874,803	87,068,980
Net income (loss) per share - basic	\$0.01	\$(0.09)	\$(0.06)
Net income (loss) per share - diluted	\$0.01	\$(0.09)	\$(0.06)
Number of full time employees	207	134	116
Number of part time employees	8	1	2
Total number of employees	215	135	118
Number of common stockholders	166	170	173
Basic EPS Excluding ExtraOrdinary Items	\$0.01		
Diluted EPS Excluding ExtraOrd Items	\$0.01		

Recent Dividends:
1. Xtant Medical Holdings Inc common.
 No dividends paid.

Annual Dividends:
1. Xtant Medical Holdings Inc common.
 No dividends paid.

YELLOW CORP (NEW)

Bankruptcy Proceedings On Nov. 17, 2023, Co. entered into: (i) Amendment No. 1 to Junior Secured Super-Priority Debtor-In-Possession Credit Agreement (this "Junior DIP Credit Agreement Amendment") by and among Co., as borrower, certain subsidiaries of Co., as guarantors, the lenders party thereto from time to time and Alter Domus Products Corp., as administrative agent and collateral agent (acting collectively in such capacities, the "Administrative Agent"), under that certain Junior Secured Super-Priority Debtor-in-Possession Credit Agreement, dated as of Sept. 6, 2023 by and among the Borrower, the Guarantors party thereto from time to time, the Lenders and the Administrative Agent; and (ii) Amendment No. 5 to Amended and

Restated Credit Agreement, dated as of November 17, 2023, by and among Co., as borrower, certain subsidiaries of Co., as guarantors, the lenders party thereto from time to time and Alter Domus Products Corp., as administrative agent and collateral agent, which amends that certain Amended and Restated Credit Agreement dated as of Sept. 11, 2019 (as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of Apr. 7, 2020, Amendment No. 2 to Amended and Restated Credit Agreement, dated as of July 7, 2020, Amendment No. 3 to Amended and Restated Credit Agreement dated as of July 7, 2023, Amendment No. 4 to Amended and Restated Credit Agreement dated as of Sept. 6, 2023, and as may be further amended, amended and restated, restated, supplemented or otherwise modified from time to time, the "Postpetition B-2 Credit Agreement Amendment"). The Junior DIP Credit Agreement Amendment amends the Junior Secured Super-Priority Debtor-in-Possession Credit Agreement to increase the Delayed Draw Term Commitments from \$70 million to \$170 million, and to increase the number of permitted Borrowings of Delayed Draw Term Loans from three (3) to seven (7) Borrowings. The increased Delayed Draw Term Commitments will be available to Co. to be Borrowed on and after Dec. 1, 2023, only if cash and Cash Equivalents of the Borrower and its Subsidiaries is less than \$25,000,000 in the aggregate immediately prior to such Borrowing. Each Borrowing of Delayed Draw Term Loans shall be no more than \$25 million. The Postpetition B-2 Credit Agreement Amendment permits the increased Delayed Draw Term Commitments under the Junior Secured Super-Priority Debtor-in-Possession Credit Agreement.

YELLOW CORP (NEW)

Bankruptcy Proceedings On Nov. 28, 2023, Co. entered into Amendment No. 2 to Junior Secured Super-Priority Debtor-In-Possession Credit Agreement (this "Junior DIP Credit Agreement Amendment"), by and among Co., as borrower, certain subsidiaries of Co., as guarantors, the lenders party thereto from time to time and Alter Domus Products Corp., as administrative agent and collateral agent (acting collectively in such capacities, the "Administrative Agent"), under that certain Junior Secured Super-Priority Debtor-in-Possession Credit Agreement, dated as of Sept. 6, 2023 by and among the Borrower, the Guarantors party thereto from time to time, the Lenders and the Administrative Agent (as amended by Amendment No. 1 to the Junior Secured Super-Priority Debtor-in-Possession Credit Agreement, dated as of November 17, 2023), the "Junior Secured Super-Priority-Debtor-In-Possession Credit Agreement"). The Junior DIP Credit Agreement Amendment amends the Junior Secured Super-Priority-Debtor-In-Possession Credit Agreement for a technical change as required by MFN Partners, L.P. and its auditors to remove the "per annum" language in Section 2.05(a) of the Junior Secured Super-Priority-Debtor-In-Possession Credit Agreement in order to provide additional clarity that the 7.5% is in regard to an exit fee and should not otherwise be construed as a ticking fee.

YELLOW CORP (NEW)

Bankruptcy Proceedings On Dec. 20, 2023, Co. consummated the sale of certain of Co.'s real estate holdings (the "Sold Real Estate") to XPO, Inc. ("XPO") for an aggregate purchase price of approximately \$870 million in cash (the "Yellow Asset Sale"). The Yellow Asset Sale was consummated pursuant to the Asset Purchase Agreement, dated as of Dec. 4, 2023, by and among Co. Parties and XPO (the "Purchase Agreement"). The Sold Real Estate includes three leases (two of which related to leased service centers) and the right to designate, in consultation with Co., additional contracts that are exclusively related to the Sold Real Estate for a period of 45 days following consummation of the Yellow Asset Sale. XPO assumed certain liabilities related to the Sold Real Estate, including liabilities under three leases, certain cure costs required to be paid pursuant to the Chapter 11 Cases in connection with the assumption of the three leases, liabilities for taxes (subject to certain exceptions), and liabilities relating to environmental, health or safety matters in connection with ownership, operation, use or maintenance of the Sold Real Estate, to the extent not extinguished by the Chapter 11 Cases. The Yellow Asset Sale was consummated pursuant to Section 363 of Bankruptcy Code and was confirmed by the previously reported order of the Bankruptcy Court, dated Dec. 12, 2023.

YELLOW CORP (NEW)

Bankruptcy Proceedings On Feb. 8, 2024, Co. had consummated the sale of certain of Co.'s real estate holdings (the "Sold Real Estate") to various purchasers for an aggregate purchase price of approximately \$1.89 billion in cash (together, the "Yellow Asset Sales"). The Yellow Asset Sales were consummated pursuant to certain Asset Purchase Agreements, dated as of Dec. 4, 2023 (each, a "Purchase Agreement"), by and among Co. Parties and the purchasers thereto. The purchasers assumed certain

Reclassified to conform with 2022 presentation; Shares increased due to the effect of private placement and issuance of common stock on vesting of restricted stock units; As of March 3, 2023; As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	5,715,000	20,298,000
Restricted cash	208,000	209,000
Trade accounts receivable, gross	21,651,000	11,368,000
Allowance for doubtful accounts - trade accounts receivable	920,000	515,000
Trade accounts receivable, net	20,731,000	10,853,000
Raw materials	7,269,000	5,628,000
Work in process	1,562,000	798,000

liabilities related to the Sold Real Estate, as applicable, including liabilities under the leases thereon, certain cure costs required to be paid pursuant to the Chapter 11 Cases in connection with the assumption of leases, liabilities for taxes (subject to certain exceptions), and liabilities relating to environmental, health or safety matters in connection with ownership, operation, use or maintenance of the Sold Real Estate, to the extent not extinguished by the Chapter 11 Cases. The Yellow Asset Sales were each consummated pursuant to Section 363 of Bankruptcy Code and were confirmed by the previously reported order of the Bankruptcy Court, dated Dec. 12, 2023.

YELLOW CORP (NEW)

Seeks Bids At auctions held the week of November 27, 2023, Co. successfully solicited binding bids from 21 bidders for 128 owned real properties and two leased real properties for a total price of \$1,882,637,655. Co. has agreed to separate asset purchase agreements with each bidder, pursuant to which, on and subject to substantially similar terms and conditions set forth therein: (i) each bidder will acquire the properties they successfully bid on during the auctions, and (ii) each bidder will assume certain liabilities related to the properties, including liabilities under certain leases, liabilities for taxes (subject to certain exceptions), and liabilities relating to environmental, health or safety matters in connection with ownership, operation, use or maintenance of the properties, to the extent not extinguished by the proceedings of the Bankruptcy Court in connection with the Chapter 11 Cases. On December 12, 2023, the Bankruptcy Court approved Co.'s entry into the Asset Purchase Agreements. Co. will solicit bids for its remaining real property at a later date. These transactions are intended to be consummated pursuant to Section 363 of the Bankruptcy Code, and remain subject to various conditions, including, among others, the entry by the Bankruptcy Court of a sale order and the satisfaction of certain other closing conditions. The bidders' asset purchase agreements were signed the week of Dec. 4, 2023.

ZENTALIS PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Acquired in-process research & development.....	45,568
Research & development expenses.....	189,590	172,734	175,601
General & administrative expenses.....	64,351	54,553	40,941
Total operating expenses.....	...	227,287	216,542
Operating income (loss).....	(299,509)	(227,287)	(216,542)
Investment & other income, net.....	22,617	5,987	401
Gain on deconsolidation of Zentera.....	51,582
Income (loss) before income taxes ..	(276,892)	(221,300)	(164,559)
Current state income taxes.....	41	11	11
Current foreign income taxes.....	249	298	550
Current income taxes.....	290	309	561
Deferred federal income taxes.....	(891)	(683)	(120)
Deferred state income taxes.....	...	(41)	(736)
Deferred foreign income taxes.....	...	(54)	(2)
Deferred income taxes.....	(891)	(778)	(858)
Loss on equity method investment ...	(16,014)	(16,282)	(1,831)
Income tax expense (benefit).....	(601)	(469)	(297)
Net income (loss).....	(292,305)	(237,113)	(166,093)
Net income (loss) attributable to noncontrolling interests.....	114	307	7,368

Net income (loss) attributable to Zentalis Pharmaceuticals, LLC.....	(292,191)	(236,806)	(158,725)
Weighted average common shares outstanding - basic ...	65,409	52,857	42,688
Weighted average common shares outstanding - diluted.....	65,409	52,857	42,688
Year end shares outstanding.....	70,766	59,280	45,491
Net earnings (loss) per share - basic	\$(4.47)	\$(4.48)	\$(3.72)
Net earnings (loss) per share - diluted	\$(4.47)	\$(4.48)	\$(3.72)
Number of full time employees.....	168	156	177
Number of common stockholders.....	12	15	25
Earnings per share from continuing operations.....	\$(4.47)
Earnings per share from continuing operations.....	\$(4.47)
Total number of employees.....	168

Reclassified to conform with 2022 presentation; Shares increased due to the effect of equity offering, underwriting discounts, commissions, offering costs, restricted stock unit vesting, exercise of options and employee stock purchase plan, As is; Approximately; As of February 27, 2023; As of February 22, 2022

Accounts payable.....	14,926	11,247
Accrued research & development expenses.....	...	32,310
Accrued employee expenses.....	14,477	11,246
Accrued general & administrative expenses.....	...	662
Lease liability.....	2,623	2,162
Income taxes payable.....	281	384
Accrued legal expenses.....	54,441	1,256
Other accrued expenses.....	37,060	...
Less long-term portion.....	...	(2,620)
Accrued expenses.....	...	45,400
Total current liabilities.....	69,367	56,647
Deferred tax liability.....	...	853
Long-term lease liability.....	43,150	45,166
Other long-term liabilities.....	1,780	2,620
Total liabilities.....	114,297	105,286
Class A common units.....	70	...
Common stock.....	...	59
Additional paid-in capital.....	1,323,576	1,031,462
Accumulated other comprehensive income.....	2,194	(1,353)
Accumulated deficit.....	(888,556)	...
Retained earnings (accumulated deficit).....	...	(596,365)
Total Zentalis Pharmaceuticals, LLC members' equity (deficit).....	437,284	433,803
Non-controlling interests.....	107	221
Total equity (deficit).....	437,391	434,024

Recent Dividends:

1. Zentalis Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Zentalis Pharmaceuticals Inc common.

No dividends paid.

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents.....	28,038	43,069
Marketable securities, available for sale.....	454,881	394,302
Prepaid insurance.....	...	1,018
Prepaid software licenses & maintenance.....	...	958
Foreign research & development expenses.....	...	659
Prepaid research & development expenses.....	...	15,002
Interest receivable.....	...	508
Zentera receivable.....	...	5,874
Other prepaid expenses.....	...	266
Total prepaid expenses & other current assets.....	...	24,285
Less long-term portion.....	13,799	(9,723)
Prepaid expenses & other current assets.....	...	14,562
Total current assets.....	496,718	451,933
Lab equipment.....	3,069	2,622
Leasehold improvements.....	4,235	4,891
Office equipment & furniture.....	...	2,065
Computer equipment.....	150	150
Construction in process.....	173	37
Office Equipment & furniture - Gross.....	1,340	...
Total property & equipment, gross.....	8,967	9,765
Less: accumulated depreciation & amortization.....	3,148	2,060
Property & equipment, net.....	5,819	7,705
Operating lease right-of-use assets.....	35,916	42,373
Prepaid expenses & other assets.....	6,818	9,723
Goodwill.....	3,736	3,736
Investment in Zentera Therapeutics.....	...	21,213
Restricted cash.....	2,681	2,627
Total assets.....	551,688	539,310

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2024 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.